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GENERAL INTRODUCTION
Dietary restriction (DR) is defined as the reduction in food intake without causing 
malnutrition1. As from the 1930s, the beneficial effects of DR became known when McCay 
et al. showed that reducing calorie intake extended the lifespan of laboratory rats by at least 
30%2 (Table 1). Much later, their results were extended to other animal species including 
yeast, fruit flies and rodents as well as non-human primates3,4. These beneficial effects were 
seen by restricting calorie intake generally around 30%, starting from early adulthood. 
Although the extension of lifespan could not be replicated in every animal model, for 
instance in the normal housefly, the beneficial effects are thought to be derived from 
evolutionary conserved mechanisms3,5. The average extension rate of the median lifespan 
by DR in healthy animals was around 30%3. This percentage was shown to be even higher in 
mice with deficiencies causing accelerated aging, including the Ercc1(∆/-) mouse, in which 
the median and maximum lifespan could be tripled by DR6. 
Shortly after the effects of DR on aging were discovered, scientists also demonstrated 
a reduction in incidence and severity of age-related diseases. One of the first 
acknowledgements of this was made in the 1940s, when Tannenbaum et al. demonstrated 
a reduction of both initiation and progression of spontaneous tumors in small rodents 
on long-term DR7. Indeed, various studies confirmed these results and showed a marked 
decrease in the incidence of tumor development and progression8-11. Other well-established 
effects of DR are the decreased incidence and reversal of the metabolic syndrome, including 
insulin resistance and diabetes mellitus4,12. Recently, two studies  showed and compared 
these effects in non-human primates, demonstrating that rhesus monkeys on a normal diet 
had a three times higher and earlier rate of dying from an age-related cause, including 
cancer, cardiovascular disease and diabetes mellitus, than did monkeys on DR13,14.
The beneficial and reproducible effects of long-term DR triggered scientists to search for the 
mechanisms inducing these benefits. Until now, the exact mechanisms underlying DR are 
still largely unknown. One of the effects of DR that has been established is a reduction of the 
formation of reactive oxygen species (ROS) and increased resistance against oxidative 
stress15. ROS, which are natural byproducts of the metabolism of oxygen, are overly 
present in times of increased oxidative stress which occurs for example during metabolic 
disturbances as hyperinsulinemia as well as chronic inflammation16.
15045-jongbloed-layout.indd   11 06/11/2017   17:20
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Table 1. A list of the durations of dietary restriction (DR), maximum lifespan extension and health 
span benefits described in various animal species
Species DR (%) Maximum lifespan 
extension (%)
Health span References
Yeast 20-60% 300% Increased reproductive period 3
Worms 10-35% 200-300% Increased stress resistance 3
Flies 20-30% 200% None reported 3
Fish 33-58% 33% Decrease in age-dependent learning and memory 17
Mice 30-60% 30-60% Decrease in age-associated diseases, auto-
immune, increased stress resistance
3
Rats 30-60% 30-60% Decrease in age-associated diseases, increased 
stress resistance
18
Monkeys 25% 30% Decrease in age-associated diseases, prevention 
of obesity
4,13,14
Increased oxidative stress is also induced by ischemia-reperfusion injury (IRI), a 
phenomenon occurring for instance during organ transplantation and which is a major 
risk factor for damage to or even failure of the transplanted organ. After organ retrieval, 
cessation of the blood flow, ischemia, leads to hypoxia, nutrient deprivation, and thereby 
accumulation of metabolic waste products. Reperfusion of the ischemic organ increases 
the generation of reactive oxygen species, triggers apoptotic cell death, and starts an 
inflammatory response which may result in profound tissue injury19,20. Especially the 
reperfusion period is thought to be a major player in the increased ROS production, which 
leads to high levels of oxidative stress21. Several studies have tried to use the increased stress 
resistance by DR in a therapeutic fashion. For instance, Sun et al. showed that rats subjected 
to 6 months of 40% DR are protected against the oxidative damage induced by a high dose 
of paraquat22. In addition, mice offered 40% DR during 8 months were protected against 
the toxicity of high doses of paracetamol23. However, the therapeutic use of DR to protect 
against oxidative stress in humans was hampered by the long period of DR that was applied. 
Since the kinetics of onset of oxidative stress resistance against IRI induced by DR were 
not yet known at this time, colleagues investigated whether short and clinically applicable 
periods of DR were able to induce resistance against oxidative stress induced by renal IRI in 
the mice. It was shown that both four and two weeks of 30% DR were capable of ameliorating 
renal IRI in mice1. Mice showed significantly improved survival rate and kidney function 
after induction of IRI compared to mice that were allowed to eat ad libitum. Subsequently, 
a short period of 100% DR, namely three days of fasting, induced similar protective effects 
against renal IRI. Antioxidant and cytoprotective molecules, including heme oxygenase-1 
(HO-1) and glutathione reductase (Gsr) were significantly induced by three days of fasting 
15045-jongbloed-layout.indd   12 06/11/2017   17:20
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compared to ad libitum fed mice, while pro-inflammatory markers, including interleukin-6, 
were significantly reduced after induction of renal IRI1. These beneficial effects were 
reproduced in models of hepatic, cardiac, and cerebral IRI, showing that the effects of DR 
are not organ specific and might be applicable in multiple settings of acute stress24-26. 
It did not take long before other research fields tried to exploit the beneficial effects of 
short-term DR, and started to apply it on different models of acute stress. One of these 
is chemotherapy, one of the treatments against cancer.  Irinotecan, a chemotherapeutic 
agent used in the treatment of colorectal carcinoma, is known to induce severe and 
unpredictable side effects including myelosuppression, diarrhea, and in some cases even 
death as a complication of side effects, thereby severely reducing the applicability of the 
drug27. Recently, it was shown that 3-day fasting prior to the administration of a high dose 
of irinotecan significantly prevented the occurrence of side effects in mice28. Furthermore, 
tumor growth was reduced equally in ad libitum fed and fasted animals, indicating that 
the antitumor effect of the drug was unimpaired by the dietary preconditioning29. The 
mechanisms underlying the beneficial effects of DR on chemotherapy have not yet been 
unraveled either, and further studies were more than warranted in order to understand 
the molecular mechanisms by which DR exerts its beneficial effects. Discovering these 
mechanisms may lead to regimens that are easier to apply in a clinical setting as well as the 
development of a dietary mimetic. 
Despite the impressive body of evidence on the positive effects of DR, a high level of 
skepticism was present among clinicians about the clinical translation of DR to surgical 
patients30. Not only would it be difficult for patients to voluntarily restrict themselves in 
their calorie intake, restricting food intake prior to surgery goes against the generally held 
beliefs that patients should be well fed before surgery to prevent malnutrition3. Even more 
so, since mice and men cannot be compared one to one, the ideal diet composition and 
duration needed for inducing similar effects in humans is not yet known31. In a pilot study 
in living kidney donors, Van Ginhoven et al. showed as one of the first that three days of 
30% DR followed by 24 hours of fasting prior to kidney donation was feasible and safe, 
and that kidney donors were highly motivated and open to participate in such a study32. 
Unfortunately, the diet had only marginal beneficial effects on surgical outcome. Although 
serum insulin levels were significantly reduced by the diet compared to the control group, it 
was uncertain whether this was the result of the 4-day dietary intervention or the 24 hours 
of fasting only33. Therefore, no clear set of objective markers for compliance to the diet was 
present up-to-date.
15045-jongbloed-layout.indd   13 06/11/2017   17:20
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To improve efficacy of a diet in a clinical setting, experiments were initiated to discriminate 
whether the calorie restriction per se or absence of one of the nutrients is responsible 
for the effects of DR. Data from fruit flies in aging studies hint towards a different role of 
individual macronutrients, where Drosophila lived up to 50% longer when restricted in 
their protein intake34. Further studies confirmed the key role of protein in the protective 
effects on both the long-term and short-term effects3,35. In animal models of IRI, a protein-
free diet given up to six days prior to IRI was found to be protective against oxidative stress 
and surgery-related outcome36,37. However, mice on protein-restricted or protein-free diets 
restricted themselves in food, and thus calorie intake, which made it difficult to distinguish 
between the effects of protein restriction and calorie restriction36. Also, the role of the other 
macronutrients, carbohydrates and fats, as well as the amino acids had not been investigated 
sufficiently to disentangle their contribution to the beneficial effects of DR38-40. Therefore, 
in the work described this thesis, my colleagues and I set out to further narrow down the 
duration and deprivation of nutrient components prior to acute stress-related injury in 
order to find a safe and effective diet that would be applicable to study in a clinical setting. 
AIMS AND OUTLINE OF THIS THESIS 
The aims of this thesis were to assess the effects of current short-term DR regimens in 
different mouse models, to investigate the effects of macronutrients and amino acids in the 
effects of DR, to broaden the knowledge about the molecular mechanisms underlying DR, 
and to develop a safe and effective DR regimen to investigate in a clinical surgical setting.  
In chapter 2, we extended our previous studies on nutritional preconditioning by testing 
the hypothesis that preoperative fasting induces the same beneficial effects on renal IRI 
in mice of a different genetic background and that were overweight, aged, and of both 
male and female gender. We compared general changes on a transcriptional level between 
young-lean and aged-overweight male mice, and focused on pathways and individual 
genes that could be involved in the protective effect of DR on renal IRI. In chapter 3, the 
reduction of chemotherapy-related toxicity by fasting was investigated on a transcriptional 
level. Tumor-bearing mice were subjected to fasting and subsequent irinotecan treatment, 
and the transcriptome of both liver and tumor was compared to that of mice that were 
ad libitum fed and/or were not given any chemotherapy. In chapter 4, we investigated 
to role of short-term macronutrient-free diets on renal IRI on both a phenotypical and 
transcriptional level. Together with the gene expression profiles of DR and fasting, we 
collected an extensive dataset of different DR strategies that are either protective or non-
protective against renal IRI. Microarray analyses enabled us to further unravel potential 
key pathways and transcription factors mediating the effects of DR, fasting and protein 
15045-jongbloed-layout.indd   14 06/11/2017   17:20
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restriction (PR). In chapter 5, we took a step further and studied the role of the building 
blocks of proteins, i.e. the essential amino acids leucine, tryptophan and methionine, on 
postoperative and transcriptional outcome after IRI of the liver. 
To further understand the role of DR on surgical outcome, in chapter 6 we used a human 
model that is the opposite of nutrient deprivation, i.e. morbid obesity, followed by a 
surgical form of DR, namely bariatric surgery. We investigated the detrimental effects of 
the metabolic syndrome on aging in morbidly obese patients. In particular, we examined 
the aging of the immune system and whether bariatric surgery is able to reverse these 
detrimental effects. We took blood samples of morbidly obese patients before and after 
bariatric surgery and measured relative telomere length and T-cell differentiation status, 
which are markers of cellular aging.
In chapter 7, a first step towards translation of short-term DR to humans was made by 
investigating the safety, feasibility of and compliance to a combined DR and PR diet in 
humans awaiting surgery. Healthy living kidney donors and morbidly obese bariatric 
surgery patients were offered a synthetic diet containing both DR and PR, or a synthetic 
placebo-diet that was isocaloric to the individual daily energy requirements. Effects of these 
diets were compared to those of a control group including donors whom were allowed to 
eat ad libitum, and were asked to fill in a diary of their nutritional intake. Safety, feasibility 
and compliance were tested via objective markers in blood samples, as well as subjective 
outcome in the form of questionnaires filled in before and after the application of the three 
dietary interventions. Since the DR and PR synthetic diet was considered safe and feasible, 
in chapter 8, the effects of this diet on clinical outcome as well as molecular changes was 
investigated in healthy living kidney donors and their kidney transplant recipients. This was 
done by examining kidney function and systemic inflammation markers in blood samples 
taken before, during and after surgery in both kidney donor and recipient. Effects on gene 
expression profiles were examined in kidney biopsies taken during surgery.
In chapter 9, a summary and discussion of the results described in this thesis are presented 
and emphasis is put on future perspectives of the research of DR in both the preclinical and 
clinical setting.
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ABSTRACT
Ischemia-reperfusion injury (IRI) is inevitable during kidney transplantation leading to 
oxidative stress and inflammation. We previously reported that preoperative fasting in 
young-lean male mice protects against IRI. Since patients are generally of older age with 
morbidities possibly leading to a different response to fasting, we investigated the effects 
of preoperative fasting on renal IRI in aged-overweight male and female mice. Male and 
female F1-FVB/C57BL6-hybrid mice, average age 73 weeks weighing 47.7 grams, were 
randomized to preoperative ad libitum feeding or 3-day fasting, followed by renal IRI. 
Body weight, kidney function and survival of the animals were monitored until day 28 
postoperatively. Kidney histopathology was scored for all animals and gene expression 
profiles after fasting were analyzed in kidneys of young and aged male mice. Preoperative 
fasting significantly improved survival after renal IRI in both sexes compared with normal 
fed mice. Fasted groups had a better kidney function shown by lower serum urea levels 
after renal IRI. Histopathology showed less acute tubular necrosis and more regeneration 
in kidneys from fasted mice. A mRNA analysis indicated the involvement of metabolic 
processes including fatty acid oxidation and retinol metabolism, and the NRF2-mediated 
stress response. Similar to young-lean, healthy male mice, preoperative fasting protects 
against renal IRI in aged-overweight mice of both genders. These findings suggest a general 
protective response of fasting against renal IRI regardless of age, gender, body weight and 
genetic background. Therefore, fasting could be a non-invasive intervention inducing 
increased oxidative stress resistance in older and overweight patients as well.
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INTRODUCTION
The rate of morbidity and mortality in patients with end-stage renal disease (ESRD) is greatly 
decreased by kidney transplantation, although it brings along its own set of complications 
like delayed graft function (DGF) and rejection1. DGF, defined as the need of dialysis in 
the first week after transplantation, occurs in almost 25% of all kidney transplantations 
in the USA2. Because elderly patients also benefit from a renal transplant, the number 
of transplantations performed in these patients has increased3. With the already existing 
shortage of donors, this has widened the gap between organ availability and demand. In an 
attempt to overcome this shortage, guidelines for extended donation are developed4. These 
extended criteria donors (ECD) are generally of older age, with existing morbidities like 
obesity and diabetes mellitus5. ECD kidneys show higher risks of DGF, acute rejection and 
graft failure, with recipient and donor age as independent risk factors6,7. Hence, practices 
improving transplantation success rates are urgently needed. 
Ischemia-reperfusion injury (IRI) is an unavoidable consequence of organ transplantation 
leading to a deleterious activation of cellular oxidases causing oxidative damage, tissue 
injury and inflammation8,9. IRI has been identified as a major risk factor for the development 
of DGF and rejection, with ECD kidneys being even more vulnerable to ischemic damage10. 
A potentially protective intervention against IRI is dietary restriction (DR), a short-term 
reduction in caloric intake before induction of ischemia. Long-term DR has been shown 
to prolong both health- and lifespan11,12. Although its mechanisms have not yet been 
elucidated, increased resistance to oxidative stress is likely to be involved. In addition, short-
term DR and fasting as a more acute approach of DR have been found to increase resistance 
against oxidative damage as well, including IRI9,13. Previously, we have shown that both 
three days of fasting and two weeks of 30% DR induce robust protection against renal IRI in 
mice9,14,15. However, these studies have been conducted with healthy young-lean male mice. 
The relevance of these findings for a heterogeneous group of patients which are generally 
older and suffer from disease is uncertain since the response induced by fasting and DR 
under these conditions is unknown16,17. Therefore, the aim of this study is to examine the 
effect of age, body weight, gender, and genetic background on the protection against renal 
IRI induced by fasting. We show that preoperative fasting protects against the effects of IRI 
in aged-overweight male and female mice comparable to young-lean mice. Subsequently, 
we compared gene expression profiles of kidneys of young-lean mice with those of aged-
overweight mice before and after fasting and identified several metabolic processes 
including fatty acid oxidation and retinol metabolism as well as pathways involved in the 
oxidative stress response as likely candidates involved in the induction of increased stress 
resistance by fasting.
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RESULTS
Fasted aged-overweight mice show a gradual weight gain after renal IRI
Male and female F1-FVB/C57BL6-hybrid mice were either fasted for three days by permitting 
water only or fed ad libitum (AL) preceding surgery. The mean baseline weight was 47.4±5.1 
and 48.0±7.6 grams for male and female mice, respectively, demonstrating their overweight 
phenotype acquired by ad libitum conditions compared to their mean body weight at 12 
weeks: 31.4±3.1 (male) and 24.2 ±2.4 (female) (data not shown). Fasting resulted in a net 
body weight loss of 8.2±0.5 and 6.5±0.9 grams in males and females, respectively, correlating 
with approximately 17% and 14% of their body weight before fasting (Figure 1A). After IRI, 
the fasted male and female mice showed a 5% and 10% weight loss, respectively, in the first 
five postoperative days (POD), after which their weight stabilized (Figure 1A). From POD7 
on, they gradually gained weight and eventually reached their preoperative weight (t=0) at 
day 28. In contrast, the AL fed mice showed a larger and faster weight loss after IRI. The 
AL fed males lost 7% in three days, after which they had all died. The AL fed females lost 
slightly more relative weight during the same period (10%). By POD5, they had lost 21% 
of their weight, resulting in a total weight slightly below that reached by the fasted animals. 
After POD7, the single surviving AL fed female mouse showed a similar trend in body 
weight gain as the fasted mice.
Three-day fasting confers resistance to renal ischemia in aged-overweight 
mice
At surgery, bilateral renal ischemia was applied for 37 minutes in male and 60 minutes in 
female mice followed by reperfusion. Both male and female fasted mice had a significant 
improved survival compared to the AL fed groups (Figure 1B). All eight AL male mice 
died or were sacrificed because of morbidity indicative of kidney failure within three days 
following reperfusion, whereas 7/8 fasted males survived through POD7. At POD7, four 
male mice were sacrificed for pathological analysis and censored in Figure 1B. Two of 
the three remaining mice survived in good health through day 28. In the fasted female 
group, one mouse was found dead on POD1 after IRI because of secondary causes (sutures 
removed by animal) and was excluded from further analyses. One of the 11 ad libitum fed 
females survived the observation period, while the majority, nine in total, died or were 
sacrificed due to morbidity within three days following IRI. At 28 days, 7/10 fasted female 
mice were still alive and appeared healthy. All fasted mice that died showed indications of 
irreversible kidney failure (morbidity and loss of kidney function, see serum and histology 
data described further on).
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Preoperative fasting leads to improved kidney function and recovery 
after IRI  
To measure the effect of fasting on kidney function after IRI, serum urea and creatinine 
levels were measured at days 0, POD1 and if applicable, POD2 and POD7 after surgery. 
Compared to AL fed mice, serum urea levels in male and female fasted aged mice were 
lower on postoperative day one, which became significant on day 2 (males P=0.001; females 
P=0.016; Figure 2A). Significance could not be determined on day 7 post-IRI as only 2 
AL females remained. Serum creatinine did not show statistically significant differences 
between groups (Figure 2B).
Figure 1. Relative body weight and survival. Relative body weight (A) and survival (B) of male and 
female mice undergoing 37 and 60 minutes of renal ischemia-reperfusion injury (IRI), respectively, 
preceded by 3-day fasting or ad libitum feeding. In the first week after surgery, both fasted groups 
gradually lost weight after which they slowly gained weight in the weeks thereafter. Both fasted 
groups show a significantly improved survival: P=0.0171 for males, P=0.0040 for females. M=male, 
F=female, Adlib=ad libitum fed.
Kidney damage after IRI was further assessed by histopathology. After sorting by cause of 
death, mice found dead and mice that were moribund and sacrificed showed severe acute 
tubular necrosis (Figure 3A), a major determinant of renal IRI. Median tubular necrosis 
scores in these groups, with 0 indicating no and 5 severe necrosis, were 5 and 4, respectively, 
with no significant differences between the two groups, demonstrating that moribund mice 
indeed suffered from severe kidney failure independent of the day histology was determined. 
In contrast, the surviving mice had a median pathology score of 1 (P<0.001) (Figure 3A).
A B
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Figure 2. Kidney function of male and female mice after undergoing 37 and 60 minutes of 
bilateral renal IRI, respectively, preceded by 3-day fasting or ad libitum feeding. (A) Serum 
urea levels are significantly lower in fasted males and females on day 2 after renal IRI. (B) Serum 
creatinine levels show no significant differences between fasted and ad libitum fed mice. M=male, 
F=female, Adlib=ad libitum fed. Δ=no standard deviation is shown as only two animals comprised 
this group.
As time after IRI might influence the severity of the pathological changes, four fasted male 
mice were sacrificed at POD7 and histology was compared with mice that died due to kidney 
failure. The tubular necrosis score of these four sacrificed mice was identical to that of the 
mice sacrificed at day 28 (median score 1), showing a similar contrast with the mice that 
died due to kidney failure, indicative of an acute protective effect of the diet. The amount of 
tubular regeneration is scored between 0 and 4 with 4 as the strongest regenerative response. 
Mice found dead or moribund scored a median pathology score for tubular regeneration 
of 0.5 and 0, respectively, and the fasted mice had a median score of 3.5, including mice 
sacrificed at POD7 and at later time-points (P<0.0001) (Figure 3B). When subdivided 
by gender and diet group, fasted male and female mice showed significantly less necrosis 
(P=0.0018 and P=0.0035, respectively) and significantly more regeneration (P=0.0089 
and 0.0036, respectively) compared to the AL fed groups (Figures 3 C/D). Representative 
images of the pathological lesions observed in the different groups are shown in Figure 4.
Gene expression profiles in kidneys show overlap between young and 
aged male mice in response to fasting
Firstly, gene expression profiles were compared between kidneys of ad libitum fed and 
three days fasted aged male mice (without renal IRI) by whole-genome mRNA microarray 
analysis. The total number of probe sets differentially regulated was assessed. In total, 854 
out of 45,141 probe sets were significantly differentially regulated (FDR ≤ 5%) in the fasted 
aged mice with a fold change ≥ 1.5. Of these 854 probe sets, 454 probe sets were upregulated 
and 400 downregulated (Figure 5A). Secondly, since fasting was shown to confer resistance 
to IRI in young-lean male mice9, we performed a similar mRNA analysis in kidneys 
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from young mice. A total of 2,408 probe sets were found to be significantly differentially 
regulated in fasted compared with ad libitum fed young mice with 1,189 upregulated and 
1,219 downregulated probe sets (Figure 5A).
Figure 3. Histopathological analysis of kidneys after renal ischemia-reperfusion injury. Mice 
sacrificed at the end of the experiment showed significantly less acute tubular necrosis (A) and 
significantly more tubular epithelial regeneration (B). Divided by intervention, both male and 
female fasted mice also showed less necrosis (C) and more regeneration (D). Fasted male mice 
sacrificed at day 7 showed similar pathology scores as the fasted mice at day 28 (mice indicated by 
the red symbols).* = significance (P<0.05) compared to the group ‘Found dead’, ** = compared to 
the group ‘Moribund’, *** = compared to ad libitum fed males, **** = compared to ad libitum fed 
females.
The Venn diagram in Figure 5A shows that most probe sets (70%) found in aged mice overlap 
with the probe sets found in young mice. Young mice show an almost three-fold increase 
of significantly regulated genes indicative of a stronger, more extensive response to fasting 
in young compared to aged mice. To verify whether gene expression changes followed the 
same directionality, the fold expression changes of all significant probe sets (FDR ≤ 5%) in 
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young or aged mice were plotted against each other (Figure 5B). The majority of these probe 
sets (85%) had similar directional changes in kidneys of young and aged mice, although the 
fold changes of the aged kidneys were generally lower compared to young.
(A)     (B)        (C) 
 
 (D)             (E) 
 
	 Figure 4. Representative images of HE stained kidney sections with acute tubular necrosis or tubular epithelial regeneration. (A) Multifocal severe acute tubular necrosis with typical diluted 
tubules, flattened epithelial lining and granular casts inside the tubules (arrows) in ad libitum fed 
male mouse four days after 37 minutes of IRI. (B) On day 7, male fasted mice already show a high 
degree of regeneration (arrows) with minimal necrosis (stars). (C) Multifocal tubular regeneration 
as shown by mitosis bodies along the epithelial line (arrows) in a fasted male mouse 28 days after 
37 minutes of IRI. (D) Multifocal severe acute tubular necrosis in ad libitum fed female mouse four 
days after 60 minutes of IRI. (E) Multifocal tubular regeneration in a fasted female mouse 28 days 
after 60 minutes of IRI.
To determine the effect on a biological level, functional annotation and pathway 
overrepresentation analyses of probe sets with FDR ≤ 5% and FC ≥ 1.5, were performed 
with Ingenuity software. The top up- and downregulated genes (FC ≥ 5) with corresponding 
P-values resulting from the functional annotation are provided as supplementary tables by age 
group (Table S1-S4). Pathway analysis in aged mice resulted in the highest overrepresented 
pathways being LXR/RXR Activation, Cholesterol Biosynthesis and Fatty Acid β-Oxidation 
(Table 1). The most overrepresented pathways in young-lean male mice were Cholesterol 
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Biosynthesis, NRF2-mediated Oxidative Stress Response and LXR/RXR Activation. Amongst 
the top 15 regulated pathways, six pathways are represented in both aged and young mice 
(Table 1), demonstrating the similarity of the individual pathway results.
The overlapping probe sets in both young and aged mice presumably contain those in the 
kidney that contribute to resistance to IRI. Therefore, the pathway overrepresentation was 
repeated for the 601 probe sets significantly expressed in both age groups (Table 2).  The 
top overrepresented pathways involve RXR Activation, Fatty Acid β-oxidation or NRF2-
mediated stress response, partly overlapping with the age group specific pathway analyses.
(A)            (B)     
 
	 Figure 5. Venn diagram and scatterplot of microarray data after fasting in young and aged 
mice. (A) Venn diagram of the significantly differentially up- and downregulated (FDR ≤ 5%, FC ≥ 
1.5) and overlapping probe sets in kidneys of three days fasted aged and young mice in comparison 
with normal fed control mice. (B) Scatter plot comparing up- and downregulated trends and their 
fold ratios of probe sets significantly regulated (FDR ≤ 5%) in young-lean (red), aged-overweight 
mice (black) or overlapping in both groups (green). Without fold change cut-off, 85% of the genes 
showed the same directionality in both age groups. The grey solid line represents the reference 
diagonal (ratio young = ratio aged); the grey dotted lines show the 1.5-fold change cutoffs applied 
in 5A.
Because of their relatively high fold change and their involvement in processes regulated by 
fasting found in the analysis, Pparα, Gst2, Cyp4a14 and Sc4mol were validated by qRT-PCR.
15045-jongbloed-layout.indd   31 06/11/2017   17:20
32
CHAPTER 2
Table 1. Top 15 canonical pathways in kidney of aged and young mice in response to fasting 
compared with ad libitum
Canonical Pathways AGED P-value Genes Ratio
LXR/RXR Activation 9.68E-08 17/139 12.2%)
Fatty Acid β-oxidation I 1.30E-07 9/45 (20.0%)
Superpathway of Cholesterol Biosynthesis 1.30E-07 9/87 (10.3%)
LPS/IL-1 Mediated Inhibition of RXR Function 6.08E-07 22/245 (9.0%)
Stereate Biosynthesis I (Animals) 6.32E-06 8/49 (16.3%)
Cholesterol Biosynthesis I/II/III 2.31E-05 5/40 (12.5%)
TR/RXR Activation 1.96E-04 10/109 (9.2%)
NRF2-mediated Oxidative Stress Response 2.96E-04 15/195 (7.7%)
Dopamine Degradation 5.84E-04 5/38 (13.2%)
Androgen Biosynthesis 5.91E-04 4/26 (15.4%)
Mevalonate Pathway I 7.87E-04 4/29 (13.8%)
Alanine Degradation III/Biosynthesis II 8.86E-04 2/6 (33.3%)
γ-linolenate Biosynthesis II (Animals) 1.31E-03 4/24 (16.7%)
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate) 2.04E-03 4/37 (10.8%)
Canonical Pathways YOUNG P-value Genes Ratio
Superpathway of Cholesterol Biosynthesis 1.19E-08 14/87 (16.1%)
NRF2-mediated Oxidative Stress Response 3.46E-07 35/195 17.9%)
LXR/RXR Activation 4.46E-07 27/139 19.4%)
Cholesterol Biosynthesis I/II/III 1.16E-06 8/40 (20.0%)
LPS/IL-1 Mediated Inhibition of RXR Function 6.87E-06 37/245 15.1%)
VDR/RXR Activation 8.03E-05 17/88 (19.3%)
Acute Phase Response Signaling 1.04E-04 28/181 15.5%)
Glucocorticoid Receptor Signaling 1.24E-04 38/299 12.7%)
Xenobiotic Metabolism Signaling 2.70E-04 38/288 13.2%)
AMPK Signaling 2.75E-04 23/181(12.7%)
Fatty Acid β-oxidation I 3.17E-04 9/45 (20.0%)
GADD45 Signaling 5.23E-04 7/24 (29.2%)
PPARα/RXRα Activation 5.39E-04 27/200 13.5%)
Production of Nitric Oxide and Reactive Oxygen Species 6.44E-04 27/212 12.7%)
FXR/RXR Activation 8.48E-04 16/110 14.5%)
Canonical pathways differentially regulated by 3-day fasting in kidneys from aged mice and young mice compared to their 
ad libitum controls. Pathways are ranked by their corresponding P-value. Genes Ratio is the number of genes significantly 
differentially regulated in the pathway.
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The qRT-PCR data confirmed the upregulation of Pparα, Gst2, Cyp4a14 with fold increases 
of 2.5, 8.0 and 106 respectively in young and 2.2, 3.4 and 147, respectively in aged kidneys. 
The downregulation of Sc4mol was also validated with qRT-PCR and showed a significant 
1.77-fold decrease in young and 1.72-fold in aged kidneys (Table 3).
Table 2. Top 15 canonical pathways overlapping in aged and young mice in response to fasting 
compared with ad libitum
Canonical Pathways OVERLAP P-value Genes Ratio
LPS/IL-1 Mediated Inhibition of RXR Function     7.85E-07 18/245 (7.3%)
LXR/RXR Activation 1.27E-06 13/139 (9.4%)
Fatty Acid β-oxidation I 2.00E-06 7/45 (15.6%)
Superpathway of Cholesterol Biosynthesis 2.85E-05 6/87 (6.9%)
Dopamine Degradation 1.10E-04 5/38 (13.2%)
Androgen Biosynthesis 1.50E-04 4/26 (15.4%)
Alanine Degradation III/Biosynthesis II 4.22E-04 2/6 (33.3%)
Retinoate Biosynthesis I 4.57E-04 5/37 (13.5%)
Stereate Biosynthesis I (Animals) 7.01E-04 5/49 (10.2%)
NRF2-mediated Oxidative Stress Response 1.29E-03 11/195 (5.6%)
Serotonin Degradation 1.56E-03 6/78 (7.8%)
TR/RXR Activation 1.84E-03 7/109 (6.4%)
FXR/RXR Activation 1.97E-03 7/110 (6.4%)
Cholesterol Biosynthesis I 2.12E-03 3/40 (7.5%)
Bile Acid Biosynthesis, Neutral Pathway 2.12E-03 3/58 (5.2%)
Canonical pathways overlapping in aged and young mice after 3-day fasting with their corresponding geometric mean P-value 
and the percentage of regulated genes.
DISCUSSION
With publications dating back 80 years, DR is one of the most extensively investigated 
interventions in biology18,19. Long-term DR leads to prolongation of health- and lifespan in 
many animal species11 as well as an increase in acute stress resistance20. Induction of organ 
ischemia is a widely used model to examine the effects of DR, since it has been shown to 
increase the resistance against ischemic injury in organs like heart and brain21,22.
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Previous research done in one of our laboratories showed that applying short periods of DR 
(two and four weeks 30% DR) as well as three days of fasting, conveyed strong protection 
against morbidity and mortality induced by IRI in the kidney as well as decreased morbidity 
and improved liver function in a non-lethal liver IRI model9,23,24.
Table 3. Validation via qRT-PCR of four genes found to be significant in the array analysis
Gene Aged (Affy) Aged - qPCR Young (Affy) Young - qPCR
Pparα 2.53/ 3.00E-09 2.5/6.83E-07 2.74/1.45E-05 2.2/0.0005
Gsta2 5.52/2.45E-08 8.0/3.12E-05 8.72/3.73E-05 3.4/1.52E-05
Cyp4a14 344.47/4.11E-09 106/6.16E-06 126.72/9.85E-07 147/0.0003
Sc4mol -2.64/5.16E-07 -1.77/0.005 -4.98/1.69E-06 -1.72/0.007
Fold ratios and corresponding p-values obtained via microarray analysis (Affy) and qRT-PCR (qPCR) of four genes found to be 
significant in the performed array analysis.
A drawback of the majority of reports is that for practical reasons the same animal model 
was utilized, namely healthy young (8-12 weeks) male mice of one genetic background 
(C57BL/6). These mice poorly represent the heterogeneous human population. In 
particular, this is valid for ECD whom are older and usually overweight. In this study, we 
showed that preoperative fasting strongly protects both male and female aged-overweight 
mice against renal IRI, with a significantly reduced mortality after IRI and better preserved 
kidney function and morphology. Compared to young mice, the recovery of body weight 
in fasted aged mice takes longer, probably at least in part due to their greater fat reserve and 
therefore reduced need to restore body weight in order to survive. Previously we observed 
that fasted young mice started eating shortly after surgery and showed a rapid increase in 
body weight. We showed that postoperative food intake and associated weight gain did 
not contribute to the observed protection9. The prolonged modest postoperative weight 
loss in the fasted aged mice provides additional evidence that postoperative feeding is not 
involved. In addition, the relative body weight loss in aged mice was less than in the young 
cohort, leaving these mice with more remaining body fat after fasting and IRI. These results 
indicate that weight loss and reduction of body fat coincide with but do not contribute to 
the protection against IRI induced by preoperative deprivation of food. 
We compared and analyzed the overlap of gene expression data of young and aged mice via 
microarray analysis, narrowing down genes and pathways possibly involved in the effect 
of fasting. We found a striking corresponding directionality in overlapping genes of both 
groups with the changes being more pronounced and more often significant in the young 
group. Possibly, aged organs and tissues are not able to mount a more vigorous response as 
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seen in young animals. Alternatively, or in addition, it could be that fasting of overweight 
mice triggers less extreme responses because of the presence of larger reserves. Taken 
together, the survival and kidney function data as well as the gene expression findings 
suggest that fasting has a more robust effect in young mice, although in aged mice it is still 
sufficient to induce a protective effect against IRI.
Although ECD are getting more and more accepted as an alternative for optimal donors, 
the outcome after transplantation of an ECD kidney is worse, with higher risks of DGF, 
acute rejection and graft failure25. Since age is a factor that cannot be influenced, reducing 
the consequences of ischemia is all the more warranted. To elucidate the mechanisms 
responsible for the protective effect induced by fasting, we performed microarray analysis 
after fasting. Our analysis revealed several interesting pathways regulated in kidneys from 
both young-lean and aged-overweight male mice, thereby being independent of age, 
weight and genetic background. After clustering of the pathways according to their known 
or predicted biological function, three biological processes stood out, namely: retinol 
biosynthesis, fatty acid oxidation and the stress response pathway Nrf2 (see Tables 1 and 
2). Upregulation of the retinoid X receptors (RXRs) together with retinol biosynthesis 
was responsible for over a quarter of all overrepresented pathways. RXRs are able to 
bind with multiple factors like the peroxisome proliferator-activated receptors (PPARs). 
Depending on the different complexes made, RXRs are involved in many processes. They 
are able to reduce inflammatory processes and contribute to the reduction of the acute 
phase response, an inflammatory response occurring after invasive surgery resembling 
renal IRI26.  Activation of RXR also stimulates fatty acid oxidation and transport and is 
thus partially responsible for the enrichment in fatty acid pathways found after short-term 
fasting, leading to reduced fat synthesis and storage and increased oxidation in order to 
burn fat for the production of energy as part of a redesign of metabolic processes upon 
lack of food27. Nrf2 and genes involved in the Nrf2-pathway were found to be significantly 
upregulated in kidneys of both young and aged mice after three days of fasting, although 
less pronounced in the aged cohort. Nrf2, nuclear factor-erythroid 2 p-45 related factor 2, 
is known to have both anti-oxidant and anti-inflammatory features and, more specific to 
IRI, a deficiency of Nrf2 leads to aggravation of ischemic injury in mice28-30. Previously, 
we showed that a downstream product of Nrf2, heme oxygenase 1 (HO-1), is markedly 
increased by 3-day fasting in young mice9. Together with the pronounced Nrf2-mediated 
oxidative stress response pathway found in the current analysis, Nrf2 is likely involved in 
the stress resistance phenotype after DR in both young-lean and aged-overweight mice. It 
was recently shown that a Nrf2 activator, CDDO-imidazolide, is able to improve survival 
after a renal IRI model in mice, inducing similar outcome found with fasting in our mouse 
model31. Whether Nrf2 induction would lead to the same beneficial effects induced by DR 
and would be safe and feasibly in the clinic, is to be elucidated.
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The upregulation of pathways involved in stress resistance suggests that DR induces a 
protective state. In addition, we previously showed in young animals that this protection was 
associated with decreased levels of oxidative injury, cytokine production and inflammation 
and at six hours after IRI, levels of the pro-inflammatory cytokine interleukin 6 (IL-6) were 
significantly lower in DR compared to ad libitum fed mice9,24. These early effects support 
the concept that DR preconditions a protective stress response resulting in a better recovery 
rather than a faster recovery per se.
In summary, we have shown that fasting induces a robust protection against renal IRI in 
aged-overweight F1-FVB/C57BL6-hybrid mice as it does in young-lean C57BL/6 mice. 
These findings suggest a general protective response induced by DR against IRI regardless 
of age, gender, body weight and genetic background. Gene expression profiles of kidneys 
of both young and aged mice after fasting show the involvement of retinol biosynthesis as 
well as stress response pathways. Whether these effects are cell-autonomous or influenced 
by systemic factors remains unknown and needs further clarification. Finally, contrary to 
common believe short-term preoperative DR rather than hyper alimentation improves 
stress resistance and recovery from surgically induced renal IRI. Therefore, translation of 
preoperative DR to the clinic seems to be the next logical step, whereby older and overweight 
patients do not have to be excluded from its benefits.
MATERIALS AND METHODS
Ethics statement
All animal experiments are done according to the Dutch National Experiments on Animal 
Act via the EU adopted Directive 86/609/EEC (1986) and had the approval of the local Animal 
Experiments Committee of the National Institute of Public Health and the Environment 
(RIVM), the Netherlands (protocol number: 201100308). To ameliorate suffering of 
the animals, the mice were given 0.5 ml PBS supplemented with 2.4 µg buprenorphine 
after surgery in order to compensate for fluid loss and provide analgesia and an identical 
analgesic dose of buprenorphine was administered in the morning after surgery. The 
method of sacrifice was exsanguination, done under anesthesia by intramuscular injection 
of a Ketamine–Rompun mixture. 
Animals
All aged mice were bred, raised and kept under identical SPF conditions as described32. 
Male (n=16) and female (n=22) wild type FVB-C57BL/6J F1-hybrid mice, with an average 
age of 72 and 74 weeks and average weight of 48.0 and 47.4 grams, respectively, were used. 
Animals were kept under standard laboratory conditions (temperature ± 20°C, 12-hour 
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light/12-hour dark) with either one animal (male) or two animals (females) per cage 
and were allowed free access to water and food (Special Diet Services, UK) unless noted 
otherwise. The conditions of and procedures done in the young male C57BL/6J mice are 
described elsewhere9.
Preoperative fasting
Mice were pair-matched based on body weight and sex. Subsequently, the animals were 
randomly assigned to one of two groups. The first group had unlimited access to food and 
water preoperatively. The average amount of food eaten in the ad libitum fed male and 
female group was approximately 5.7 and 4.4 grams/day respectively. The second group was 
fasted for three days preoperatively with no access to food and unlimited access to water. 
Fasted animals did not show any morbidity due to the fasting. Directly after surgery, all 
mice had unlimited access to food and water. For the microarray analysis, 10 other male 
mice were also assigned to either ad libitum food or fasting for three days, after which the 
mice were sacrificed.  
Surgical procedure
Renal IRI was performed as described previously9,14. In brief, mice were anesthetized by 
isoflurane inhalation (5% isoflurane initially and then 2-2.5% with oxygen for maintenance). 
A midline abdominal incision was performed and the renal artery and vein of both kidneys 
were exposed. In the male mice, the pedicles of both kidneys were occluded for 37 minutes. 
As female mice are more resistant to ischemic renal damage33,34, the ischemic time in female 
mice was extended to 60 minutes. Purple discoloration of the kidneys confirmed ischemia 
macroscopically. After removal of the clamps, reperfusion was confirmed when the kidney 
color turned back to normal. The incision was closed in two layers with 5/0 sutures. After 
closure, the animals were subcutaneously injected with 0.5 ml PBS supplemented with 
2.4 µg buprenorphine in order to compensate for fluid loss and provide analgesia. An 
identical analgesic dose of buprenorphine was administered in the morning after surgery 
to ameliorate suffering. The mice used for microarray analysis did not undergo renal IRI, 
instead were sacrificed right after the dietary intervention. 
Follow-up and serum measurements
The animals were followed up to 28 days postoperatively unless they died or were sacrificed 
as a result of morbidity (ruffled fur, decreased mobility, cold to the touch, excessive weight 
loss), or noted otherwise. During follow-up, they were inspected at least daily. Body weight 
was measured daily in the first postoperative week and on day 10, 14, 17, 21 and 28 if 
applicable. At day 28, all remaining animals were euthanized after which the abdominal 
cavity was opened for inspection of the kidneys. A blood sample of 50 μl was collected 
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by orbital puncture while the animals were anesthetized as well as on postoperative day 
1, 2, 3, 7 and 28 if applicable. Serum urea and creatinine levels were measured using the 
QuantiChrom™ assay kits (DIUR-500 and DICt-500, Gentaur Europe, Brussels, Belgium). 
Statistical analysis was performed with IBM SPSS statistics version 20.0, GraphPad Prism 
version 5.0, R software and/or Microsoft Excel. Statistical significance was defined as P<0.05 
unless noted otherwise. For assessment of the kidney function, the one-way ANOVA was 
used including the Bonferroni test for multiple comparisons. Means were compared using 
either the non-parametric Mann-Whitney U test or the independent t-test for parametric 
data. The survival curves were compared using the Log-rank (Mantel-Cox) test and 
visualized by the Kaplan-Meier curve.
Histology
After euthanasia, both kidneys were harvested. Half of the left and the right kidney of 
each mouse were fixed in formalin for histological analysis in Hematoxylin and Eosin 
(HE) stained sections. Kidneys were analyzed in a blinded manner. Semi-quantitative 
scoring of the severity of the lesions was performed for acute tubular necrosis (0-5) and 
tubular epithelial regeneration (0-4). Scores were defined as: 0= none; 1=minimal; 2=mild; 
3=moderate; 4=marked and, if applicable, 5=severe necrosis or regeneration. Pathology 
scores were analyzed with the Kruskal-Wallis test for K independent samples and the 
Dunn’s test for multiple comparisons.
Microarray analysis
Of the 10 male mice used for microarray analysis, half of both the left and the right kidney 
(taken in longitudinal direction) were snap frozen in liquid nitrogen until further analysis 
directly after fasting. For gene expression analysis, total RNA was extracted from frozen 
kidney tissue using the QIAzol lysis Reagent and miRNAeasy Mini Kit (QIAGEN, Hilden, 
Germany), as described in the Qiagen protocol (males: fasted n=5, ad libitum n=5). Addition 
of wash buffers RPE and RWT (QIAGEN) was done mechanically by using the QIAcube 
(QIAGEN, Hilden, Germany) via the miRNeasy program. RNA was eluted in RNase free 
water and stored at -80°C. The concentration of RNA was measured by Nanodrop (Thermo 
Scientific). Quality assessment of the RNA was done using the 2100 Bio-Analyzer (Agilent 
Technologies, Amstelveen, the Netherlands). The quality of the RNA is expressed as the 
RNA integrity number (RIN, range 0-10). Samples with a RIN below 8 were excluded from 
analysis. RNA was further processed for hybridization to Affymetrix HT MG-430 PM Array 
Plates at the Microarray Department of the University of Amsterdam, the Netherlands 
according to Affymetrix protocols. Four to six biological replicates were used for each 
group. Quality control and normalization were performed using the pipeline at the www.
arrayanalysis.org website (Maastricht University, the Netherlands). Normalization was done 
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via the Robust Multichip Average (RMA) algorithm. Normalization output consisted of data 
for 45,141 probe sets, with several probe sets corresponding to the same Entrez Gene ID. 
Complete raw and normalized microarray data and their MIAME compliant metadata have 
been deposited at GEO (www.ncbi.nlm.nih.gov/geo) under accession number GSE52982. 
Gene expression data were compared using ANOVA with correction for multiple testing 
using the false discovery rate (FDR) according to Benjamini and Hochberg35. Fold changes 
are expressed as the geometric mean per fasted group against the corresponding ad libitum 
group. Cutoff values for a significant difference were put at FDR < 5%. Functional annotation 
and overrepresentation analyses were performed with Ingenuity software (http://www.
ingenuity.com/products/ipa).  For comparison analysis with young male mice, the same 
procedure was performed in kidney tissue of male C57BL/6J mice (fasted n=4, ad libitum 
fed n=5). For the analyses done in the genes overlapping between aged-overweight and 
young-lean male mice, the mean fold ratios and geometric mean p-values of both groups 
were used. No female mice were available for the microarray analysis in young and aged 
mice.
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SUPPLEMENTARY DATA 
Table S1. Top genes upregulated in aged mice fasted for three days
Genes AGED upregulated Symbol Log FR P-value
Cytochrome P450, family 4, subfamily a, polypeptide 14 Cyp4a14 5.842 5.46E-06
3-hydroxy-3-methylglutaryl-CoA synthase 2 HMGCS2 5.125 1.48E-06
Phosphoenolpyruvate carboxykinase 1 PCK1 3.260 1.83E-04
Acyl-CoA thioesterase 1 ACOT1 2.609 6.18E-06
Pyruvate dehydrogenase kinase, isozyme 4 PDK4 2.508 2.44E-03
Solute carrier family 38, member 3 SLC38A3 2.365 5.57E-05
Cytochrome P450, family 4, subfamily a, polypeptide 11 Cyp4a11 2.250 2.15E-05
Mitochondrial amidoxime reducing component 1 MARC1 2.209 6.23E-03
WD repeat and SOCS box containing 1 WSB1 2.020 3.64E-06
Inhibitor of DNA binding 1 ID1 1.937 6.18E-06
Kv channel-interacting protein 2 Kcnip2 1.913 6.50E-06
inhibitor of DNA binding 3 ID3 1.903 7.35E-06
acyl-CoA thioesterase 1 Acot1 1.902 4.94E-06
betaine--homocysteine S-methyltransferase BHMT 1.890 2.60E-02
insulin-like growth factor binding protein 1 IGFBP1 1.860 8.55E-03
group-specific component (vitamin D binding protein) GC 1.853 3.60E-03
apolipoprotein D APOD 1.808 3.82E-03
fibrinogen alpha chain FGA 1.802 9.00E-04
microsomal glutathione S-transferase 1 MGST1 1.792 6.30E-06
nuclear factor, erythroid 2-like 2 NFE2L2 1.767 4.56E-03
fibrinogen gamma chain FGG 1.766 1.29E-02
complement component 3 C3 1.756 1.18E-04
aldehyde dehydrogenase family 1, subfamily A7 Aldh1a7 1.722 2.02E-06
glutathione S-transferase alpha 5 GSTA5 1.708 1.63E-05
amylase, alpha 1A (salivary) AMY1A 1.706 1.16E-03
acyl-CoA thioesterase 2 ACOT2 1.705 1.48E-06
ATP-binding cassette, sub-family B (MDR/TAP), member 1B Abcb1b 1.662 5.84E-06
aldehyde dehydrogenase 1 family, member A1 ALDH1A1 1.655 4.12E-05
arginase 2 ARG2 1.641 8.57E-05
cytochrome c oxidase subunit VIb polypeptide 2 (testis) COX6B2 1.624 1.98E-06
Top gene lists of upregulated genes in aged-overweight mice fasted for three days, with corresponding symbols, log fold ratios 
and P-values. All genes with a fold change >5 (log fold ratio (-)1.609) are listed.
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Table S2. Top genes downregulated in aged mice fasted for three days
Genes AGED downregulated Symbol Log FR P-value
Solute carrier family 22, member 7 SLC22A7 -2.670 7.74E-05
Major facilitator superfamily domain containing 2A MFSD2A -2.357 2.03E-04
Solute carrier family 8, member 1 SLC8A1 -2.302 1.76E-04
Antisense Igf2r RNA Airn -2.097 1.17E-05
Midkine MDK -1.850 2.84E-04
Branched chain amino-acid transaminase 1 BCAT1 -1.686 1.64E-03
Carbonix anhydrase IV CA4 -1.680 2.62E-06
Isopentenyl-disphosphate delta isomerase 1 IDI1 -1.674 2.25E-05
Solute carrier family 9, subfamily A, member 8 SLC9A8 -1.647 1.29E-06
Ring finger protein 183 RNF183 -1.606 6.58E-05
Top gene lists of downregulated genes in aged-overweight mice fasted for three days, with corresponding symbols, log fold 
ratios and P-values. All genes with a fold change >5 (log fold ratio (-)1.609) are listed.
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Table S3. Top genes upregulated in young mice fasted for three days
Genes YOUNG upregulated Symbol Log 
FR
P-value
3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) HMGCS2 5.227 1.69E-07
cytochrome P450, family 4, subfamily a, polypeptide 14 Cyp4a14 4.842 9.85E-07
carbonyl reductase 3 CBR3 3.565 4.18E-08
aldehyde dehydrogenase 1 family, member A1 ALDH1A1 3.307 5.82E-09
pyruvate dehydrogenase kinase, isozyme 4 PDK4 3.071 4.25E-07
cell death-inducing DFFA-like effector a CIDEA 2.841 2.45E-02
receptor accessory protein 6 REEP6 2.757 2.82E-07
aldehyde dehydrogenase family 1, subfamily A7 Aldh1a7 2.625 2.57E-07
phosphoenolpyruvate carboxykinase 1 (soluble) PCK1 2.608 5.70E-05
acyl-CoA thioesterase 1 ACOT1 2.590 8.71E-07
arbonyl reductase 1 CBR1 2.573 8.78E-08
nuclear factor, erythroid 2-like 2 NFE2L2 2.573 2.00E-07
cytochrome P450, family 2, subfamily d, polypeptide 22 Cyp2d22 2.531 1.21E-07
fibrinogen gamma chain FGG 2.508 2.66E-06
solute carrier family 25, member 25 SLC25A25 2.507 5.74E-06
atonal homolog 7 (Drosophila) ATOH7 2.478 3.35E-08
solute carrier family 38, member 3 SLC38A3 2.456 4.25E-07
group-specific component (vitamin D binding protein) GC 2.437 5.65E-06
monoamine oxidase B MAOB 2.363 1.67E-05
mitochondrial amidoxime reducing component 1 MARC1 2.270 1.94E-05
arginase 2 ARG2 2.180 3.60E-06
complement component 3 C3 2.176 9.85E-07
glutathione S-transferase alpha 5 GSTA5 2.166 3.73E-05
fibrinogen alpha chain FGA 2.086 2.12E-05
lectin, galactoside-binding, soluble, 4 LGALS4 2.051 5.67E-06
insulin-like growth factor binding protein 1 IGFBP1 2.035 1.03E-03
CCR4 carbon catabolite repression 4-like (S. cerevisiae) CCRN4L 2.006 8.54E-05
perilipin 5 PLIN5 1.981 1.05E-06
abhydrolase domain containing 15 ABHD15 1.964 3.11E-07
paternally expressed 3 PEG3 1.947 1.97E-05
retinol dehydrogenase 1 (all trans) Rdh1 1.916 4.25E-07
early growth response 1 EGR1 1.901 2.54E-02
pyridoxal (pyridoxine, vitamin B6) kinase PDXK 1.894 1.15E-05
betaine--homocysteine S-methyltransferase BHMT 1.886 4.91E-03
15045-jongbloed-layout.indd   45 06/11/2017   17:20
46
CHAPTER 2
Table S3. (continued)
Genes YOUNG upregulated Symbol Log 
FR
P-value
suprabasin SBSN 1.879 5.74E-06
cold inducible RNA binding protein CIRBP 1.875 1.38E-05
regulation of nuclear pre-mRNA domain containing 2 RPRD2 1.850 3.04E-06
period circadian clock 1 PER1 1.848 4.56E-05
RIKEN cDNA 6030422H21 gene 6030422H21Rik 1.847 2.93E-03
retinol saturase (all-trans-retinol 13,14-reductase) RETSAT 1.825 8.77E-07
chromosome 10 open reading frame 10 C10orf10 1.822 2.73E-03
inhibitor of DNA binding 1 ID1 1.814 4.89E-07
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, 
candidate 12
ALS2CR12 1.814 1.21E-04
cytochrome P450, family 4, subfamily A, polypeptide 11 CYP4A11 1.792 3.47E-07
cytochrome c oxidase subunit VIIIb Cox8b 1.769 4.64E-02
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 1.764 1.10E-06
angiopoietin-like 4 ANGPTL4 1.748 2.64E-05
zinc finger CCCH-type containing 6 ZC3H6 1.743 7.07E-06
solute carrier family 22 (organic anion transporter), member 8 SLC22A8 1.730 3.19E-05
Kv channel-interacting protein 2 Kcnip2 1.702 5.03E-07
ganglioside-induced differentiation-associated-protein 10 Gdap10 1.690 5.67E-06
NAD(P)H dehydrogenase, quinone 1 NQO1 1.688 7.41E-07
ATP-binding cassette, sub-family B (MDR/TAP), member 1B Abcb1b 1.686 3.40E-07
acyl-CoA thioesterase 2 ACOT2 1.679 1.55E-05
FBJ murine osteosarcoma viral oncogene homolog FOS 1.660 4.41E-02
2-hydroxyacyl-CoA lyase 1 HACL1 1.660 5.67E-06
DAZ interacting zinc finger protein 1 DZIP1 1.657 1.08E-03
butyrobetaine, 2-oxoglutarate dioxygenase 1 BBOX1 1.656 7.42E-07
amylase, alpha 1A AMY1A 1.644 6.26E-06
ceruloplasmin (ferroxidase) CP 1.641 4.15E-06
fatty acid binding protein 4, adipocyte FABP4 1.640 1.16E-04
G0/G1switch 2 G0S2 1.629 1.05E-06
vanin 1 VNN1 1.621 4.25E-07
ethanolamine-phosphate phospho-lyase ETNPPL 1.617 5.58E-06
apolipoprotein D APOD 1.617 6.81E-04
Top gene lists of upregulated genes in young-lean mice fasted for three days, with corresponding symbols, log fold ratios and 
P-values. All genes with a fold change >5 (log fold ratio (-)1.609) are listed.
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Table S4. Top genes downregulated in young mice fasted for three days
Genes YOUNG downregulated Symbol Log 
FR
P-value
Solute carrier family 22, member 7 SLC22A7 -3.713 8.28E-08
Kinesin family member 20B KIF20B -3.379 4.11E-06
Hydroxy-delta-5-steroid dehydrogenase 3, beta- and steroid-isomerase 1 HSD3B1 -2.950 1.04E-06
Branched chain amino-acid transaminase 1 BCAT1 -2.838 1.94E-05
Histone cluster 2, H3c HIST2H3C -2.818 5.05E-07
major facilitator superfamily domain containing 2A MFSD2A -2.756 1.27E-04
isopentenyl-diphosphate delta isomerase 1 IDI1 -2.712 2.96E-08
solute carrier family 9, subfamily A, member 8 SLC9A8 -2.679 1.07E-07
gamma-aminobutyric acid (GABA) A receptor, beta 3 GABRB3 -2.502 1.25E-05
solute carrier family 7, member 13 SLC7A13 -2.418 3.09E-02
heat shock transcription factor 2 binding protein HSF2BP -2.337 7.43E-07
myosin VA (heavy chain 12, myoxin) MYO5A -2.334 5.95E-06
synapsin III SYN3 -2.324 4.15E-06
collagen, type III, alpha 1 COL3A1 -2.229 1.05E-06
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 ST8SIA1 -2.212 7.42E-07
chemokine ligand 9 CXCL9 -2.184 1.17E-04
ornithine decarboxylase 1 ODC1 -2.106 4.25E-07
cytochrome P450, family 51, subfamily A, polypeptide 1 CYP51A1 -2.088 2.82E-07
family with sequence similarity 151, member A FAM151A -2.018 5.95E-06
GRB10 interacting GYF protein 2 GIGYF2 -1.968 6.45E-06
aldo-keto reductase family 1, member C3 AKR1C3 -1.943 1.11E-04
C1q and tumor necrosis factor related protein 3 C1QTNF3 -1.943 1.60E-06
midkine (neurite growth-promoting factor 2) MDK -1.937 6.72E-05
kinesin family member 12 KIF12 -1.928 8.78E-08
SLIT and NTRK-like family, member 6 SLITRK6 -1.890 9.74E-05
McKusick-Kaufman syndrome MKKS -1.843 2.30E-05
3-hydroxy-3-methylglutaryl-CoA reductase HMGCR -1.838 7.06E-06
solute carrier family 35, member F1 SLC35F1 -1.809 6.67E-07
solute carrier family 34, member 3 SLC34A3 -1.782 3.50E-05
C-type lectin domain family 2, member h Clec2h -1.780 7.84E-05
guanylate binding protein 6 Gbp6 -1.778 1.10E-04
solute carrier family 8, member 1 SLC8A1 -1.770 6.25E-06
UDP-Gal:beta GlcNAc beta 1,4- galactosyltransferase, polypeptide 5 B4GALT5 -1.755 6.58E-07
protein Z, vitamin K-dependent plasma glycoprotein PROZ -1.745 9.18E-07
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Table S4. (continued)
Genes YOUNG downregulated Symbol Log 
FR
P-value
centromere protein J CENPJ -1.737 1.24E-06
histone cluster 1, H2ab Hist1h2ab -1.708 5.22E-05
UDP glucuronosyltransferase 2 family, polypeptide B15 UGT2B15 -1.680 6.53E-04
annexin A13 ANXA13 -1.678 1.23E-04
glycerate kinase GLYCTK -1.611 7.42E-07
Top gene lists of downregulated genes in young-lean mice fasted for three days, with corresponding symbols, log fold ratios and 
P-values. All genes with a fold change >5 (log fold ratio (-)1.609) are listed.
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THE TRANSCRIPTOMIC RESPONSE TO IRINOTECAN 
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ABSTRACT
Irinotecan use is limited due to severe toxicity. Fasting protects against side effects of 
irinotecan while preserving its antitumor activity. The mechanisms underlying the effects 
of fasting still need to be elucidated. Here, we investigated the transcriptional responses 
to fasting and irinotecan in both tumor and healthy liver tissue. Male BALB/c mice 
were subcutaneously injected with C26 colon carcinoma cells. Twelve days after tumor 
inoculation, two groups were fasted for three days and two groups were allowed food ad 
libitum (AL). Within each diet group, one group received irinotecan intraperitoneally, the 
other vehicle. Twelve hours after injection mice were sacrificed, and blood, tumor and liver 
tissue were harvested. Blood samples were analyzed for side effects, tissues were used for 
microarray analyses. The AL irinotecan group had worsened organ function and leukocyte 
numbers. These effects were abated in fasted animals. A dampened transcriptional response 
to irinotecan was observed in liver of fasted compared to AL fed mice, including a decreased 
inflammatory and increased stress resistance response. Tumor tissue did not show a 
homogeneous response amongst groups. The transcriptional response after fasting as seen 
in liver was absent in tumor tissue. Fasting reduces toxicity of irinotecan by inducing a 
protective stress response in healthy liver but not in tumor tissue. These data further help 
to unravel the mechanisms involved in the effects of fasting on chemotherapeutic side 
effects and preservation of antitumor activity, and pave the way to improve outcome of 
chemotherapeutic treatment in cancer patients.
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PROTECTION OF FASTING ON IRINOTECAN TOXICITY
INTRODUCTION
Colorectal cancer (CRC) is the second most diagnosed cancer in women and the third 
most diagnosed in men. Estimated new colorectal cancer cases account for 1.4 million 
cases and 693,900 deaths worldwide occurring in 20121. At initial presentation, 15-20% of 
patients already has liver metastases and another 45% is diagnosed with liver metastases 
in the follow-up after resection of the primary tumor2. Irinotecan is a pro-drug of the 
topoisomerase-I inhibitor SN-38, and is applied in first and second line chemotherapy 
treatment for colorectal carcinoma3,4. Irinotecan can induce severe and unpredictable 
side effects including myelosuppression, diarrhea, and in some cases even death as a 
complication of side effects5. 
Dietary restriction (DR) is a method to trigger highly conserved survival mechanisms that 
enhance the resistance of organisms against stressors and diseases6. We recently showed 
that 3-day fasting prior to a toxic dose of irinotecan significantly prevented the occurrence 
of side effects in Apc-mutant mice7. Furthermore, tumor size and proliferation were 
reduced equally in ad libitum (AL) fed and fasted animals. Levels of the active metabolite 
of irinotecan, SN-38, were significantly lower in plasma and liver tissue from fasted mice, 
indicating that dietary precondition was able to reduce the systemic toxicity of SN-38 while 
the phenotypic effect on tumor tissue remained unaltered7,8. These data support the concept 
of differential stress resistance (DSS), which states that tumor cells are unable to elicit a 
protective response since they remain driven towards growth due to mutations in onco- 
and tumor suppressor genes8,9. However, the molecular mechanisms that govern these 
processes remain largely unknown.
Insight into these mechanisms could facilitate translational research into the clinic 
since it may reveal alternative approaches to DR such as specialized forms of DR or DR 
mimetics which may induce similar effects without the disadvantages of fasting, including 
additional body weight loss in cancer patients. Therefore, in this study we investigated the 
transcriptional responses to fasting and irinotecan exposure in tumor and in healthy liver 
tissue.
RESULTS
Fasting induces a chemoprotective phenotype in the liver
Male BALB/c mice with subcutaneously injected C26 colon carcinoma tumors were 
divided in two groups of six mice each. One group was housed under AL food conditions, 
while the other group was fasted for three days prior to irinotecan administration. After 
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administration of either vehicle or irinotecan, all mice were fasted for two hours, after 
which they were given AL access to food for 10 hours until the moment of sacrifice. Food 
intake during this period was measured by weighing the food before and afterwards. The 
mice in both AL groups, AL vehicle and AL irinotecan, ate around three grams per mouse 
in this 10-hour period. The fasting vehicle group had the highest food intake, 4.3 grams per 
mouse, whereas the fasted irinotecan mice had an average intake of 3.5 grams per mouse. 
The systemic toxic effects of irinotecan and the effects of fasting were analyzed via markers of 
common (LDH) and liver specific (ALT and AST) cellular injury, and kidney function (urea 
and creatinine). Levels of these markers in the serum increase upon cell damage and death. 
Leukocyte numbers were determined as markers of bone marrow toxicity.  Administration 
of irinotecan increased markers of both liver (Figure 1A), and kidney injury (Figure 1B). 
These increases were suppressed in the fasted animals that received irinotecan. 
A common side effect of irinotecan therapy is depletion of white blood cells from the 
blood. Irinotecan treatment caused a significant depletion of white blood cells, which was 
also ameliorated by fasting (Figure 1C).  Collectively, these results demonstrate successful 
replication of the fasting induced chemo-protective phenotype in the liver as described 
before10.
Liver transcriptome analysis
Principal component analysis 
To investigate variability between and within our experimental groups, we performed an 
unbiased principal component analysis (PCA) including all probe sets in the microarray of 
liver and tumor tissue samples. In the PCA plot of the liver samples, 50.77% of the variance 
was explained by principal component (PC) 1 and 16.81% by PC2 (Figure 2A). A pattern 
of distinct clustering of the four individual groups was seen, with the smallest intragroup 
variability in the fasting vehicle group. Using the AL vehicle group as reference, the fasting 
vehicle and fasting irinotecan groups diverged mainly by PC1, while the difference with the 
AL irinotecan group was for the most part by PC2. The fasting irinotecan group differed 
almost exclusively by PC1 from AL vehicle, in direction and distance similar to that of 
fasting vehicle, making fasting vehicle and fasting irinotecan the two groups in closest 
proximity. These data point towards a more differential regulated and homogeneous 
response to irinotecan in the liver due to fasting.
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Figure 1. (A) Liver function of the different experimental groups, measured via serum AST, 
ALT and LDH levels. (B) Measurement of kidney function of the experimental groups via serum 
urea and creatinine levels. (C) Leukocyte numbers of all the experimental groups. All values 
correspond to time point 12 hours after administration of either vehicle or irinotecan. AST = 
aspartate transaminase, ALT = alanine transaminase, LDH = lactate dehydrogenase. *= P<0.05, 
**= P<0.01. 
Expression profiles 
To compare expression profiles between the different experimental groups, the numbers of 
differentially expressed probe sets (DEPS) were calculated. In the liver, 2,667 DEPS were 
found between the AL vehicle and AL irinotecan group, with 1,144 DEPS downregulated 
and 1,523 upregulated (Figure 2B). The number of DEPS between fasting vehicle and 
fasting irinotecan was 754, a 3.5-fold lower number than found in the AL vehicle and AL 
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irinotecan comparison. Of these 754 genes, 459 DEPS were downregulated and 295 were 
upregulated. To analyze common expression patterns between the AL and fasting groups, 
the overlapping DEPS were visualized using a Venn diagram and a scatterplot. The Venn 
diagram showed that 329 DEPS overlapped between the AL irinotecan and fasting irinotecan 
groups, corresponding to 44% of the DEPS found after fasting, and only 14% of the DEPS 
after AL vehicle vs. AL irinotecan (Figure 2C). Directionality and expression intensity of 
the unique and overlapping genes were visualized in a scatterplot. This scatterplot showed 
that 83% of all DEPS had a similar directionality in both comparisons, but fold change 
expressions of the AL irinotecan groups (red symbols) were on average higher than the 
fasting irinotecan groups (green symbols). Of the overlapping DEPS (black symbols), 
99% had a similar directionality (Figure 2D). Collectively, these results point towards a 
dampened response upon irinotecan exposure in the fasted group compared to that found 
in AL fed mice. 
Pathway analyses
To explore the pathways regulated by irinotecan, the 2,667 DEPS resulting from the 
comparison of AL vehicle with AL irinotecan were analyzed. A total of 20 pathways were 
found to be regulated, defined as pathways with a significant P-value of <0.05 and a z-score 
of ≥1 or ≤-1 (Table 1A). Of these 20 pathways, 17 were activated and three were inhibited. 
Analysis of these pathways resulted in an image of an activated genotoxic response. This 
genotoxic response revealed itself via the activation of multiple pathways involved in 
intracellular and second messenger signaling, including the RhoA DNA damage pathway. 
Both cellular stress and cytokine signaling pathways were activated as well, of which 
most notable eIF2 and interleukin signaling. Apoptosis was stimulated via activation of 
MAPK signaling. A similar pathway analysis between the fasting groups was performed 
after exposure to irinotecan which revealed 39 pathways, of which 35 were downregulated 
and four were upregulated (Table 1B). In contrast to the response in the AL fed animals, 
an overall inhibition of the response was shown. Comparison of the regulated pathways 
between the AL groups and the fasting groups revealed a near opposite image (Table 1).
Especially cytokine signaling and cellular immune response appeared downregulated, 
including chemokine signaling and the IL-8 signaling pathway. Irinotecan exposure in a 
fasting state also resulted in an inhibition of cellular growth and proliferation, including 
the inhibition of P70S6K signaling, indicating a decrease in activity of the nutrient-sensor 
mammalian target of rapamycine (mTOR). Xenobiotic metabolism appears reduced via 
an inhibition of the aryl hydrocarbon receptor (AHR) pathway, while the stress resistance 
inducing NRF2-pathway was upregulated.
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Figure 2. (A) Unbiased principal component analyses (PCA) of liver samples, based on all 
probe sets in the microarray. Principal component (PC) 1 is depicted on the x-axis and PC2 is 
depicted on the y-axis, including the percentage of variance explained by each PC. Each symbol 
represents one sample of one mouse. Samples of the same group are shown in the same color. AL 
= ad libitum. (B) Number of significantly differentially expressed probe sets (DEPS) in livers of 
AL and fasted mice. (C) Venn diagram of overlapping DEPS due to irinotecan exposure in AL and 
fasted mice. (D) Scatterplot of probe set fold expression changes with false discovery rates of 5% or 
less after irinotecan administration in liver of either AL fed mice (x-axis) or fasted mice (y-axis). 
Red symbols = AL groups; green symbols = fasting groups; black symbols = overlapping DEPS.
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Table 1. Overview of the top overrepresented canonical pathways in liver ranked by their P-value
Canonical Pathway Pathway classification P-value Genes Ratio Z-score
Liver – AL vehicle vs. AL irinotecan
Signaling by Rho Family GTPases Intracellular and second messenger signaling 4.99E-03 34/248 (13.7%) +3.128
LPS/IL-1 Mediated Inhibition of 
RXR Function
Nuclear Receptor Signaling 2.74E-03 32/221 (14.5%) +2.840
RhoA Signaling Intracellular and second messenger signaling 1.02E-02 19/124 (15.3%) +2.668
EIF2 Signaling Intracellular and second messenger signaling; 
cellular stress and injury; cellular growth and 
proliferation and development
9.16E-03 30/221 (13.6%) +2.500
Role of NFAT in Cardiac 
Hypertrophy
Cardiovascular Signaling 4.72E-03 28/193 (14.5%) +2.000
Ephrin Receptor Signaling Organismal growth and development; 
neurotransmitter and other nervous system 
signaling
2.12E-03 27/174 (15.5%) +1.789
Sumoylation Pathway Cellular stress and injury; cellular growth and 
proliferation and development
1.36E-03 18/96 (18.8%) +1.604
IL-1 signaling Cytokine Signaling 5.31E-03 16/92 (17.4%) +1.604
Integrin Signaling Cell cycle regulation; intracellular and second 
messenger signaling; cellular growth and 
proliferation and development
8.08E-03 30/219 (13.7%) +1.512
Remodeling of Epithelial Adherens 
Junctions
Cellular growth and proliferation and 
development
3.40E-02 11/69 (15.9%) +1.414
LPS-stimulated MAPK Signaling Apoptosis 3.61E-02 13/87 (14.9%) +1.387
fMLP Signaling in Neutrophils Cytokine signaling; cellular immune response 1.25E-04 24/123 (19.5%) +1.279
NRF2-mediated Oxidative Stress 
Response
Cellular stress and injury 4.55E-02 24/193 (12.4%) +1.291
IL-8 Signaling Cytokines signaling; cellular immune 
response
3.34E-05 35/197 (17.8%) +1.219
Sphingosine-1-phosphate Signaling Organismal growth and development 2.20E-02 18/125 (14.4%) +1.213
CXCR4 Signaling Cytokine signaling; cellular immune response 7.63E-05 30/165 (18.2%) +1.177
Phospholipase C Signaling Intracellular and second messenger signaling 9.43E-03 32/240 (13.3%) +1.000
Calcium-induced T Lymphocyte 
Apoptosis
Apoptosis; cellular immune response 3.87E-03 13/66 (19.7%) -1.732
Huntington’s Disease Signaling Neurotransmitter and other nervous system 
signaling
3.06E-02 30/243 (12.3%) -1.606
eNOS Signaling Cardiovascular Signaling 1.25E-03 27/168 (16.1%) -1.091
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Table 1. (continued)
Canonical Pathway Pathway classification P-value Genes Ratio Z-score
Liver – Fasting vehicle vs. Fasting irinotecan
RhoGDI Signaling Intracellular and second messenger signaling 5.03E-03 11/173 (6.4%) +2.333
Toll-like Receptor Signaling Apoptosis; humoral/cellular immune 
response
4.50E-02 5/76 (6.6%) +1.342
NRF2-mediated Oxidative Stress 
Response
Cellular stress and injury 4.63E-04 14/193 (7.3%) +1.000
PTEN Signaling Apoptosis; cancer 3.51E-03 9/119 (7.6%) +1.000
Dopamine-DARPP32 Feedback in 
cAMP Signaling
Intracellular and second messenger signaling; 
neurotransmitter and other nervous system 
signaling
2.45E-02 9/163 (5.5%) -2.121
Aryl Hydrocarbon Receptor 
Signaling
Cell cycle regulation; apoptosis; xenobiotic 
metabolism; nuclear receptor signaling
2.76E-02 8/140 (5.7%) -2.121
GNRH Signaling Neurotransmitters and other nervous system 
signaling
1.19E-04 12/129 (9.3%) -1.732
Huntington’s Disease Signaling Neurotransmitter and other nervous system 
signaling
1.00E-02 13/243 (5.3%) -1.732
Synaptic Long Term Potentiation Neurotransmitter and other nervous system 
signaling
3.92E-03 9/121 (7.4%) -1.667
Chemokine Signaling Cytokine signaling; organismal growth and 
development
9.55E-03 6/71 (8.5%) -1.633
Sperm Motility Organismal growth and development 4.47E-02 7/127 (5.5%) -1.633
Cardiac Hypertrophy Signaling Cardiovascular signaling 1.16E-03 15.236 (6.4%) -1.604
Signaling by Rho Family GTPases Intracellular and second messenger signaling 6.85E-04 16/248 (6.5%) -1.508
Leukocyte Extravasation Signaling Cellular Immune response 2.02E-02 11/211 (5.2%) -1.508
Colorectal Cancer Metastasis 
Signaling
Cancer 2.63E-02 12/248 (4.8%) -1.508
eNOS Signaling Cardiovascular Signaling 1.13E-02 10/168 (6.0%) -1.414
STAT3 Pathway Cellular growth and proliferation and 
development
4.09E-02 5/74 (6.8%) -1.342
Thrombin Signaling Cardiovascular signalling 2.54E-04 15/204 (7.4%) -1.291
Glioma Signaling Cancer 1.40E-04 11/112 (9.8%) -1.265
Renin-Angiotensin Signaling Cardiovascular signaling; growth factor 
signaling
1.17E-03 10/122 (8.2%) -1.265
fMLP Signaling in Neutrophils Cytokine signaling; cellular immune response 1.24E-03 10/123 (8.1%) -1.265
Tec Kinase Signaling Intracellular and second messenger signaling 1.46E-03 12/170 (7.1%) -1.265
P2Y Purigenic Receptor Signaling 
Pathway
Cardiovascular signaling 2.23E-03 10/133 (7.5%) -1.265
Glioblastoma Multiforme Signaling Cancer 8.21E-03 10/160 )6.2%) -1.265
Dendritic Cell Maturation Cytokines signaling; cellular immune 
response
1.07E-02 11/192 (5.7%) -1.265
IL-8 Signaling Cytokines signaling; cellular immune 
response
1.33E-05 17/197 (8.6%) -1.213
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Table 1. (continued)
Canonical Pathway Pathway classification P-value Genes Ratio Z-score
Phospholipase C Signaling Intracellular and second messenger signaling 9.09E-03 13/240 (5.4%) -1.155
Estrogen-Dependent Breast Cancer 
Signaling
Cancer 1.50E-04 9/77 (11.7%) -1.134
EGF Signaling Growth Factor Signaling; cellular growth and 
proliferation and development
1.73E-03 7/68 (10.3%) -1.134
Androgen Signaling Nuclear receptor signaling 2.19E-03 9/111 (8.1%) -1.134
Cholecystokinin/Gastrin-mediated 
Signaling
Neurotransmitters and other nervous system 
signaling
2.87E-07 14/101 (13.9%) -1.069
CXCR4 Signaling Cytokine signaling; cellular immune response 2.30E-05 15/165 (9.1%) -1.069
Gaq Signaling Intracellular and second messenger signaling 6.96E-05 14/161 (8.7%) -1.069
Production of Nitric Oxide and 
Reactive Oxygen Species in 
Macrophages
Cellular immune response 4.88E-04 14/194 (7.2%) -1.069
14-3-3-mediated Signaling Cell Cycle Regulation; Apoptosis 2.00E-03 10/131 (7.6%) -1.000
P70S6K Signaling Cellular stress and injury; cellular growth and 
proliferation and development
2.11E-03 10/132 (7.6%) -1.000
HGF Signaling Growth Factor Signaling; cellular growth and 
proliferation and development; organismal 
growth and development
2.79E-03 9/115 (7.8%) -1.000
CREB Signaling in Neurons Neurotransmitters and other nervous system 
signaling; cellular growth and proliferation 
and development
8.20E-03 11/185 (5.9%) -1.000
Agrin Interactions at 
Neuromuscular Junction
Neurotransmitters and other nervous system 
signaling
3.16E-02 5/69 (7.2%) -1.000
All canonical pathways with a z-score of ≤-1.000 or ≥+1.000 are listed. Pathways with a significant z-score of ≤-2.000 or ≥+2.000 
are depicted in bold. Genes ratio=the number and percentage of genes differentially expressed in ratio to the total number of 
genes involved in the pathway. 
A partial opposite response due to irinotecan administration presented itself via the 
upregulation of RhoGDI and PTEN signaling, indicative of growth suppression (Table 1A). 
The AHR pathway and the p70S6K signaling pathways were not regulated in the AL groups. 
Tumor transcriptome analysis
Principal component analysis
Next, the transcriptomes of the tumor samples were analyzed using a similar approach as 
for the liver samples. With a total of 59.49% of the variance explained by PC1 and 10.88% 
by PC2, the PCA plot of the tumor samples of the four experimental groups showed high 
heterogeneity among the groups with large intragroup variability (Figure 3A). The individual 
groups were not clearly separated as clusters, and showed only minor differences between 
groups. The tumor tissue of the fasting vehicle group showed the smallest intragroup 
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variability. A shift on both the PC1 and PC2 axes could be detected between the AL vehicle 
and AL irinotecan groups, while the fasting comparison diverged more on the PC1 axis in 
an opposite direction but converging with the AL irinotecan group. Both irinotecan-treated 
groups showed high overlap and no clear clustering of groups. The data derived from these 
PCA plots show a heterogeneous response in tumor tissue treated with irinotecan, and this 
response could not be altered by three days of fasting. 
Expression profiles
Calculation of the number of DEPS in the tumor groups was done similarly as in the liver. 
The comparison of AL vehicle and AL irinotecan showed 610 DEPS, of which 321 were 
downregulated and 289 upregulated (Figure 3B). The number of regulated DEPS between 
fasting vehicle and fasting irinotecan was 3,093, of which 1,922 were upregulated and 1,171 
downregulated. A total of 138 DEPS overlapped between the AL vehicle vs. AL irinotecan 
and the fasting vehicle vs. fasting irinotecan comparison, corresponding to 23% of the DEPS 
in the AL groups and only 5% of the fasting groups (Figure 3C). All DEPS considered, only 
17% had the same directionality in both comparisons, while the other DEPS had opposite 
directionalities (Figure 3D), contrasting sharply to the 83% similar directionality found in 
the liver (Figure 2D). 
Pathway analyses
Similarly as done in the liver, pathway analyses were performed in tumor tissue using the 
DEPS of the AL comparison and the fasting comparison groups. The 610 DEPS as found 
between the AL vehicle and AL irinotecan group, revealed 11 pathways. Of these pathways, 
three were upregulated: PTEN Signaling, P53 Signaling and Apoptotic Signaling (Table 
2A). The majority of the eight downregulated pathways was involved in inhibition of 
neurotransmitter signaling. Comparing the fasting groups, 72 pathways were differentially 
regulated of which 18 were significantly upregulated and one downregulated (Table 2B). 
Eight overly expressed pathways were involved in cell cycle, cell growth or apoptosis, others 
mainly regulated cellular growth and the immune response. The tumor AL and tumor 
fasting groups showed one pathway in common, Huntington’s Disease Signaling, which was 
oppositely regulated.
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Figure 3. (A) Unbiased principal component analyses (PCA) of tumor samples, based on all 
probe sets in the microarray. Principal component (PC) 1 is depicted on the x-axis and PC2 is 
depicted on the y-axis, including the percentage of variance explained by each PC. Each symbol 
represents one sample of one mouse. Samples of the same group are shown in the same color. AL 
= ad libitum. (B) Number of significantly differentially expressed probe sets (DEPS) in the tumor 
in AL and fasted groups. (C) Venn diagram of overlapping DEPS between the DEPS after the AL 
tumor groups and the fasting tumor groups, including the unique DEPS of both comparisons. (D) 
Scatterplot of the number of DEPS found in the tumor with false discovery rate of 5%. On the x-axis 
are the fold changes found in the comparison of AL vehicle vs. AL irinotecan, on the y-axis the fold 
changes of fasting vehicle vs. fasting irinotecan. Red symbols = AL groups; green symbols = fasting 
groups; black symbols = overlapping DEPS. 
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Next, we compared the pathways of liver and tumor tissue of both the AL and fasting groups. 
The AL groups only had one inhibited pathway in common, involved in neurotransmitter 
signaling (i.e. Huntington’s Disease Signaling). In the fasting groups, three pathways 
downregulated in the liver appeared to be significantly upregulated in the tumor fasting 
groups: Colorectal Cancer Metastasis Signaling, Aryl Hydrocarbon Receptor Signaling and 
Huntington’s Disease Signaling. Of all 72 pathways regulated in tumor tissue of fasted 
animals, 17/39 (43%) of the pathways in liver tissue of fasting pathways were oppositely 
regulated.
Examining genes specifically of interest in tumor tissue, three genes came forward. Heat 
shock protein 90 (Hsp90) is prominently expressed in tumor cells and may play a pivotal 
role in tumor growth11. Hsp90 was found to be activated in the tumor AL irinotecan 
group, whereas the activation in the fasted irinotecan treated tumors was decreased. Two 
damage response genes either upstream or downstream of P53, Mdm2 and Ccng1, were also 
activated in both AL and fasting irinotecan groups. Mdm2 appeared downregulated in the 
fasting vehicle group, while an activation of Ccng1 in this group could be detected.
Irinotecan metabolism related gene expression profiles in liver and tumor 
tissue 
We have previously shown that both irinotecan and its active metabolite SN-38 levels are 
lower in the livers of fasted mice, while plasma levels of irinotecan showed a trend towards 
higher values compared to AL fed mice10. Here, we examined expression of genes involved 
in the metabolism and transportation of irinotecan (Figures 4, S2).
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Table 2. Overview of the top overrepresented canonical pathways in tumor ranked by their P-value
Canonical Pathway Pathway classification P-value Genes Ratio Z-score
Tumor – AL vehicle vs. AL irinotecan
PTEN Signaling Apoptosis; Cancer 1.57E-02 7/119 (5.9%) +2.646
P53 Signaling Cancer 3.51E-02 6/111 (5.4%) +1.342
Apoptotic Signaling Apoptosis 4.74E-02 5/90 (5.6%) +1.000
Glioma Signaling Cancer 7.94E-04 9/112 (8.0%) -2.121
Neuropathic Pain Signaling in 
Dorsal Horn Neurons
Neurotransmitters and Other Nervous 
System Signaling
3.78E-05 8/115 (7.0%) -2.121
CREB Signaling in Neurons Neurotransmitters and Other Nervous 
System Signaling; Cellular Growth, 
Proliferation and Development
2.08E-02 9/185 (4.9%) -2.121
Nitric Oxide Signaling in the 
Cardiovascular System
Cardiovascular Signaling 3.78E-02 6/113 (5.3%) -2.000
Huntington’s Disease Signaling Neurotransmitters and Other Nervous 
System Signaling
4.18E-02 10/243 (4.1%) -1.890
Synaptic Long Term Potentiation Neurotransmitters and Other Nervous 
System Signaling
4.99E-02 6/121 (5.0%) -1.633
STAT3 Pathway Cellular Growth, Proliferation and 
Development; Transcriptional Regulation
2.30E-02 5/74 (6.8%) -1.342
Synaptic Long Term Depression Neurotransmitters and Other Nervous 
System Signaling
4.29E-02 7/147 (4.8%) -1.134
Tumor – Fasting vehicle vs. Fasting irinotecan
Signaling by Rho Family GTPases Intracellular and Second Messenger Signaling 1.10E-03 35/248 (14.1%) +3.286
Gaq Signaling Intracellular and Second Messenger Signaling 2.26E-02 21/161 (13.0%) +2.828
IL-9 Signaling Apoptosis; Cytokine Signaling; Cellular 
Immune Response
2.81E-02 8/45 (17.8%) +2.828
CD40 Signaling Humoral Immune Response; Cellular 
Immune Response
1.85E-04 17/79 (21.5%) +2.668
TNFR2 Signaling Apoptosis; Cytokine Signaling 9.29E-03 7/30 (23.3%) +2.646
Type II Diabetes Mellitus Signaling Cellular Stress and Injury 8.16E-03 19/128 (14.8%) +2.500
Colorectal Cancer Metastasis 
Signaling
Cancer 1.31E-04 38/248 (15.3%) +2.401
ILK Signaling Cellular Growth, Proliferation and 
Development
6.47E-04 30/196 (15.3%) +2.353
Wnt/Ca+ pathway Cancer; Organismal Growth and 
Development
1.84E-02 10/58 (172%) +2.333
RANK Signaling in Osteoclasts Cellular Growth, Proliferation and 
Development
6.79E-05 21/102 (20.6%) +2.236
Aryl Hydrocarbon Receptor 
Signaling
Cell Cycle Regulation; Apoptosis; Xenobiotic 
Metabolism; Nuclear Receptor Signaling
8.10E-06 28/140 (20.0%) +2.200
Acute Myeloid Leukemia Signaling Cancer 4.85E-04 18/93 (19.4%) +2.183
Huntington’s Disease Signaling Neurotransmitters and Other Nervous 
System Signaling
4.74E-07 44/243 (18.1%) +2.132
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Table 2. (continued)
Canonical Pathway Pathway classification P-value Genes Ratio Z-score
B Cell Activating Factor Signaling Humoral Immune Response; Cellular 
Growth, Proliferation and Development
7.34E-05 12/41 (29.3%) +2.111
CD27 Signaling in Lymphocytes Apoptosis; Cellular Immune Response 2.68E-04 13/53 (24.5%) +2.111
Pancreatic Adenocarcinoma 
Signaling 
Cancer 3.34E-03 19/118 (16.1%) +2.111
NF-kB Signaling Organismal Growth and Development; 
Humoral Immune Response; Cytokine 
Signaling; Cellular Immune Response
3.98E-06 34/181 (18.8%) +2.058
IL-6 Signaling Cytokine Signaling; Cellular Immune 
Response
1.03E-04 24/128 (18.8%) +2.041
PPARa-RXRa Activation Nuclear Receptor Signaling 1.26E-06 35/180 (19.4%) -2.121
All canonical pathways with a z-score of ≤-1.000 or ≥+1.000 are listed in table A. Due to the high number of differentially 
regulated pathways, in table 2B only the canonical pathways with z-score ≤-2.000 or ≥+2.000 are listed. Pathways with a 
significant z-score of ≤-2.000 or ≥+2.000 are depicted in bold. Genes ratio= the number and percentage of genes differentially 
expressed in ratio to the total number of genes involved in the pathway.
Using the AL vehicle group as reference, the analysis in the liver revealed activation of 
mRNA expression of carboxylesterase 1 (Ces1) and Ces2 in both fasting groups, i.e. with 
and without irinotecan, while both genes were inhibited in the AL irinotecan group. Ces3 
expression was activated by fasting alone and significantly inhibited by irinotecan alone. 
In combination, the net effect of Ces3 expression by irinotecan and fasting was practically 
cancelled out. In tumor tissue, regulation of the carboxylesterases was not distinctly 
present. Carboxylesterases one to three are needed to convert irinotecan in to its active 
metabolite SN-38 (Figure 4). Cyp3a16, the mouse homolog of Cyp3a4, was not regulated 
in any of the groups, while other members of the cytochrome P450 family involved in drug 
metabolism appeared to be higher expressed in the fasting groups. Both Ugt1a1 and Abcc1, 
genes involved in the transport of SN-38 out of the cell, were higher expressed in the fasting 
irinotecan group compared to the AL irinotecan group. 
DISCUSSION
In this study, we confirm that three days of fasting prior to treatment with irinotecan is able 
to reduce liver toxicity as well as bone marrow depression in mice carrying subcutaneous 
colorectal carcinoma. Previously, we showed that these signs of somatic resistance to 
irinotecan were accompanied by a reduction in other side effects as body weight reduction 
and diarrhea without compromising the antitumor effect7,10. Here we set out to retrieve 
mechanistic insights in the chemoprotective effects of fasting through transcriptomic 
analyses of healthy liver and tumor tissue after an irinotecan challenge.
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Figure 4. Heatmap of irinotecan-related probe sets in the different treatment groups in liver 
(left lanes) as well as in tumor tissue (right lanes). Expression profiles were calculated using the 
ad libitum vehicle group of the corresponding tissue as a reference. In case a multitude of probe 
sets were related to one gene, the average of the sum of the expression values of all probe sets 
was calculated. The legend represents the fold ratio of the expression values in a coloring scale, 
in which a value >1 corresponds to an activation state, and a value <1 to an inhibition state of the 
gene expression value. Abcc = ATP-binding cassette, subfamily C; Abcg = ATP-binding cassette, 
subfamily G; Ccng1 = cyclin G1; Ces = carboxylesterase; Cyp = Cytochrome P450; Mdm2 = Mouse 
double minute 2 homolog; Ugt1a1 = UDP-glucuronosyltransferase 1-1; Hsp = heatshock protein. 
Since the most prominent effect of fasting is the reduction of toxic side effects of 
chemotherapy, its effects should be sought primarily in the healthy tissues including the 
liver in which the majority of its drug metabolism takes place. In this study, fasting led 
to a more homogeneous gene expression profile in healthy liver tissue. Together with the 
3-fold lower number of genes significantly regulated in the liver upon irinotecan exposure 
under fasting compared AL conditions, these results point towards a dampened response to 
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irinotecan in healthy tissue due to fasting. This may be an indication that fasting results in 
a state that favors maintenance and repair and in which normal cells are protected against 
toxic stressors during periods of nutrient deprivation8,10,12.
Fasting is able to amend and dampen the genotoxic response in the liver; in AL fed mice 
treated with irinotecan growth signaling induction and general activation of signaling 
pathways are prominent adaptations, whereas these pathways are blunted by fasting. 
Particular of interest is the reduction in cellular injury and cytokine signaling. Cytokines 
are crucial players in the activation and adaptation to oxidative stress, and therefore the 
reduction is strong evidence of increased stress resistance induced by fasting13. Another 
marker of cellular stress is RhoA, which is activated by reactive oxygen species (ROS) in 
fibroblasts and may lead to apoptosis when activated by caspase 314,15. RhoA signaling was 
activated in the fasting vehicle group of the liver as indication of a preconditioned state 
of stress. In the fasting irinotecan group, RhoA activation did not come forward whereas 
a known inhibitor of RhoA (i.e. RhoGDI) was highly activated. An inhibition of RhoA 
results in a dampening of TGF-beta 1, a transcription factor able to activate ROS and stress-
induced injury16,17. These findings are consistent with reduction of cellular stress by fasting, 
possibly via blunting of cytokine and RhoA signaling, which may play a key role in the 
protection of DR against adverse side effects of irinotecan. 
The mTOR signaling was downregulated as well via inhibition of the p7056 pathway, thereby 
initiating autophagy18,19. Autophagy is a process initiated for cell survival in healthy tissue, 
however autophagy in tumor cells also promotes tumorigenesis and tumor progression and 
therefore has an outcome dependent on the nature of the cells13. The effect of mTOR on stress 
resistance20 also refers to the anti-inflammatory response due to fasting, and the beneficial 
role for promoting stress resistance after DR therefore holds also true for the side effects of 
chemotherapy9,10. The activation of the NRF2 stress response might also provide protection 
against the damage-induced response after irinotecan21-23. Posttranscriptional validation is 
needed to further understand the exact role of cytokine signaling, RhoA, mTOR and NRF2 
on stress resistance and prevention of side effects of chemotherapy. 
The changes induced by fasting in healthy liver tissue did not come forward in the 
tumor transcriptome analysis. The PCA plots of the AL and fasting groups revealed a 
high heterogeneity within all the groups of tumor tissue, which is in contrast with the 
orchestrated response of the liver. Especially both AL groups (with and without irinotecan 
treatment) revealed a small number of DEPS. This number was about a 5-fold higher after 
fasting, however these genes showed only little overlap with the response in liver tissue 
of fasted irinotecan treated mice. On pathway level, the AL and fasting comparisons 
with and without irinotecan did not show a common response either; in the AL group 
15045-jongbloed-layout.indd   67 06/11/2017   17:20
68
CHAPTER 3
an upregulation of pathways involved in growth inhibition, tumor suppression and cell 
death was seen. Strikingly, the response of fasted tumor tissue appeared partially oppositely 
regulated as compared to fasted liver tissue since upregulation of various cell cycle, apoptosis 
and cytokine pathways in fasted tumor tissue was predominantly found. These results are 
partially in line with the recently described DSS8,10,12. In addition, the decreased activation of 
Hsp90 in tumor tissue of fasted mice after irinotecan administration might point towards an 
additional inhibitory effect of irinotecan after fasting8,11,12. Thus, although the transcriptomic 
response of fasted tumor tissue differs significantly from that of AL tumor tissue, this does 
not affect the antitumor activity of irinotecan7,10. Due to the heterogeneity within the tumor 
groups, any common pathway responses should be interpreted with care as more studies are 
needed to fully discern between partly orchestrated -common and heterogenic- individual 
responses to chemotherapeutic insults in tumor tissue after dietary intervention.
Previously, we found decreased levels of the active metabolite of irinotecan, SN-38, in 
plasma as well as liver, but not in tumor tissue of fasted mice10. The relative upregulation 
of the carboxylesterases in this study would suggest an increased hydrolysis of irinotecan 
into SN-387,24. Upregulation of Ugt1a1 and ABC transporter Abcc1 is indicative of increased 
transport of SN-38 out of the cell25-27. An increased production of SN-38 in the liver and 
more efficient excretion by transporters may explain the lowered SN-38 levels in the liver 
and increased plasma levels we found previously10. Ugt1a1 is involved in conversion of 
SN-38 into its inactive from SN-38G, which reduces the levels of the active drug in the 
intestine. Since one of the main side effects of irinotecan, diarrhea, is thought to be due to 
high concentrations of intra-luminal SN-38, this inactivation of SN-38 by Ugt1a1 could be 
responsible for the absence of diarrhea in fasted mice28-30. Further studies should examine 
in depth the activity of the enzymes involved in irinotecan drug metabolism and at various 
time points after exposure in order to understand their role in the reduced side effects 
induced by fasting. The changes occurring in the drug metabolism of irinotecan as seen in 
liver tissue were far less prominent in tumor tissue without obvious changes due to fasting. 
This is consistent with the previous findings that irinotecan and its metabolite levels were 
not affected by fasting in tumor tissue. The inhibition of mouse double minute 2 homolog 
(Mdm2) in the tumor fasting vehicle group is partially maintained in the fasting irinotecan 
group, which may point towards an activation of tumor suppressor p53 by fasting31. 
Further research is needed in order to understand the etiology of fasting on the effects of 
chemotherapy on tumor tissue.   
Since pharmacokinetic studies showed that the half-life of SN-38 is approximately 12 
hours10, we choose to explore the transcriptional changes at one time point, using one dosage 
of irinotecan in the therapeutic window in which the effects of both irinotecan and fasting 
would be maximal. Analyses of multiple time points and with different dosages of irinotecan 
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would likely improve our understanding of the results we obtained. In addition, in this 
experimental model we compare healthy liver tissue and C26 colon cancer cells induced by 
subcutaneous injection. Other models might provide more information about the effects 
of fasting on various cancer tissues. Finally, this study only partially explains how fasting 
changes irinotecan metabolism and how it protects the organism, but not the tumor, against 
irinotecan exposure. Addressing the impact of fasting on posttranscriptional level will likely 
improve our understanding of the mechanisms of fasting-induced chemoprotection.
In conclusion, we show that three days of fasting results in protection against the side effects 
of irinotecan treatment and activates a protective stress response in healthy liver, but not 
in tumor tissue. Although fasting leads to an increase in differentially regulated pathways 
following irinotecan treatment in tumor tissue, it does not abrogate its antitumor efficacy. 
These results further strengthen the oncologic safety of DR in cancer patients, where short-
term fasting could improve both efficacy of treatment and quality of life in patients with 
colorectal cancer treated with irinotecan. 
MATERIALS AND METHODS
Animals
Male BALB/c mice of 6-8 weeks old, weighing approximately 25 grams, were obtained from 
Charles River, Maastricht, the Netherlands. Upon arrival, animals were housed at random 
in individually ventilated cages (n=4 animals per cage) in a licensed biomedical facility 
at Erasmus University Medical Center, Rotterdam, the Netherlands. Standard laboratory 
conditions were maintained, i.e. temperature ~22ºC, humidity ~50%, and a 12 h light/12 
h dark cycle. All mice had free access to water and food (Special Diet Services, Witham, 
UK) unless mentioned otherwise. Animals were allowed to acclimatize for one week before 
the start of the experiments. The experimental protocol was approved by the Animal 
Experiments Committee under the Dutch National Experiments on Animals Act, and 
complied with the 1986 directive 86/609/EC of the Council of Europe.
C26 colon carcinoma cells
The murine colon carcinoma cell line C26 originally derived from the BALB/c mouse and 
was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma Aldrich, St. Louis, 
MO), supplemented with 10% fetal calf serum (Lonza, Verviers, Belgium), penicillin (100 
units/ml) and streptomycin (100 units/ml) (Invitrogen, Auckland, NZ) at 37 degrees Celsius 
in a 5% carbon dioxide environment. Cells were harvested by brief trypsinization (0.05% 
trypsin in 0.02% ethylenediamine tetra-acetic acid (EDTA)). For subcutaneous injection, 
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cells were harvested and after centrifugation, single-cell suspensions were prepared in 
phosphate buffered saline (PBS) to a final concentration of 2.5 x 105 cells/100 µL. Cell 
viability was determined by trypan blue staining, and was always ≥90%. 
Experimental setup
Mice (n=36) were anesthetized (isoflurane inhalation, 5% isoflurane inhalation initially 
and then 2% isoflurane with a 1:1 air:oxygen mixture for maintenance of anesthesia) 
(Figure S1). Both flanks were shaved for precise injection. 2.5 x 105 C26 cells were injected 
subcutaneously on both sides in a volume of 100 µL, using a 21G needle. Tumors were 
allowed to grow for 12 days before start of the experiment. Mice were weighed and tumors 
were measured daily with digital calipers. The mice were randomly divided into four groups 
(n=6/group). Two groups were fasted for three days and two groups were fed ad libitum 
(AL). After the fasting period, mice were fed AL again. One AL fed group, and one group of 
fasted animals, were treated with a single weight-adjusted dose of 133 mg/kg (±3.3 mg/kg, 
and ±2.7 mg/kg respectively) of irinotecan intraperitoneally. The control groups received 
vehicle treatment (sodium chloride 0.9%). Two hours after injection, all groups received 
unlimited access to food for 10 hours until the moment of sacrifice. The difference between 
starting amount and remaining amount of food was used to calculate food consumption 
per mouse for this 10-hour period. Subsequently, 12 hours after irinotecan administration, 
the mice were sacrificed by exsanguination. 
Fasting protocol
Mice in the AL fed groups were allowed unrestricted access to food, and amount of food 
eaten per cage was measured daily. Before the start of the fasting period, all mice were 
transferred to a clean cage and mice in the fasting groups were withheld food for three 
days starting at 4:00 PM on a Friday until 10:00 AM on a Monday. All animals were given 
continuous access to water.
Chemotherapy
Irinotecan, HCl-trihydrate 20 mg/mL (Hospira, Benelux) was used for in vivo experiments. 
Irinotecan was diluted in sodium chloride 0.9% (Braun, Melsungen, Germany) to a final 
volume of 200 µL per injection, and was given intraperitoneally. 
Serum measurements
Mice were killed by exsanguination with cardiac puncture under anesthesia (isoflurane 
inhalation, 5% isoflurane inhalation initially and then 2% isoflurane with a 1:1 air:oxygen 
mixture for maintenance of anesthesia). After cardiac puncture, ± 900 µL of blood per 
mouse was transferred directly into 1 mL tubes (MiniCollect, Greiner Bio-one), containing 
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EDTA. Samples were directly centrifuged (3,500 rpm; 10 min) after which the serum was 
transferred to a separate tube. Serum aspartate transaminase (AST), alanine transaminase 
(ALT), lactate dehydrogenase (LDH), urea, and creatinine levels were analyzed at the 
Central Clinical Chemical Laboratory of the Erasmus University Medical Center. Fifty µL 
of blood was used to measure the number of leukocytes with a Z-series Coulter Counter 
(Beckman Coulter, Woerden, The Netherlands).
Tissue sampling
Livers and tumors were collected and weighed. The median liver lobe was isolated for array 
analysis and directly stored in RNAlater® Solution (Life Technologies Europe BV, Bleijswijk, 
the Netherlands) and stored at 4ºC until further analysis. Parts of viable tumor border were 
identified and also directly stored in RNAlater® until further analysis.   
RNA isolation
Tumor and liver samples were kept at 4ºC in the RNAlater® Solution (Thermo Fisher 
Scientific™, Breda, the Netherlands) until further analyses. RNA isolation took place between 
24 hours and 96 hours after sample collection. Total RNA was extracted via the QIAzol lysis 
Reagent and miRNAeasy Mini Kits (QIAGEN, Hilden, Germany), according to Qiagen 
protocol. Concentrated buffers RPE and RWT (QIAGEN) for washing of membrane-bound 
RNA and purification were added mechanically by using the QIAcube (QIAGEN, Hilden, 
Germany) via the miRNeasy program. Subsequently, isolated RNA was stored at -80°C. 
RNA concentrations were measured using the Nanodrop (Thermo Fisher Scientific™, Breda, 
the Netherlands) and RNA quality was assessed using the 2100 Bio-Analyzer (Agilent 
Technologies, Amstelveen, the Netherlands), according to manufacturer’s instructions. The 
RNA quality was quantitatively expressed as the RNA Integrity Number (RIN, range 0-10). 
Out of the six tumor samples and six liver samples per group, the four samples with the 
highest RIN were used for microarray analyses. RIN-values of the tumor samples ranged 
between 7.8 and 10, the RIN-values of the liver samples ranged between 7.6 and 8.6.
Array analysis
Microarray hybridization was done at the Microarray Department of the University of 
Amsterdam (the Netherlands) to Affymetrix HT MG-430 PM Array Plates, according to 
the Affymetrix protocols. For each group, four biological replicates were used. The output 
of the hybridization contained raw mean expression data put into CEL files. Subsequent 
quality control and normalization were done using the pipeline at the www.arrayanalysis.
org website (Maastricht University, the Netherlands)32. Normalization was performed via 
the Robust Multichip Average (RMA) algorithm, and the output of the normalization 
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consisted of 45,141 probes33. Both raw and normalized microarray data and their MIAME 
compliant metadata were deposited at the Gene Expression Omnibus (GEO) database, with 
number GSE72484 (www.ncbi.nlm.nih.gov/geo). 
Statistical analyses
For each set of parameters means and standard errors of the mean were computed. All 
standard statistical tests were performed using SPSS version 21 for Windows software 
(Statistical Package for Social Sciences, Chicago, IL) and GraphPad Prism (GraphPad 
Software Inc., version 5.01). A P-value <0.05 was considered to be significant. Microarray 
analyses were performed using the free software package R (R foundation). Gene expression 
profiles were compared using the Linear Models for Microarray Data (limma) method 
with correction for multiple testing using the false discovery rate (FDR) according to 
Benjamini and Hochberg 34. Fold changes were expressed as the geometric mean per diet 
group against the corresponding AL fed control group, and cutoff values for a significant 
difference were put at FDR <5%. Functional annotation and analyses were performed using 
the Ingenuity software (http://www.ingenuity.com/products/ipa). Inhibition or activation 
prediction of the upstream transcription regulators (upstream analysis) was predicted with 
Ingenuity software by calculating statistical z-scores based on the observed gene expression 
changes in our dataset. Via z-scores, the chance of significant prediction based on random 
data is reduced (http://ingenuity.force.com/ipa/articles/Feature_Description/Upstream-
Regulator-Analysis). Cutoff values for a significant activation or inhibition were put at a 
z-score of ≥2 or ≤-2, respectively.
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SUPPLEMENTARY DATA
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Figure S1. Schematic overview of the experimental set-up, including a timeline from arrival of 
the mice until sacrifice and subsequent RNA isolation for further analyses. Ip = intraperitoneal.
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Figure S2. Overview of the pathway of irinotecan and its metabolism outside and inside the 
liver cell, including the transportation into the intestine. The main genes and transporters known 
to be involved in the pathway are depicted. Ces = carboxylesterase; SN-38= active metabolite 
of irinotecan; SN-38G = SN-38 glucuronide form; Abcc = ATP binding cassette subfamily 
C; NPC/APC = carbonyloxycamptothecin; Cyp3a = cytochrome P450 3A; Ugt1a1 = Uridine 
glucuronosyltransferase 1A1. 
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ABSTRACT
During kidney transplantation, ischemia-reperfusion injury (IRI) induces oxidative 
stress. Short-term preoperative 30% dietary restriction (DR) and 3-day fasting protect 
against renal IRI. We investigated the contribution of macronutrients to this protection 
on both phenotypical and transcriptional levels. Male C57BL/6 mice were fed control 
food ad libitum, underwent two weeks of 30% DR, 3-day fasting, or received a protein-, 
carbohydrate- or fat-free diet for various periods of time. After completion of each diet, 
renal gene expression was investigated using microarrays. After induction of renal IRI by 
clamping the renal pedicles, animals were monitored seven days postoperatively for signs 
of IRI. In addition to 3-day fasting and two weeks 30% DR, three days of protein-free diet 
protected against renal IRI as well, whereas the other diets did not. Gene expression patterns 
significantly overlapped between all diets except the fat-free diet. Detailed meta-analysis 
showed involvement of nuclear receptor signaling via transcription factors, including 
FOXO3, HNF4A and HMGA1. In conclusion, three days of a protein-free diet is sufficient 
to induce protection against renal IRI similar to 3-day fasting and two weeks of 30% DR. 
The elucidated network of common protective pathways and transcription factors further 
improves our mechanistic insight into the increased stress resistance induced by short-term 
DR.
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INTRODUCTION
Dietary restriction (DR) is a reduction in food intake without malnutrition1. Long-term 
DR is known to extend lifespan, increase overall health and improve resistance to multiple 
stressors in a wide variety of organisms1-5. Although the effect of DR on human lifespan 
is unknown, studies demonstrate a favorable impact on metabolic parameters associated 
with long-term health6-8. In addition, DR has been shown to protect against acute stressors 
including toxic chemotherapy9, paracetamol intoxication10, and oxidative stress induced 
by ischemia-reperfusion injury (IRI)1,11,12. In clinical kidney transplantation, renal IRI is 
a major risk factor for organ damage which may result in acute kidney injury13, primary 
non-function14, delayed graft function15, and acute and chronic rejection16 of the graft. 
After kidney retrieval, cessation of the blood flow (ischemia) leads to hypoxia, nutrient 
deprivation, and accumulation of metabolic waste products15,16. Reperfusion of the ischemic 
kidney promotes the generation of reactive oxygen species, triggers apoptotic cell death, 
and promotes the activation of an inflammatory response resulting in profound tissue 
injury17. Prevention or amelioration of renal IRI could increase graft quality, and prolong 
graft survival. Unfortunately, no effective treatment to reduce or prevent IRI is currently 
available.
Using renal IRI as a model, we previously demonstrated that the benefits of DR on IRI 
are induced rapidly: two and four weeks of 30% preoperative DR as well as three days of 
fasting reduce renal injury and strongly improve survival and kidney function after renal 
IRI in mice1,12. Hence, DR is a potential intervention for living kidney donors to reduce 
IRI and improve the transplantation success rate. Whether the protective effect of short- 
and long-term DR is based on the reduction of calories per se, or specific nutrients, was 
first investigated in fruit flies, in which long-term protein restriction contributed more to 
lifespan extension than a reduction in carbohydrates18. In mice, glucose supplementation 
did not interfere with fasting-induced protection against renal IRI, which also points 
towards a role for specific (macro-) nutrients in inducing acute stress resistance11. 
In this study, we investigated the role of specific macronutrients in inducing resistance 
against renal IRI by unrestricted feeding of protein-, carbohydrate-, and fat-free diets. We 
showed that the absence of protein for three days is sufficient to induce resistance against 
renal IRI, and revealed common pathways and transcription factors that are implicated in 
the protective effect of calorie restriction induced by two weeks of 30% DR, three days of 
fasting, and protein restriction.
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RESULTS
Absence of dietary protein induces protection against renal IRI 
To determine the effect of short-term macronutrient deficiency on renal IRI, we provided 
10-day, 14-day or 3-day regimens of protein-free, carbohydrate (CHO)-free and fat-free 
diets before inducing renal IRI. 
As previously shown, mice that were fed a protein-free diet for six or 14 days tend to 
voluntarily decrease their food intake as compared to animals that were fed a normal diet19. 
We indeed found that mice fed a protein-free diet for 10 days decreased their dietary food 
intake by approximately 30% (Figure S1A), resulting in significant body weight loss up 
until 20% on day 10 (Figure S1B). The reduction in food intake and body weight was less 
substantial in mice fed a carbohydrate (CHO)-free diet for 14 days. A fat-free diet for 14 
days led to a small increase in body weight. Only the protein-free diet improved survival 
(Figure S1C) and kidney function (Figure S1D) following renal IRI. However, due to the 
reduction in food intake and body weight, the effect of the absence of protein per se could 
not be disentangled from the effect of calorie restriction. 
Subsequently, to separate the effect of the absence of protein-from calorie restriction, mice 
were fed a protein-free diet for three consecutive days. We first showed that survival and 
kidney function of mice receiving 30% DR for three days did not differ from mice fed ad 
libitum (Figure 1A, B)11.  Mice fed the protein-free diet for three days had significantly 
improved survival (Figure 1C) and kidney function compared to control mice (P<0.05) 
(Figure 1D). The energy intake during the 3-day protein-free dietary intervention was 
decreased, but did not significantly differ from the intake of animals fed the control diet for 
three days (P=0.13) (Figure 1E). Body weight of mice on the protein free diet decreased by 
9%, while body weight of mice that were fed a control diet did not change. Mice receiving 
30% DR for three days lost about 8% of their body weight (Figure 1F). 
Common gene expression profiles between macronutrient-free diets, 
fasting and DR 
To examine, in an unbiased manner, the transcriptomic response of the kidney, microarray 
analysis was performed on 45,141 probe sets in kidney samples after three days of fasting, 
three days and two weeks of 30% DR, and three days of a protein-, fat- or carbohydrate-free 
diet. Each diet was subsequently compared to its corresponding AL fed control group.
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Figure 1. A protein-free diet protects against renal IRI. (A) Three days of 30% DR did not protect 
against renal IRI. (B) Serum urea levels before and at day one after renal IRI did not differ between 
mice fed ad libitum (AL) for three days of 30% DR and a control diet. (C) Three days of protein-free 
diet improved survival compared with AL fed controls. (D) Serum urea levels of AL fed protein-
free mice were significantly better compared to AL fed control mice (P<0.05). (E) Three days of 
protein-free diet resulted in 30% calorie restriction. (F) Mice fed a protein-free diet or a 30% DR 
diet for three days lost significantly more body weight than mice fed the control diet. Body weight 
changes did not differ between the protein-free diet and 3-day 30% DR. AL Control= ad libitum fed 
SDS chow, Control= control diet for the macronutrient diets, protein free= ad libitum fed protein-
free diet. *= significance with P<0.05.
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As the three days of fasting on the one hand and two weeks 30% DR and 3-day 30% DR 
on the other hand were each performed as individual cohorts using their own control 
group, we had three different control groups for all interventions combined. No significant 
differences in gene expression profiles were observed between the different control diets 
(data not shown). The highest number of significantly differentially expressed probe sets 
(DEPS) was found after three days of fasting, namely 2,604, of which 1,268 were up- and 
1,336 downregulated. Two weeks of 30% DR gave rise to a five times lower number: 492 
DEPS, of which 265 were upregulated and 227 were downregulated. Three days of protein-
free diet induced 391 DEPS, with 230 probe sets up- and 161 downregulated. Of the non-
protective diets, the 3-day fat-free diet did not induce any DEPS when compared to control 
diet fed mice, while three days of a CHO-free diet induced 1,717 DEPS containing 613 
up- and 1,104 downregulated sets. Three days of 30% DR resulted in 454 DEPS, of which 
284 up- and 170 downregulated.
Several analytic approaches were performed to compare the transcriptomic response 
between all diets. First, a comparison was made based on the number of overlapping DEPS 
and the corresponding significance of the overlap (Table 1). Based on the maximum relative 
overlap, the 3-day protein-free diet and 3-day fasting demonstrated the most resemblance 
to each other with 222 DEPS in common, corresponding to 53.3% relative overlap. Two-
weeks 30% DR showed 45.9% relative overlap with three days of fasting, with 247 DEPS 
in common. To compare the significance of these overlapping fractions, the enrichment 
factors (EF) with corresponding P-values were calculated. Comparison of the two identically 
modified diets differing only in intervention time, namely 3-days 30% DR and two weeks 
30% DR, resulted in the highest EF with a 39 times higher number of DEPS in common than 
would have been expected by chance (Table 1). Comparison of the 3-day protein-free diet 
with 3-day 30% DR resulted in an EF of 29. All enrichments were significant, with values 
lower than 8.66E-48, suggesting a significant common transcriptomic response between 
dietary interventions with the exception of a 3-day fat-free diet. As directionality of the 
DEPS was not accounted for in this comparison, we explored dendographic heat maps. 
Since the 3-day fasting dataset was hybridized on a different date, the date of hybridization 
caused a stronger effect than the biological signal (Figure S2). It was therefore not possible 
to integrate all complete datasets in one informative heat map analysis. As a solution, we 
assumed 3-day fasting to represent the widest transcriptomic protective response, and 
all data sets were limited to its highest number of 2,604 DEPS. The resulting heat map 
(Figure 2A) shows that the majority of the DEPS have similar directionalities, with the 
lowest expression levels in the fat-free diet. The horizontal dendogram, based on the (dis)
similarity between expression data for probe sets, shows that three days of fasting portrays 
the largest differences with the other groups, however, this was an assumption, since the 
heat map is based on the probe sets differentially regulated after three days of fasting. 
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Compared to 3-days of fasting, a 3-day CHO-free diet is the least clustered with the other 
dietary groups. The 3-day protein-free diet clusters closely with the non-protective 3-day 
fat-free diet, based on the number of probe sets as well as the expression levels. Three days 
30% DR had a similar cluster pattern as two weeks of 30% DR.
Table 1. Comparison of the overlapping DEPS between the five dietary interventions and their 
corresponding P-value and enrichment factor 
Comparison Overlapping 
DEPS
Overlap (%)* Enrichment 
factor
P-value
Protein-free vs. Fasting 222 53.3 9.8 5.27E-169
2wks 30% DR vs. Fasting 247 45.9 8.7 8.88E-171
3d 30% DR vs. Fasting 208 42.0 8.7 3.12E-156
2wks 30% DR vs. 3d 30% DR 195 28.1 39.4 3.44E-270
Protein-free vs. CHO-free 113 24.9 6.0 5.84E-55
Fasting vs. CHO-free 584 23.7 5.9 3.73E-300
2wks 30% DR vs. CHO-free 122 20.4 8.2 5.71E-76
3d 30% DR vs. CHO-free 107 19.6 5.8 8.66E-48
Protein-free vs. 3d 30% DR 116 18.5 29.5 2.22E-138
Protein-free vs. 2wks 30% DR 95 15.2 22.3 1.15E-99
The highest percentage of relative overlap was found between three days of protein-free diet and three days of fasting. The 
enrichment factor indicates the number of times the overlapping DEPS is higher than expected by chance. All diets showed 
a significantly overlapping number of DEPS, as shown by the corresponding p-values in the last column. *Relative overlap is 
calculated by the number of DEPS in common between the two groups, divided by the total number of unique DEPS across 
both groups, relative to the theoretical maximum overlap according to this formula.  
Subsequently, the same set of 2,604 DEPS significantly regulated after fasting compared to AL 
fed controls, was used for a principal component analysis (PCA) among the macronutrient-
free diets, two weeks- and three days 30% DR, and their control diets (Figure 2B). Samples 
from the control diets and the 3-day fat-free diet clustered together, with high overlap and 
corresponding directionality between the groups. With a large distance on the principal 
component (PC) 2 axis, a similar clustering was seen among the 3-day 30% DR and two 
weeks 30% DR samples. The protein-free diet had its own cluster, separated on both PC axes 
from the other groups. The 3-day CHO-free diet resembled the DR diets, but showed no 
overlap with these diets and showed a large dissimilarity to the other groups.
To compare the transcriptomic responses between all dietary interventions, all DEPS were 
visualized in a Venn diagram (Figure 3A). This revealed a total of 40 overlapping DEPS in the 
three protective diets, while 30 overlapping DEPS were also present in the non-protective 
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CHO-free diet. The genes corresponding to the 70 DEPS in common are listed in Table 
S1. Comparing 3-day 30% DR with the protective diets, a similar pattern was observed; 
only 15 DEPS overlapped in the three protective diets, while 47 DEPS were also present in 
the non-protective 3-day 30% DR diet (Figure 3B). However, both numbers of overlapping 
genes appeared too small to perform pathway analysis with the aim to find a common 
denominator of protection against renal IRI, and therefore an alternative approximation for 
analysis was used.
Figure 2. Heat map and PCA plots of directional and cluster patterns in all dietary interventions 
based on the differentially expressed probe sets (DEPS) after three days of fasting compared to 
its control group. (A) The majority of the DEPS in the kidney after three days of fasting showed 
the same directionality in the other dietary interventions. The 3-day CHO-free diet was the least 
clustered with the other diets, followed by two weeks 30% DR and a 3-day protein-free diet. The 
fat-free diet, showing no significant DEPS, clustered together with a 3-day protein-free diet. Red= 
upregulation, blue = downregulation, white = no change. CHO-free = carbohydrate-free. (B) 
Principal component analysis (PCA) plot, based on the 2604 significantly regulated probe sets after 
three days fasting compared to the control diet fed animals. Both two weeks 30% DR and three days 
of 30% DR diet clustered close to each other based on the DEPS found after three days of fasting. 
The two control diets, control and SDS diet, clustered together with the non-protective fat-free diet. 
Three days of CHO-free diet positioned closely to two weeks and three days of 30% DR, but did not 
overlap with these diets. The protein-free diet had its own cluster, separated from the other groups 
on both PC axes.
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Pathway analyses and transcription factor analyses
To explore the biological value of these transcriptomic responses, we used an individual 
approximation to identify significantly enriched pathways. The highest enriched pathways 
after the different dietary interventions were ranked by their –log P-value and summarized 
in Table S2. No clear pattern in overlapping pathways between all diets, or between the 
protective diets and the non-protective CHO-free diet, was observed. One pathway that 
emerged was the NRF2-mediated oxidative stress response pathway, since this pathway was 
activated by four out of five dietary interventions (Table S2).
Figure 3. Venn diagram of multiple dietary interventions combined. (A) Venn diagram showing 
the number of DEPS after three days of fasting, two weeks 30% DR, three days of protein-free 
diet, three days of CHO-free diet, and their overlap with each diet. Thirty DEPS are differentially 
regulated in all four diets including the non-protective CHO-free (centre). The protective diets have 
70 DEPS in common, of which 40 of those in common with the CHO-free diet are excluded (lower 
right). (B) Venn diagram showing the number of DEPS after three days of fasting, three days of a 
protein-free diet, two weeks and three days of 30% DR with their overlap. Forty-seven DEPS are 
differentially regulated in all fours diets (centre). A total of 15 DEPS were overlapping between the 
three protective diets.
To further identify a common protective response and dissect it from the response of the 
non-protective CHO-free diet, a more comprehensive meta-analytic approximation was 
used. A combining rank orders methodology was implemented to prevent bias of the 
results based on outliers as well as the stronger transcriptomic response after three days 
of fasting20. By eliminating all significant probe sets induced by the CHO-free diet in this 
meta-analysis, only 140 DEPS remained. Pathway analysis revealed no significant pathways 
(data not shown). Theorizing that the protective response might be partially overlapping 
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with the response of the non-protective CHO-free diet, we repeated the meta-analysis 
with the three protective diets and the CHO-free diet into the approximation, thus not 
excluding the 3-day CHO-free diet. This meta-analysis yielded 640 DEPS. The majority 
of these DEPS in common showed a similar fold change and directionality among the 
three protective dietary interventions. A pathway analysis of these DEPS demonstrated 
regulation of nuclear receptor signaling as well as inhibition of cellular stress and injury 
and biosynthesis pathways amongst the top 10 overrepresented pathway categories (Table 
2). Adding the 3-day 30% DR diet in the meta-analysis yielded 279 DEPS. No significant 
enriched pathways emerged. The 10 highest enriched pathways are depicted in Table S3.
Table 2. Overview of the top 10 overrepresented canonical pathways in the meta-analysis ranked 
by their P-value 
Canonical Pathway Pathway Category P-value Genes Ratio Z-score
LXR/RXR Activation Nuclear Receptor Signaling 7.24E-09 16/121 (13.2%) +0.302
FXR/RXR Activation Nuclear Receptor Signaling 3.63E-06 13/127 (10.2%) N/A
LPS/IL-1 Mediated Inhibition of 
RXR Function
Nuclear Receptor Signaling 2.24E-05 16/219 (7.3%) -2.646
Superpathway of Cholesterol 
Biosynthesis
Fatty Acids and Lipids 
Biosynthesis, Sterol Biosynthesis
2.40E-05 6/28 (21.4%) N/A
NRF2-mediated Oxidative Stress 
Response
Cellular Stress and Injury 3.72E-05 14/180 (7.8%) -1.000
Aryl Hydrocarbon Receptor 
Signaling
Cell Cycle Regulation; Apoptosis; 
Xenobiotic Metabolism, Nuclear 
Receptor Signaling
5.13E-05 12/140 (8.6%) +1.633
PXR/RXR Activation Nuclear Receptor Signaling 9.12E-05 8/67 (11.9%) N/A
Intrinsic Prothrombin 
Activation Pathway
Cardiovascular Signaling; 
Cellular Stress and Injury
3.47E-03 5/29 (17.2%) N/A
Superpathway of 
Geranylgeranyldiphosphate 
Biosynthesis I
Cofactors, Prosthetic Groups and 
Electron Carriers Biosynthesis
3.98E-03 4/17 (23.5%) N/A
Aldosterone Signaling in 
Epithelial Cells
Cardiovascular Signaling; 
Nuclear Receptor Signaling
4.57E-03 11/152 (7.2%) N/A
The top 10 overrepresented pathways derived from the 640 DEPS in common between 3-days of fasting, two weeks 30% DR, 
three days of a protein-free diet and three days of a carbohydrate-free diet. These pathways are mostly involved in regulation of 
nuclear receptor signalling (five out of 10), biosynthesis signalling (two out of 10) and cellular stress and injury (two out of 10).
To further explore the regulated DEPS and pathways in relation to the protective response 
against renal IRI, we examined the involvement of upstream transcription factors (TFs) 
in the DEPS that emerged from the meta-analysis. In the meta-analysis, 16 TFs were 
identified of which 12 were predicted to be activated and six inhibited (Table 3). Critical 
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denominators might be TFs showing the same directionality in the protective diets, but 
are oppositely directed or not regulated in the non-protective CHO-free diet. The TFs 
complying with these criteria, in descending order of absolute z-score, were forkhead box 
O3 (FOXO3), heat shock factor protein 1 (HSF1), and high mobility group AT-hook 1 
(HMGA1). Furthermore, hepatocyte nuclear factor 4-alpha (HNF4A) was highly activated 
in the protective diets, but only minimally in the non-protective CHO-free diet. Also, 
sterol regulatory element-binding transcription factor 1 (SREBF1) and 2 (SREBF2) were 
significantly downregulated after three days of fasting and in the protein-free diet, activated 
in the CHO-free diet but not regulated after two weeks 30% DR. The non-protective three 
days 30% of DR showed similar results as the protective diets, since all TFs after three days 
of 30% DR were similarly regulated as after three days of fasting, two weeks 30% DR and 
the three days of a protein-free diet.
The validity of these findings was further examined by determining mRNA expression levels. 
The expression levels of Foxo1 were significantly higher after all diets except the fat-free diet 
(Figure S4A), while Foxo3 was significantly upregulated in all diets except after two weeks of 
30% DR (Figure S4B). Foxo4 was only significantly upregulated after three days of protein-
free and three days of a carbohydrate-free diet (Figure S4C). Hnf4α was not significantly 
regulated after any of the dietary interventions (Figure S4D). The mRNA expression level of 
downregulated transcription factor Srebf1 was only significantly downregulated after three 
days of fasting (Figure S4E), while Srebf2 was significantly downregulated after three days 
of fasting and three days of a protein-free diet (Figure S4F).
Target pathways possibly involved in the protective effect of renal IRI 
Various pathways have been proposed to be involved in the protective response against 
renal IRI induced by DR and protein restriction. One of these is the eukaryotic translation 
factor 2 (eIF2α) signaling pathway, in which eIF2α is phosphorylated by the general control 
nonderepressible 2 (Gcn2) kinase, thereby inhibiting initiation of translation19. The role 
of Gcn2 and the eIF2α pathway is subject of debate, and the relevance of this pathway still 
needs to be elucidated19,21. Our microarray analyses showed a significant upregulation of 
eIF2α transcription factor only after three days of fasting, while the Gcn2 gene and other 
target genes of the eIF2α pathway were not significantly differentially regulated after any of 
the dietary interventions. The mammalian Target of Rapamycin (mTOR) signaling pathway 
mediates between growth factors, hormones and nutrients to regulate essential cellular 
functions including survival and protein translation. Inhibition of the mTOR pathway has 
been demonstrated to increase lifespan in various animal species22,23 mTOR is part of mTOR 
complex 1 (mTORC1), a nutrient sensor complex that is involved in induction of oxidative 
stress resistance24. We found a downregulation of mTOR after two weeks 30% DR (-0.6; 
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P<0.01) and 3-days of protein-free diet (-1.7; P<0.001) diets, while MTORC1 (-1.6; P<0.01) 
and mTOR (-0.6; P<0.001) were downregulated after three days of fasting. Both non-
protective diets 3-day CHO-free (+0.8; P<0.01) and 3-day 30% DR (+1.3; P<0.001) showed 
an upregulation of mTOR. mTOR activity was examined at protein level by examining 
ribosomal protein S6 phosphorylation through immunoblotting in kidney extracts from all 
intervention and control groups. S6 is a down-stream target of mTOR through S6 kinase25. 
Table 3. List of upstream transcription factors after meta-analysis with corresponding z-scores in 
the different dietary interventions
Transcription Factor
Dietary intervention
Meta-
analysis
3-days 
fasting
2 weeks 
30% DR
Protein-
free
CHO-
free
3 days 
30% DR 
SMAD7 – SMAD family member 7 +2.890 +0.718 -0.128 +2.466 N/A N/A
* FOXO3 - Forkhead box O3 +2.729 +3.303 +1.042 +1.701 -0.314 +1.893
FOXO1 - Forkhead box O1 +2.692 +1.599 -0.109 +0.269 -1.850 +0.360
* HNF4A – Hepatocyte nuclear factor 4 
alpha
+2.462 +2.122 +1.179 +2.089 +0.109 +1.327
MYCN – v-myc avian myelocytomatosis 
viral oncogene
+2.414 +1.982 N/A +1.245 -2.464 +1.091
CLOCK – Circadian Locomotor Output 
Cycles Kaput
+2.373 +1.980 +1.119 N/A +1.940 +1.925
* HMGA1 – High mobility group AT-hook 
1
+2.051 +1.432 +2.177 +0.356 N/A +0.785
MED1 – Mediator complex subunit 1 +2.008 +2.058 N/A N/A +0.102 N/A
SPDEF – SAM pointed domain containing 
ETS transcription factor
+2.000 +2.170 N/A +1.000 N/A N/A
LYL1 – Lymphoblastic leukemia associated 
hematopoiesis regulator 1
+2.000 +2.000 N/A N/A N/A +1.982
SIM1 – Single-minded homolog 1 +2.000 +0.557 N/A N/A N/A N/A
ARNT2 – Aryl hydrocarbon receptor 
nuclear translocator 2
+2.000 +0.557 N/A N/A N/A N/A
GLI1 – GLI family zinc finger 1 -2.183 N/A N/A +0.057 N/A N/A
* HSF1 – Heat shock factor protein 1 -2.697 -1.659 -2.653 -2.376 +0.462 -0.451
SREBF2 - Sterol regulatory element-
binding transcription factor 2
-2.923 -3.420 N/A -0.243 +0.660 N/A
SREBF1 - Sterol regulatory element-
binding transcription factor 1
-3.889 -2.794 N/A -1.304 +1.229 -0.779
Upstream regulator analysis of the DEPS found in common after 3-days of fasting, two weeks 30% DR and 3-days of protein-
free diet (meta-analysis) revealed 16 transcription factors (TFs) significantly regulated, of which 12 were activated and four 
were inhibited. Highest activated TFs were SMAD7 and FOXO3. *: TFs of interest, that are not or oppositely regulated in the 
non-protective CHO-free diet. 
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Compared to the corresponding control group, three days of fasting showed a significant 
two-fold increase in relative ribosomal protein S6 phosphorylation (Figure 4). In the other 
dietary interventions, a large variation in phosphorylation levels was observed which did 
not reach statistical significance.
DISCUSSION
Since the discovery of the beneficial effects of short-term dietary restriction (DR) on stress 
resistance, optimizing its duration and content to eventually lead to a clinical applicable DR 
regimen has been an important part of the body of literature about DR2,11,19. Previously we 
have shown that two and four weeks of 30% DR as well as three days of fasting decreased 
morbidity and mortality, and improved kidney function in a murine renal IRI model1,12. 
In the present study, we show that a protein-free diet administered for only three days is 
sufficient to induce similar protection, whereas fat- and carbohydrate-free diets did not. 
Initially, we attempted longer periods of diet interventions, but found that mice fed a 
protein-free diet during 10 days applied self-restriction of approximately 30% of their 
normal intake (Figure S1). Therefore, the possible beneficial effects of calorie and protein 
restriction on kidney function and survival were indistinguishable. In a recent publication, 
Peng et al. found that mice fed a protein-free diet for six days restricted calorie intake. 
However, they stated that corrected for body weight, their calorie intake was similar to that 
of ad libitum fed mice19. It is unknown whether six days of 30% DR induces protection 
against IRI, therefore a distinction between protein restriction and calorie restriction is still 
difficult to make. We showed that three days of 30% DR does not induce protection against 
renal IRI, and therefore we could disentangle the effects of calorie and protein restriction 
per se (Figure 1).  A protein-free diet, given for three days induced protection, whereas both 
a CHO-free and fat-free diet given for three or 14 days did not protect against renal IRI 
(Figure S1). A recent publication by Solon-Biet et al26 showed that the ratio of proteins and 
carbohydrates rather than DR per se influenced the lifespan of mice as well as metabolic 
parameters such as insulin and lipids. Since proteins fully substituted the carbohydrates 
in our CHO-free diet, and carbohydrates fully substituted the proteins in our protein-
free diet, these diets further emphasize the importance of the ratio between proteins and 
carbohydrates (Table S4).
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Figure 4. Relative S6 phosphorylation signals in kidney after various diet interventions. The 
ratio of phosphorylated S6 over total S6 was significantly lower after three days of fasting compared 
to its control diet. All other dietary interventions showed a large variation in phosphorylation levels 
that did not reach statistical significance.
Although the beneficial effects of both long-term and short-term DR have been 
acknowledged, the mechanisms underlying DR are still subject of investigation. Various 
pathways, factors and genes have been proposed to play a central role in the protective 
effects27, but attempts to validate these yielded conflicting results28-31. We produced extensive 
expression datasets of diets proven to be either protective or not protective against renal 
IRI. Gene expression profiles of the non-protective CHO-free diet showed a considerable 
overlap with gene expression profiles of protective diets, namely three days of fasting, two 
weeks 30% DR and 3-days of protein-free diet (Figure 3). A PCA plot demonstrated the 
partial different directionality of gene expression in the CHO-free diet compared to the 
other dietary interventions. The 3-day 30% DR diet also showed considerable overlap 
with the protective diets, mainly with two weeks 30% DR, and a partially different but also 
partially overlapping directionality in response. These findings could either indicate that 
overlapping probe sets and pathways are not involved in the induction of protection against 
renal IRI, or that they may require additional changes in other probe sets to induce this effect. 
Particularly, the striking similarity between three days and two weeks 30% DR suggests that 
three days is sufficient to activate a transcriptomic response which is not yet sufficient to 
induce phenotypical protection.  In addition, the non-protective fat-free diet showed strong 
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similarity with the protective 3-day protein-free diet, but with gene expression levels that 
were lower. These results indicate that the directionality, the number of probe sets and the 
expression levels are of importance in order to induce protection against renal IRI. 
To provide structure in the infinite amount of data generated by microarray analysis, we 
used meta-analytic approximations to specify for overlapping pathways and factors in all 
diets. A specific meta-analysis in which the DEPS were oppositely regulated in the protective 
diets versus the non-protective CHO-free diet, resulted in only 160 DEPS and yielded no 
additional pathways of interest compared to a meta-analysis including the CHO-free diet. 
In this meta-analysis several TFs, including FOXO3 and HNF4A, remained significantly 
upregulated in the protective diets whilst not or oppositely regulated in the CHO-free diet 
(data not shown). 
Activation of nuclear receptor signaling pathways dominated the top 10 overrepresented 
pathways after three days of fasting, two weeks of 30% DR and three days of a protein-
free diet (Table 2). Specific retinoid receptors, including the retinoid X receptor (RXR), 
the pregnane X receptor (PXR) and the peroxisome proliferator-activated receptor 
(PPAR)32, were also prominently upregulated in our analysis, pointing towards a pivotal 
role for nuclear receptor signaling. Nuclear receptors are transcription factors that can be 
activated by steroid hormones and lipid-soluble agents, such as the retinoid acids (RAs)33. 
Administration of RAs induces many of the beneficial effects observed after DR. DR is able 
to ameliorate age-related insulin resistance and degenerative brain diseases, and similar 
results have been described after treatment with RAs34-36. Both DR and administration of 
RAs are able to protect from ischemic stroke in the brain37-39. Signaling pathways activated 
by the interaction between RAs and nuclear receptors have also been considered to have 
tumor-, and immune suppressive effects, just as DR9,33,40. 
Involvement of nuclear receptor signaling is further supported by the upstream TF analysis 
(Table 3), since the majority of the activated or inhibited TF could be directly or indirectly 
linked to the activation of nuclear receptors. The activated TFs in all protective diets that 
were oppositely or not regulated in the non-protective CHO-free diet are FOXO3, HNF4A, 
HMGA1 and HSF1.  A role for each of these four TFs in increased stress resistance has 
been previously observed. For example, FOXO3 phosphorylation via the c-Jun N-terminal 
kinase -pathway results in its nuclear inclusion and activation of various processes involved 
in cellular stress resistance, biosynthesis, cell cycle regulation as well as apoptosis and 
autophagy41,42. A fasting-induced interaction, mediated by insulin signaling, with members 
of the FOXO family and RXR has been described as well43. HMGA1 is a downstream 
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target of the insulin receptor pathway and could function as an important nuclear factor 
mediating the binding of FOXO proteins to other nuclear receptors, including the retinoid 
nuclear receptor family and thereby regulating insulin target genes44. 
HNF4A is a nuclear TF that is involved in the development as well as in the metabolism 
of mainly the liver and kidney45. Upregulation of HNF4A occurs via co-stimulation 
of LXR and FXR and usually depends on the presence of low levels of stressors, such as 
interleukin-1 and tumor necrosis factor alpha. Transcriptional activity of HNF4A is also 
regulated indirectly by insulin through the action of FOXO145. Activation of HNF4A results 
in inhibition of the activity of metabolic sensors, including SREBF and the mammalian 
target of Rapamycin (mTOR)46,47. This leads to downregulation of metabolism, in 
particular cholesterol metabolism, and may contribute to increased stress resistance via the 
downregulation of mTOR47,48. We showed that the activity of mTOR, as determined by the 
phosphorylation of the ribosomal protein S6, was significantly downregulated after three 
days of fasting. A trend towards lower phosphorylation levels was seen after the other two 
protective diets: two weeks 30% DR and a 3-day protein-free diet. These data indicate that 
mTOR may play an important role in the protection against IRI, which may vary according 
to the type of nutrient deprivation that is offered. Another pathway involved in nutrient 
sensing is GCN2, of which eIF2α is an important downstream target. GCN2 becomes 
transcriptionally activated by deprivation of amino acids and phosphorylates eIF2α, 
which leads to the activation of pathways involved in stress resistance. We did not find 
transcriptional regulation of the Gcn2 gene in any of the three protective diets. Although 
our data do not preclude posttranscriptional regulation of this pathway, they corroborate 
with those of Robertson et al 49, who observed that GCN2 signaling was not required for 
protection against renal IRI by protein restriction.
In summary, we demonstrated that three days of a protein-free diet in mice protects 
against renal IRI, similar to two weeks of 30% DR and three days of fasting. Comparative 
transcriptional analysis of kidney tissue following these dietary interventions demonstrated 
a significant overlap in differentially expressed genes and pathways, which are involved 
in resistance against oxidative damage induced by renal IRI. A meta-analysis of pathways 
and TFs indicates that DR upregulates at least four TFs that activate a transcriptional 
response, which, in turn, increases nuclear receptor signaling dependent and independent-
cellular stress resistance. However, our attempt to understand the beneficial effects of 
different dietary restriction regimens on renal IRI by transcriptome analysis suggests that 
pivotal molecular changes also occur beyond the transcriptional level, and that additional 
‘omics” analyses, including proteomics, are needed to come to a complete understanding. 
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Therefore, more research is warranted to further elucidate the role of these pathways in the 
induction of acute stress resistance by short-term DR, which may ultimately lead to “dietary 
restriction mimetic” therapeutic strategies that exploit the benefits of DR in humans. 
MATERIALS AND METHODS
Study design
Sample size calculation of our previous study was based on a 25% decrease of serum urea 
levels at time point 24 hours after renal IRI, with a standard deviation (SD) of 20% and a 
power of 0.81,11. These experiments demonstrated that our renal IRI model was feasible and 
stable, and we therefore reduced the number of mice to six mice per group in the dietary 
intervention groups. Primary endpoint of this study was kidney function 24 hours after 
surgery, measured via serum urea concentrations. Secondary endpoints of this study were 
mortality rate in the first seven days after surgery and changes in gene expression profiles 
measured directly after each dietary intervention. Experimental data of two weeks 30% DR 
and three days of fasting groups were previously obtained1. Animals were euthanized and 
excluded from the experiment if their body weight decreased ≥20% of their preoperative 
weight or if they developed a moribund phenotype, including ruffled fur, hunched body 
posture, hypothermia, and decreased activity11,12. 
Animals
C57BL/6 male mice, 10-12 weeks old (20-25 grams), were obtained from Harlan, the 
Netherlands. Animals were housed in individually ventilated cages (3-4 animals/cage) under 
standard conditions. All mice had ad libitum (AL) food and water (acidified with HCl to a 
pH of 2.4-2.7) except where noted. All experiments were performed with the approval of 
the Animal Experiments Committee of the Erasmus University Medical Center, Rotterdam, 
the Netherlands under the Dutch National Experiments on Animals Act and according to 
the ARRIVE Guidelines, Animal Research: Reporting of In Vivo Experiments50.
Diets and experimental design
The control chow for the fasting and dietary restriction groups was obtained from Special 
Diet Services (SDS, Witham, UK). All other diets were purchased from Research Diets, 
Inc. (New Brunswick, NJ, USA). The macronutrient composition and energy content of all 
diets are shown in Table S4. The control diet differed from the standard chow given (Special 
Diet Services, SDS) in the protein source, which consisted of lactic casein protein in case of 
control diet, while the SDS control consisted of crude protein. These two control diets are 
designated as “Control” and “SDS” throughout the manuscript.
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Long-term dietary intervention
Upon arrival, mice were allowed ad libitum (AL) access to the SDS chow for seven days. 
At the start of the dietary intervention period, all mice were transferred to clean cages at 
4:00 pm. Mice were randomly divided into a group with 30% DR (n=5) or AL access to a 
carbohydrate-free (CHO-free) diet (n=6) or a fat-free diet (n=6) for 14 days, or a protein-
free diet (n=6) for 10 days (Figure S3). Mice in the control group for DR had AL access to 
the control SDS chow (n=10), the control group for CHO-free and fat-free had AL access 
to Control diet (n=12). The effect of food intake was measured using pair-fed (PFed) 
control groups. Pair-feeding of each group was accomplished by giving the PFed groups 
the identical isocaloric amount of the control diet as the mice on the experimental diet had 
consumed the day before. The CHO-free, fat-free and protein-free diets were PFed in this 
manner (n=6/group). Mice with 30% DR were given 70% of the normal daily intake of mice 
on the control diet, which was administered once daily at 4:00 pm. Since the phenotypical 
effects of two weeks 30% DR were reported previously, microarray analysis was used as the 
only outcome for this group1. 
Short-term dietary intervention
Upon arrival, the same procedure was followed as for the long-term experiment. Mice were 
randomly divided into groups with AL access to control diet (n=4), a protein-free diet (n=6 
per group) for three days or 30% DR for three days (n=6), or into groups with AL access to 
SDS chow or fasting for three days (n=5 per group). Since the phenotypical effects of three 
days fasting were reported previously, transcriptome analysis was the only parameter for 
this group1. For a graphical overview of the experimental setup see Figure S3. 
Dietary intake and body weight
Food intake and body weight were measured daily. To determine calorie intake, the daily 
food intake was corrected for the variation in the energy content (per gram of food) in 
the diets as follows: food intake per mouse times the number of calories per gram of food. 
Change in body weight was addressed in percentages calculated by dividing the body 
weight measurements during the dietary intervention through body weight at onset of the 
intervention period times 100. 
Surgical procedure
Following each dietary intervention, bilateral renal IRI was induced as previously 
described1. In brief, mice were anesthetized via inhalation of isoflurane (5% isoflurane 
initially followed by 2-2.5% with oxygen for maintenance). Via midline abdominal 
incisions, the renal arteries and veins were exposed followed by occlusion of both renal 
pedicles for 37 minutes using non-traumatic vascular clamps. Purple discoloration of the 
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kidneys confirmed ischemia macroscopically, while reperfusion was established when the 
color of both kidneys normalized after removal of the clamps. The incision was closed with 
5/0 sutures in two layers. Following closure, mice received 0.5 ml PBS subcutaneously to 
compensation for fluid loss. The morning after surgery, another identical dose of PBS was 
given. Mice intended for microarray analysis were sacrificed immediately after the dietary 
intervention, without induction of renal IRI.   
Kidney function
Kidney function was determined as previously described1 by measuring serum urea levels 
in blood samples, collected via retro-orbital puncture while mice were anesthetized, before 
(T=0) and day 1 (T=1) after induction of renal IRI1. 
Immuno-blotting
Mouse kidney extracts from nine different intervention diets were prepared by sonification 
with Soniprep 150 (Company, Place, Country) 2-3 times 30 seconds on ice in Laemmli 
buffer (135 mM Tris-HCl pH 6.8, 4.5% SDS, 22.5% glycerol), supplemented with 
complete protease inhibitors and PhosSTOP phosphates inhibitors (Roche Diagnostics, 
Indianapolis, IN, USA) After sonification, lysates were centrifuged at 4 degrees Celsius for 
10 minutes. Protein concentrations were measured using the BCA Protein Assay Kit (Pierce 
Biotechnology, Rockford, USA). 25 µg protein was loaded on a NuPAGE 10% Bis-Tris Gel 
(Life Technologies LTD, Paisley, UK) and transferred to a PVDF Hybond-P (GE-Healthcare 
Life Sciences, Uppsala, Sweden) transfer membrane. Immunoblotting was performed 
with antibodies directed against S6 (#2217S Lot5; 1:1.000) and Phospho-S6 (Ser240/244; 
#2215 Lot14; 1:500) (Cell Signaling Technology, Danvers, MA, USA). Blotting membranes 
were incubated with primary antibodies overnight at 4 degrees Celsius, before they were 
washed and incubated with 1:5000 diluted secondary anti-rabbit-IgG-HRP antibody (GE-
Healthcare Life Sciences). Detection was performed by enhanced chemiluminescence using 
the ECL 2 Western Blotting Substrate (Pierce Biotechnology). Levels of S6 and Phospho-S6 
were semi-quantified using the ImageJ software package (http://rsb.info.nih.gov/ij/index.
html) and S6-phospho/S6-total ratios relative to the control diet were calculated and 
differences between groups were assessed with a t-test. Β-Actin was used as loading control 
(Sigma; A5441 Lot064M4789V; 1:25.000).
Microarrays
The duration of dietary interventions that were used to study gene expression profiles was 
three days for all diets with exception of 30% DR, which was given for two weeks. Kidneys 
were obtained directly after each intervention and were snap frozen in liquid nitrogen 
until further analyses. An overview of the dietary interventions, the groups of mice and 
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numbers used for phenotypical and transcriptional endpoints is summarized in Table S5. 
Total RNA was extracted using QIAzol lysis Reagent and miRNAeasy Mini Kits (QIAGEN, 
Hilden, Germany), following Qiagen protocol. Addition of wash buffers RPE and RWT 
(QIAGEN) was done mechanically by using the QIAcube (QIAGEN, Hilden, Germany) via 
the miRNAeasy program. Isolated RNA was and stored at -80°C. The concentration of RNA 
was measured by Nanodrop (Thermo Fisher Scientific™, Breda, the Netherlands) and RNA 
quality was assessed using the 2100 Bio-Analyzer (Agilent Technologies, Amstelveen, the 
Netherlands) according to manufacturer’s instructions. The RNA quality was expressed as the 
RNA integrity number (RIN, range 0-10). RIN values of included samples ranged between 
6.6 and 8.5. Hybridization to Affymetrix HT MG-430 PM Array Plates was performed at 
the Microarray Department of the University of Amsterdam (the Netherlands), according 
to Affymetrix protocols. Four to six biological replicates were used for each group. Quality 
control and normalization were performed using the pipeline at the www.arrayanalysis.org 
website (Maastricht University, the Netherlands)26. Normalization was done via the Robust 
Multichip Average (RMA) algorithm51. Due to a range in hybridization dates between 
fasting and the other diets (i.e. September 2011 versus August 2012), normalization of 
the data for fasted animals and their controls was done separately. Normalization output 
consisted of data for 45,141 probes, with several probes corresponding to the same Gene ID. 
Complete raw and normalized microarray data and their MIAME compliant metadata have 
been deposited at the Gene expression Omnibus (GEO) database GEO GSE65656 (www.
ncbi.nlm.nih.gov/geo). After normalization, outliers were found in the control SDS (control 
30% DR), the 3-day fasting and 3-day fat-free diet groups, defined as a deviation in array-
array intensity correlations, principal component analysis and cluster dendograms. These 
outliers were excluded from further analyses (Table S5).
Statistical analysis
Data are expressed as means ± standard error of the mean (SEM). Statistical analyses were 
performed using SPSS (version 21.0) and GraphPad Prism (version 5.0). Differences in 
serum urea concentrations were compared by Mann-Whitney U tests, food intake via 
the paired t-test and survival rates were analyzed by Log-rank tests. A P-value of <0.05 
was considered significant. Microarray analyses were performed using the free software 
package R (R foundation). Gene expression data were compared using the Linear Models 
for Microarray Data (limma) method with correction for multiple testing using the false 
discovery rate (FDR) according to Benjamini and Hochberg 52. Fold changes were expressed 
as the geometric mean per diet group against the corresponding ad libitum fed control group. 
Cutoff values for a significant difference were put at FDR <5% with fold change ≥1.5. The 
enrichment factor (EF) was calculated via the formula: EF=nAB/((nA×nB)/nC), where nA 
is the number of differentially expressed probe sets (DEPS) in experimental group A, nB the 
15045-jongbloed-layout.indd   98 06/11/2017   17:20
99
4
A PROTEIN-FREE DIET PROTECTS AGAINST RENAL IRI
number of DEPS in experimental group B, nC the number of total genes in the microarray, 
and nAB the number of common DEPS between nA and nB. Data integration of microarrays 
hybridized in different dates was performed with meta-analysis. The methodology applied 
was combining rank orders. It is a non-parametric approach based on rank orders. The 
R package RankProd implemented in INMEX was used20. In summary, for each dataset, 
the fold changes (FC) were calculated for all possible pairwise comparisons. The ranks of 
the fold changes within each comparison were used to calculate the rank product for each 
gene. To assess the null distribution of the rank product within each data set, a permutation 
test was performed. The process was repeated several times to compute the P-value and 
false discovery rate (FDR) associated with each gene. A gene was selected as differentially 
expressed if it had an FDR <5% and an absolute combined FC ≥1.5. Functional annotation and 
analyses were performed using Ingenuity software (http://www.ingenuity.com/ products/
ipa). The prediction inhibition or activation of the upstream transcription regulators 
is calculated via de statistical z-score based on the observed gene expression changes in 
our dataset. Calculating the z-score reduces the chance of significant predictions based 
on random data (http://ingenuity.force.com/ipa/articles/FeatureDescription/Upstream 
-Regulator-Analysis). Cutoff values for a significant activation or inhibition were met with 
a z-score of ≥ 2 or ≤-2, respectively.
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SUPPLEMENTARY DATA 
Figure S1. Effects on food intake, body weight and survival by macronutrient free diets and 
effects on kidney function upon subsequent renal ischemia-reperfusion injury. (A) Relative to 
their control food intake during the 7-day acclimatization period, mice consumed (cumulatively 
during the whole intervention period) 21.7% less of the CHO-free diet, 10.1% of the fat-free diet 
and 32.7% of the protein-free diet. (B) Body weight of mice fed a CHO-free diet decreased during 
the 14-day period with 6.7%, while mice on a 14-day fat-free diet showed an increase in body weight 
with 2.3%. Mice fed a protein-free diet for 10 days lost more than 20% of their body weight on day 
10. Because of this substantial loss of body weight, the protein-free diet was limited to a period of 
10 days or less in the subsequent ischemia-reperfusion experiments. (C) Mouse mortality rates 
upon renal ischemia-reperfusion injury after both the CHO- and fat-free diet were significantly 
higher than their PFed controls (P<0.05). Mice fed a protein-free diet for 10 days showed a 100% 
survival following renal IRI. (D) Kidney function as determined by serum urea levels on day 1 
after induction of renal IRI were significantly worsened in both the CHO-free (P<0.05) and fat-
free (P<0.05) groups compared to PFed groups. Mice fed a protein-free diet showed lower serum 
urea levels one day after induction of IRI compared with CHO-free (P<0.01), the PFed CHO-free 
(P<0.05), the fat-free (P<0.01) and the PFed fat-free group (P<0.05). ** = P<0.05 compared to AL 
CHO-free diet on day 0. ## = P<0.05 compared to AL fat-free diet on day 0. ^^ = P<0.05 compared 
to AL protein-free diet on day 0. 
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Figure S2. PCA of all probes on the microarray chip. This unbiased analysis shows the largest 
source of variability, PC1, is related to the date of hybridization. The 3-day fasting group and their 
corresponding control group were hybridized on a different date than the other groups. This result 
made the joint analysis of all datasets impracticable. PC2 explains only 15% of the variability, and 
it is related to the dietary interventions compared to the control samples. AL SDS (Fast)=  control 
group of the 3-day fasting mice. AL SDS (DR) = control group of the 2 weeks 30% DR mice. Control 
= control group of the macronutrient-free diets. 
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Figure S3. Schematic overview of the experimental design. After an acclimation period for all 
groups of 7 days on SDS chow, the long-term experiments started with diets given for either 10- or 
14 days. At day -3 relative to induction of ischemia-reperfusion injury (IRI) the short-term dietary 
intervention and gene expression profiling experiments were started. At day 0, animals used for 
transcriptomic profiling were sacrificed for further analyses. In the other groups, blood collection 
was followed by induction of bilateral renal IRI for 37 minutes and collection of blood one day later. 
Mice were followed until day 7 after IRI, after which they were sacrificed.
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Figure S4. PCR data of mRNA expression levels of genes related to significantly regulated 
transcription factors. (A) Foxo1 was significantly higher after all diets except the fat-free diet. 
(B) Foxo3 showed significant upregulation after all diets except the 2 weeks 30% DR. (C) FOXO4 
expression levels were significant higher after 3 days of 30% DR and 3-days of a CHO-free diet. 
(D) Hnf4α was not significantly regulated after any of the dietary interventions. (E) Srebf1 was 
downregulated after 3 days of fasting, while (F) Srebf2 was significantly downregulated after both 3 
days of fasting and a 3-day protein-free diet. FOXO = forkhead box O; Hnf4α = hepatocyte nuclear 
factor 4-alpha; Srebf = sterol regulatory element-binding transcription factor 1. * = P<0.05; ** = 
P<0.01.
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A        B 
 
	
	
Slot Dietary intervention 
Mr Marker lane 
1 Control 
2 CHO-free 
3 Fat-free 
4 Protein-free 
5 3-day 30% DR 
6 2-week 30% DR 
7 SDS control 
8 3-day fasting 
9 Reference sample 
Slot Dietary intervention
Mr Marker lane
1 Control
2 CHO-free
3 Fat-free
4 Protein-free
5 3-day 30% DR
6 2-week 30% DR
7 SDS control
8 3-day fasting
9 Reference sample
Figure S5. Representative Western blots of kidney extracts for both phosphorylated (A) and total 
(B) ribosomal protein S6 with β-actin as a loading control used for the relative quantification 
in Figure 4. The depicted exemplary blots show a full set of kidneys extracts from each indicated 
diet group (lanes 1 – 8) next to a marker lane (lane Mr) and a reference sample (lane 9). In total, 
four such sets of Western blots were generated, each with four unique complete series for each 
diet group. For interblot comparison the exact same amount of the reference sample (lane 9) was 
loaded on each blot. The relative phosphorylation ratios depicted in Figure 4. are derived from the 
quantified signal of the main band in each lane, subtracted with background and corrected for both 
the sample dependent β-actin signal and the blot dependent signal of the reference sample.
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Table S1. List of genes corresponding to the DEPS found in common between all dietary 
interventions combined
Affymetrix ID
Entrez 
Gene 
ID
Symbol Gene Name LogRatio
1415802_PM_at 20501 SLC16A1 solute carrier family 16 (monocarboxylate 
transporter), member 1
-0,488
1415828_PM_a_at 28146 SERP1 stress-associated endoplasmic reticulum protein 1 -0,639
1416414_PM_at 100952 EMILIN1 elastin microfibril interfacer 1 -0,623
1416630_PM_at 15903 ID3 inhibitor of DNA binding 3, dominant negative helix-
loop-helix protein
1,008
1417150_PM_at 15567 SLC6A4 solute carrier family 6 (neurotransmitter transporter), 
member 4
0,537
1418591_PM_at 58233 DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 -0,709
1419040_PM_at 56448 Cyp2d22 cytochrome P450, family 2, subfamily d, polypeptide 
22
1,033
1422974_PM_at 23959 NT5E 5’-nucleotidase, ecto (CD73) -1,037
1423392_PM_at 29876 CLIC4 chloride intracellular channel 4 -0,782
1423627_PM_at 18104 NQO1 NAD(P)H dehydrogenase, quinone 1 1,024
1424618_PM_at 15445 HPD 4-hydroxyphenylpyruvate dioxygenase 1,064
1424983_PM_a_at 78832 CACUL1 CDK2-associated, cullin domain 1 -0,746
1426568_PM_at 117591 SLC2A9 solute carrier family 2 (facilitated glucose 
transporter), member 9
0,684
1426896_PM_at 59057 ZNF24 zinc finger protein 24 -0,495
1427364_PM_a_at 18263 ODC1 ornithine decarboxylase 1 -0,975
1427931_PM_s_at 216134 PDXK pyridoxal (pyridoxine, vitamin B6) kinase 1,251
1428332_PM_at 216505 PIK3IP1 phosphoinositide-3-kinase interacting protein 1 0,828
1433557_PM_at 52609 CBX7 chromobox homolog 7 0,618
1434437_PM_x_at 20135 RRM2 ribonucleotide reductase M2 -0,128
1434974_PM_at 228026 PDK1 pyruvate dehydrogenase kinase, isozyme 1 0,683
1436893_PM_a_at 57438 MARCH7 membrane-associated ring finger (C3HC4) 7, E3 
ubiquitin protein ligase
0,585
1438211_PM_s_at 13170 DBP D site of albumin promoter (albumin D-box) binding 
protein
1,768
1439797_PM_at 19015 PPARD peroxisome proliferator-activated receptor delta -0,838
1443870_PM_at 239273 ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 4
1,063
1449183_PM_at 12846 COMT catechol-O-methyltransferase -0,944
1449460_PM_at 142688 ASB13 ankyrin repeat and SOCS box containing 13 -0,686
1449848_PM_at 14675 GNA14 guanine nucleotide binding protein (G protein), alpha 
14
-0,832
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Table S1. (continued)
Affymetrix ID
Entrez 
Gene 
ID
Symbol Gene Name Log Ratio
1451122_PM_at 319554 IDI1 isopentenyl-diphosphate delta isomerase 1 -1,173
1452264_PM_at 209039 TNS2 tensin 2 0,757
1454709_PM_at 100201 TMEM64 transmembrane protein 64 -0,867
1455293_PM_at 235497 LEO1 LEO1 homolog, Paf1/RNA polymerase II complex 
component
-0,727
1455343_PM_at 233765 PLEKHA7 pleckstrin homology domain containing, family A 
member 7
0,922
1455393_PM_at 12870 CP ceruloplasmin (ferroxidase) 1,037
1455490_PM_at 18703 PIGR polymeric immunoglobulin receptor 0,924
1457689_PM_at 319934 SBF2 SET binding factor 2 0,761
1458176_PM_at 18628 PER3 period circadian clock 3 1,072
1460239_PM_at 66109 TSPAN13 tetraspanin 13 -0,925
The Afymmetrix probe sets, their corresponding Entrez Gene ID, symbol, gene name and log ratio are depicted in ascending 
order of the Affymetrix probe set. Only the probe sets with a corresponding gene ID are listed, therefore probe sets corresponding 
to the same gene ID are excluded. Log Ratio = log transformed fold change. 
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Table S2. Top 10 overrepresented canonical pathways after fasting, dietary restriction and 
macronutrient free diets individually ranked by their –log P-value
Canonical Pathway P-value Genes Ratio
3-day FASTING
Superpathway Cholesterol Biosynthesis 3.41E-08 14/87 (16.1%)
Cholesterol Biosynthesis I / II / III 2.18E-06 8/40 (20.0%)
LXR / RXR Activation 2.20E-06 27/139 (19.4%)
NRF2-mediated Oxidative Stress Response 6.27E-06 34/195 (17.4%)
LPS/IL-1 Mediated Inhibition of RXR Function 7.46E-06 39/245 (15.9%)
Acute Phase Response Signaling 7.24E-05 30/181 (16.6%)
GADD45 Signaling 1.25E-04 8/24 (33.3%)
AMPK Signaling 1.25E-04 25/180 (13.9%)
VDR/RXR Activation 2.18E-04 17/88 (19.3%)
Xenobiotic Metabolism Signaling 3.00E-04 42/304 (13.8%)
2-week 30% DR
Circadian Rhythm Signaling 1.41E-05 6/38 (15.8%)
Aldosterone Signaling Epithelial Cells 3.20E-05 11/168 (6.5%)
Guanosine Nucleotides Degradation II 7.85E-04 3/22 (13.6%)
Urate Biosynthesis 1.01E-03 3/22 (13.6%)
Phenylalanine Degradation IV 1.27E-03 3/39 (7.7%)
2-ketoglutarate Dehydrogenase Complex 1.48E-03 2/9 (22.2%)
Adenosine Nucleotides Degradation II 1.57E-03 3/26 (11.5%)
NRF2-mediated Oxidative Stress Response 2.39E-03 9/195 (4.6%)
Protein Ubiquitination Pathway 2.63E-03 11/270 (4.1%)
Purine Nucleotides Degradation II 2.71E-03 3/35 (8.6%)
3-day PROTEIN-FREE
Intrinsic Prothrombin Activation Pathway 5.18E-04 4/37 (10.8%)
Superpathway Cholesterol Biosynthesis 6.79E-04 4/87 (4.6%)
LPS/IL-1 Mediated Inhibition of RXR Function 8.81E-04 10/245 (4.1%)
Mevalonate Pathway I 9.87E-04 3/29 (10.3%)
Creatine-phosphate Biosynthesis 1.77E-03 2/9 (22.2%)
Superpathway of Geranylgeranyl 2.02E-03 3/37 (8.1%)
PXR/RXR Activation 2.12E-03 5/92 (5.4%)
GADD45 Signaling 2.35E-03 3/24 (12.5%)
Tryptophan Degradation 4.84E-03 2/18 (11.1%)
Nicotine Degradation II 9.33E-03 4/85 (4.7%)
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Table S2. (continued)
Canonical Pathway P-value Genes Ratio
3-day CARBOHYDRATE-FREE
Histamine Degradation 9.52E-05 6/29 (20.7%)
Pyrimidine Deoxygenase De Novo Biosynthesis I 1.57E-04 6/34 (17.6%)
Superpathway of Serine and Glycine Biosynthesis I 2.57E-04 4/18 (22.2%)
Glycolysis I 6.98E-04 7/41 (17.1%)
NRF2-mediated Oxidative Stress Response 8.17E-04 24/195 (12.3%)
Cholesterol Biosynthesis I / II / III 1.04E-03 5/40 (12.5%)
Colanic Acid Building Blocks Biosynthesis 1.52E-03 5/36 (13.9%)
Fatty Acid β-oxidation 1.52E-03 5/21 (23.8%)
Protein Ubiquitination Pathway 1.58E-03 30/270 (11.1%)
Folate Transformations I 1.84E-03 4/32 (12.5%)
3-day 30% DR
Dopamine Degradation 1.08E-04 5/35 (14.3%)
Aryl Hydrocarbon Receptor Signaling 1.37E-04 9/140 (6.4%)
LPS/IL-1 Mediated Inhibition of RXR Function 2.48E-04 11/221 (5.0%)
PXR/RXR Activation
Circadian Rhythm Signaling
2.63E-04
1.03E-03
6/65 (9.2%)
4/33 (12.1%)
NRF2-mediated Oxidative Stress Response 1.42E-03 9/193 (4.7%)
Tyrosine Degradation I 1.82E-03 2/5 (40.0%)
Histamine Degradation 2.09E-03 3/19 (15.8%)
Noradrenaline and Adrenaline Degradation 2.14E-03 4/40 (10.0%)
Adipogenesis Pathway 2.52E-03 7/134 (5.2%)
Top 10 overrepresented pathways after dietary restriction and macronutrient free diets, with the exception of the 3-day fat-free 
diet that showed no differentially expressed probe sets. Analysis revealed no pathways regulated in common between the three 
protective diets. Furthermore, no pathways were oppositely regulated in the non-protective CHO-free diet. Genes ratio is the 
number and percentage of genes differentially expressed in ratio to the total number of genes involved in the pathway.
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Table S3. Top 10 overrepresented canonical pathways after the meta-analysis including fasting, 
dietary restriction and macronutrient free diets ranked by their –log P-value
Meta-analysis II (including 3-day 30% DR)
Canonical Pathway Pathway Category P-value Genes Ratio Z-score
LPS/IL-1 Mediated 
Inhibition of RXR Function Nuclear Receptor Signaling 4.68
E-05 10/221 (4.5%) N/A
NRF2-mediated Oxidative 
Stress Response Cellular Stress and Injury 8.92
E-05 9/193   (4.7%) N/A
PXR/RXR Activation Nuclear Receptor Signaling 3.59E-04 5/65     (7.7%) N/A
Noradrenaline and 
Adrenaline Degradation
Degradation/Utilization/ Assimilation; 
Hormones 5.25
E-04 4.40     (10.0%) N/A
Aryl Hydrocarbon Receptor 
Signaling
Cell Cycle Regulation; Apoptosis; 
Xenobiotic Metabolism, Nuclear 
Receptor Signaling
2.08E-03 6/140   (4.3%) N/A
Superpathway of 
Cholesterol Biosynthesis
Fatty Acids and Lipids Biosynthesis, 
Sterol Biosynthesis 2.23
E-03 3/28     (10.7%) N/A
Glutathione-mediated 
Detoxification
Degradation/Utilization/ Assimilation; 
Detoxification 2.47
E-03 3/29     (10.3%) N/A
Circadian Rhythm Signaling Neurotransmitters and Other Nervous System Signaling 3.59
E-03 3/33     (9.1%) N/A
Retinoate Biosynthesis I
Vitamin (A) Biosynthesis; Cofactors, 
Prosthetic Groups and Electron 
Carriers Biosynthesis
3.91E-03 3/34     (8.8%) N/A
Dopamine Degradation Degradation/Utilization/ Assimilation; Amines and Polyamines Degradation 4.25
E-03 3/35     (8.6%) N/A
The top 10 overrepresented pathways derived from the 279 DEPS in common between 3-days of fasting, 2 weeks 30% DR, 
3 days of a protein-free and 3 days of a 30% DR diet. These pathways are mostly involved in regulation of nuclear receptor 
signalling (5 out of 10), biosynthesis signalling (2 out of 10) and cellular stress and injury (2 out of 10). 
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Table S4. Composition and energy content of the individual diets
Ingredient Control SDS-CRMP Carbohydrate-free Fat-free Protein-free
Crude protein* (%/g)
Casein, lactic (%/g) 20.0
16.4
99.2 31.3 0
 Total kcal/g 3.8 3.3 3.4 3.5 3.8
Protein (g/kg) 179.0 183.5 887.9 280.1 0.0
Carbohydrate (g/kg)  710.0 574.0 1.0 710.0 889.0
Fat (g/kg) 45.0 33.6 45.0 0.0 45.0
Fiber (g/kg) 50.0 24.8 50.0 50.0 50.0
Protein (g%) 17.0 22.0 77.2 24.9 0
Carbohydrate (g%) 67.3 68.9 0.1 63.1 86.2
Fat (g%) 4.3 9.1 3.9 0.0 4.4
Fiber (g%) 4.7 4.2 4.3 4.4 4.8
Protein (kcal/kg) 716 734 3551 1121 0
Carbohydrate (kcal/kg) 2840 2296 4 2840 3556
Fat (kcal/kg) 405 303 405 0 405
Protein (kcal%) 18 22 90 28 0
Carbohydrate (kcal%) 72 69 0 72 90
Fat (kcal%) 10 9 10 0 10
*protein sources: wheat, barley, soya, maize, potato protein 
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Table S5. Overview of the dietary interventions, the groups and numbers of mice used for 
phenotypical and transcriptional endpoints
Dietary 
Intervention
Model Duration 
(days)
Number 
of mice
Follow-
up (days)
Parameters measured
(A) Overview IRI long-term experiments
Control SDS C57BL/6 14 10 7 Survival, body weight, kidney function
Control C57BL/6 14 12 7 Survival, body weight, kidney function
Fat-free C57BL/6 14 6 7 Survival, body weight, kidney function 
Pair-fed fat-
free 
C57BL/6 14 6 7 Survival, body weight, kidney function
Carbohydrate-free C57BL/6 14 6 1 Survival, body weight, kidney function
Pair-fed 
carbohydrate-free
C57BL/6 14 6 7 Survival, body weight, kidney function
Protein-free C57BL/6 10 6 7 Survival, body weight, kidney function
(B) Overview IRI short-term experiments
Control C57BL/6 3 4 7 Survival, body weight, kidney function
Protein-free C57BL/6 3 4 7 Survival, body weight, kidney function
AL Control 
(control to 3-day 
30% DR)
C57BL/6 3 4 7 Survival, body weight, kidney function
3 days 30% DR C57BL/6 3 6 7 Survival, body weight, kidney function
(C) Overview of gene transcription experiments
Control SDS 
(control 2-week 
30% DR)
C57BL/6 14 4 0 Gene expression profiling in kidney 
tissue
2-week 30% DR C57BL/6 14 5 0 Gene expression profiling in kidney 
tissue
Control SDS 
(control 3-day 
fasting)
C57BL/6 3 5 Gene expression profiling in kidney 
tissue
3-day fasting C57BL/6 3 4 0 Gene expression profiling in kidney 
tissue
Control C57BL/6 3 5 0 Gene expression profiling in kidney 
tissue
Protein-free C57BL/6 3 5 0 Gene expression profiling in kidney 
tissue
Fat-free C57BL/6 3 4 0 Gene expression profiling in kidney 
tissue
Carbohydrate-free C57BL/6 3 5 0 Gene expression profiling in kidney 
tissue
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ABSTRACT
Ischemia-reperfusion injury (IRI) is inevitable during major liver surgery and liver 
transplantation leading to oxidative stress. Preoperative short-term 30% dietary restriction 
(DR), 3-days of fasting and 3-days of a protein-free diet protect against IRI. Here, we 
further disentangled the role of essential amino acids on the effects of DR on liver IRI. 
Male C57BL/6 mice were randomized to preoperative ad libitum control food or 3 days 
of 30% DR, methionine-free, leucine-free or tryptophan-free diet for three days. Liver IRI 
was induced by partial occlusion of the blood flow (70%) of the liver for 75 minutes. Food 
intake and body weight were monitored until postoperative day 1. Hepatic damage was 
measured biochemically and histologically at six and 24 hours after IRI. After completing 
each diet, liver gene expression profiles we determined by microarray analysis. All amino 
acid free diets resulted in body weight loss prior to IRI. Liver IRI was already significantly 
decreased by both the leucine- and tryptophan-free diets at six hours after IRI, and by 
the methionine-free diet at 24 hours. Microarray analysis showed similar transcriptomic 
responses in all amino acid-free diets, yet with a lower magnitude in the methionine-free 
diet. Detailed analysis of overlapping genes suggested a role for pathways involved in nuclear 
receptor signaling, stress resistance and cell cycle regulation via transcription factors NRF2, 
FOXM1, SREBF2 and SMARCB1. A short-term preoperative tryptophan-free, leucine-free 
and methionine-free diet protect against hepatic IRI similar to a protein-free diet, through 
a network of pathways potentially activated by NRF2, FOXM1, SREBF2 and SMARCB1.
15045-jongbloed-layout.indd   118 06/11/2017   17:20
119
5
ABSENCE OF PROTEIN AND AMINO ACIDS PROTECT AGAINST HEPATIC IRI
INTRODUCTION
Dietary restriction (DR) is defined as a reduction in food intake without malnutrition1. 
Long-term DR is known to extend lifespan1, increase health span2 and improve resistance 
to multiple stressors1,3 in a wide variety of organisms4-6. Although the effect of DR on 
lifespan in humans is not known, studies show a favorable impact on metabolic parameters 
associated with long-term health7-9. In addition, previous studies showed that two weeks of 
30% DR and three days of fasting increase stress resistance and protect against oxidative 
stress induced by ischemia-reperfusion injury (IRI) in mice1,10.  
During major liver surgery and liver transplantation IRI is inevitable and a risk factor for 
complications including primary graft dysfunction and primary non-function, thereby 
causing morbidity and mortality11-13. Cessation of the blood flow (ischemia) leads to 
hypoxia, nutrient deprivation and activation of anaerobic metabolic system13. Reperfusion 
of the liver promotes the activation of an inflammatory response, causing further cellular 
damage and the generation of reactive oxygen species (ROS)13. Therefore, counteracting 
the adverse effects of IRI could improve the outcome after liver transplantation and liver 
resection. Unfortunately, at this moment no effective treatment for IRI is available. 
Whether the protection by short-term DR is based on a reduction of calories or based on 
the reduction of specific nutrients is not yet completely unraveled. Also, the search for the 
underlying mechanisms of DR is still ongoing. In mice, liquid glucose supplementation did 
not interfere with the protective effect of three days of fasting against renal IRI14. In fruit 
flies, long-term protein restriction contributed more to extension of the life span compared 
to the reduction of carbohydrates or fat15, 16. We previously investigated the role of specific 
macronutrients by unrestricted feeding of protein-, carbohydrate-, and fat-free diets in 
inducing resistance against renal IRI. We showed that three days of a protein- but not a 
carbohydrate- or a fat-free diet, before the induction of renal IRI improved survival and 
kidney function similarly as DR and fasting17. These results point towards a role for specific 
nutrients in the protective effect against renal IRI.
In the present study, we investigated the role of preoperative essential amino acid (EAA)-free 
diets by unrestricted feeding of methionine (Met)-free, leucine (Leu)-free and tryptophan 
(Trp)-free diets in reducing oxidative damage in the liver, and analyzed the transcriptomic 
response of the liver to these diets.
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RESULTS
Single EAA deprivation protects against hepatic IRI 
To disentangle the role of single EAA in the protection against hepatic IRI, mice were 
administered a Met-free, Leu-free or Trp-free diet for three days. The results were compared 
with a control diet and diets that are known to either protect or not protect against IRI17. 
We have demonstrated that three days of a protein-free diet induces protection against 
renal IRI, while others also showed these results in other IRI models, including hepatic 
IRI1. On the contrary, three days of 30% DR does not induce resistance against renal IRI17, 
which makes it a control group for reduced calorie intake and concomitant body weight 
loss observed during feeding of EAA free diets.
Mice fed a protein- or EAA-free diet during three days restricted themselves on calorie 
intake (Figure 1A). Mice fed the Met-free diet restricted food intake by 44%, while the 
Leu-free diet resulted in a restriction of 45%. A Trp-diet resulted in the smallest decrease in 
calorie intake, namely an average of 9% fewer calories than mice fed a control diet.
Mice fed three days of a protein-free diet lost on average 9.8% of their body weight, while 
mice fed the non-protective 3-days of 30% DR showed a similar pattern in body weight loss 
(Figure 1B). Mice fed a single EAA-free diet also lost body weight: a Met-free diet resulted 
in 9.5% body weight loss, a Leu-free diet 6.2% and a Trp-free diet 8.5% (Figure 1C). After 
induction of hepatic IRI, mice on a protein-free diet resumed intake of the control food 
within 24 hours and showed no further weight loss, while ad libitum fed mice or mice 
restricted for 30% during three days lost weight after surgery. Mice fed the EAA-free diet 
resumed food intake postoperatively and stabilized their body weight (Figure 1C).
Serum levels of liver enzymes ALT (Figure 2A) and LDH (Figure 2B) were significantly 
lower in the Leu-free and Trp-free groups than in the control group at six and 24 hours 
postoperatively. At 24 hours after hepatic IRI, all EAA-free diets showed significantly lower 
liver enzymes (Figure 2A/B). Histological analysis of the livers supports these findings. 
At six hours after reperfusion, the percentage of hemorrhagic necrosis was significantly 
lower in the Leu-free and Trp-free diets than in the control group (Figure 2C). At 24 hours 
postoperatively, the percentage of necrosis was increased compared to six hours, but still a 
significant lower percentage of necrosis was seen in the Leu-free and Met-free diet, while 
the reduction did not reach significance in het Trp-free diet. The number of neutrophils, 
as a marker for the acute inflammatory response in the liver, was significantly higher in het 
Leu-free and Trp-free diets than in the control group at six hours (Figure 2D), despite the 
lower percentage of hemorrhagic necrosis.
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Livers from animals fed the non-protective 3-days of 30% DR showed a significantly 
increased number of neutrophils, suggesting an ongoing inflammatory response after IRI 
in this group (Figure 2D). 
Taken together, deprivation of essential amino acids methionine, leucine and tryptophan 
for three days induces protection against liver IRI similar to a 3-day protein-free diet 
independent of preoperative body weight loss and voluntary DR. The beneficial effects of 
Leu and Trp are more pronounced at six hours after IRI while the effects of all EAA-free 
diets are seen at 24 hours postoperatively.
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Figure 1. Food intake and body weight. (A) Relative dietary energy intake during the 3-day 
intervention. Mice fed a tryptophan-free consumed on average 9% fewer calories than mice fed the 
control diet. Mice fed a methionine-free diet had 44.2% fewer calories, while mice on a leucine-
free diet consumed 45.2% fewer calories than mice fed the control diet. In comparison, mice fed 
a protein-free diet ate 39.1% fewer calories. (B+C). The 3-day nutritional interventions started at 
day -3 and hepatic IRI was induced at day 0, after which all mice received control chow. During the 
dietary intervention all mice, except the control chow fed group, showed a decrease in body weight. 
Postoperative day 1, mice that had been fed an essential amino acid (EAA)-free diet lost less body 
weight compared to the control mice. Besides that, the protein-free mice gained weight. 
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Transcriptional responses after a methionine-, leucine- and tryptophan-
free diet are highly overlapping 
To examine transcriptome responses amongst the different EAA-free diets and their 
controls, a principal component analysis (PCA) was made based on all probe sets in the 
microarray data (Figure 3A).
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Figure 2. Essential amino acid free diets reduce liver injury. (A) Serum concentration of the 
liver-specific enzyme alanine aminotransferase (ALT), indicative of liver damage, were significantly 
lower levels at six and 24 hours after IRI in mice fed a protein-free or amino acid-free diet. *P<0.05, 
**P<0.01 versus the control group at the same time point. (B) Twenty-four hours after IRI, serum 
concentration of lactate dehydrogenase (LDH), indicative of tissue breakdown, was significant 
lower in mice on a protein-free or amino acid-free diet. *P<0.05, **P<0.01 versus the control 
group at the same time point. (C) Six hours after reperfusion, livers from mice fed leucine-free and 
tryptophan-free diets showed less hemorrhagic necrosis compared to the control group. Twenty-
four hours after reperfusion the protein-, leucine- and methionine-free diets induced significantly 
less damage compared to the control group. *P<0.05, **P<0.01 versus the control group. (D) At 24 
hours post-reperfusion, the protein-free diet had a lower number of neutrophils than the control 
group, while the 30% DR remained with a significantly higher neutrophil count. *P<0.05, versus 
the control group.  
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In this unbiased PCA plot, PC1 explains 15% and PC2 explains 13% of the total variance 
of the probe sets. Examination of the PCA showed distinct separation of the mice in the 
control group and in the Met-free group, with uniformity within these groups along PC2. 
However, the Met-free cluster was grouped closely on PC1 with the cluster of control 
mice. In contrast, the Leu-free and Trp-free groups showed a high degree of overlap, 
differentiating as a whole from the former two groups on PC1 and with an intermediate 
response on PC2 (Figure 3A). A dendogram, based on the unbiased hierarchical clustering 
of all mice, showed two distinct clusters of the control group and the Met-free group, which 
were connected higher up the dendogram (Figure 3B). The Leu-free and Trp-free groups 
had a similar hierarchy, with no distinctive clustering between the two groups.
The transcriptomic response was further analyzed by determining the differentially 
expressed probe sets (DEPS) after each dietary intervention compared to the control group. 
The Met-free diet induced the smallest number of DEPS, namely 572 with 348 upregulated 
and 224 downregulated DEPS. The Leu-free diet resulted in 933 DEPS, of which 476 were 
upregulated and 457 downregulated. The Trp-free diet induced 1,155 DEPS of which 579 
were upregulated and 576 were downregulated. To analyze the overlap between the groups, 
a Venn diagram was made with these DEPS, and 137 genes overlapped between all three 
diets (Figure 3C). The DEPS of the Leu-free and Trp-free diets showed the most similarity, 
with 603 genes present in both diets, comprising 65% of the DEPS induced by the Leu-free 
diet and 52% by the Trp-free diet. Of all differentially regulated genes in common between 
the Leu-free and Trp-free diets, 99% had the same directionality (results not shown). The 
Met-free induced the highest percentage of unique DEPS, namely 334 out of the 573 (58%). 
However, the directionality pattern of all differentially regulated genes reached an 84% 
agreement between Met-free and Leu-free diet and an 86% agreement between Met-free 
and Trp-free. Despite the stronger response induced by the Leu-free and Trp-free diets, 
there is a high overlap in transcriptional responses between all three EAA-free diets.
Essential amino acid-free diets regulate the cellular stress response, 
nuclear signaling and cell cycle  
Subsequent unbiased analysis of the gene expression profiles was performed via pathway 
analysis and upstream transcription factor analysis. Analyses of differentially regulated 
pathways by the EAA-free diets focused on canonical pathways with a positive or negative 
z-score, which indicates a significant activation or inhibition of the pathway, respectively. 
Three days of Met-free diet resulted in 11 regulated pathways, of which eight activated and 
three inhibited. The most prominent activated pathways were involved in cellular stress 
and injury, cell cycle regulation and growth signaling. Inhibition occurred mainly of the 
nuclear receptor signaling pathway (Table 1A). The Leu-free diet induced 29 differentially 
regulated pathways, of which 21 activated and eight inhibited (Table 1B). These pathways 
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represented mainly an activation of the cellular immune response and intracellular and 
second messenger signaling, in combination with an inhibition of nuclear receptor signaling 
and cellular stress and injury.  Analysis of the Trp-free diet revealed 15 pathways, including 
eight activated and seven inhibited pathways. The activated pathways were mostly involved 
in cellular immune responses and cell cycle regulation, while inhibited pathways included 
nuclear receptor signaling and cancer pathways (Table 1C).
Comparison of overlapping pathways revealed that five out of the 11 pathways regulated by 
the Met-free diet were also regulated by the Leu-free diet, and four out of the 11 pathways by 
the Trp-free diet, all with similar directionalities. These overlapping pathways were amongst 
the highest regulated pathways including activation of NRF2-mediated stress response and 
G2/M Checkpoint Regulation pathways, and inhibition of the LPS/IL-1 mediated inhibition 
of RXR Function as well as the LXR/RXR activation pathway. In addition to the pathways 
in common between the three EAA-free diets, the Leu-free and Trp-free diets had another 
four pathways in common of which two had the same directionality, namely Calcium-
induced T-lymphocyte apoptosis and Sphingosine-1-phosphate signaling. 
Analysis of the upstream transcription factors (TFs) activated or inhibited by the EAA-
free diets resulted in a list of factors depicted in Table S1. The highest activated TF by the 
Met-free diet was NFE2L2, i.e. NRF2, followed by ATF4 and SMARCB1. NFE2L2 and 
SMARCB1 were also significantly activated by the Leu-free and Trp-free diets, while ATF4 
met a significant z-score in the Trp-free diet and showed a trend towards significance in the 
Leu-free diet (1.838). The strongest inhibited TF by the Met-free diet was SREBF2, followed 
by FOXM1 and MYBL2. Both SREBF2 and FOXM1 were also significantly inhibited by the 
Leu- and Trp-free diets, while MYBL2 only reached significance in the after the Leu-free 
(-2.000) and not in the Trp-free diet (-1.633) (Table 2). Of the 18 significantly regulated TFs 
by the Met-free diet, 14 and 13 TFs were also regulated by the Leu-free and Trp-free diet, 
respectively. All of these TFs showed the same directionality in all three EAA-free diets.
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A      B 
     
C 
       
	 Figure 3. Principal component analysis and overlapping probe sets. (A) Unbiased principal 
component analysis (PCA) after normalization of all genes in the dataset. A distinct clustering of 
the control group and the methionine-free group is seen, with a clear separation of the groups on 
the principal component (PC) 2 but not on the PC1. The leucine-group and tryptophan-free have 
a highly overlapping clustering, with small intergroup variability. Their combined cluster is mainly 
separated from the control group and the methionine-free group on the PC1. (B) Dendogram 
based on the unbiased hierarchical clustering of all mice. The control group and methionine-free 
group have individual branches, but are connected higher up in the dendogram. The leucine-free 
and tryptophan-free group overlap and are intertwined in the dendogram. (C). Venn diagram of 
the differentially expressed probe sets (DEPS) overlapping between the methionine-free, leucine-
free and tryptophan-free diets. A total of 137 genes overlapped between all diets. Of all genes in the 
leucine-free diet, 64% overlapped with the tryptophan-free diet. The methionine-free diet had the 
highest percentage of unique DEPS, namely 334 out of the 573 (58%).
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Table 1. Overview of the top overrepresented activated and inhibited canonical pathways after each 
amino acid-free diet ranked by their –log P-value
Canonical Pathway Pathway Classification P-value Genes Ratio Z-score
Methionine-free
LXR/RXR Activation Nuclear Receptor Signaling 3.24E-02 6/121 (5%) -2.236
LPS/IL-1 Mediated Inhibition of 
RXR Function
Nuclear Receptor Signaling 5.61E-10 22/222 (10.0%) -1.897
Antioxidant Action of Vitamin C Cellular Stress and Injury 1.61E-02 6/103 (5.8%) -1.000
PPARa/RXRa Activation Nuclear Receptor Signaling 8.78E-03 9/178 (5.1%) +0.378
eNOS Signaling Cardiovascular Signaling 3.37E-02 7/155 (4.5%) +0.447
ERK5 Signaling Intracellular and Second 
Messenger Signaling
3.53E-02 4/63 (6.3%) +1.000
CNTF Signaling Cytokine Signaling/ 
Neurotransmitters and Other 
Nervous System Signaling/
Cellular Growth
3.53E-02 4/63 (6.3%) +1.000
UVA-Induced MAPK Signaling Cellular Stress and Injury 1.54E-02 6/102 (5.9%) +1.000
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation
Cell Cycle Regulation 2.68E-03 5/49 (10.2%) +1.342
Melanocyte Development and 
Pigmentation Signaling
Growth Factor Signaling 3.94E-02 5/95 (5.3%) +2.000
NRF2-mediated Oxidative Stress 
Response
Cellular Stress and Injury 1.54E-07 18/193 (9.3%) +2.646
Leucine-Free
NRF2-mediated Odixative Stress 
Response
Cellular Stress and Injury 3.46E-05 18/193 (9.3%) +2.309
Calcium-induced T-lymphocyte 
Apoptosis
Apoptosis/Cellular Immune 
Response
1.94E-04 9/66 (13.6%) +1.000
LPS/IL-1 Mediated Inhibition of 
RXR Function
Nuclear Receptor Signaling 2.09E-04 18/222 (8.1%) -0.816
Role of NFAT in Regulation of 
the Immune Response
Intracellular and Second 
Messenger Signaling
6.87E-04 15/185 (8.1%) +1.069
Cholecystokinin/Gastrin-
mediated Signaling
Neurotransmitters and Other 
Nervous System Signaling
1.18E-03 10/101 (9.9%) +1.265
CD28 Signaling in T Helper Cells Cellular Immune Response 2.61E-03 11/131 (8.4%) +0.447
PKCo Signaling in T 
Lymphocytes
Cellular Immune Response 2.77E-03 11/132 (8.3%) +1.508
Tec Kinase Signaling Intracellular and Second 
Messenger Signaling
6.95E-03 12/170 (7.1%) +0.333
Phospholipase C Signaling Intracellular and Second 
Messenger Signaling
7.42E-03 15/237 (6.3%) +1.291
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Table 1. (continued)
Canonical Pathway Pathway Classification P-value Genes Ratio Z-score
Thrombin Signaling Cardiovascular Signaling 1.11E-02 13/203 (6.4%) +0.905
LXR/RXR Activation Nuclear Receptor Signaling 1.31E-02 9/121 (7.4%) -1.000
CXCR4 Signaling Cellular Immune Response / 
Cytokine Signaling
1.42E-02 11/165 (6.7%) +0.378
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation
Cell Cycle Regulation 1.76E-02 5/49 (10.2%) +1.000
Production of Nitric Oxide and 
Reactive Oxygen Species in 
Macrophages
Cellular Immune Response 1.77E-02 12/193 (6.2%) -0.302
PI3K Signaling in B Lymphocytes Cellular Immune Response 1.85E-02 9/128 (7.0%) -0.333
G Beta Gamma Signaling Intracellular and Second 
Messenger Signaling
1.96E-02 7/88 (8.0%) +0.378
Relaxin Signaling Organismal Growth and
Development / Growth Factor 
Signaling
2.05E-02 10/152 (6.6%) -0.447
Colorectal Cancer Metastasis 
Signaling
Cancer 2.27E-02 14/247 (5.7%) +0.577
Actin Nucleation by ARP-WASP 
Complex
Intracellular and Second 
Messenger Signaling
2.96E-02 5/56 (8.9%) +1.342
Synaptic Long Term Potentiation Neurotransmitters and Other 
Nervous System Signaling
3.36E-02 8/120 (6.7%) +0.707
Dendritic Cell Maturation Cytokine Signaling/ Cellular 
Immune Response 
3.55E-02 11/190 (5.8%) +1.897
ICOS-ICOSL Signaling in T 
Helper Cells
Cellular Immune Response 3.65E-02 8/122 (6.6%) +1.890
Sphingosine-1-phosphate 
Signaling
Intracellular and Second 
Messenger Signaling 
3.81E-02 8/123 (6.5%) +1.414
Macropinocytosis Signaling Cellular Immune Response 4.01E-02 6/81 (7.4%) +1.000
UV-Induced MAPK Signaling Cellular Stress and Injury 4.07E-02 4/42 (9.5%) -1.000
Antioxidant Action of Vitamin C Cellular Stress and Injury 4.14E-02 7/103 (6.8%) -1.000
RhoGDI Signaling Intracellular and Second 
Messenger Signaling
4.40E-02 10/173 (5.8%) -0.378
IL-8 Signaling Cytokine Signaling 4.42E-02 11/197 (5.6%) +1.508
ERK5 Signaling Intracellular and Second 
Messenger Signaling
4.58E-02 5/63 (7.9%) +0.447
Tryptophan-free
LPS/IL-1 Mediated Inhibition of 
RXR Function
Nuclear Receptor Signaling 1.25E-05 23/222 (10.4%) -1.667
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Table 1. (continued)
Canonical Pathway Pathway Classification P-value Genes Ratio Z-score
NRF2-mediated Oxidative Stress 
Response
Cellular Stress and Injury 1.40E-05 21/193 (10.9%) +1.941
Colorectal Cancer Metastasis 
Signaling
Cancer 4.77E-04 21/247 (8.5%) -0.447
Sumoylation Pathway Cellular Stress and Injury/ 
Transcriptional Regulation
9.90E-04 11/96 (11.5%) +0.333
Calcium-induced T Lypmhocyte 
Apoptosis
Apoptosis/Cellular Immune 
Response
3.32E-03 8/66 (12.1%) +1.134
LXR/RXR Activation Nuclear Receptor Signaling 2.11E-03 12/121 (9.9%) -0.447
Wnt/B-catenin Signaling Cancer / Organismal Growth 
and Development
1.20E-02 13/169 (7.7%) -0.333
Cholecystokinin/Gastrin-
mediated Signaling
Neurotransmitters and Other 
Nervous System Signaling
1.42E-02 9/101 (8.9%) -0.333
MIF Regulation of Innate 
Immunity
Cellular Immune Response 1.85E-02 5/41 (12.2%) +1.342
IGF-1 Signaling Growth Factor Signaling 1.90E-02 9/106 (8.5%) +0.447 
UVC-Induced MAPK Signaling Cellular Stress Injury 2.04E-02 5/42 (11.9%) -1.342
MIF-mediated Glucocorticoid 
Regulation
Cellular Immune Response / 
Nuclear Receptor Signaling
3.47E-02 4/33 (12.1%) +2.000
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation
Cell Cycle Regulation 3.69E-02 5/49 (10.2%) +2.000
Mitotic Roles of Polo-Like Kinase Cell Cycle Regulation 3.81E-02 6/66 (9.1%) -2.000
TWEAK Signaling Apoptosis / Cytokine Signaling 3.82E-02 4/34 (11.8%) -1.000
Sphingosine-1-phosphate 
Signaling
Intracellular and Second 
Messenger Signaling
4.36E-02 9/123 (7.3%) +0.707
Pathways are defined via the canonical pathways and pathway classification. Only pathways with a z-score were included. 
Analyses are based on the analyses done in Ingenuity and Ingenuity Target Explorer. Genes ratio = the number and percentage 
of probe sets differentially expressed in ratio to the total number of genes involved in the pathway. Z-score = based on the 
observed gene expression changes in the specific array datasets.
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Table 2. List of significantly up-or downregulated upstream transcription factors in the liver with 
corresponding z-scores regulated by all three amino-acid-free diets
Methionine-free Tryptophan-free Leucine-free
Upstream 
Regulator
State Z-score P-value Z-score P-value Z-score P-value
NFE2L2 Activated 4.545 6.28E-13 2.975 3.12E-11 2.919 3.92E-07
SMARCB1 Activated 2.026 9.12E-06 2.436 9.74E-04 2.465 2.14E-06
SREBF2 Inhibited -2.804 1.26E-04 -5.540 8.96E-26 -5.159 1.87E-28
FOXM1 Inhibited -2.671 1.66E-04 -3.096 1.76E-05 -2.391 6.91E-06
Upstream regulator analysis of the differentially regulated genes found in common after 3-day methionine-free, tryptophan-
free and leucine-free diet revealed four significantly regulated transcription factors, of which two were activated and two were 
inhibited. 
DISCUSSION
In this study we demonstrated that, in addition to a protein-free diet, a Met-free, a Leu-
free and a Trp-free diet for three days induce a similar protection against hepatic IRI. We 
show that cellular stress-, nuclear receptor-, and cell cycle regulation pathways are regulated 
by all three EAA-free diets, and that transcription factors NRF2, FOXM1, SREBF2 and 
SMARCB1 may be implicated in orchestrating this response. 
Previously, we have shown that two weeks of 30% DR as well as three days of fasting are 
sufficient to induce resistance against hepatic and renal IRI1,10,18. Recently, we and others 
showed that absence of protein is the main contributor to these effects17,19. Here, we further 
dissected the role of essential amino acids, and demonstrated that the absence of one single 
essential amino acid is sufficient to induce the increased stress resistance associated with 
DR leading to protection against hepatic IRI. Mice fed EAA-free diets voluntarily restricted 
food intake by approximately 30%. Since we showed that three days of 30% DR without 
deprivation of EAA is insufficient to induce protection against hepatic IRI, the restricted 
food intake due to EAA-free diets is ruled out as a factor and the absence of EAA during 
three days is therefore responsible for inducing these beneficial effects. 
All three EAA-free diets induced a similar protective effect, indicative of a common 
denominator of induction of the beneficial response. To extract this denominator, we 
determined mRNA expression profiles of liver tissue following administration of the EAA-
free diets and performed microarray analyses. These data show that EAA deprivation 
modifies the transcriptome at three different pathway levels. 
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First, cell metabolism is altered as indicated by the nuclear receptor signaling response via 
the activation of the retinol pathway. Nuclear receptors are transcription factors that are 
known to be activated by steroid hormones and lipi-soluble agents, such as the retinoid 
acids (RAs)20. As previously shown, RAs are able to induce many of the beneficial effects 
observed after DR. RAs are able to protect from ischemic stroke in the brain and have a 
positive effect on insulin resistance21-24. This activation is in line with our previous results, 
where nuclear receptor signaling activation was proposed as one of the main contributors 
to the beneficial effects of DR against renal IRI17. In our renal IRI model, upstream 
transcription factor FOXO3 was identified as a main player of the activation of the nuclear 
receptor response. FOXO3 was upregulated after all three EAA-free diets, however only 
reached statistical significance after the Trp-free diet. Besides cell metabolism, FOXO3 
phosphorylation and activation is at the basis of many processes, most importantly stress 
resistance and autophagy25,26. These data strengthen the role of nuclear receptor signaling 
mediated by FOXO3, however excludes FOXO3 as the only contributor for the beneficial 
effects. For instance, the LXR/RXR pathway has been implicated in the response as well27. 
The liver X receptor (LXR) is mainly expressed in the liver and is an important factor of 
its lipid metabolism28. However, we found an inhibition of this pathway in our EAA-free 
analysis. The downregulation of the LXR/RXR pathway might in part be a response to the 
massive downregulation of SREBF2 by all EAA-free diets, which is a main regulator of 
the pathway29. Blocking SREBF2 in a mouse model showed to be effective in preventing 
the development of hepatic steatosis and insulin resistance, and might be more important 
than the activation of the LXR/RXR pathway itself27. Our results suggest that inhibition of 
SREBF2 might play a role in the protective effect on hepatic IRI. Future studies with for 
instance SREBF2 -/- mouse models could highlight the effects of SREBF-2 deficiency on 
IRI. 
Second, we found two transcription factors involved with inhibition of cellular proliferation. 
FOXM1, which increases G2/M DNA damage checkpoint activity30, and SMARCB1 which 
inhibits cellular proliferation by mediating between various signaling pathways as part 
of the SWI/SNF complex. In recent work, SMARCB1 has been named often as a tumor 
suppressor via inhibition of cell growth31,32. Inhibition of cell growth is a common feature 
induced by DR regimens. We propose that the evolutionary adaptive response to DR that 
shifts resources from growth (metabolism and temporary withdrawal from the cell cycle) 
to maintenance occurs already after three days of essential amino acid deprivation33. The 
associated increase in stress resistance is rapidly induced and offers robust protection 
against hepatic IRI. 
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Third, all three EAA-free diets induced a strong activation of the NRF2-mediated oxidative 
stress response, both on transcription factor and pathway level. NRF2 increases stress 
resistance30, and we have already implicated NRF2 in the protection against renal IRI after 
three days of fasting1,17,18. In response to environmental stress, including protein deprivation, 
NRF2 is activated by phosphorylation of eIF2α via Gcn230,34,35 and results in the transcription 
of genes involved in antioxidant defense, reduction of inflammation and cell survival. In 
NRF2 knock-out models, similar effects of DR on cellular stress injury as in NRF2 proficient 
models could not be induced30,36. This indicates that NRF2 is indeed a major player yet not 
the only player in the protection against IRI. Our results demonstrate that activation of 
nuclear receptors signaling, inhibition of cellular proliferation and activation of the NRF2-
pathway might be the essential package required to induce the beneficial effects of hepatic 
IRI. Validation studies should further emphasize on how these regulators induce protection 
against oxidative stress induced by IRI.
Taken together, we report that three essential amino acid-free diets given for three days 
protect against hepatic IRI in a mouse model possibly mediated via transcription factors 
NRF2, FOXM1, SREBF2 and SMARCB1. Further in depth analysis through functional and 
pharmacological modulation of these factors may provide mimetics for treatment against 
ROS-related injury. 
MATERIAL AND METHODS
Animals
Male C57BL/6 (approximately 25 grams) were obtained from Harlan (Horst, the 
Netherlands). Animals were kept under standard laboratory conditions, and were housed 
in individually ventilated cages (n = 3 animals/cage). All mice had ad libitum (AL) access to 
food and water (acidified with HCl). All experiments were performed with the approval of 
the appropriate local ethical board.
Diets
Before dietary intervention, all mice were acclimatized during seven days and fed the 
standard Special Diet Services (SDS) chow. All other diets used for dietary intervention 
were purchased from Research Diets, Inc. (New Brunswick, NJ, USA). The SDS chow was 
used as a control diet for the fasted and 30% dietary restricted mice1. As a control for the 
protein-free and EAA-free diet, a specific control diet was used since this diet has the same 
protein source as the EAA-free diets, including all EAA (Table S2). The protein source of 
the EAA-free diets is derived from a crystalline L-amino acid mixture leaving out one of the 
specific amino acids (Met-free, Leu-free or Trp-free). During the experiment, 3-day 30% 
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DR was used as a negative control group while previous studies showed that this dietary 
intervention did not protect against IRI17. Mice on three days of 30% DR were given 70% 
of their normal daily intake of the SDS chow. Three days of protein-free diet was used as 
a positive control since this diet protects against IRI12. Mice on protein-, Trp-free, Met-
free and Leu-free diets were transferred to clean cages with the specific diet given at 4:00 
pm. Mice on the control diet were used as the control group. Body weight of the mice was 
recorded daily. An overview of the composition of the diets used is shown in Table S2.
Hepatic ischemia-reperfusion model
Mice were anesthetized by isoflurane/N2/O2 inhalation. To maintain their body temperature 
mice, were placed on a heating pad. All surgeries were performed between 9:00 am and 1:00 
pm. Partial (70%) hepatic IRI was induced by occlusion of the blood flow of the left lateral 
and median liver lobes with a non-traumatic microvascular clamp for 75 minutes, which 
causes ischemia of the liver tissue. After clamp removal, the restoration of blood flow in 
the liver leads to reperfusion. No mortality was observed associated with this amount of 
damage to the liver. After surgery, all mice received 0.5 mL of phosphate-buffered saline 
subcutaneously and were placed under a heating lamp until they recovered from anesthesia. 
Directly after, all mice had free access to SDS chow and water.
Hepatocellular injury
Preoperatively fed and fasted mice were euthanized before surgery (baseline), six hours 
and 24 hours after reperfusion (n = 5-6 per time point). Serum levels of hepatic damage 
markers alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate 
dehydrogenase (LDH) at the Central Clinical Chemical Laboratory of the Erasmus 
University Medical Center. Hemorrhagic necrosis was scored before, and at six and 24 hours 
after reperfusion (n = 5-6 per time point) in 3µm thick Hematoxylin and Eosin stained liver 
sections at a magnification of 100x by two observers blinded to the treatment. Hemorrhagic 
necrosis was characterized by the loss of the cellular architecture and the presence of 
erythrocytes in necrotic areas. The percentage of hemorrhagic necrosis per microscopic 
field was determined using the following scoring system: 0% (absent), 0% to 20% (<20% 
necrosis per microscopic field), 20% to 40% (20% to <40% necrosis per microscopic field) 
etcetera until 100% necrosis.
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Immunohistochemistry
Frozen liver sections (5 µm) from different time points (baseline, six and 24 hours after 
reperfusion) were stained with a monoclonal antibody against neutrophils and visualized 
with an alkaline phosphatase secondary antibody. Per section two observers blinded to the 
treatment counted the number of neutrophils in 10 microscopic fields at magnifications of 
400x.
Microarray analysis
For microarray analysis, mice were either fed the control diet or put on either a protein-, 
Leu-free, Trp-free or Met-free diet for three consecutive days, after which the mice were 
sacrificed. Directly after each intervention, liver samples were taken and snap frozen in 
liquid nitrogen for further analyses. RNA isolation of the liver samples was performed as 
described previously17,18. RNA quality was tested via the RNA integrity number (RIN, range 
0-10). All samples used scored a RIN between 7.7 and 9.5. Hybridization to Affymetrix 
HT MG-430 PM Array Plates was performed at the Microarray Department of the 
University of Amsterdam (the Netherlands), according to Affymetrix protocols and as 
described previously17,18. The procedure for all samples was performed on the same batch. 
Normalization was done using the Robust Multichip Average (RMA) algorithm at the 
website www.arrayanalysis.org. Data output consisted of 45,141 probes, whereby more 
probes could present the same Gene ID.
Statistical analysis
Data were expressed as mean ± standard error of the mean. Differences in groups were 
analyzed by Mann-Whitney U tests with SPSS (version 21). Differences were considered 
significant at P<0.05. Microarray analyses were performed using the free software package 
R (R foundation), using the Linear Models for Microarray Data (limma) method with 
correction for multiple testing using the false discovery rate (FDR) according to Benjamini 
and Hochberg. Fold changes were expressed as the geometric mean per diet group against 
the corresponding ad libitum fed control group. An FDR <5% with fold change ≥1.5 were 
used as cut-off values for significance. The enrichment factor (EF), defined as the number 
of times an observation was higher than expected by chance, was calculated via the formula: 
EF=nAB/((nA×nB)/nC), where nA is the number of differentially expressed probe sets 
(DEPS) in experimental group A, nB the number of DEPS in experimental group B, nC the 
number of total genes in the microarray, and nAB the number of common DEPS between 
nA and nB. Functional annotation and analyses were performed QIAGEN’s Ingenuity® 
Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). Subsequent 
pathway and target categories were generated using the QIAGEN’s Ingenuity Target 
Explorer (QIAGEN’s, https://targetexplorer.ingenuity.com/). The prediction inhibition or 
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activation of the upstream transcription regulators are calculated via de statistical z-score 
based on the observed gene expression changes in our dataset. Calculating the z-score 
reduces the chance of significant predictions based on random data (http://ingenuity.force.
com/ipa/articles/Feature_Description/Upstream-Regulator-Analysis).  A z-score ≥ 2 or ≤-2 
was set as significant.
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SUPPLEMENTARY DATA
Table S1. List of significantly up-or downregulated upstream transcription factors in the liver by a 
methionine-free, leucine-free or tryptophane-free diet with the corresponding z-scores
Upstream Regulator Gene ratio (Log2) Z-score P-value Z-score P-value Z-score P-value
Methionine-free Tryptophan Leucine
NFE2L2 0.297 4.545 6.28E-13 2.975 3.12E-11 2.919 3.92E-07
ATF4 0.393 2.911 7.45E-05 2.686 7.60E-09 1.838 2.41E-06
NUPR1 1.593 2.558 8.47E-04 2.846 2.92E-05 1.667 1.06E-05
KMT2D 0.180 2.449 1.15E-01 N/A N/A N/A N/A
CEBPD 0.390 2.194 8.83E-04 1.994 3.42E-01 1.104 1.39E-02
NFKB1 0.007 2.182 1.37E-01 N/A N/A 0.344 7.05E-03
KLF4 0.782 2.110 7.47E-02 1.994 4.08E-01 3.101 3.00E-01
SMARCB1 -0.164 2.026 9.12E-06 2.436 9.74E-04 2.465 2.14E-06
TAF4 0.393 2.000 2.57E-03 N/A N/A N/A N/A
MAFF 1.398 2.000 3.37E-05 N/A N/A N/A N/A
TBX2 0.047 -2.000 6.89E-02 -2.530 7.43E-04 -1.890 1.11E-02
Esrra 0.327 -2.000 4.14E-02 N/A N/A N/A N/A
ATF6 0.216 -2.000 7.27E-03 -0.553 1.78E-05 -1.161 1.15E-04
FOXO1 -0.167 -2.139 9.30E-07 -0.465 1.51E-09 -1.269 6.53E-11
STAT5B 0.123 -2.157 2.12E-02 -0.901 3.17E-04 -1.463 4.42E-02
MYBL2 0.157 -2.236 1.79E-04 -1.633 1.79E-04 -2.000 1.03E-02
FOXM1 -0.080 -2.671 1.66E-04 -3.096 1.76E-5 -2.391 6.91E-06
SREBF2 0.086 -2.804 1.26E-04 -5.540 8.96E-26 -5.159 1.87E-28
Leucine-free Tryptophan-free Methionine-free
KLF4 0.907 3.101 3.00E-01 1.994 4.08E-01 2.110 7.47E-02
NFE2L2 0.397 2.919 3.92E-07 2.975 3.12E-11 4.545 6.28E-13
KDM5B -0.376 2.739 8.34E-08 2.999 3.88E-07 1.615 1.13E-04
TRIM24 -0.415 2.714 3.19E-04 3.043 1.20E-04 N/A N/A
SMARCB1 -0.126 2.465 2.14E-06 2.436 9.74E-04 2.026 9.12E-06
POU5F1 -0.120 2.234 4.60E-01 -1.103 9.75E-04 N/A N/A
ETS1 0.829 2.198 2.28E-02 N/A N/A N/A N/A
NOTCH1 -0.165 2.137 8.04E-02 0.309 4.59E-02 0.727 9.18E-03
MYBL2 0.097 -2.000 1.03E-02 -1.633 1.79E-04 -2.236 1.79E-04
NFYA -0.197 -2.007 1.27E-11 -0.840 5.51E-12 -0.128 7.02E-06
ARNTL 0.217 -2.180 2.56E-03 -1.539 1.41E-03 N/A N/A
E2F2 -0.287 -2.236 5.13E-03 N/A       N/A N/A N/A
PDX1 0.029 -2.321 1.75E-05 -0.739 6.55E-06 N/A N/A
FOXM1 -0.309 -2.391 6.91E-06 -3.096 1.76E-05 -2.671 1.66E-04
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Table S1. (continued)
Upstream Regulator Gene ratio (Log2) Z-score P-value Z-score P-value Z-score P-value
E2F1 -0.217 -2.480 1.50E-05 -1.068 6.08E-06 -1.564 8.48E-04
MLXIPL -0.039 -2.510 1.27E-09 -2.345 1.35E-07 -0.927 3.18E-03
IRF7 -0.338 -2.599 2.83E-01 -3.088 1.15E-01 N/A N/A
SIRT2 0.113 -2.646 8.82E-07 -2.646 3.30E-06 N/A N/A
PPARGC1B -0.681 -3.396 1.96E-07 -3.248 1.06E-05 -1.980 2.81E-02
SREBF1 -0.534 -4.605 2.68E-24 -4.998 1.55E-23 -1.020 6.88E-05
SREBF2 -0.453 -5.159 1.87E-28 -5.540 9.96E-26 -2.804 1.26E-04
Tryptophan-free Leucine-free Methionine-free
TRIM24 0.241 3.043 1.20E04 2.714 3.19E-04 N/A N/A
KDM5B -0.602 2.999 3.88E-07 2.739 8.34E-08 1.615 1.13E-04
NFE2L2 0.198 2.975 3.12E-11 2.919 3.92E-07 4.545 6.28E-13
NUPR1 0.772 2.846 2.92E-05 1.667 1.06E-05 2.558 8.47E-04
HTT -0.347 2.784 1.12E-03 N/A N/A N/A 3.16E-04
ATF4 0.317 2.686 7.60E-09 1.838 2.41E-06 2.911 7.54E-05
SMARCB1 0.188 2.436 9.74E-04 2.465 2.14E-06 2.026 9.12E-06
HAND2 0.931 2.224 4.42E-02 N/A N/A N/A N/A
FLI1 0.635 2.150 5.36E-05 1.364 6.55E-05 N/A N/A
FOXO3 -0.209 2.095 2.00E-10 0.448 9.73E-08 0.588 1.75E-06
GATA4 -0.378 2.071 1.12E-01 N/A N/A N/A N/A
TCF3 0.171 2.032 7.48E-05 1.265 9.72E-04 1.890 1.66E-02
IRF5 -0.327 -2.138 5.91E-03 N/A N/A N/A N/A
STAT1 -0.661 -2.145 5.93E-05 -0.540 1.73E-06 -1.706 1.34E-03
MLX -0.124 -2.181 1.20E-09 -1.977 1.09E-07 N/A 7.61E-03
MLXIPL 0.054 -2.345 1.35E-07 -2.510 1.27E-09 -0.927 3.18E-03
MYOD1 0.108 -2.465 1.20E-01 -1.242 1.85E-02 -1.657 5.12E-03
EGR1 -0.180 -2.520 2.14E-03 -1.925 7.99E-04 -1.344 3.23E-02
TBX2 -0.001 -2.530 7.43-04 -1.890 1.11E-02 -2.000 6.89E-02
SIRT2 0.170 -2.646 3.30E-06 -2.646 8.82E-07 N/A N/A
IRF7 -0.349 -3.088 1.15E-01 -2.599 2.83E-01 N/A N/A
FOXM1 -0.181 -3.096 1.76E-05 -2.391 6.91E-06 -2.671 1.66E-04
IRF3 0.254 -3.128 4.08E-03 -1.359 5.45E-04 N/A N/A
PPARGC1B -0.755 -3.248 1.06E-05 -3.396 1.96E-07 -1.980 2.81E-02
SREBF1 -0.247 -4.998 1.55E-23 -4.605 2.68E-04 -1.020 6.88E-05
SREBF2 -0.474 -5.540 8.96E-26 -5.159 1.87E-28 -2.804 1.26E-04
All significantly up-or downregulated transcription factors (TF) after completion of each diet are shown, together with then 
log-ratio of the gene corresponding to the TF. Of all TF, the z-scores of the other two diets are compared and shown in the same 
table. N/A = not available. 
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Table S2. Composition and energy content of the restricted and control diets.
Diet Control 
SDS
Control Protein-
free
Methionine-
free
Leucine-free Tryptophan-
free
Ingredient g g g g g g
Casein, Lactic 0 200 0 0 0 0
L-Cystine 0 3 0 4.2 4.2 4.2
L-Isoleucine 0.77 0 0 7.6 7.6 7.6
L-Leucine 1.46 0 0 15.8 0 15.8
L-Lysine 1.04 0 0 13.2 13.2 13.2
L-Methionine 0.28 0 0 0 5.1 5.1
L-Phenylalanine 0.96 0 0 8.4 8.4 8.4
L-Threonine 0.69 0 0 7.2 7.2 7.2
L-Tryptophan 0.22 0 0 2.1 2.1 0
L-Valine 0.91 0 0 9.3 9.3 9.3
L-Histidine-HCl-H2O 0 0 0 4.6 4.6 4.6
L-Alanine 1.19 0 0 5.1 5.1 5.1
L-Arginine 0 0 0 6 6 6
L-Aspartic Acid 1.00 0 0 12.1 12.1 12.1
L-Glutamic Acid 3.72 0 0 38.2 38.2 38.2
Glycine 1.55 0 0 3 3 3
L-Proline 1.34 0 0 17.8 17.8 17.8
L-Serine 0.78 0 0 10 10 10
L-Tyrosine 0.69 0 0 9.2 9.2 9.2
Total L-Amino Acids 3 0 173.8 163.1 176.8
Corn Starch 42.37% 315 344 320.1 330.8 317.1
Maltodextrin 10 35 35 35 35 35
Sucrose 350 500 350 350 350
Cellulose, BW200 3.89% 50 50 50 50 50
Soybean Oil 25 25 25 25 25
Lard 20 20 20 20 20
Mineral Mix S10026 10 10 10 10 10
DiCalcium Phosphate 13 13 13 13 13
Calcium Carbonate 5.5 5.5 5.5 5.5 5.5
Potassium Citrate, 1 
H2O
16.5 16.5 16.5 16.5 16.5
Vitamin Mix V10001 10 10 10 10 10
15045-jongbloed-layout.indd   140 06/11/2017   17:20
141
5
ABSENCE OF PROTEIN AND AMINO ACIDS PROTECT AGAINST HEPATIC IRI
Table S2. (continued)
Diet Control 
SDS
Control Protein-
free
Methionine-
free
Leucine-free Tryptophan-
free
Ingredient g g g g g g
Vitamin Mix V10001C 0 0 0 0 0
Choline Bitartrate 2 2 2 2 2
Sodium Bicarbonate 0 0 7.5 7.5 7.5
FD&C Blue Dye #1 0 0 0.025 0.025 0
FD&C Yellow Dye #5 0.05 0 0 0.025 0.025
FD&C Red Dye #40 0 0.05 0.025 0 0.025
Total 1055.05 1031.05 1038.45 1038.45 1038.45
kcal/g 3.59 3.8 3.8 3.8 3.8 3.8
Protein 200.3 179.0 0.0 173.8 163.1 176.8
Carbohydrate 627.5 710.0 889.0 715.1 725.8 712.1
Fat 36.2 45.0 45.0 45.0 45.0 45.0
Fiber 50.0 50.0 50.0 50.0 50.0
g%
Protein 22.3 17.0 0 16.7 15.7 17.0
Carbohydrate 68.9 67.3 86.2 68.9 69.9 68.6
Fat 9.08 4.3 4.4 4.3 4.3 4.3
Fiber 4.23 4.7 4.8 4.8 4.8 4.8
kcal
Protein 801 716 0 695 652 707
Carbohydrate 2510 2840 3556 2860 2903 2848
Fat 326 405 405 405 405 405
kcal%
Protein 22 18 0 18 16 18
Carbohydrate 69 72 90 72 73 72
Fat 9.0 10 10 10 10 10
Control SDS = control diet given during acclimatization period and the diet of which the 3-days 30% DR diet is based; 
Control = control diet for the protein-free, methionine-free, leucine-free and tryptophan-free diet. 
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ABSTRACT
Morbid obesity adversely affects health and is associated with subclinical systemic 
inflammation and features of accelerated aging, including the T-cell immune system. 
The presence of metabolic syndrome (MetS) may potentiate these phenomena. Bariatric 
surgery might delay or reverse accelerated aging in morbidly obese patients. To examine the 
effects of bariatric surgery on accelerated immune aging, we measured telomere length and 
phenotypic characteristics of circulating T-cells in morbidly obese patients before and after 
bariatric surgery. Ten healthy controls (HC) and 108 morbidly obese patients scheduled 
for bariatric surgery were included: 41 without MetS and 67 with MetS. Relative telomere 
length (RTL) and differentiation status were measured in circulating CD4+ and CD8+ T-cells 
via flowcytometry. T-cell characteristics were compared for age, MetS, cytomegalovirus 
(CMV)-serostatus and gender prior to, and at three, six and 12 months after bariatric 
surgery. Data were compared with those of age-matched HC. Thymic output, represented 
by numbers of CD31-expressing naive T-cells, was significantly higher in patients ≤50 years 
of age without MetS. MetS, CMV-seropositivity, older age and male gender significantly 
enhanced T-cell differentiation. Patients with MetS had significant lower CD4+ RTL than 
patients without MetS and HC, which was most pronounced in patients ≤50 years of age 
and CMV-seropositive. Within the first year after bariatric surgery, telomere attrition was 
increased in CD4+ T-cells. Interestingly, T-cells were less differentiated following bariatric 
surgery, which was most pronounced in the MetS group. Especially in morbidly obese 
patients ≤50 years of age, MetS significantly decreased the RTL of CD4+ and enhanced 
T-cell differentiation. This was only partially reversed following bariatric surgery. These 
data suggest that obese patients with MetS are at risk for accelerated aging of the T-cell 
immune system and might benefit from bariatric surgery at an earlier stage.
Cytomegalovirus (CMV)
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MORBID OBESITY, BARIATRIC SURGERY AND T-CELL AGING
INTRODUCTION
Obesity (BMI >30) is a risk factor for a wide variety of diseases including hypertension, 
liver steatosis and cancer1. The metabolic syndrome (MetS), characterized by biochemical 
dysregulation of triglycerides, high-density lipoprotein (HDL) cholesterol, glucose, blood 
pressure and increase in abdominal waist circumference increases this risk2. MetS in the 
context of obesity is associated with the development of a chronic subclinical systemic 
inflammatory state3. Major players in the development of this inflammatory milieu are 
adipocytokines, adipokines and cytokines produced by white adipocytes that closely 
regulate lipid metabolism and the inflammatory response4. Adipocytokines contribute to 
the development of insulin resistance and production of reactive oxygen species3,5,6. 
Immunological changes also have been linked to the reduced lifespan seen in morbidly 
obese patients7. The link between chronic (sub)clinical inflammation and advancing 
age, a phenomenon called ‘inflammaging’, leads to accelerated aging and frailty8. This 
inflammaging might present itself via a decrease in circulating naive T-cells as well as 
an increase in more mature T-cells, such as terminally differentiated effector memory 
RA (EMRA) T-cells. The pro-inflammatory state in morbid obese patients resembles 
that of inflammaging seen in older people, as the production of adipocytokines leads to 
impairment of the T-cell system3. Total T-cell numbers as well as cytotoxic CD8+ and CD4+ 
T-cells are reported to be positively associated with BMI and the prevalence of MetS by 
some authors9-11, but not by others12,13. Studies investigating the full T-cell differentiation 
status in obesity in relation to obesity with or without MetS are currently lacking.
Cytomegalovirus (CMV) prevalence ranges from 30-100% and depends on socio-
economic and ethnic background14. CMV leaves a clear fingerprint on circulating T-cells, 
which resembles T-cell aging. A decreased CD4+/CD8+ ratio, a more differentiated memory 
T-cell compartment and expansion of T-cells lacking expression of the costimulatory 
molecule CD28 have been associated with CMV-seropositivity and attrition of telomeres in 
T-cells15-19. Therefore, we considered CMV-seropositivity as a separate entity in our study. 
Validated biomarkers for human T-cell aging are reduced numbers of circulating recent 
thymic emigrants (RTE) as representatives of thymic involution, an enhanced T-cell 
differentiation status, and attrition of telomeres15,20,21. Telomeres are small DNA repeats 
located at the end of chromosomes that protect from fusion but shorten with each cell 
division22. Several studies find that BMI is inversely correlated with telomere length in 
T-cells22,23. However, this has not been established in all studies22,24.The effect of MetS on 
T-cell aging has not yet been investigated.
Cytomegalovirus (CMV)
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Bariatric surgery may be indicated as a treatment for morbidly obese patients25. Besides 
rapid loss of body weight, bariatric surgery has been reported to reverse obesity-related 
diseases including diabetes mellitus and dyslipidemia25. Whether this procedure also 
induces reversal of aging, in particular premature T-cell aging, is unclear. 
Therefore, we aimed to determine the effects of morbid obesity and MetS on aging 
of circulating T-cell subsets as well as the potential reversal of T-cell aging by bariatric 
surgery. We show that the presence of MetS is an individual risk factor for premature aging 
of the T-cell immune system of morbidly obese patients and a partial reversal of the aging 
process may be established by bariatric surgery. These data show that MetS predisposes 
to accelerated T-cell aging and may be a biomarker identifying patients that benefit from 
bariatric surgery. 
RESULTS
Baseline characteristics 
A total of 118 participants were included in this study, consisting of 10 HC and 108 morbidly 
obese patients. Of the latter, 41 persons with a BMI of ≥35 did not have MetS and 67 had 
MetS. Table 1 summarizes the baseline characteristics of the included participants. Patients 
without MetS were more often female than patients with MetS. When dividing the groups 
in patients ≤50 and >50 years, patients with MetS were significantly older in the group 
≤50 years. No significant differences were observed with respect to distribution of CMV-
seropositivity amongst the study groups. 
Lower numbers of recent thymic emigrants due to MetS and age 
In both CD4+ and CD8+ T-cell compartments, no significant differences were induced by 
obesity and MetS (Table 2). No age-related decline in CD4+ RTE in the total group was 
observed, however the group without MetS did show a significant decline. The effects were 
stronger in the CD8+ T-cell population, which showed an age-related decline in RTE for 
morbidity obese patients as well as for patients with and without MetS (Table 2). These 
data suggest an age-related decline in RTE which is most significant in the CD8+ T-cell 
compartment and intensified by the presence of MetS. CMV-seropositivity had no effect on 
RTE. Female patients had a significantly higher number of CD4+ RTE compared to male 
patients, whereas no significant differences were observed for CD8+ RTE (Table 2).
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Table 1. Baseline characteristics of the three different patient cohorts
Characteristics/ Subjects BMI ≥ 35 no MetS BMI ≥ 35 with MetS Healthy Individuals
N 41 67 10
Gender (male/female)* 5/36* 21/44* 2/8
BMI (Kg/m2)* 43 (35-66)* 43 (35-65) 25±1.5*
Age (yrs) 39 (18-62) 43 (22-60) 45 (27-59)
AGE ≤50/ >50 YEARS
N 28/13 41/26 6/4
Age (yrs)* 31(18-49)*/54(51-62) 36(22-48)*/55(50-60) 36(27-48)/57(55-59)
CMV-/CMV+
N 27/14 30/29 5/5
Age (yrs) 39(18-62)/38(25-56) 42(22-60)/45(25-60) 42(27-54)/56(28-59)
MetS = metabolic syndrome; BMI = Body Mass Index; CMV = cytomegalovirus. Significance between two groups are 
highlighted with an asterisk at the groups within the significant comparisons. * = P<0.05
Obesity and metabolic syndrome enhance T-cell differentiation status
Obesity resulted in a significant higher number of CD4+ central memory (CM; CD45R0+/
CCR7+) cells compared to HC (Table 2). This significance remained in both MetS and no MetS 
groups. The presence of MetS resulted in an advanced T-cell differentiation, with significant 
increased numbers of CD4+ CD28null T-cells. In the CD8+ compartment, obesity led to a 
higher number of more differentiated effector memory RA (EMRA; CD45R0-/CCR7-) cells. 
Upon dissection into the presence or absence of MetS, this higher number of EMRA CD8+ 
T-cells only remained significant in the MetS group. The presence of MetS also induced a 
significantly higher number of total memory, central memory, differentiated EMRA and 
CD28null cells in the CD8+ compartment. (Table 2). Advanced age led to a significant lower 
number of CD8+ naive T-cells (CD45RO-/CCR7+). In patients ≤50 years, the presence of 
MetS gave rise to a higher number of CD4+CD28null T-cells. In the CD8+ compartment, 
the younger age resulted in significantly more mature CD8+ EMRA T-cells, while patients 
>50 years having MetS showed higher total number of CD8+ cells, central memory cells and 
total number of memory T-cells, including EMRA and CD28null T-cells. Taken together, 
in both age groups MetS resulted in a shift towards a more mature T-cell differentiation 
status, which was most pronounced in the older age group. CMV-seropositivity resulted in 
more differentiated (EMRA and CD28null) T-cells in both CD4+ and CD8+ T-cells. Gender 
differences were reflected by the higher number of CD4+ CD31 naive and EMRA T-cells 
in female patients compared to males (Table 3). A multivariate analysis including MetS, 
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age, CMV-seropositivity and gender revealed that CMV-seropositivity was an independent 
factor for the enhanced CD4+ T-cell differentiation status. For the CD8+ T-cell markers, 
independent factors were age, CMV-seropositivity as well as gender (Table S1). 
Table 2. P-values of the different T-cell differentiation markers of the different patient cohorts prior 
to bariatric surgery
Parameter Obesity MetS Age MetS x 
Age
CMV Gender
CD4 T-cells 0.73 0.37 0.97 0.25 0.54 0.38
CD4 naive T-cells 0.58 0.76 0.67 0.17 0.15 0.17
CD4 CD31 naive T-cells 0.82 0.84 0.32 0.97 0.19 0.02 (↑) 
CD4 memory T-cells 0.26 0.26 0.69 0.65 0.70 0.92
CD4 central-memory T-cells 0.003 (↑) 0.23 0.98 0.74 0.39 0.34
CD4 effector-memory T-cells 0.20 0.99 0.42 0.84 0.02 (↑) 0.07
CD4 EMRA T-cells 0.11 0.19 0.24 0.22 0.02 (↑) 0.008 (↑)
CD4 CD28null memory T-cells 0.16 0.01(↑) 0.64 0.03(↑) <0.001 (↑) 0.35
CD8 T-cells 0.86 0.11 0.60 0.009(↓) 0.006 (↓) 0.15
CD8 naive T-cells 0.75 0.85 0.008 (↓) 0.46 0.34 0.46
CD8 CD31 naive T-cells 0.41 0.92 <0.0001 (↓) 0.002(↓) 0.82 0.36
CD8 memory T-cells 0.01(↑) 0.004(↑) 0.35 0.02(↑) 0.002(↑) 0.07
CD8 central-memory T-cells 0.39 0.004(↑) 0.93 0.002(↑) 0.15 0.03(↑) 
CD8 effector-memory T-cells 0.14 0.47 0.50 0.38 0.11 0.80
CD8 EMRA T-cells 0.002(↑) 0.005(↑) 0.27 0.03(↑) 0.001(↑) 0.12
CD8 CD28null memory T-cells 0.57 0.01(↑) 0.15 0.01(↑) <0.001(↑) 0.17
Explanation of group comparisons: Obesity = total obesity group vs. healthy controls; MetS = MetS vs. no MetS; Age = total 
group >50 years vs. ≤50 years. MetS x Age = MetS group >50 years vs. ≤50 years; CMV = total group CMV vs. no CMV; Gender = 
total group female vs. male patients. MetS = metabolic syndrome. CMV = cytomegalovirus. Significant comparisons are 
depicted in bold. Arrows indicate direction of significance. 
Metabolic syndrome and age affect relative telomere length of T-cells 
prior to bariatric surgery  
One-way analysis of variance showed a significant decline in the RTL of CD4+ T-cells in the 
MetS group (P=0.046) (Figure 1A). Individual comparisons revealed that this difference was 
based on the significant decline in RTL in the MetS group compared to the no MetS group 
(P=0.03). Age did not influence RTL (Figure 1B). In patients ≤50 years, MetS significantly 
shortened RTL in CD4+ T-cells (P=0.04) (Figure 1C). No significance was seen in the group 
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>50 years with or without MetS, however a large dispersion in interquartile ranges was seen 
in both groups. No significant differences were seen in CD8+ RTL in either the different 
MetS (Figure 1D), age (Figure 1E) or combined MetS and age (Figure 1F) groups. These 
results demonstrate that MetS enhances telomere attrition in the CD4+ compartment, with 
most pronounced changes in the younger patients. CMV-related attrition of telomeres was 
only observed within the CD4+, but not the CD8+ T-cell compartment of morbidly obese 
patients without MetS (P=0.03). In a multivariate analysis including MetS, age, CMV-
seropositivity and gender none of these were independent factors for RTL in both CD4+ 
and CD8+ T-cells (Table S1). 
T-cell aging is partially reversed following bariatric surgery
Up to 12 months after surgery, a significant decrease in CD4+ RTE was observed, which was 
most significant between time points zero and six months (Table 3).  No differences were 
seen for these RTE within the CD8+ T-cell compartment for the total obesity, no MetS and 
the MetS groups (Table 3). 
A decrease in both EM and CD28null differentiated T-cells was noted for in CD4+ T-cells 
in the total obesity group (Table 3). Pairwise comparisons revealed the most significant 
decrease in the period between zero to six months postoperatively. Comparison of the 
groups with and without MetS, the decrease in CD28null CD4+ T-cells remained significant 
in the MetS group only. A decrease in CD8+ T-cell differentiation was reflected by a 
significant increase in CM and a decrease in EM T-cells. A trend towards decrease was 
seen for both EMRA and CD28null CD8+ T-cells. Upon dissection of the morbidly obese 
patients into the no MetS and MetS group, a trend towards lower numbers of CD8+ EMRA 
T-cells was observed for the MetS group (Table 3). 
Relative telomere length restores in the first months after bariatric 
surgery 
Telomere attrition seemed to restore following bariatric surgery in morbidly obese patients 
with MetS up to six months after surgery, with a significant increase in RTL between zero 
and three months postoperatively. However, a shortening was observed at 12 months 
postoperatively with an overall significant effect between zero and 12 months (P=0.02) 
(Figure 2A). Comparison between individual time points showed a significant increased 
directionality in CD4+ RTL within the first three months after surgery, however a decline in 
RTL was shown at the later time points, of which the decrease between three and 12 months 
remained significant after adjusting (P=0.04).
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Figure 1. Relative telomere length (RTL) prior to bariatric surgery. (A) RTL of CD4+ T-cells was 
significantly lower in the MetS group compared to no MetS. (B) Age did not have an effect on RTL 
of CD4+ T-cells. (C) In patients ≤50 years, MetS resulted in lower CD4+ RTL than in the absence of 
MetS. In patients >50 years, a large spread in interquartile range was seen in both groups. (D) No 
changes were seen in the CD8+ RTL due to MetS, (E) due to age or (F) due to both MetS and age. 
MetS = metabolic syndrome. HC = healthy controls. * = P<0.05.
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These significances were lost after dividing the group into a no MetS (Figure 2B) and a MetS 
(Figure 2C) group. The CD8+ RTL showed no significant changes over time in either the 
total obesity (Figure 2D), the no MetS (Figure 2E) or the MetS (Figure 2F) group. 
Table 3. P-values of the different T-cell differentiation markers of both CD4+ and CD8+ of the 
different patient cohorts between 0 and 12 months after bariatric surgery
Parameter Obesity No MetS MetS
CD4 T-cells 0.18 0.24 0.24
CD4 Naive T-cells 0.11 0.15 0.33
CD4 CD31 naive T-cells 0.03 (↓) 0.15 0.12
CD4 Memory T-cells 0.27 0.24 0.62
CD4 Central-memory T-cells 0.39 0.24 0.80
CD4 Effector-memory T-cells 0.02 (↓) 0.07 0.07
CD4 EMRA T-cells 0.19 0.83 0.20
CD4 CD28null memory T-cells 0.01 (↓) 0.15 0.048 (↓)
CD8 T-cells 0.47 0.80 0.15
CD8 Naive T-cells 0.78 0.90 0.53
CD8 CD31 naive T-cells 0.32 0.24 0.80
CD8 Memory T-cells 0.06 0.15 0.12
CD8 Central-memory T-cells 0.03 (↑) 0.31 0.12
CD8 Effector-memory T-cells 0.045 (↓) 0.31 0.15
CD8 EMRA T-cells 0.07 0.19 0.07
CD8CD28null memory T-cells 0.07 0.11 0.15
Obesity = total group of patients. No MetS = all patients without MetS. MetS = all patients with MetS. Significant comparisons 
are depicted in bold. Arrows indicate direction of significance. 
DISCUSSION
In present study, we show that prior to bariatric surgery morbidly obese patients with 
metabolic syndrome (MetS) have shorter telomeres than morbidly obese patients 
without MetS, which is most pronounced in the younger age group. This attrition of 
telomeres is accompanied by a more differentiated T-cell compartment, indicating that 
MetS results in accelerated aging of T-cells. After surgery, this more differentiated T-cell 
status was ameliorated including a partial restoration of telomeres in the first six months 
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postoperatively. Our results suggest that bariatric surgery may facilitate partial restoration 
of this accelerated T-cell aging and thus may help to ameliorate morbidity in morbidly 
obese patients.
The underlying chronic inflammatory state in obesity resembles the consequences of 
inflammaging as seen in older healthy individuals. Inflammaging affects the immune 
system, causing a release of cytokines which eventually leads in a vicious circle to increased 
damage on cells and tissues28. Also, the thymus involutes with age resulting in remodeling 
of the CD4/CD8 T-cell ratio and an enhanced T-cell differentiation state8,26. T-cells are part 
of the adaptive immune system and are derived from lymphoid precursor cells in bone 
marrow, migrating towards the thymus to further differentiate. In response to infectious 
agents, either T-helper (CD4+) or T-cytotoxic (CD8+) cells differentiate from naive to into 
memory cells to generate a potent second response to the same stimuli. Within the memory 
T-cell pool, central (CM) and effector memory (EM) T-cells can be distinguished, both with 
different phenotypical and functional characteristics. CM and EM T-cells are predominant 
within circulating CD4+ and CD8+ T-cells, respectively27. Changes to the T-cell mediated 
adaptive immunity due to obesity has been shown before, for instance obesity increases 
both the total numbers of CD4+ and CD8+ T-cells28 while causing a decrease in CD4+ 
regulatory T-cells11,29,30. The effects of obesity on maturation of the T-cell system has only 
been investigated in children, where obesity led to an increase in differentiated EM and 
EMRA T-cells31. In patients with renal failure, uremia causes a chronic inflammatory 
environment inducing a severe depletion of naive T-cells and a shift to more differentiated 
T-cells, reflected by a decrease in CM and increase in EM and EMRA15,32,33. In this study, 
we show that obesity causes a shift towards fully differentiated T-cell effector memory cells 
(EMRA) with a much stronger effect in older patients with MetS. Presumably, the number 
of differentiated T-cells increases with age while the number of naive cells decreases34. We 
confirm the latter, however after correcting for age and the presence of MetS we showed 
a strikingly different T-cell compartment with a decrease in naive T-cells and a marked 
increase in EMRA and CD28null T-cells. These results were much more pronounced in 
the CD8+ T-cell compartment, which is in line with the latest literature showing that the 
immunological changes due to obesity affect mostly CD8+ T-cells13. This pronounced effect 
of MetS on T-cell immunity and telomere length is of clinical interest, since it enables us to 
identify patients within the morbidly obese patients who have a potentially increased risk 
of morbidity and therefore a higher need for surgical intervention.
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Figure 2.  Relative telomere length (RTL) after bariatric surgery. (A) CD4+ RTL of the total 
obesity group significantly increased up to six months postoperatively, after which RTL significantly 
declined again. (B) No CD4+ RTL differences were seen in the group without MetS, or (C) in the 
group with MetS. (D) No changes were seen in the CD8+ RTL due to obesity, or (E) in the group 
without MetS or (F) with MetS. A paired samples test was used; missing values were excluded from 
the analysis. MetS = metabolic syndrome.  * = P<0.05.
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T-cell aging is associated with attrition of telomeres, which can be easily measured in 
circulating T-cells via flowcytometry22,35. A relationship between obesity and telomere 
attrition in circulating leukocytes and T-cells has been previously been described, however 
the results are ambiguous11,24,36,37. One study also investigated the importance of MetS 
but could not find a deleterious role of MetS on telomere shortening in leukocytes39. In 
addition to obesity itself, we show that enhanced telomere attrition occurs when MetS 
as a comorbidity is present in morbidly obese patients, most notable in patients of ≤50 
years. Differences in the methods used to measure telomere length might contribute to the 
discrepancies with other studies. Namely, the other groups used a quantitative PCR assay 
technique to measure relative telomere length and our flowcytometry assay might be more 
sensitive to pick up differences within a particular population of T-cells36. 
The hypothesis that bariatric surgery ameliorates attrition of telomeres in addition to 
resolving the obesity-associated diseases such as diabetes mellitus, has been investigated 
previously but results are inconclusive36,37. These studies are not directly comparable since 
the follow-up period after bariatric surgery differs between one and 10 years. Formichi 
et al.37  showed a significant decline at three, six and 12 months postoperatively, while we 
showed a trend towards increase in RTL in the first three months postoperatively until a 
decline was seen only at 12 months postoperatively. This improvement induced earlier on 
after surgery is in line with the rapid weight loss and reversal of diabetes mellitus as seen 
after bariatric surgery25. As Formichi et al. mentioned, the decline in RTL could be induced 
by the acute catabolic state induced by bariatric surgery37. Further research and larger cohort 
studies are warranted in order to investigate whether RTL might be further restored after 
bariatric surgery and at which time point this might be visible. In addition to the effects on 
RTL, bariatric surgery also induced subtle changes in the T-cell differentiation state, a link 
that has not been investigated previously. Especially in the total obesity group a decrease 
in more matured T-cells was shown, while MetS revealed to be an independent factor for 
the decrease in CD4+ CD28null T-cells. These results underscore that bariatric surgery may 
restore the premature immunological T-cell aging seen in morbidly obese patients. Since 
the eligibility of bariatric surgery is still largely dependent on general indicators such as 
BMI, this study justifies the need for clarification of the criteria for bariatric surgery based 
on individual patient characteristics. 
Telomere attrition and T-cell differentiation status are influenced by various, mostly non-
adjustable factors such as age and CMV-seroposivity22. While we show no differences in 
RTL due to these factors, we do demonstrate that CMV and age are both independent 
factors for enhanced T-cell differentiation status. These results were most prominent in 
the CD8+ T-cell population, which is in line with previous findings34. We also identified 
the effect of gender on RTL as well as T-cell differentiation, since the restoration of RTL 
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and T-cell differentiation was more pronounced in the female patients.  This suggests a 
dominant effect of gender on T-cell aging. These effects could be mitigated since female 
patients undergoing bariatric surgery are usually younger than males. Whether female 
patients might benefit more from bariatric surgery concerning T-cell aging remains unclear. 
Further studies should fortify the role of gender on premature aging of morbidly obese 
patients. 
There are several limitations attached to this study. The sample size of morbidly obese 
patients and the healthy control group is relatively small which could conceal effects 
on different subpopulations within our cohort. Especially the selected group of patients 
investigated after surgery is small as well as the short follow-up period of one year. Further 
inclusions would increase the likelihood of revealing differences in the studied cohort. 
Also, a longer follow-up period gives additional information about the long-term effects of 
bariatric surgery on T-cell differentiation. In addition, since we measured RTL in the total 
circulating CD4+ and CD8+ T-cell compartments the effects seen in RTL might be the result 
of shifts in specific T-cell subsets as seen for the significant increase in CD28null T-cells 
due to obesity and MetS. Further studies should identify the changes in RTL within these 
specific subsets to correlate these findings. Finally, not all effects of obesity are reflected in 
the circulation and therefore investigating the effects on the corner stone of obesity, the fat 
tissue itself, will allow the association between the effect of excess of fat tissue and changes 
seen in the immune system.
In conclusion, we show that the metabolic syndrome induced by morbid obesity causes 
telomere attrition in combination with enhanced T-cell differentiation in both circulating 
CD4+ and CD8+ T-cells, indicative of accelerated aging of the T-cell compartment. This 
shortening of telomeres and enhanced T-cell differentiation state are ameliorated shortly 
after bariatric surgery. These data suggest that obese patients with MetS are at risk for 
accelerated aging of the T-cell immune system and might benefit from bariatric surgery at 
an earlier stage.
SUBJECTS AND METHODS 
Study design
This study was designed as a non-randomized prospective cohort-study. The study was 
approved by the general Medical Ethical Committee (METC) with MEC identification 
number 2012-134 of the Erasmus University Medical Center, Rotterdam, the Netherlands. 
Approval of the inclusion center occurred via the Board of Directors of the Maasstad 
Hospital, Rotterdam, the Netherlands, with local identification number 2012-51. The 
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study is performed in accordance with the local METC guidelines. The trial is registered 
as part of the PROTECT trial in the Dutch trial registry database using trial code 3663 
(www.trialregister.nl). This study was performed in accordance with the CONSORT 2010 
statement, according to the Declaration of Helsinki38. 
Healthy living kidney donors and healthy volunteers that gave written informed consent 
served as age-matched healthy controls (HC) (n=10) and the study was approved by the 
Medical Ethical Committee of the Erasmus MC (Biobank of the METC, METC number 
2012-022). 
Study population
Patients with obesity and morbid obesity scheduled to undergo bariatric surgery whom 
visited the outpatient clinic at the Maasstad Hospital between March 2014 and August 2015 
were invited to participate in the study. All participating patients gave written informed 
consent before inclusion. A patient flowchart showing all inclusions and exclusions is 
depicted in Figure S1. To be eligible for bariatric surgery, patients had to have a body mass 
index (BMI, kg/m2 ≥35 with or without he presence of the metabolic syndrome (MetS). 
MetS was defined in accordance to the National Cholesterol Education Program ATPIII 
Guidelines, as fulfilling 3 out of 5 criteria39. Exclusion criteria were a BMI<35, other 
comorbidities than MetS, patients without basic understanding of the Dutch or English 
language, or patients undergoing another form of bariatric surgery than a laparoscopic 
gastric bypass procedure (LGBP). 
Bariatric surgery
The LGBP was used in all patients. In short, the jejenum is divided at 50 cm from the 
ligament of Treitz into a biliopancreatic limb and a 150-cm alimentary Roux-limb. The 
proximal segment of the stomach is made into a small pouch with stapling devices. A side-
to-side anastomosis is created between the pouch and the Roux-limb. The biliopancreatic 
limb is connected to the Roux limb, 150 cm distally.  
Blood collection
After providing written informed consent, a venous blood sample was obtained prior to 
surgery. The duration until scheduled surgery was between several days and five months after 
first blood sample. At time points prior to bariatric surgery, venous samples of 108 patients 
were collected for analysis. A selection of patients was asked to donate another venous 
blood sample at time points three (n=48), six (n=10) and 12 (n=11) months after surgery 
(Figure S1). The selection was made since not all patients showed up in the outpatient clinic 
during their scheduled follow-up clinics, or patients decided to be followed-up elsewhere 
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(for example by their general practitioner). All blood samples were collected in 10.0 mL BD 
Lithium-Heparin tubes (Franklin Lakes, NJ, USA), with a maximum of two tubes per time 
point.  
CMV serology 
Cytomegalovirus (CMV) serology was assessed of all participants included in the study 
at the diagnostic Department of Virology of Erasmus University Medical Center, by 
determining the presence of plasma IgG antibodies to CMV with an enzyme immune assay 
(Biomerieux, VIDAS, Lyon, France). The results were expressed as arbitrary units/mL (AU/
mL), and an outcome of ≥ 6 AU/mL was considered positive. 
T-cell phenotyping and PBMC isolation
A whole blood staining was performed and analyzed on the BD FACSCanto II (BD 
(Erembodegem, Belgium) using FACSDiva software version 6.1.2 (BD) in order to 
determine percentages and absolute numbers of T-cell subsets (Table 1).  The analysis 
procedure as well as further characterization of the T-cells has been described previously40. 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples 
by Ficoll gradient centrifugation as described in detail before41. PBMC were stored at -150oC 
at 10x106 per vial until further experiments.
Table 1. T-cell subsets and their corresponding staining markers
T-cell subset Marker
Recent thymic emigrants (RTE) CD31+ naive 
Naive T-cells CD45RO- / CCR7+
Central memory T-cells (CM) CD45RO+ / CCR7+
Effector memory T ceclls (EM) CD45RO+ / CCR7-
Terminally differentiated effector memory T-cells (EMRA)
Total memory T-cells (MEM)
CD45RO - / CCR7-
Sum of CM, EM & EMRA
Advanced differentiated T-cells CD28null
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Relative telomere length 
The relative telomere length of peripheral blood T-cells was determined by flow fluorescent 
in situ hybridization (flowFISH) technique, as described previously15. By using the subcell 
line 1301 of CCRF-CEM (known for its long telomeres) as a reference, a relative telomere 
length was calculated using the following formula:
RTL =
(median FL1 sample cells with probe -median FL1 sample cells without probe) × DNA index of control (=2)cells
× 100
(median FL1 control cells with probe -median FL1 control cells without probe) × DNA index of sample (=1)cells
Statistical analysis
Statistics were computed with use of SPSS version 23 (IBM Corp, released 2015, IBM SPSS 
Statistics for Mac, Version 23.0, Armonk, NY: IBM Corp), and GraphPad Prism (GraphPad 
Software Inc., version 5.01). For all individual parameters, median and interquartile 
ranges were computed. Comparison of more than two parameters was done via One-Way 
ANOVA, considering normal distribution as tested by the Gaussian approximation. Related 
samples from the same patient were analyzed via the related-samples Friedman’s test. Prior 
to bariatric surgery a multivariate analysis was computed via general linear models option 
in SPSS, considering the Wilks’ Lambda test to evaluate which variables contributed to 
T-cell characteristics measured in the circulation. Figures were made in Graphpad. For all 
parameters, P<0.05 was considered significant. 
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SUPPLEMENTARY DATA
	
Approached at 3 
months after surgery 
(n=87) 
Inclusions prior to 
surgery (n=108) 
Exclusions (n=31): 
Another trial (n=1) 
Surgery not approved (n=7) 
Exclusion criteria (n=24) 
Exclusions (n=39): 
No longer in follow-up 
or 
No participation 
Approached at 6 
months after surgery 
(n=48) 
Inclusions 3 months 
(n=48) 
Informed (n=132) 
Assessed for 
eligibility (n=163) 
No participation (n=24) 
Exclusions (n=38): 
No longer in follow-up 
or 
No participation 
Approached at 12 
months after surgery 
(n=20) 
Inclusions 6 months 
(n=10) 
Exclusions (n=9) 
No longer in follow-up 
or 
No participation 
Inclusions 12 months 
(n=11) 
Figure S1. Flowchart showing patient inclusion and exclusion criteria. Exclusion criteria were 
based on the preset exclusion criteria, mainly based on the criteria for the presence of metabolic 
syndrome as set by the National Cholesterol Education Program ATPIII Guidelines. Eligible 
patients set for undergoing bariatric surgery were approached at the outpatient clinic at the 
Maasstad Hospital, Rotterdam, the Netherlands. 
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Table S1. Multivariate analysis of the factors MetS, age, CMV-status and gender on relative telomere 
length and T-cell differentiation status prior to bariatric surgery 
Model
Factors
MetS Age CMV-status Gender
Model 1:
RTL: CD4+ & CD8+ 0.13 0.64 0.47 0.98
Model 2
T-cell phenotype: CD4+ 0.36 0.57 <0.001 0.29
Model 3
T-cell phenotype: CD8+ 0.77 0.03 0.005 0.01
Significant P-values (P<0.05) are depicted in bold. Model = the generalized linear model based on mentioned variables. MetS: 
MetS vs. no MetS; Age: >50 vs. ≤50 years; CMV-status: CMV+ vs. CMV-; Gender: female vs. male. T-cell phenotype included 
the following T-cell subsets: naive, CD31 naive, central memory, effector memory, effector memory RA, memory, CD28null and 
absolute T-cell numbers. MetS = metabolic syndrome; CMV = cytomegalovirus; RTL = relative telomere length.
15045-jongbloed-layout.indd   165 06/11/2017   17:20
15045-jongbloed-layout.indd   166 06/11/2017   17:20
CHAPTER 7
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ABSTRACT
Surgery-induced oxidative stress increases the risk of perioperative complications and delay 
in postoperative recovery. In mice, short-term preoperative dietary and protein restriction 
protect against oxidative stress. We investigated the feasibility of a calorie- and protein-
restricted diet in two patient populations. In this pilot study, 30 living kidney donors and 38 
morbidly obese patients awaiting surgery were randomized into three groups: a restricted 
diet group, who received a synthetic liquid diet with 30% fewer calories and 80% less protein 
for five consecutive days; a group who received a synthetic diet containing the daily energy 
requirements (DER); and a control group. Feasibility was assessed using self-reported 
discomfort, body weight changes, and metabolic parameters in blood samples. Twenty 
patients (71%) complied with the restricted and 13 (65%) with the DER-diet. In total, 68% 
of the patients reported minor discomfort that resolved after normal eating resumed. The 
mean weight loss on the restricted diet was significantly greater (2.4 kg) than in the control 
group (0 kg, P=0.002), but not in the DER-diet (1.5 kg). The restricted diet significantly 
reduced levels of serum urea and plasma prealbumin (PAB) and retinol binding protein 
(RBP). A short-term preoperative calorie- and protein-restricted diet is feasible in kidney 
donors and morbidly obese patients. Compliance is high and can be objectively measured 
via changes in urea, PAB, and RBP levels. These results demonstrate that this diet can be 
used to study the effects of dietary restriction on surgery-induced oxidative stress in a 
clinical setting.
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INTRODUCTION
Reactive oxygen species (ROS) that the body produces during surgical procedures 
induce oxidative stress and lead to imbalances in homeostasis1,2. The subsequent stress 
response elicits hormonal, metabolic, and immunological changes that increase the risk 
of perioperative complications and may hamper postoperative recovery1,3. This risk is 
increased by pre-existing factors such as obesity4, and by perioperative factors such as 
ischemia-reperfusion injury (IRI) during organ transplantation5,6. Although treatments 
that decrease ROS production could reduce perioperative and postoperative complications, 
no effective clinical therapy is currently available. 
In animal studies, dietary restriction (DR) protects against ROS-induced damage. We 
demonstrated previously that short-term preoperative 30% DR protects against the 
oxidative damage induced by renal IRI in mice and improves postoperative survival and 
kidney function7–9, and similarly protects against liver IRI10. The beneficial effects of fasting 
on renal IRI are also observed in aged obese mice of both genders, suggesting that DR 
induces protection against ROS independent of age and gender11.
Translating DR to humans in a clinical setting is difficult, because of the effort required by 
patients to voluntarily restrict their calorie intake. In addition, DR goes against the generally 
held beliefs that patients should be well fed before surgery to prevent malnutrition. Finally, 
the diet composition and duration that induce similar benefits in humans as observed in 
rodents is not known12. Studies examining the effects of a very low-calorie diet prior to 
bariatric surgery report contradictory effects on perioperative and postoperative outcomes, 
and adherence to the diet in these studies was not measured objectively13,14. In our previous 
pilot study in living kidney donors, we showed that three days of 30% DR followed by 
24 h of fasting prior to kidney donation was feasible and safe, but had limited effects on 
outcome15,16. Subsequent results from murine experiments suggested that the beneficial 
effects were mainly due to restriction in protein intake17. The effect of protein restriction 
(PR) has not yet been investigated in a clinical setting. 
Therefore, our current pilot study investigated the feasibility of a preoperative diet 
combining DR and PR in two patient populations: living kidney donors and morbidly obese 
patients scheduled for laparoscopic donor nephrectomy or laparoscopic bariatric surgery, 
respectively. To identify objective markers of diet adherence, we measured both standard 
and experimental metabolic markers. Our results showed that short-term DR is feasible 
and represents a promising next step in investigating the effects of preoperative DR on 
surgery-related outcome in a clinical setting.
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RESULTS
Study population
Of the 45 living kidney donors that were included initially and who underwent 
randomization, 30 were equally distributed (n = 10) in the three groups and completed the 
study. Of the 54 morbidly obese patients that were included initially, 38 were distributed 
in the three groups with 18 patients in the restricted diet group, 10 in the DER-diet group, 
and 10 in the control group (Figure S1). At baseline, the morbidly obese patients group had 
significantly higher average body weight and BMI and was significantly more often female 
(Table 1). There were no differences in the baseline characteristics after randomization 
between dropouts and patients who completed the study. 
Table 1. Baseline characteristics of the study population
Parameter Living Kidney Donors (n = 30) Morbidly Obese Patients (n = 38) P-Value
Age, years 47 ± 13 43 ± 9 0.17
Gender, F/M 12/18 31/7 0.003
Body weight, kg 82.8 ± 17.3 129.1 ± 24.6 <0.001
BMI, kg/m2 26.6 ± 4.6 44.5 ± 5.4 <0.001
Baseline characteristics of the study population; Values are depicted as mean ± standard deviation; Significant P-values are 
depicted in bold; At baseline, the morbidly obese patients group had a significantly higher average body weight and BMI and 
were significantly more often female. F=female; M=male; BMI= body mass index.
Compliance with the diets by kidney donors and morbidly obese patients
A total of 10 living kidney donors and 18 morbidly obese patients were randomized into the 
restricted diet group. This group received a synthetic diet with a mean calorie restriction 
of 30% and a mean protein restriction of 80% relative to each patient’s DER. Twenty 
individuals (71%) reported completing the five-day diet (Figure S2). Eight out of 10 kidney 
donors (80%), and 12 out of 18 morbidly obese patients (67%) reported completing the 
restricted diet.
Ten donors and 10 morbidly obese patients were randomized into the DER-diet. This group 
received a synthetic diet which resulted in a mean DR of 4% without PR. Thirteen out of 20 
(65%) individuals receiving this diet reported completing the diet. Of the kidney donors, 
four out of 10 (40%) completed the diet; nine out of 10 (90%) morbidly obese patients 
completed the diet (Figure S2). 
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Twenty patients were randomized into the control group. Nine out of 10 donors (90%) 
filled in the diary for five consecutive days, while seven out of 10 (70%) morbidly obese 
patients filled in the diary. An analysis of the dietary diaries was performed to calculate 
average percentages of protein, carbohydrate and fat-intake. Nine patients in the control 
group had complete filled-in diaries and were included in the analysis. Average nutrient 
content consisted of 18% protein, 48% carbohydrates and 34% fat. 
DISCOMFORT DURING THE DIETARY INTERVENTIONS
No major side effects were reported during or after the dietary interventions. 
Twenty out of 28 individuals (71%) receiving the restricted diet reported 35 instances of minor 
discomfort that resolved during or directly after finishing the diet (Figure 1). In general, the 
shake drinks were well tolerated and were reported to be palatable. A higher percentage of 
kidney donors (40%) than morbidly obese patients (20%) reported discomfort related to 
nutritional intake, e.g., hunger and appetite. In contrast, a higher percentage of morbidly 
obese patients (90%) than kidney donors (20%) reported gastrointestinal discomfort, e.g., 
stool change, nausea, stomachache and dyspepsia. Three out of eight patients whom did not 
complete the diet mentioned gastrointestinal discomfort as the main reason.
Of patients on the DER-diet, 13 out of 20 (65%) reported 26 instances of minor discomfort 
during the diet. Kidney donors reported mostly gastrointestinal discomfort (90%), while 
the morbidly obese reported gastrointestinal discomfort (50%) and discomfort related to 
nutritional intake, such as distaste and appetite (50%). 
Discomfort was scored semi-quantitatively using the VAS questionnaires at time points 
before, during, and after the diet. Patients that completed the restricted diet had significantly 
higher levels of nausea (P=0.009) and decreased wellbeing (P=0.02) during the diet than 
before the diet (Figure 2). These scores returned to baseline on day 1 after finishing the diet. 
There were no differences in pain scores at the three time points. Those on the DER-diet 
also reported higher nausea scores during the intervention (P=0.04). No differences were 
seen for the pain scores before, during, and after the diet for either dietary intervention, no 
changes were reported in the control group.
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Figure 1. The number of side effects as percentages of participants in groups consuming a 
restricted diet and a daily energy requirements diet (DER-diet). (A) Side effects of the dietary 
restriction and protein restriction diet in the kidney donors were mostly related to nutritional intake 
and to the gastrointestinal tract; (B) Morbidly obese patients showed relatively more gastrointestinal 
discomfort; (C) A total of 90% of the kidney donors reported gastrointestinal discomfort during 
the DER-diet; (D) This percentage was lower in the morbidly obese patients and was the same as 
discomfort related to nutritional intake. Effects are clustered based on the origin of the symptoms. 
Within each cluster, each side effect is depicted in a different shade of color. 
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Figure 2. Visual Analogue Scores (VAS) for nausea, pain, and wellbeing before, during, and 
after each dietary intervention. (A) The nausea scores increased significantly for patients on the 
restricted diet and the DER-diet but normalized to baseline levels directly after the intervention 
period was over; (B) The pain scores did not change significantly during the dietary interventions; 
(C) The restricted diet resulted in significant decreased VAS wellbeing scores during the diet 
compared to before, but normalized again directly after the intervention period was over; * P<0.05. 
Bars represent the standard error of the mean; DER = daily energy requirements.
Body weight
Individuals who adhered to the restricted diet lost on average 2.5% of their total body 
weight, corresponding to 2.4 ± 1.4 kg, based on the body weight measurements at the 
outpatient clinic before the start of the dietary restriction and on the day after its completion 
(Figure 3). This body weight loss was significantly greater (P=0.002) than in individuals 
without dietary restriction (n=6), who did not lose weight (0.2% of their total body weight). 
The body weight changes were not significantly different between the kidney donors and 
bariatric surgery patients. The DER-diet (n=3) resulted in an average loss of 1.5 ± 1.4 kg 
(1.7%), which was not significantly different from either the restricted diet group or the 
control group. 
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Markers of metabolism and compliance
Before and after all dietary interventions, blood samples were collected and serum and 
plasma was stored for further analyses. Only samples taken from fasted patients were used 
for these analyses. Due to the exclusion of samples from patients who did not fast, too few 
samples were available from the kidney donors for statistical analysis within this group. 
Therefore, the data from both kidney donors and morbidly obese patients were pooled. Due 
to a variation in baseline levels between the different patient groups, relative differences 
were compared between groups using the change in values before and after the intervention. 
Figure 3. Body weight changes in the three dietary intervention groups. Patients on the restricted 
diet lost an average of 2.5% of their body weight, corresponding to 2.4 ± 1.4 kg; This body weight 
loss was significantly greater than in the control group, which showed no change; The DER-diet 
resulted in a 1.7% loss in body weight (1.5 ± 1.4 kg), which was not significantly different than 
the two other groups; Changes are shown as percentages compared to the body weight at baseline; 
**P<0.01. Bars represent the standard error of the mean. DER = daily energy requirements.
Metabolic changes due to the dietary interventions as well as intragroup variations were 
extensively assessed via a panel of 147 metabolic parameters (Table S1). The impact of the 
two diets on protein metabolism was measured using serum albumin, urea and amino acids 
levels. The restricted diet did not significantly change serum albumin (Figure 4A). Serum 
albumin was increased by 7% after the DER-diet, but did not reach significance (P=0.006). 
The increase after the DER-diet showed a trend towards higher levels compared to the 
relative change in the restricted diet (P=0.006) and the control group (P=0.003) (Table 2). 
No significant changes were seen in the control group. Serum urea was on average 37.5% 
lower after the restricted diet than before the diet (P=0.002), which was also significantly 
different from the DER-diet (P<0.001) and the control group (P<0.001) (Figure 4B). There 
were no significant changes in serum urea in the DER-diet group or in the control group. 
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Of the serum amino acids measured, none differed significantly between the groups (Figure 
4C/D). The relative decrease of 18% in valine levels was significant compared to the relative 
difference of the DER-diet and the control group (Table 2). The cumulative sum of BCAAs, 
namely isoleucine, leucine and valine, showed a trend towards a decrease after the restricted 
diet (P=0.005), but not after the DER-diet or in the control group. The relative decrease of 
16% in the combined BCAAs also showed a trend compared to the relative change after the 
DER-diet (P=0.004) and the control group (P=0.004). Other amino acid levels were not 
significantly changed after any of the diets.
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Figure 4. Serum levels of albumin, urea, valine and leucine after the three dietary interventions. 
(A) Serum albumin did not significantly change in any of the groups. (B) Serum urea was decreased 
significantly after the restricted diet, while it did not change after the DER diet or in the control 
group; both serum valine (C) and leucine (D) did not differ between groups, but did show a trend 
towards a decrease after the restricted diet; red symbols = kidney donors, as opposed to morbidly 
obese individuals (black or gray symbols); DER = daily energy requirements.
Neither serum markers glucose nor insulin changed significantly before versus after 
the intervention in three diet groups (Table 3). After the restricted diet, high-density-
lipoprotein (HDL) was significantly decreased (P=0.006), but did not remain significant 
after the Bonferroni correction for multiple testing. 
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Table 2. Relative changes in metabolic parameters, amino acids and compliance markers after the 
dietary interventions with their corresponding P-value of intragroup differences
Parameter
Intervention
Restricted 
Diet 
(% Change)
DER-Diet 
(% Change)
Control 
(% Change)
P-Value 
Restricted- 
DER
P-Value 
Restricted- 
Control
P-Value 
DER- 
Control
Metabolic
Albumin (g/L) −9 +7.2 −1.9 0.006 0.212 0.003
Urea (mmol/L) −37.5 +13.8 −2.6 <0.0001 <0.0001 0.067
Creatinine (mmol/L) +15.1 12.2 −2.0 0.51 0.009 0.03
Glucose (mmol/L) −1.8 −0.6 +6.2 0.76 0.10 0.20
Ferritin +17.5 +21.2 +20.2 0.73 0.89 0.95
Insulin (pmol/L) +27.2 +13.7 +52.2 0.70 0.68 0.34
Amino Acids
Alanine (mmol/L) −3.6 +3.1 −5.8 0.37 0.74 0.20
Glutamine (mmol/L) +2.1 +0.1 +2.9 0.72 0.90 0.51
Glycine (mmol/L) +7.8 +3.3 +5.0 0.37 0.61 0.73
Histidine (mmol/L) −11.0 −8.6 −0.2 0.72 0.15 0.12
Isoleucine (mmol/L) −12.8 −2.7 +11.0 0.15 0.03 0.15
Leucine (mmol/L) −11.1 +2.1 +8.0 0.01 0.01 0.37
Phenylalanine (mmol/L) −4.9 +5.3 +6.4 0.06 0.03 0.81
Tyrosine (mmol/L) −10.0 +5.0 0.6 0.09 0.19 0.56
Valine (mmol/L) −17.9 +0.7 +11.6 0.002 0.003 0.22
BCAA * (mmol/L) −16.4 −1.3% +8.8% 0.004 0.004 0.22
Miscellaneous
Prealbumin (mg/L) −17.2 +1.0 −1.2 0.002 0.0001 0.77
Retinol Binding Protein 
(mg/L)
−20.5 +5.6 −0.9 0.0002 0.0001 0.26
Relative changes in metabolic parameters, amino acids and compliance markers after the dietary interventions with their 
corresponding p-value of intragroup differences. Values are depicted as mean ± standard error of the mean. Significant p-values 
are depicted in Italics. Significant p-values after the Bonferroni correction for multiple testing are depicted in bold and Italics. * 
BCAA = branched chain amino acids; cumulative sum of isoleucine, leucine and valine.
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Table 3. Changes in metabolic parameters after the dietary intervention groups
Parameter
Intervention
Restricted Diet DER-Diet Control
Before After P-Value Before After P-Value Before After P-Value
Metabolic
Albumin (g/L) * 35.2 ± 
1.2
32.3 ± 
2.4
0.09 41.3 ± 
0.8
44.2 ± 
0.9
0.006 39.9 ± 
1.0
39.0 ± 
1.3
0.57
Urea (mmol/L) 4.3 ± 
0.3
2.6 ± 
0.2
0.0002 5.5 ± 
0.3
6.1 ± 
0.4
0.19 4.7 ± 
0.4
4.5 ± 
0.4
0.36
Creatinine 
(mmol/L)
72.6 ± 
3.3
83.4 ± 
4.4
0.002 69.5 ± 
3.7
78.5 ± 
5.6
0.01 66.4 ± 
6.4
63.5 ± 
5.5
0.92
Glucose (mmol/L) 4.9 ± 
0.2
4.8 ± 
0.2
0.53 5.7 ± 
0.2
5.6 ± 
0.2
0.85 5.2 ± 
0.3
5.8 ± 
0.3
0.13
Insulin (pmol/L) ** 62.4 ± 
18.6
60.9 ± 
18.9
1.00 98.4 ± 
18.1
106.1 
± 23.2
0.28 157.6 
± 46.3
195.5 
± 65.1
0.46
Cholesterol 
(mmol/L)
5.1 ± 
0.5
4.5 ± 
0.6
0.03 4.7 ± 
0.3
4.5 ± 
0.3
0.13 4.4 ± 
0.3
4.8 ± 
0.3
0.19
Free fatty acids 
(mmol/L)
0.52 ± 
0.03
0.72 ± 
0.09
0.09 0.55 ± 
0.05
0.67 ± 
0.04
0.01 0.48 ± 
0.05
0.56 ± 
0.09
0.49
Saturated fatty 
acids (mmol/L)
4.18 ± 
0.25
4.01 ± 
0.21
0.11 3.46 ± 
0.25
3.03 ± 
0.19
0.002 3.59 ± 
0.17
3.60 ± 
0.17
0.27
Triglycerides 
(mmol/L)
1.31 ± 
0.19
1.37 ± 
0.25
0.97 1.60 ± 
0.42
1.51 ± 
0.28
0.92 1.57 ± 
0.27
1.66 ± 
0.31
0.70
HDL (mmol/L) 1.32 ± 
0.09
1.12 ± 
0.12
0.006 1.27 ± 
0.09
1.24 ± 
0.10
0.30 1.18 ± 
0.11
1.28 ± 
0.11
0.59
LDL (mmol/L) 3.9 ± 
0.7
4.0 ± 
0.7
0.69 2.9 ± 
0.3
2.7 ± 
0.3
0.06 2.6 ± 
0.3
2.9 ± 
0.3
0.32
Amino Acids
Alanine (mmol/L) 0.45 ± 
0.02
0.43 ± 
0.4
0.49 0.44 ± 
0.02
0.45 ± 
0.02
0.77 0.45 ± 
0.02
0.42 ± 
0.02
0.37
Glutamine 
(mmol/L)
0.47 ± 
0.02
0.47 ± 
0.02
0.63 0.49 ± 
0.02
0.49 ± 
0.02
1.00 0.45 ± 
0.02
0.46 ± 
0.02
0.35
Glycine (mmol/L) 0.26 ± 
0.007
0.28 ± 
0.01
0.08 0.28 ± 
0.009
0.29 ± 
0.01
0.85 0.25 ± 
0.006
0.26 ± 
0.009
0.18
Histidine 
(mmol/L)
0.06 ± 
0.003
0.06 ± 
0.004
0.08 0.07 ± 
0.003
0.06 ± 
0.002
0.01 0.07 ± 
0.003
0.07 ± 
0.004
0.83
Isoleucine 
(mmol/L)
0.06 ± 
0.004
0.05 ± 
0.002
0.06 0.05 ± 
0.005
0.05 ± 
0.003
0.43 0.06 ± 
0.004
0.06 ± 
0.005
0.40
Leucine (mmol/L) 0.08 ± 
0.005
0.07 ± 
0.003
0.02 0.08 ± 
0.004
0.08 ± 
0.003
0.63 0.08 ± 
0.005
0.09 ± 
0.006
0.50
Phenylalanine 
(mmol/L)
0.08 ± 
0.005
0.08 ± 
0.003
0.23 0.08 ± 
0.003
0.09 ± 
0.003
0.08 0.08 ± 
0.004
0.09 ± 
0.005
0.03
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Table 3. (continued)
Parameter
Intervention
Restricted Diet DER-Diet Control
Before After P-Value Before After P-Value Before After P-Value
Tyrosine 
(mmol/L)
0.05 ± 
0.003
0.05 ± 
0.002
0.08 0.06 ± 
0.003
0.06 ± 
0.004
0.70 0.06 ± 
0.004
0.06 ± 
0.003
0.58
Valine (mmol/L) 0.16 ± 
0.007
0.13 ± 
0.004
0.004 0.19 ± 
0.01
0.18 ± 
0.007
1.00 0.18 ± 
0.01
0.20 ± 
0.01
0.17
Changes in metabolic parameters after the dietary intervention groups. Values are depicted as mean ± standard error of the 
mean. Significant P-values are depicted Italics, while significant p-values after the Bonferroni correction for multiple testing are 
depicted in bold and Italics. * baseline levels in the restricted diet group are significantly lower than in the DER-diet and control 
group. This is due to a high percentage of patients with serum albumin levels which lay below the normal values of 35–55 g/L. 
** baseline levels in the control group are higher, due to patients with levels of serum insulin of >180 pmol/L.
Detailed analysis of HDL-subclasses showed a trend towards a decrease in the medium 
HDL-particles, while other HDL-subclasses were not affected (data not shown). The DER-
diet group had higher free fatty acids after the intervention (P=0.01), based on an increase 
of saturated fatty acids (SFA) (P=0.002). Furthermore, the DER-diet resulted in a significant 
decrease in serum cholesterol (P=0.03) Lipoprotein subclasses very small very-low-density-
lipoprotein (XS-VLDL), intermediate-density-lipoprotein (IDL) and large low-density-
lipoprotein (L-LDL) showed a trend towards a decrease due to the DER-diet, but this did 
not reach significance (data not shown). 
Both plasma prealbumin (PAB) (Figure 5A) and plasma retinol binding protein (RBP) 
(Figure 5B) were significantly lower after the restricted diet compared to levels before 
starting the diet, decreasing on average 27% (P=0.0002) and 22% (P=0.001), respectively. 
All except one patient in the restricted diet group showed a decrease in serum PAB and 
RBP. The eight patients who did not complete the restricted diet showed an average increase 
of 10% in PAB (Figure 5C) and 7% in RBP (Figure 5D), which was significantly different 
than the measures of those who completed the diet. No significant changes were seen in the 
DER-diet and in the control group in both PAB (Figure 5A) and RBP (Figure 5B).
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Figure 5. Plasma levels of prealbumin (PAB) and retinol binding protein (RBP) after the three 
dietary interventions. (A) Prealbumin (PAB) and (B) retinol binding protein (RBP) both decreased 
significantly after the restricted diet, with no changes seen in the DER-diet group or in the control 
group. (C) PAB and (D) RBP did not change in patients who did not complete the restricted diet. 
The two corresponding values for the individual patients are connected with a line. * P≤ 0.002. Red 
symbols = kidney donors in the restricted diet group. DER = daily energy requirements.
DISCUSSION
In this study, we showed that both kidney donors and morbidly obese patients are able to 
adhere to a synthetic calorie- and protein-restricted diet for five consecutive days with only 
minor discomfort. The metabolic markers PAB and RBP showed the strongest correlation 
with adherence to the diet, and together with serum urea could form a potential objective 
marker set to validate compliance to a diet comprising 30% DR and 80% PR. 
The rationale for combining DR and PR in this clinical diet was based on the known 
beneficial effects of short-term DR and short-term PR17-18. We showed previously that several 
DR regimens protect against renal IRI in mice and result in upregulation of anti-oxidants, 
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reduction of pro-inflammatory cytokines, improved kidney function, and increased 
survival7,19. DR also protects against IRI in aged-obese mice of both sexes, suggesting that 
the DR-induced effects on the stress response could be broadly applied11.
It is not clear how the benefits of DR should be translated to humans in a clinical setting. 
Longer-term DR (e.g., for weeks) is considered undesirable, since feelings of hunger and 
fatigue and the risk of malnutrition could alter the wellbeing of patients prior to surgery. 
However, a shorter period could be insufficient to confer the same beneficial effects as in 
animal studies. Most clinical studies of preoperative DR have been performed in bariatric 
surgery patients and were designed to evaluate the effects of DR on weight loss and liver 
size reduction13,14. One study showed reduction in steatosis and steatohepatitis after liver 
resection due to preoperative dietary and fat restriction20. We previously used a DR regimen 
of three days of 30% DR followed by 24 hours of fasting in living kidney donors, which 
proved to be feasible; unfortunately, this did not induce a beneficial response similar to that 
seen in mice15,16. This could be because the DR duration or restriction level was insufficient, 
or because the diet did not include PR. Based on this experience15,16, we extended the 
number of days of the diet, and restricted protein intake by 80% in addition to the 30% DR. 
A total adherence rate of 71% was reached, which was comparable between kidney donors 
and morbidly obese patients. Many factors influence adherence, such as the duration of the 
intervention as well as the frequency of daily doses. Osterberg et al. showed that the average 
adherence rate in clinical trials ranges between 43 and 78%21. They also reported an average 
adherence rate between 30 and 80% in patients who took three to four medication doses a 
day21, which is comparable to the three to four shakes per day in the restricted diet group of 
our study. In light of these results, our compliance rate is acceptable considering the fact that 
these patients did not receive the diet immediately prior to surgery, and therefore did not 
expect a beneficial effect. Further studies investigating the potential beneficial effects of this 
dietary regimen might further increase the compliance rate in these patient populations. 
Safety and discomfort of a preoperative diet are important factors to consider in terms 
of compliance and applicability. We found that serum albumin, insulin and ferritin 
measures did not change as a result of the restricted diet, indicating that malnutrition was 
not induced. As a measurement of discomfort, the VAS nausea scores were significantly 
increased in patients following the restricted diet, but since the scores did not exceed 2.5 
points out of 10, nausea cannot be considered highly clinically relevant. The patients that 
withdrew early from the diet reported discomfort, mostly gastrointestinal tract-related, as 
the reason for withdrawal. This discomfort could be due to the liquid composition of the 
diet, since the change from normal food to liquid meal replacements has a direct effect 
on defecation. Offering patients more solid nutrition could reduce this discomfort and 
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increase compliance. Interestingly, the morbidly obese patients more often complained 
about gastrointestinal symptoms during the restricted diet than the kidney donors did. A 
possible explanation is provided by the link between obesity and functional gastrointestinal 
disorders (FGIDS), such as irritable bowel syndrome and diarrhea22. FGIDS could make 
obese people more vulnerable to gastrointestinal symptoms when nutritional intake 
changes. During the DER-diet, both serum albumin and free saturated fatty acids increased. 
Together with the complaints related to gastrointestinal tract and nutritional intake, these 
results indicate that the patients on the DER-diet received relatively more fat than during 
normal food consumption. This could be the cause of nausea and stool change reported by 
the DER-diet groups. Based on the incidence and severity of the discomfort, together with 
the percentage of withdrawals from the DER-diet group and metabolic changes, we do not 
consider the DER-diet an appropriate control diet for future studies. 
Ideally, determination of adherence to the diet would be based on objective measures. It 
has been shown that higher intake of calories and protein significantly increases PAB and 
RBP in patients at risk for malnutrition23-25. Both PAB and RBP significantly decreased in 
patients receiving the restricted diet in this study, while no changes were seen in the DER-
diet group, in the control group, or in individuals who did not complete the diet. With only 
small interpatient variability, both markers therefore have great value in terms of objectively 
measuring compliance to a restricted diet. In addition, serum levels of BCAAs valine and 
leucine as well as the combination of all three BCAAs decreased in the restricted diet, with 
no changes in the DER-diet and the control group. This decrease with lowered protein intake 
is in line with a recent study by Solon-Biet et al. who showed that higher levels of circulating 
BCAAs were correlated with the percentage of protein intake17. Patients who received the 
restricted diet also showed a significant decrease in serum urea. Previous studies have shown 
a relationship between dietary protein intake and serum urea26. Interestingly, one patient 
provided the restricted diet showed no decrease in four of these five markers, raising doubts 
regarding diet compliance by this individual. Hence, a combination of these markers may 
very well distinguish between compliance and non-compliance to a diet comprising DR 
and PR. Further research is needed to validate these markers in larger cohorts of different 
patient populations in order to establish their independent value as compliance markers. 
This pilot study has some limitations, including a high percentage of dropouts, a small 
sample size, and the exclusion of some blood samples that were obtained from non-fasted 
patients. The high number of dropouts was mostly due to logistical reasons; in some cases, 
the surgery date was moved up, and in others the patients did not undergo surgery. Some of 
the included patients declined to participate after providing written informed consent due 
to the stressful period prior to surgery; these patients were subsequently excluded. These 
logistical problems are difficult to solve, and further studies should anticipate a relatively 
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high percentage of dropouts. Ensuring that the patients fast overnight before blood is drawn 
will increase the sample size and the potential value of the study. Finally, a larger sample size 
is needed in order to validate the results of this study and to investigate the effects of a diet 
comprising DR and PR on perioperative and postoperative responses.
Although safety was not an outcome measure, we have carefully monitored the patients’ 
peri- and postoperative course in the present study, and have observed no differences in 
type and rate of complications and length of hospital stay between the three study groups.
In conclusion, our results show that a diet comprising DR and PR is feasible in both 
living kidney donors and in morbidly obese patients awaiting surgery. This restricted 
diet was easily instituted and adherence to the diet could be measured objectively using a 
combination of laboratory parameters. Minor adaptations to the diet, such as increasing the 
amount of non-liquid food during the diet, could lead to an even higher compliance rate 
and to decreased discomfort. This short-term dietary intervention is feasible and ready for 
further investigation of the effects of DR on perioperative and postoperative responses in a 
clinical setting.
SUBJECTS AND METHODS
Study design
This pilot study was designed as a prospective multicenter pilot study. The study was 
approved by the Medical Ethics Committee (METC, MEC number 2012-134) of the 
Erasmus University Medical Center, Rotterdam, The Netherlands, and by the Board of 
Directors of the Maasstad Hospital, Rotterdam, The Netherlands. The study procedures 
were in accordance with the METC guidelines. The trial is registered as the PROTECT 
trial in the Dutch trial registry database using trial code 3663 (www.trialregister.nl). This 
manuscript was prepared in accordance with the CONSORT 2010 statement27, according 
to the Declaration of Helsinki.
Inclusion and exclusion criteria
The coordinating investigator approached patients at the hospitals’ outpatient clinic during 
their scheduled doctor appointments. All patients included in the study gave written 
informed consent to participate. Patients were informed that this study only aimed to 
establish the feasibility of the diet in surgical patients. A patient flowchart showing inclusions/
exclusions and randomization procedures is depicted in Figure S3.
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Kidney donors
Kidney donors visited the outpatient clinic at the Erasmus MC, University Medical Center 
Rotterdam between February 2013 and May 2014. To be eligible for the study, patients 
had to be between 18 and 70 years old, have a BMI ≥19, could not participate in another 
clinical trial in the 30 days prior to the day they were approached, and could have no known 
allergies to any of the ingredients in the diets. An additional exclusion criterion was a surgery 
performed outside the Erasmus MC due to participation in the cross-over kidney donation 
program28. Out of 124 kidney donors, 90 were eligible to participate in the study and were 
approached. Initially, 45 donors gave informed consent. After the outpatient clinic visit and 
before the scheduled surgery, 15 donors withdrew from the study for personal or logistical 
reasons (Figure S3). Included dropouts after randomization were replaced until the desired 
number of inclusions was reached. Thirty donors were equally (n = 10) randomized into 
each of the three intervention groups. 
Bariatric surgery patients
The morbidly obese patients visited the outpatient clinic at the Maasstad Hospital between 
March 2013 and August 2014. To participate in the study, patients had to be between 18 
and 60 years of age with a BMI ≥40, could not have participated in another clinical study 
in the 30 days prior to the day they were approached, and could have no known allergies 
to any of the ingredients in the diets. Additional exclusion criteria were the presence of 
diabetes mellitus or morbid obesity caused by a known genetic syndrome or genetic defect. 
Diabetic patients were excluded to eliminate this confounding variable between the two 
surgery groups, as diabetic patients are not admitted to the living kidney donor program. 
Diabetes mellitus was defined as a fasted plasma glucose level ≥7 mmol/L as measured on 
two different days, or as either a fasted plasma glucose level ≥7 mmol/L or a non-fasted 
plasma glucose level ≥11.1 mmol/L with symptoms of hyperglycemia (such as thirst and 
polyuria). Out of 143 morbidly obese patients, 84 were eligible to participate and were 
therefore approached; 54 provided written informed consent. Sixteen patients dropped 
out of the study for various reasons (Figure S3). Included dropouts after randomization 
were replaced until the desired number of inclusions was reached. Since a high number of 
dropouts after randomization and start of the restricted occurred due to logistical reasons, 
additional patients were included in the restricted diet group. Eventually, 18 patients were 
randomized to the restricted diet, 10 patients to the DER-diet and 10 patients to the control 
group.
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Dietary intervention
All dietary interventions lasted for five consecutive days and were given in an outpatient 
setting. For the kidney donors, the diet was initiated six days prior to surgery. For the 
morbidly obese patients, the diet started between several weeks to five days prior to the 
surgery date. After providing written informed consent, patients were randomized into one 
of three groups. During the study, patients were offered a contact person whom they were 
able to approach with an accessibility of 24 hours per day with questions regarding the 
diet, which they frequently did. Directly after completion of the diet, patients visited the 
outpatient clinic to evaluate their experience, and to donate a venous blood sample. The first 
group received a 30% DR and 80% PR restricted diet. This synthetic liquid diet containing 
an estimated 70% of the individual’s required calories and 20% of the individual’s protein, 
based on the basal metabolic rates and on the daily energy requirements (DER) as calculated 
with the Harris–Benedict formula29. The Harris–Benedict formula takes into account 
gender, height, age, body weight and estimated activity level. This formula is validated up to 
a BMI of 40. Whenever an individual had a BMI >40, the body weight corresponding to a 
BMI of 40 was used to calculate the DER. Normal protein intake was set at 15% of the total 
calories based on the DER. Participants received calorie- and protein-restricted powder 
shakes (Scandishake® Mix, Nutricia Advanced Medical Nutrition, The Netherlands) as the 
main component of the diet. The shake was provided as a powder consisting of 4% protein, 
53% carbohydrates and 43% fat, and was diluted with water. The main protein source was 
casein with a limited amount of whey protein (Table S2). The shakes were combined with 
a limited number of protein-restricted products (mainly fruits and vegetables) until the 
desired individual diet was reached. These protein-restricted products included: all fruits 
except bananas, all vegetables in a limited amount of 200 g per day with the exception of 
asparagus, and a maximum of one piece of gingerbread per day. The second group received 
a synthetic diet that was isocaloric to each individual’s DER (termed the DER-diet), which 
was also calculated using the Harris–Benedict formula20. The DER-diet was offered as a 
shake (Nutridrink® Compact, Nutricia Advanced Medical Nutrition, The Netherlands) 
and was consumed without further dilution. This shake consisted of 16% protein, 49% 
carbohydrates and 35% fat (Table S2). A limited number of protein-restricted products as 
offered to the restricted diet group, was added until the individual’s DER was reached and 
average protein intake was an estimated 15% of all calories. All participants, randomized 
to either the restricted diet or the DER-diet, were blinded to which diet they received. The 
third group did not receive a synthetic diet or a dietary intervention. This group continued 
their usual daily eating pattern. Patients were asked to keep a diet diary during the period 
in which patients in the other two groups received the synthetic diet. Using this diary, their 
daily nutritional intake was measured and calculated for five days, resulting in mean overall 
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daily nutritional intake values. Experienced dieticians analyzed the diaries and calculated 
the DER, the average kilocalorie intake, and the average protein, fat and carbohydrate 
intake.
Outcome parameters
Subjective measurements
To analyze subjective health outcomes, all patients were asked to fill in a standardized 
questionnaire, the Visual Analogue Score (VAS), for evaluation of nausea, pain and 
general wellbeing30. The VAS questionnaire uses a scale ranging from zero to 10, with 
zero representing no pain, nausea or decrease in wellbeing and 10 corresponding to the 
worst pain, nausea or decrease in wellbeing. The questionnaires were completed at three 
different time points: one day prior to starting the dietary intervention, on day three of the 
intervention and one day after completion of the 5-day intervention period when normal 
food intake was resumed. Side effects and discomfort were defined as any secondary effect 
related to the intervention. A distinction was made between major side effects and minor 
discomfort. Major side effects were defined as symptoms related to the intervention that 
remained days or weeks after the intervention or that required hospitalization. Minor 
discomfort included symptoms that caused discomfort during the intervention, but 
immediately disappeared after the dietary intervention.
Objective measurements
Before and after the dietary intervention, the following data were obtained from all patients: 
body weight, age, gender, length, and estimated physical activity level and duration. During 
the outpatient clinic visit and one day after the dietary intervention, two tubes of blood were 
collected: a 5.0 mL BD Vacutainer CPT tube (Franklin Lakes, NJ, USA) and a 5.0 mL BD 
Vacutainer® SST™ II Advance serum tube. After centrifuging for 20 min at 1500× g or for 10 
min at 2300× g, respectively, both the plasma and serum were collected and stored at −80 °C 
until further analysis. Only blood samples from patients that had fasted overnight were 
used for the analysis. “Fasted” was defined as no food intake overnight, i.e. for at least eight 
hours prior to blood withdrawal. In serum samples the metabolic parameters albumin, 
urea, creatinine, glucose, ferritin, cholesterol, free fatty acids, triglycerides and high-density 
lipoprotein (HDL), and in plasma samples parameters prealbumin (PAB) and retinol 
binding protein (RBP) were measured and processed on the UniCel D×C 800 Synchron 
(R) Chemistry System (Beckman, Poway, CA, USA). Insulin was analyzed using the Access 
2 ImmunoAssay System (Beckman) (Table S2). In addition, 143 metabolic markers were 
measured in serum samples by Brainshake (Brainshake Ltd., Helsinki, Finland), as summed 
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up in a list of the service deliverables provided by Brainshake (http://www.brainshake.
fi/ service-deliverables-web-v1_0)31. A schematic overview of all of the parameters and 
measurements, as well as the experimental timeline, is shown in Figure S2. 
Randomization 
Randomization was performed using computer-generated lists, which were printed out 
and put into opaque envelopes by an employee not involved in the study. The first 30 
sequential numbers of each group (i.e., kidney donors and morbidly obese patients) where 
generated at once. Sequential numbers for the two groups were distinguishable. After these 
blocks, the total number of dropouts was randomized in one block by the same procedure. 
The coordinating investigator approached patients eligible for the study at the hospitals’ 
outpatient clinic during their scheduled doctor appointments. Allocation occurred after 
informed consent was given. All participants randomized to either the restricted diet or the 
DER-diet were blinded to which diet they received.
Statistical analysis
Categorical data are presented as numbers (percentage) and continuous variables as mean 
(SD/normal distribution) or median (interquartile distance/no normal distribution). 
The data were tested for normality using the Shapiro–Wilks test and visual assessment. 
Continuous data were compared using either the non-parametric Mann-Whitney test or 
the t-test for parametric data. Related samples were analyzed using the non-parametric 
Wilcoxon signed rank test. Semi-quantitative scoring of the questionnaires was performed 
via the paired t-test. Significance was set at P<0.05. A Bonferroni correction for multiple 
testing was performed on the metabolic parameters. A P-value of ≤0.002 was considered 
significant. The analyses were performed using Statistical Packages for Social Sciences 21.0 
(SPSS Inc., Chicago, IL, USA), GraphPad Prism (GraphPad Software Inc., La Jolla, CA, 
USA, version 5.01), and Office Excel (2010). This study was designed as a pilot study and 
therefore no power calculations were performed.
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SUPPLEMENTARY DATA
(A) LIVING KIDNEY DONORS 
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(B) MORBIDLY OBESE PATIENTS          
            
 
 
 
 
   
 
 
 
 
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
 
 
	
Restricted diet 
(n=18) 
Randomization (n=38) 
DER-diet 
(n=10) Control (n=10) 
Stopped at day 
1 (n=1) 
Completed 
(n=12) 
Completed 
(n=9) 
Completed 
(n=7) 
Stopped at day 
2 (n=1) 
Stopped at day 
3 (n=3) 
Did not fulfill 
diary (n=3) 
Stopped at day 
4 (n=1) 
Stopped at day 
5 (n=1) 
Figure S1. Flowchart of the randomization and follow-up of the inclusions. (A) Thirty kidney 
donors were equally randomized into each of the three intervention groups. Eight out of 10 kidney 
donors completed the diet; 1 stopped at day 1 and 1 at day 3. The DER-diet was completed by 4 
donors; 3 stopped at day 1, 1 at day 2 and 2 at day 3. One donor did not complete the diet diary. 
(B) Twelve out of 18 morbidly obese patients completed the diet; 1 stopped at day 1, 3 at day 3, 1 at 
day 4 and 1 at day 5. Nine out of 10 completed the DER-diet, with only one patient who stopped at 
day 2. Three out of 10 patients did not complete the diet diary. DER = daily energy requirements.
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	Figure S2. Timeline of the study from the first outpatient clinic visit until the end of the trial. 
Each patient was approached at the first outpatient clinic appointment, and informed consent was 
signed a week later. Subsequently, the randomization procedure was performed and pre-study 
blood samples were taken. The diets were consumed or, for the control group, the dietary diary was 
kept, for five consecutive days. The day after the diet ended, blood samples were taken again, and 
the trial ended. VAS = Visual Analogue Score. 
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LIVING KIDNEY DONORS               MORBIDLY OBESE PATIENTS 
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(n=54) 
Inclusions (n=38) 
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(n=143) 
Exclusions (n=53): 
Another trial (n=11) 
Age restriction (n=15) 
Cross-over (n=5) 
Other (n=22) 
No participation 
(n=45) 
Dropout (n=15): 
Surgery cancelled / 
postponed (n=8) 
Withdrew IC (n=7) 
Exclusions (n=40): 
Another trial (n=17) 
DM II (n=15) 
BMI < 40 (n=3) 
Other (n=5) 
No participation 
(n=30) 
Dropout (n=16): 
Surgery cancelled / 
forwarded (n=6) 
Withdrew IC (n=10) 
Figure S3. Flowchart showing patient inclusions and exclusions. Exclusions were based on preset 
exclusion criteria. Eligible kidney donors were approached at the outpatient clinic at the Erasmus 
MC, University Medical Center Rotterdam, and eligible morbidly obese patients were approached 
at the Maasstad Hospital, Rotterdam, The Netherlands. Additional morbidly obese patients were 
included after many were withdrawn due to logistical reasons. BMI = body mass index. Cross-over = 
cross-over program at which the surgery takes place outside of the Erasmus MC, University Medical 
Center Rotterdam. DM II = diabetes mellitus type II. IC = informed consent.
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Table S1. List of all parameters measured and the material and method of analysis
Biomarker Abbreviation Matrix Method of analysis
Company of 
assay
Assay product 
number
Albumin ALB Serum Autoanal Beckman 442765
Cholesterol CHOL Serum Autoanal Beckman 467825
Creatinine CREA Serum Autoanal Beckman 442760
Ferritin FER Serum Immunoanal Beckman 33020
Free fatty acids FFA Serum Autoanal Wako NEFA-HR2
Glucose GLU Serum Autoanal Beckman 442640
High-density lipoprotein HDL Serum Autoanal Beckman 650207
Insulin INS Serum Immunoanal Beckman 33410
Prealbumin PAB Plasma Immunoturbi Beckman 475106
Retinol binding protein RBP Plasma Immunoturbi Diazyme DZ187A-K
Triglycerides TG Serum Autoanal Beckman 445850
Urea UREA Serum Autoanal Beckman 442820
Abbreviations: Autoanal = autoanalyzer; immunoanal: immunoanalyzer; immunoturbi = immunoturbidimetry
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Table S2. The composition and energy content of the restricted diet and DER-diet
Diet
Average content per 100 gram/mL Restricted diet DER-diet
Energy  (kcal) 507 240
             (kJ) 2120 1010
Protein (g) 4.98 9.6
Protein (% of energy intake) 4.0 16.0
Casein (g) 4.3 8.8
Whey protein (g) 0.4 0.8
Carbohydrates (g) 67.0 29.7
Carbohydrates (% of energy intake) 53.0 49.0
Glucose (g) 0.8 0.3
Fructose (g) 0.0 0.0
Lactose (g) 3.2 <0.5
Maltose (g) 2.5 14.6
Sucrose (g) 14.0 0.0
Polysaccharides (g) 46.3 14.3
Other (g) 0.2 0.4
Fat (g) 24.5 9.3
Fat (% of energy intake) 43 35.0
Saturated fat (g) 7.7 0.9
Monounsaturated fat (g) 7.3 5.7
Polyunsaturated fat (g) 9.4 2.7
Linoleic acid (g) 8.1 2.1
Α-linoleic acid (g) 0.9 0.4
Fibres 0.0 0.0
Sodium (mg) 128 96
Potassium (mg) 272 236
Chloride (mg) 163 91
Calcium (mg) 85 174
Phosphor (mg) 147 174
Magnesium (mg) 30 33
Ferritin (mg) 0.0 3.8
Zinc (mg) 0.0 2.9
Copper (mg) 0.0 0.43
Manganic (mg) 0.0 0.8
Fluoride (mg) 0.0 0.2
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Table S3. (continued)
Diet
Average content per 100 gram/mL Restricted diet DER-diet
Molybdenum (µg) 0.0 24.0
Selenium (µg) 0.0 14
Chrome (µg) 0.0 16
Iodine (µg) 0.0 32
Vitamin A (µg-RE) 0.0 240
Carotenoids (mg) 0.0 0.0
Vitamin D (µg) 0.0 1.8
Vitamin E (mg α-TE) 0.0 3.0
Vitamin K (µg) 0.0 13.0
Thiamin (mg) 0.0 0.4
Riboflavin (mg) 0.0 0.4
Niacin (mg NE) 0.0 4.3
Panthotheenzuur (mg) 0.0 1.3
Vitamin B6 (mg) 0.0 0.4
Foliumzuur  (µg) 0.0 64
B12 (µg) 0.0 0.7
Biotin (µg) 0.0 9.6
Vitamin C (mg) 0.0 224
Choline (mg) 0.0 88
Kcal=kilocalories; kJ=kilojoule; g= grams; mg=milligrams; µg=micrograms; DER=daily energy requirements
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ABSTRACT
Dietary restriction prolongs life- and health span and increases stress resistance in 
numerous species. A previous clinical study showed that five days of combined calorie 
and protein restriction (CCPR) before invasive surgery was safe in kidney donors and that 
adherence to the diet was high. In the present study, the effects of preoperative CCPR in 
living kidney donors and their transplanted kidneys was investigated. Thirty-five living 
kidney donors were randomized into either the CCPR (n=15) or control (n=20) group. The 
CCPR diet reduced calorie intake by 30% and protein intake by 80% during the five days 
immediately prior to organ donation. Donors in the control group had no restrictions and 
ate their own regular diet. All patients adhered to the diet. From postoperative day (POD) 
2 up until month 1, kidney function of the donors was significantly better in the CCPR 
group compared with control donors. Recipients of CCPR donors also showed significantly 
improved kidney function compared with their control group. In addition, the recipients 
of CCPR kidneys showed a significantly lower incidence of slow graft function and acute 
rejection. CCPR inhibited cellular immune response pathways and activated stress-
resistance signaling. Thus, short-term preoperative CCPR significantly improves recovery 
of kidney function in donors and the function of the transplanted kidney in recipients. 
These observations are the first to show that the benefits of CCPR can be induced rapidly 
in humans and that CCPR may be used clinically to improve outcomes in clinical settings 
involving ischemia-reperfusion damage.
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INTRODUCTION
Dietary restriction (DR) increases resistance to reactive oxygen species (ROS) during both 
acute and chronic stress, and recently we found that DR at the level of genome function 
reduces transcriptional stress by attenuating DNA damage accumulation1-4. Consequently, 
DR enhances defense and maintenance mechanisms including cellular programs, enabling 
resistance to a variety of stressors including ischemia-reperfusion injury (IRI). IRI arises 
from acute oxidative stress that inevitably occurs during organ (e.g. kidney) transplantation 
and many other surgical procedures. The phase of ischemia after kidney retrieval leads to 
hypoxia and an increase in metabolic waste products, while reperfusion after restoration 
of renal blood flow results in the production of ROS and an inflammatory response5-7. 
Living donor kidney transplantation (LDKT) greatly improves function and survival of 
the kidney allograft compared to kidneys from deceased donors8. Nonetheless, and despite 
the markedly shorter ischemia times following LDKT, IRI remains a risk factor for poor 
outcome9,10. Amelioration of renal IRI could therefore greatly improve both graft and 
thereby transplant recipient survival11.
Previously, we showed that short-term DR counteracts perioperative stress and protects 
against both renal and hepatic IRI in mice, irrespective of gender, age, body weight and 
genetic background12,13. Subsequently, we demonstrated that this protection could also be 
induced by dietary deprivation of protein alone for three days prior to renal IRI, indicating 
that the effects of calorie and protein restriction might act synergistically14.
Translation of the beneficial effects of short-term DR to humans has mostly proven difficult 
and unsuccessful15. Recently, we reported the results of a randomized, controlled clinical 
trial which demonstrated that prescription of a combined calorie and protein restricted 
(CCPR) diet is feasible and safe in living kidney donors, as well as in patients undergoing 
bariatric surgery16. Here, we demonstrate that a CCPR diet has beneficial effects on the 
postoperative outcomes of both living kidney donors and their kidney transplant recipients.
RESULTS
Baseline characteristics
Thirty-five living kidney donors were randomized into either the CCPR (n=15) or the 
control group (n=20) between May 2, 2014 and November 18, 2015 (Figure S1). The 
difference in patient numbers between the groups is due to the additional inclusions to 
replace dropouts. The baseline characteristics of these 35 donors are listed in Table 1A. 
Donors in the CCPR group were more often female (P=0.024) and consequently had a 
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lower serum creatinine concentration at the outpatient clinic visit (P=0.018). Baseline 
characteristics of all transplant recipients (Table 1B) and the donors of whom biopsies were 
used for transcriptomic profiling (Table S1) showed no differences between the two groups. 
Table 1A. Baseline characteristics of living kidney donors 
Parameter CCPR (n=15) Control (n=20) P-value
Age (years) 55 (51-55) 54 (46-59) 0.395
Gender (Male/Female) 4/11 13/7 0.028
BMI (kg/m2) 23.7 (22.4-27.6) 26.0 (26.6-29.1) 0.157
Systolic blood pressure (mm/Hg) 128 (123-137) 128 (122-137) 1.000
Creatinine (mmol/L) 71 (66-78) 80 (71-91) 0.021
CKD-EPI eGFR (mL/min) 86 (72-90) 80 (73-89) 0.672
Urea (mmol/L) 5.3 (4.4-5.8) 5.3 (4.2-6.1) 0.986
Glucose (mmol/L) 5.3 (5.0-5.7) 5.0 (4.8-5.9) 0.217
Albumin (g/L) 47 (44-48) 46 (45-47) 0.398
Triglycerides (mmol/L) 1.22 (0.85-1.50) 1.31 (1.00-1.68) 0.488
Hemoglobin (mmol/L) 8.8 (8.4-9.0) 9.2 (8.7-9.6) 0.031
Trombocytes (109/L) 234 (213-294) 253 (206-289) 0.972
CRP (mg/L) 1.1 (0.7-1.9) 1.5 (0.6-2.4) 0.259
Leukocytes (109/L) 6.6 (5.5-7.4) 6.6 (5.5-7.8) 0.652
Bilirubin (µmol/L) 6 (5-10) 7 (5-12) 0.467
Potassium (mmol/L) 4.4 (4.2-4.6) 4.3 (4.1-4.7) 0.444
Type of donation (R/U/A) 3/3/9 4/12/4 0.083
Side of nephrectomy (Left/Right) 8/7 12/8 0.712
Method used (Laparoscopic/HARP) 12/3 14/6 0.523
Table 1B. Baseline characteristics of kidney transplant recipients 
Parameter CCPR (n=15) Control (n=20) P-value
Age (years) 56 (44-67) 54 (45-58) 0.250
Gender (Male/Female) 8/7 10/10 0.863
Kreatinine (mmol/L) 495 (442-637) 449 (321-902) 0.351
CKD-EPI eGFR (mL/min) 9 (7-11) 11 (5-14) 0.471
Urea (mmol/L) 19.9 (16.2-31.4) 22.6 (15.0-27.1) 0.881
Potassium (mmol/L) 5.4 (4.7-5.8) 4.7 (4.4-5.3) 0.092
Hemoglobin (mmol/L) 6.6 (6.2-7.5) 7.3 (6.6-8.3) 0.166
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Table 1B. (continued)
Parameter CCPR (n=15) Control (n=20) P-value
CRP (mg/L) 2.7 (1.5-4.7) 2.1 (0.6-5.2) 0.205
Leukocytes (109/L) 7.8 (6.8-9.7) 6.1 (5.5-8.2) 0.106
Type of donation (R/U/A) 3/3/9 4/12/4 0.083
Immunosuppressive therapy prior to transplantation 
(Yes/No) 4/11 5/15 1.000
Dialysis prior to transplantation (Yes/No) 6/9 9/11 0.687
Side of transplantation (Left/Right) 4/11 7/12 0.549
Values are depicted as median ± interquartile range. Significant values are depicted in bold. BMI = body mass index; CKD-
EPI eGFR = estimated glomerular filtration rate using the CKD-EPI formula; CRP = C-reactive protein. Type of donation: 
R = related; U = unrelated; A = anonymous. HARP = hand-assisted retroperitoneal nephrectomy. #= both creatinine and 
hemoglobin levels of the living kidney donors were lower in the CCPR than the control group as a consequence of the gender 
differences in both groups. * = all kidney transplant recipients met the criteria for end-stage renal disease with a CKD-EPI eGFR 
<15 mL/min. Significance = P<0.05. 
Compliance to the diet and surgical outcome
All 15 donors in the CCPR group indicated they had adhered to the diet. This was in line 
with a number of independent parameters investigated. Serum levels of the adherence 
markers prealbumin (PAB), retinol binding protein (RBP), and the branched-chain amino 
acids valine and leucine were all significantly decreased after the CCPR diet (Figure S2). All 
donors in the CCPR group showed a decline in adherence markers, and they lost an average 
of 2.0 kilograms (range -4;0 kilograms) of body weight during the diet, which differed 
significantly from the slight average weight gain of 0.4 kilograms (range -4; +1 kilograms) 
observed in the control group (P=0.006). Perioperative outcomes did not significantly differ 
between the two arms in both donors and recipients (Table S2).
Postoperative outcome 
Comparison of kidney donors receiving a control or CCPR diet 
Prior to the dietary intervention, serum creatinine levels significantly differed between 
donors in the CCPR and the control group (Figure 1A, POD-pre). One day before surgery 
(i.e. at day 5 of dietary intervention), serum creatinine levels were similar (Figure 1A, 
POD-1). To assess postoperative changes in kidney function, a linear mixed-effects model 
analysis correlating with repeated follow-up measurements in each patient was used with 
random intercepts per patient. The donors on CCPR showed a significantly better clearance 
of absolute serum creatinine levels than the control group on postoperative day (POD) 
2, POD3 and on postoperative month (POMo) 1, with a mean difference of 14,5 µmol/L 
(Table 2A). Absolute CKD-EPI eGFR (eGFR) values did not significantly differ in both 
groups. To correct for baseline interpatient variability, the relative values of both creatinine
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Figure 1. Kidney function of living kidney donors before and after kidney donation. (A) At 
start of the study (POD-pre), creatinine levels were significantly higher in the control group. 
Postoperatively, a trend towards lower levels of creatinine were observed in the CCPR-group. (B) 
Taking POD-1 as cut-off value, relative creatinine clearance was significantly improved in the CCPR-
group at POD2, POD3 and POMo1. (C) Absolute glomerular filtration rate did not significantly 
differ between the groups. (D) Relative eGFR showed significant improvement in the CCPR group 
at POD3. (E) Serum urea levels were significantly lower in the CPPR-group on POD1 and remained 
so in the first two postoperative days. Values are depicted as median ± interquartile range. CCPR = 
combined calorie and protein restriction; POD = postoperative day; POMo = postoperative month; 
eGFR = estimated glomerular filtration rate using the CKD-EPI formula. *=significant values.
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and eGFR clearance were calculated and analyzed. Again, relative creatinine clearance 
was significantly improved in the CCPR donors compared to the control group on POD2, 
POD3 and POMo1 with a difference of 14,6% on average. In addition, relative eGFR was 
significantly better in the CCPR group as well, both on POD2, POD3 and POMo1 with 
an improvement difference of 6% on average (Table 2A). Subsequently, changes per time 
point were assessed. The CCPR donors showed a trend towards better clearance of absolute 
creatinine compared to the control group (Figure 1A). During the first three postoperative 
days, relative creatinine clearance was significantly better in the CCPR donors on POD2 
(P=0.030) and POD3 (P=0.042). These values remained significantly different at month 
1 after surgery (P=0.040, Figure 1B), indicating long-term improvement. Absolute eGFR 
values did not differ between the groups (Figure 1C). In the first postoperative days, relative 
eGFR was significantly better in the CCPR donors on POD3 (P=0.033) (Figure 1D). Serum 
urea levels were significantly lower in the CCPR group on POD-1 (P<0.001), suggesting 
effects of the CCPR diet on kidney function per se. This difference persisted after surgery on 
POD1 (P=0.003), POD2 (P=0.005) and lower on POD3 (P=0.09) (Figure 1E).
Table 2A. Random intercept mixed-effects differences, standard errors (Std. Error) and P-values 
for kidney function outcome of the living kidney donors
Time point
Parameter
Creatinine (µmol/L) CKD-EPI eGFR (mL/min)
Absolute values
Difference Std. Error P-value Difference Std. Error P-value
POD-pre - 1,83 6,09 0.765 - 6,68 3,66 0.074
POD1 - 6,57 6,09 0.286 - 2,82 3,66 0.445
POD2 - 14,02 6,13 0.027 + 0,38 3,67 0.918
POD3 - 15,35 6,29 0.018 + 1,22 3,78 0.748
POMo1 - 14,52 6,19 0.023 + 1,73 3,70 0.643
POMo3 - 10,23 6,13 0.102 - 1,42 3,68 0.701
Relative values
Difference Std. Error P-value Difference Std. Error P-value
POD1 - 4,38 72,44 0.399 + 1,30 2,34 0.579
POD2 - 13,95 76,15 0.010 + 5,36 2,38 0.027
POD3 - 15,53 88,28 0.006 + 5,78 2,51 0.024
POMo1 - 14,35 80,27 0.009 + 7,14 2,42 0.004
POMo3 - 9,28 77,61 0.084 + 3,04 2,39 0.208
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Although the postoperative C-reactive protein (CRP) concentrations tended to be lower in 
the CCPR donors, no statistically significant difference was observed with control donors 
(Figure 2A). No differences in leukocyte numbers were seen (Figure 2B). Thus, the CCPR 
diet induced a specific nephroprotection postoperatively, but had no significant effect on 
systemic inflammatory markers.
Comparison of kidney recipients receiving a control or CCPR diet 
Ideally, urine production in kidney transplant recipients starts directly after revascularization 
of the graft. In the CCPR group, urine production was delayed in 1/15 (7%) patients 
compared with 5/20 (25%) in the control group (P=0.135) (Table 3 and S2B). On POD1, 
a trend towards lower incidence of partial acute tubular necrosis (ATN) as indicated on a 
MAG3 scan, was found in the CCPR group (Table 3). As expected in a living kidney donor 
setting, delayed graft function (DGF) did not occur. Slow graft function (SGF) occurred 
significantly more often in the control group: 5/20 (25%) versus 0/15 (0%) (P=0.020). The 
incidence of biopsy-proven acute rejection (BPAR) was significantly higher in the control 
group than in the CCPR group: 8/20 (40%) versus 1/15 (7%) (P=0.013). Two kidney 
transplant recipients (both in the control group) developed severe acute rejection and 
subsequently underwent a transplant nephrectomy on days 6 and 12 after transplantation, 
respectively. Data from these patients were censored from the day of transplant removal. 
The postoperative immunosuppressive drug regimen was similar in both groups (tacrolimus 
(Tac), mycophenolate mofetil (MMF) and prednisolone), except for two patients in the 
control group who received belatacept instead of Tac. These two patients experienced 
BPAR and were switched from belatacept to Tac. The Tac pre-dose concentrations showed 
a trend towards higher concentrations in the CCPR group on POD3 (P=0.065) and POD5 
(P=0.094). No significant differences were seen in the duration of hospital stay nor in the 
incidence or severity of the other postoperative complications during hospital stay (Table 
3). 
Linear mixed-effects model analysis showed a significant improved absolute creatinine 
clearance in the CCPR recipients as from POD1 until POD5, with on average an 
improvement of 200 µmol/L per day in the CCPR group. No significant differences in 
absolute eGFR values were observed (Table 2B).
Again, relative values of both creatinine and eGFR clearance showed significantly improved 
creatinine values in the CCPR group as from POD1 until POD5, correlating with a difference 
of 25% improved values compared to the control group (Table 2B). Assessment per time 
point showed no significant differences of absolute serum creatinine concentrations 
between groups throughout the postoperative follow-up (Figure 3A). Relative creatinine 
concentrations showed a trend towards improvement in the CCPR group on POD4 
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(P=0.057), POD6 (P=0.037), and POD14 (P=0.020), with an average decrease of 70% in 
the CCPR group compared with 40% in the control group (Figure 3B). Absolute eGFR 
values did not differ between groups throughout the postoperative period (Figure 3C), 
while relative eGFR showed a trend towards better values in the CCPR group on POD 6 
(P=0.032) (Figure 3D).
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Figure 2. Systemic inflammatory markers in living kidney donors before and after kidney 
donation. (A) Levels of systemic inflammatory marker C-reactive protein before and after live 
kidney donation were not significantly different between the CCPR and the control group. (B) 
Levels of leukocytes did not significantly differ between both groups either, and only reached high-
normal levels on POD1 after surgery. Values are depicted as median ± interquartile range.  CCPR = 
combined calorie and protein restriction; POD = postoperative day.
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Table 2B. Random intercept mixed-effects differences, standard errors (Std. Error) and P-value for 
kidney function outcome of the kidney transplant recipients
Time point
Parameter
Creatinine (µmol/L) CKD-EPI eGFR (mL/min)
Absolute values
Difference Std. Error P-value Difference Std. Error P-value
POD-pre - 23,43 85,23 0.784 -  1,15 5,969 0.848
POD1 - 161,60 85,23 0.062 + 1,10 5,969 0.854
POD2 - 188,02 85,23 0.031 + 2,37 5,969 0.693
POD3 - 199,73 85,23 0.022 + 6,50 5,969 0.280
POD4 - 202,02 85,23 0.021 + 8,82 5,969 0.144
POD5 - 185,74 85,60 0.033 + 11,28 5,969 0.063
POD6 - 140,75 85,23 0.103 + 7,46 5,995 0.218
POD7 - 142,53 85,62 0.100 + 5,98 5,996 0.322
POD14 - 84,16 86,04 0.331 + 7,94 6,027 0.192
POD21 - 52,44 86,50 0.546 + 3,46 6,027 0.568
POMo1 - 59,44 86,50 0.494 + 8,44 6,027 0.166
POMo2 - 50,75 86,50 0.559 + 7,16 6,027 0.239
POMo3 - 50,74 86,50 0.559 + 5,05 6,027 0.405
POMo6 - 53,36 86,04 0.537 + 2,85 6,027 0.638
Relative values
Difference Std. Error P-value Difference Std. Error P-value
POD1 - 21,82 10,46 0.040 + 29,25 121,47 0.810
POD2 - 28,63 10,46 0.007 + 43,05 121,47 0.724
POD3 - 28,82 10,46 0.007 + 89,63 121,47 0.463
POD4 - 28,47 10,46 0.008 + 123,00 121,47 0.315
POD5 - 21,33 10,46 0.044 + 166,78 121,47 0.174
POD6 - 15,90 10,46 0.132 + 180,70 121,47 0.141
POD7 - 16,71 10,52 0.116 + 119,54 122,05 0.331
POD14 - 12,13 10,59 0.255 + 107,60 122,67 0.383
POD21 - 8,50 10,67 0.428 + 19,12 122,67 0.877
POMo1 - 9,94 10,67 0.354 + 82,78 122,67 0.502
POMo2 - 9,52 10,67 0.374 + 7,67 122,67 0.950
POMo3 - 9,20 10,67 0.391 - 23,77 122,67 0.847
POMo6 - 6,10 10,67 0.569 - 55,09 122,67 0.655
CCPR= Combined Calorie and Protein Restriction; CKD-EPI eGFR = Chronic Kidney Disease Epidemiology Collaboration 
estimated Glomerular Filtration Rate. Differences are based on the outcomes of the CCPR group versus the control group. 
Relative values are set with POD-pre as baseline value, and therefore this time point was not included in the analysis of the 
relative differences. Significant P-values are depicted in bold.
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Table 3. Postoperative outcome and complications in kidney transplant recipients in the first 14 
days after surgery
Parameter CCPR (n=15) Control (n=20) P-value
Urine production during surgery (yes/no (%)) 1/15 (7%) 5/20 (25%) 0.135
ATN on MAG3 scan (yes/no) 2/15 (7%) 6/20 (30%) 0.209
Delayed graft function (yes/no) 0/15 (0%) 0/20 (0%) 1.000
Slow graft function (yes/no) 0/15 (0%) 5/20 (25%) 0.020
Acute rejection, biopsy-proven (yes/no) 1/15 (7%) 8/20 (40%) 0.013
Hospital stay (days) 13 ± 1 14 ± 1 0.556
Any complication (yes/no) 10/5 (73%) 16/4 (75%) 0.445
Clavien-Dindo score (0-4) 1.5 ± 0.3 1.5 ±0.2 0.986
Tacrolimus level POD3 15.0 ± 1.8 10.6 ± 1.4 0.065
Tacrolimus level POD5 14.5 ± 1.8 10.8 ± 1.2 0.094
Tacrolimus level POD10 (µg/L) 12.7 ± 1.5 10.6 ± 1.0 0.251
Values are depicted as median ± interquartile range. ATN = acute tubular necrosis; MAG3 = renal scintigraphy scan; POD = 
postoperative day; Clavien-Dindo = official classification score for postoperative surgical complications. CCPR = combined 
calorie and protein restriction. Significance is considered at P<0.05 and is depicted in bold. 
Gender based differences
Since baseline characteristics between the two study groups differed concerning gender, a 
subgroup analysis stratified by gender was performed. In the female donors, a consistent 
trend in improved relative creatinine clearance and eGFR was observed for prolonged 
periods after POD1 (Figure S3). In male donors, relative creatinine concentrations were 
significantly improved in the CCPR group at POMo1 (P=0.009) and POMo3 (P=0.022) 
(Figure S4). Division based on gender of the donors showed for female CCPR kidneys a 
consistent trend for improved relative creatinine and eGFR that did not reach statistical 
significance (Figure S3F and S3H). The most pronounced CCPR-related differences in the 
kidney transplant recipients were observed in kidneys of the male donors; absolute and 
relative creatinine clearance was improved in the recipients of the male CCPR donors as 
from POD1 until POD7 (Figure S4E-H).
Comparison of the transcriptome in kidneys from control or CCPR diet 
To get a more detailed insight into the main differences between both groups of donors that 
might help to explain the clinical impact of the CCPR diet, we performed a full genome 
expression profile analysis of the kidneys using renal biopsies from all 20 donors taken during 
transplantation before implantation and directly after cold-ischemia. Moreover, several 
other gene expression profiling studies have been published, providing an interesting basis 
15045-jongbloed-layout.indd   209 06/11/2017   17:20
210
CHAPTER 8
for comparison. A principal component analysis (PCA) showed that gender represented the 
largest discriminator (Figure S5). Therefore, we decided to separately analyze male (n=3-5) 
and female (n=5-7) kidneys. 
The PCA of the female kidney transcriptome showed the largest differentiation between 
the control and CCPR groups on the PC axis 1 (Figure 4A). For male donors, some 
differentiation was seen on PC axis 2 (Figure 4B). Since one sample had to be excluded 
due to a low RNA yield, only 3 male patients in the CCPR group remained. In view of the 
statistics, the analysis was restricted to the females and later, the data of the males were 
compared to search for similarities. Results of the analysis of these male kidney tissues are 
given in Table S3.
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Figure 3. Kidney function of transplant recipients before and after surgery. (A) Serum 
creatinine showed a trend towards absolute lower levels in the CCPR-group throughout the first 14 
days after surgery. (B) Relative creatinine levels, calculated using POD-1 as cutoff value, showed a 
down sloping trend as from POD4 up to POD14. (C) Following the creatinine clearance, eGFR also 
showed a trend towards improvement in the CCPR-group throughout the first days after surgery. 
(D) Relative eGFR showed an improvement in clearance in the CCPR-group as well. Values are 
depicted as median ± interquartile range. CCPR = combined calorie and protein restriction; POD 
= postoperative day; POMo = postoperative month; eGFR = estimated glomerular filtration rate 
using the CKD-EPI formula. 
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(A) Female donors    (B) Male donors  
	 	 	 	 	 	 	
	 	 	 		
	
	 	 	 		
	
		=	CCPR																	=	Control	
Figure 4. Principal component analysis of kidney tissue in female and male donors. (A) The 
unbiased principal component analysis (PCA) of all female donors showed the most variation of 
genes on the principal component (PC) axis 1 and some clustering of the two intervention groups 
is shown. (B) The PCA of the male donors was based on only three kidneys in the CCPR group, 
and showed little variation on PC axis 2. Principal component (PC) 1 is depicted on the x-axis and 
PC2 is depicted on the y-axis, followed by the percentage of variance explained by each axis. Each 
symbol represents one sample of one donor. Samples of the same group are shown in the same 
color. CCPR = combined calorie and protein restriction.
The CCPR group of female donors showed 480 differentially expressed transcripts (DET), 
of which 239 were downregulated and 241 upregulated. Pathway analysis showed a trend 
towards downregulation of pathways as shown by the more pronounced presence of 
downregulated genes in these pathways. However, the inhibitory directionality of these 
pathways was not statistically significant as evidenced by the absence of a z-score. One 
pathway was significantly upregulated with a z-score >2, namely EIF2 Signaling (Table 4A). 
Other, not significantly activated pathways included the NRF2-mediated Oxidative Stress 
Response, cell cycle regulator Cell Cycle: G2/M DNA Damage Checkpoint Regulation and 
amino acid metabolism. Analysis of upstream transcription factors (TFs) in female donors 
revealed three significantly activated TFs, namely MYCN, MYC and NKX2-3. In addition, 
two TFs were significantly inhibited, namely PRDM1 and SMARCB1 (Table 3B).
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Table 4A. Pathway analysis in female kidney tissue
Ingenuity Canonical Pathways Ratio
Up/
Down P-value Z-score
eIF2 Signaling 9/221 (4.1%) 9/0 6.50E-04 2,449
Primary Immunodeficiency Signaling 4/48 (8.3%) 0/4 1.72E-03 N/A
Interferon Signaling 3/36 (8.3%) 0/3 6.65E-03 N/A
Complement System 3/37 (8.1%) 0/3 7.18E-03 N/A
Aldosterone Signaling in Epithelial Cells 6/166 (3.6%) 5/1 9.03E-03 N/A
Autoimmune Thyroid Disease Signaling 3/47 (6.4%) 0/3 1.39E-02 N/A
Hematopoiesis from Pluripotent Stem Cells 3/47 (6.4%) 0/3 1.39E-02 N/A
Communication between Innate and Adaptive Immune Cells 4/89 (4.5%) 0/4 1.53E-02 N/A
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 3/49 (6.1%) 2/1 1.55E-02 N/A
NRF2-mediated Oxidative Stress Response 6/193 (3.1%) 6/0 1.79E-02 N/A
Asparagine Degradation I 1/2 (50.0%) 0/1 2.13E-02 N/A
β-alanine Degradation I 1/2 (50.0%) 0/1 2.13E-02 N/A
Proline Degradation 1/2 (50.0%) 0/1 2.13E-02 N/A
Alanine Degradation III 1/2 (50.0%) 0/1 2.13E-02 N/A
Alanine Biosynthesis II 1/2 (50.0%) 0/1 2.13E-02 N/A
A. The top 15 overrepresented pathways derived from the differentially expressed transcripts (DET) in the CCPR diet compared 
to the control group in kidney tissue of female donors. The pathways show their corresponding ratio of regulated genes as 
percentage of total genes in the pathway, the E -value and the Z-score for predicted activation or inhibition of the pathways. 
Significantly activated pathway is depicted in bold.
Table 4B. Upstream transcription factor analysis in female kidney tissue
Upstream 
regulator
Description Z-score P-value Gene 
log ratio
MYCN MYCN proto-oncogene, bHLH transcription factor +2.985 8.83E-04 -0.102
MYC MYCN proto-oncogene, bHLH transcription factor +2.191 1.00 E-00 -0.325
NKX2-3 NK2 homeobox 3 +2.000 2.07 E-01 0.197
NKFBIA NFκB inhibitor alpha +1.492 4.64 E-02 -0.349
SMARCA4 SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 4
+0.600 1.44 E-02 -0.387
MITF Melanogenesis associated transcription factor + 0.447 4.31 E-02 0.322
STAT3 Signal transducer and activator of transcription 3 + 0.391 7.60 E-04 -0.433
PITX2 Paired like homeodomain 2 + 1.065 2.23 E-03 -0.065
SATB1 SATB homeobox 1 +0.128 8.67 E-03 0.365
WT1 Wilms tumor 1 + 0.101 4.24 E-02 0.265
HNF4A Hepatocyte nuclear factor 4 alpha -0.315 7.41 E-03 -0.239
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Table 4B. (continued)
Upstream 
regulator
Description Z-score P-value Gene 
log ratio
HSF1 Heat shock transcription factor 1 -0.251 4.50 E-02 -0.271
GATA3 GATA binding protein 3 -0.425 2.77 E-02 -0.360
KMT2D Lysine methyltransferase 2D -0.447 3.99 E-02 -0.251
EGR1 Early growth response 1 -0.600 4.68 E-02 0.130
TCF7L2 Transcription factor 7 like 2 -0.632 2.99 E-03 -0.329
PML Promyelocytic leukemia -0.785 4.28 E-04 -0.558
SMAD4 SMAD family member 4 -1.067 1.21 E-02 -0.361
STAT1 Signal transducer and activator of transcription 1 -1.534 1.23 E-02 -0.431
CREB1 cAMP responsive element binding protein 1 -1.591 1.97 E-02 0.295
IRF7 Interferon regulatory factor 7 -1.671 8.91 E-03 -0.374
BRCA1 BRCA1, DNA repair associated -1.719 1.24 E-04 0.228
POU2AF1 POU class 2 associating factor 1 -1.987 2.87 E-03 +0.287
PRDM1 PR/SET domain 1 -2.121 2.75 E-03 -0.429
SMARCB1 SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily b, member 1
-2.236 9.96 E-03 0.351
B. Differentially regulated upstream transcription factors (TFs) derived from the DET in the CCPR diet compared to the control 
group in kidney tissue of female donors, with their corresponding Z-score, P-value and gene log ratio. Significantly activated 
or inhibited TFs are depicted in bold.
DISCUSSION
Extensive animal studies have unequivocally established the beneficial effects of various 
short-term DR regimens on stress resistance, including renal and hepatic IRI, with the largest 
protection seen by fasting, calorie and protein restriction10,12,14,17. However, translation to 
clinical interventions has proven difficult because of concerns about the possible side effects 
of preoperative restrictive diets, lack of voluntary adherence and uncertainty regarding the 
DR strategy to be used15. Our randomized, controlled clinical trial demonstrates that five 
days of CCPR before live kidney donation is feasible, safe and significantly improves renal 
recovery in both donors and their recipients. These findings have wide clinical impact. 
DR was feasible as evidenced by the fact that all 15 donors adhered to the diet. Next to 
the self-reported adherence, we independently confirmed compliance to the diet based 
on significant weight loss and altered adherence markers prealbumin and retinol binding 
protein in the CCPR group. Levels of systemic postoperative inflammation markers were 
similar in both groups, which suggests that CCPR diet does not affect the postoperative 
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inflammatory response15. The incidence of perioperative and postoperative complications 
in the kidney donors did not differ between groups either, which shows that concerns 
regarding a compromised immune response and wound healing following DR in a surgical 
setting are unwarranted and which underscores the safety of a CCPR diet15. 
The beneficial protective effects of the CCRP diet on the kidney were shown by significantly 
improved renal function: creatinine clearance and glomerular filtration rate in the first 
postoperative days until hospital discharge of the donors, as well as the significant decrease 
of serum urea concentrations both preoperatively and postoperatively. The improved 
postoperative kidney function in donors due to the CCPR diet in a setting of only marginal 
decrease in creatinine clearance due to kidney removal itself18, further underscores the 
powerful effects of the CCPR diet. Subgroup analyses showed a common improved renal 
outcome in both male and female donors, albeit this improvement seemed to occur earlier 
after surgery in females. 
The ameliorated outcome in the kidney donors is further strengthened by the significantly, 
clinically highly relevant improvement of creatinine clearance in the kidney transplant 
recipients from CCPR donors. Interestingly, male recipients appeared to show better serum 
creatinine clearance compared to female recipients. To determine whether females have a 
different susceptibility to IRI or response to DR, these results need to be validated in larger 
cohorts. Transplant recipients of CCPR donors showed a trend towards higher Tacrolimus 
pre-dose concentrations which suggests CCPR alters the metabolism of Tac. Despite 
higher exposure to Tac, which is correlated with increased nephrotoxicity19, the creatinine 
clearance was superior in the CCPR recipients. Together with the significantly lower 
incidence of acute rejection and SGF, these data indicate that short-term CCPR induces 
increased stress resistance in humans resulting in protecting the transplanted kidney from 
ischemic damage and from acute rejection. Two recipients in the control group developed 
uncontrollable acute rejection which necessitated transplant nephrectomy20. However, 
these patients received belatacept rather than Tac-based immunosuppression. Although 
non-nephrotoxic, belatacept is a less potent immunosuppressant than Tac, we feel that these 
two severe cases of rejection are explained by the type of immunosuppressive therapy21. 
Excluding both patients from the statistical analysis did not impact the creatinine clearance 
and eGFR results in the recipients (data not shown). 
Transcriptome analysis in kidney tissue obtained during surgery revealed changes in cell 
cycle and stress resistance pathways due to the CCPR diet. In particular, the suggested 
inhibition of cell cycle G2M phase regulation and upregulation of NRF2-mediated stress 
response and eIF2 signaling revealed a strong overlap with our preclinical data in kidneys 
of mice subjected to protein-free, calorie-restricted or fasting diets12,14,22. Activation of 
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eIF2 reduces global translation, allowing cells to switch from growth to maintenance and 
inducing stress resistance23. These similarities highlight the evolutionary conservation of 
the response to DR, which is already present in humans after five days of CCPR. In addition, 
a trend towards inhibition of the immune response was seen. However, this did not reach 
statistical significance, presumably due to the small sample size and the heterogeneity of the 
human tissue. Other studies using DR in heart, skeletal muscle and liver tissue in animal 
models showed similar inhibition of cell cycle regulation and immune system signaling 
as well as an upregulation of stress response pathways, including the NRF2 pathway24-27. 
Transcriptome profiles of aged rat kidneys revealed an opposite image of our results induced 
by CCPR, such as the upregulation of immune pathways, including cytokine and T-cell 
signaling as well as NF-kB activation 28, and are in agreement with our current results as 
long term diet restriction delays aging2. Recently, the transcription factor Myc was found as 
an important signaling molecule activated by protein restriction in Drosophila, potentiating 
innate immunity and increasing stress resistance29. We found MYC as one of the highest 
activated transcription factors following CCPR. Since pharmacological overexpression of 
Myc mimicked the effect of DR, MYC might well be a target to develop a dietary restriction 
mimetic29. No transcriptome analysis studies have been performed in human kidneys 
following DR. However, several reports on transcriptome profiling in human kidneys after 
transplantation were published recently. One of those performed gene expression analysis 
on biopsies three months after transplantation and identified 13 genes of interest that were 
correlated to worse allograft outcome at 12-months post-transplantation. Ankyrin repeat 
and SOCS Box containing 15 (ASB15), was significantly decreased in their analysis and this 
downregulation was associated with worse kidney function at 12 months30. This gene was 
upregulated in the CCPR diet group in our unbiased profiling and might have a potential 
role in the protection against acute and chronic rejection30. Asb15 was discovered in 2002 
as a member of the suppressor of cytokine box superfamily (SOCS) and is expressed 
mainly in the heart and kidney31. Not much is known about the function of the gene. The 
SOCS family, however, has been identified as a regulator of protein turnover and protein 
degradation, especially degradation of cytokines32. Another study, examining the link 
between interstitial fibrosis and gene expression profiles at 12 months after transplantation, 
revealed no similarities with our results 33 but found a relationship between increased 
serum levels of RBP and worse creatinine clearance. We showed that RBP levels decrease 
due to the diet, and it is worth looking into the functional role of RBP in relation to renal 
outcome33. Taken together, our transcriptome analysis shows hints towards increased stress 
resistance and possible downregulation of the immune response by DR. In addition, ASB15 
revealed to be a gene of interest to investigate in future studies. 
15045-jongbloed-layout.indd   215 06/11/2017   17:20
216
CHAPTER 8
This study has several limitations. It was designed as a pilot study in a single transplantation 
center, therefore only a small cohort of patients was included and no power calculations 
were performed. Replacement of donor-recipient pairs that were excluded from the waiting 
list for various reasons (Figure S1) was performed until the desired number of 15 donors 
in the CCPR group was reached. As a result, the number of donors included in the control 
group was higher. In addition, expression analysis was only performed at mRNA level. 
Investigating the effects of CCPR in a larger cohort, in a different surgical population, 
and on a posttranscriptional level might underscore its clinical potential as well as reveal 
the mechanisms by which short-term DR acts in humans. Two patients received the 
immunosuppressive agent belatacept rather than Tac after inclusion and randomization. 
These patients developed acute rejection, and were excluded from the study after their 
rejected kidney was removed. A significantly higher number of female than male donors 
was included due to the difference in willingness to donate between men and women that 
has been described earlier34. Future studies should strive for inclusion of equal numbers of 
both sexes.
In conclusion, we show that a CCPR diet given during five days immediately before kidney 
donation accelerates adaptation of kidney function of the remaining kidney and increases 
resistance to IRI in human kidney transplantation as evidenced by a more rapid recovery of 
kidney transplant function. On a transcriptional level, hints towards a switch from growth 
to maintenance and increased stress resistance were found. Given its non-invasive character 
and safety, our CCPR diet may have great impact on increasing resistance to surgical-related 
stress in humans. 
SUBJECTS AND METHODS
Study design
This pilot study was designed as a randomized, controlled trial and was approved by the 
Medical Ethics Committee (METC, MEC number 2012-134) of the Erasmus MC, University 
Medical Center Rotterdam, The Netherlands. The study procedures were in accordance 
with the local METC guidelines. All subjects provided written informed consent before 
inclusion. The trial was registered on October 12, 2012 in the Dutch trial registry under 
trial code 3663 (www.trialregister.nl). This manuscript was prepared in accordance with the 
CONSORT 2010 statement 35.
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Subjects 
Living kidney donors were approached by the trial coordinator (FJ) and then included 
during the work up for donation at the outpatient clinic of the department of Surgery of the 
Erasmus MC, University Medical Center Rotterdam, between May 2, 2014 and November 
18, 2015. To be eligible for participation in the study, donors had to be between 18 and 
70 years old, had to have a BMI ≥ 19 kg/m2, were not allowed to participate in another 
clinical trial in the 30 days prior to the day they were approached, and could have no known 
allergies to any of the ingredients in the diets. Figure S1. Randomization was performed 
using computer-generated lists as described previously16. No statistical power calculation 
for sample size was performed due to the pilot design of the study. In addition, since the 
detrimental effects of laparoscopic surgery on healthy living kidney donors was expected 
to be marginal, the inclusion of a substantially large number of donors was to be expected 
to reveal a significance based on a power calculation. With only a limited number of 
procedures per year, this inclusion rate would not have been feasible. 
Dietary intervention
Patients in the CCPR group received a diet containing 30% fewer calories and 80% fewer 
protein. Dietary needs were calculated using the Harris–Benedict formula36 as described 
previously16. The diet was given for five consecutive days and was initiated five days prior 
to surgery. The diet was based on a synthetic liquid diet as described previously 16, and 
was supplemented with a limited number of low-protein and protein-free products (mainly 
fruits and vegetables) until the desired preset individual needs were met (Table S3). The 
calorie- and protein-restricted powder Scandishake® Mix shakes were kindly provided by 
Nutricia Advanced Medical Nutrition, The Netherlands. As described previously, the shake 
was provided as powder which was diluted with water. The powder consisted of 4% protein, 
53% carbohydrate and 43% fat, respectively16 (Table S3).  The control group had no dietary 
restrictions and continued their normal diet. 
Surgical procedures
Preoperative, perioperative, and postoperative anesthetic care concerning drug 
administration, ventilation and fluid regimens was carried out according to our local 
protocol for the kidney donors and kidney recipients. Donor kidneys were obtained 
via either a laparoscopic nephrectomy or a hand-assisted retroperitoneal nephrectomy 
(HARP)37. Kidney transplantation was performed via an open approach, and the kidney 
was positioned supra-inguinally on the external iliac artery and the external iliac vein. 
Additional informed consent was asked from the transplant recipients to obtain kidney 
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biopsies. Biopsies of the renal cortex were taken at the end of the cold ischemia time (kidney 
off ice), just before implantation in the recipient was started using a punch biopsy with a 
diameter of 4 mm. 
Immunosuppressive therapy
Kidney transplant recipients received the same initial immunosuppressive therapy, except 
for two patients in the control group who received betalacept (Bristol-Myers Squib, 
NYC, NY) instead of tacrolimus. The initial immunosuppressive treatment consisted of 
tacrolimus (Prograf®; Astellas Pharma, Leiden, The Netherlands), mycophenolate mofetil 
(MMF; CellCept®; Roche Pharmaceuticals, Woerden, The Netherlands) and prednisolone 
treatment. All patients received induction therapy with basiliximab (Simulect®, Novartis 
Pharma, Arnhem, the Netherlands). The doses, target whole blood or plasma concentrations, 
and phasing of immunosuppressive therapy has been described elsewhere in detail38.
Outcome parameters 
Living kidney donors
Before and after the dietary intervention, the following data were obtained from all donors: 
body weight, age, gender, length, and systolic blood pressure. The time point before dietary 
intervention was set at the moment of inclusion in the trial during a visit at the outpatient 
clinic. The time point of first blood withdrawal before start of the dietary intervention, 
POD-pre, varied from one day up to over a year. Therefore, we used POD-1 values after 
the dietary intervention as cutoff levels for the calculation of relative values. Before and 
at various time points after surgery, serum levels of parameters shown in Table S4 were 
determined. Since kidney function is dependent on various factors, including gender and 
age, relative values for serum creatinine and CKD-EPI eGFR were calculated. A schematic 
overview of the experimental timeline of the study is shown in Figure S2. Processing of the 
blood samples was done as described previously16.
Kidney transplant recipients
Before and after the dietary intervention, the following data were obtained from all 
transplant recipients: body weight, age, gender, length, and systolic blood pressure. Before 
and at various time points after surgery, serum values of parameters shown in Table S4 were 
determined. For assessment of standard laboratory values of transplant recipients without 
informed consent for the kidney biopsies, a non-WMO study addendum was handed 
in to the local METC of the Erasmus MC, Rotterdam, the Netherlands. In our center, 
all patients routinely undergo a mercaptoacetyltriglycine (MAG3) renal scintigraphy on 
postoperative day (POD) 1 to assess renal perfusion. In case of a gradual increase of activity 
in the parenchyma of the transplanted kidney without evidence of cortical excretion, acute 
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tubular necrosis (ATN) was suspected and recorded. Delayed graft function (DGF) was 
defined as the need for dialysis in the first postoperative week39. Slow graft function (SGF) 
was defined as an estimated glomerular filtration rate (eGFR) ≤10 ml/min per 1.73 m2 at 
day 6 after transplantation39. Classification of surgical complications was done using the 
Clavien-Dindo classification of surgical complications40.
mRNA-sequence analysis 
For gene expression analysis, 10 donors were included in the CCPR group and 10 donors in 
the control group. Biopsies were taken at the end of the cold preservation period (kidney off 
ice), directly before implantation. Biopsies were put in 2 mL Eppendorf tubes (Eppendorf 
Group, New York, USA) containing 1 mL of RNAlater RNA Stabilization Reagent (QIAGEN 
Benelux B.V., Venlo, the Netherlands), and were kept at 4°C for at least 48 hours. Total RNA 
extraction and measurement of RNA concentration was done as described previously13,14. 
The RNA quality was expressed as the RNA integrity number (RIN, range 0-10), and values 
ranged between 6.1 and 8.2. Handling, analysis and visualization of the data was performed 
in R. Principal component analysis (PCA) and density plots of the raw counts revealed an 
outlying sample that had a very low RNA concentration. This sample was omitted from 
further analysis. A filtering step was performed to remove low count transcripts: transcripts 
had to be sequenced at least three times per sample and two times per experimental group 
within gender. The filtering step resulted in 175,756 transcripts for analysis. Differentially 
expressed transcripts between diet type within gender were calculated using DESeq2. 
False Discovery Rate correction was performed as described by Storey and Tibshirani 41,42. 
Complete raw and normalized microarray data and their MIAME compliant metadata have 
been deposited at the Gene expression Omnibus (GEO) database GSE103532 (www.ncbi.
nlm.nih.gov/geo).
End points
The primary end point was the postoperative kidney function in the kidney donors as 
measured by serum creatinine and CKD-EPI eGFR43. The main secondary end point was the 
transcriptional changes induced by the CCPR diet as measured by gene expression analysis 
in kidney biopsies. Additional secondary end points of the donors included: compliance to 
the CCPR diet, metabolic changes induced by the CCPR diet, and perioperative outcome. 
Secondary end points of the recipients were postoperative kidney transplant function, 
perioperative outcome (including blood loss, urine production), and the incidence of DGF, 
SGF and ATN defined as described previously 39.
15045-jongbloed-layout.indd   219 06/11/2017   17:20
220
CHAPTER 8
Statistical analysis
Categorical data are presented as numbers (percentage) and continuous variables as 
median ± interquartile range (IQR). The data were tested for normality using the Shapiro–
Wilks test and subsequent visual assessment. Continuous data were compared using the 
non-parametric Mann–Whitney U test. A Bonferroni correction for multiple testing was 
performed on the postoperative kidney function parameters. In the living kidney donors, 
this correction was done separately for the short-term outcome until POD3 and the long-
term outcome until POMo3. In the transplant recipients, the cutoff for short-term outcome 
was set at POD7, and the cutoff for the long-term outcome on POMo6. To assess changes in 
GFR and creatinine levels over time for both donors and recipients, lme4 (Bates, Maechler 
& Bolker, 2012) for R 3.3.3 was used to perform a linear mixed effects analysis of the 
relationship between the outcomes of interest and treatment category. Random intercepts 
per patient were modelled. Visual inspection of residual plots did not reveal any obvious 
deviations from homoscedasticity or normality. Significance for the linear mixed-effects 
model analysis was set at P<0.05 with t-tests using Satterthwaite approximations to degrees 
of freedom. The analyses were performed using Statistical Packages for Social Sciences 23.0 
(IBM Inc., Chicago, IL, USA), R (R foundation), GraphPad Prism (GraphPad Software Inc., 
version 5.01), and Office Excel (Microsoft (Office) 2016). 
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SUPPLEMENTARY DATA 
            
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Informed	(n=113)	
Preliminary	inclusions	
(n=53)	
Inclusions	(n=35)	
Assessed	for	eligibility	
(n=132)	
Exclusions	(n=19):	
Another	trial	(n=1)	
Age	restriction	(n=4)	
Cross-over	(n=2)	
Not	yet	KT	needed	(n=4)	
Surgery-related	(n=6)	
Language	difficulty	(n=1)	
Allergies	ingredients	diet	(n=1)	
	
No	participation	(n=60):	
Surgery	related	(n=8)	
Cross-over	(n=5)	
No	informed	consent	(n=47)	
Dropout	(n=18):	
Surgery	cancelled	/	postponed	(n=6)	
Withdrew	informed	consent	(n=12)	
CCPR	diet	(n=15)	 Control	group	(n=20)	
Figure S1. Flowchart of the inclusions and exclusions of the living kidney donors. Exclusions 
were based on preset exclusion criteria. Eligible kidney donors were approached at the outpatient 
clinic at the Erasmus MC, University Medical Center Rotterdam, the Netherlands. After information 
about the study was given, 57% of eligible donors refrained from participating in the study. Cross-
over = cross-over program at which the surgery takes place outside of the Erasmus MC. KT = 
kidney transplantation. CCPR = combined calorie and protein restriction.
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Figure S2. Compliance markers in living kidney donors before and after the CCPR diet 
compared to the control group. (A) Levels of prealbumin were significantly decreased after the 
CCPR diet compared to the control group. (B) Retinol binding protein levels were also significantly 
decreased after the CCPR diet. (C) Absolute levels of the branched-chain amino acid leucine 
were decreased after the CCPR diet. (D) The absolute numbers of valine were also significantly 
decreased after the CCPR diet. Values are depicted as mean ± 95% confidence interval. * = P<0.05; 
*** = P<0.001; NS = not significant. CCPR = combined calorie and protein restriction.
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Figure S3. Kidney function of female living kidney donors before and after live kidney donation. 
(A) Absolute levels of serum creatinine of the female kidney donors did not differ between the two 
intervention groups, while the (B) Relative creatinine levels showed a trend towards improvement 
in the CCPR diet group in the first postoperative days. (C) Estimated glomerular filtration rate 
(eGFR) showed a similar result, with no changes in absolute eGFR levels and a (D) trend towards 
improvement in the first postoperative days. In the kidney transplant recipients of female living 
kidney donors, no significant changes were seen in the (E) absolute creatinine level, the (F) relative 
creatinine levels, the (G) absolute eGFR and the (H) relative eGFR postoperatively. Values are 
depicted as median ± interquartile range. CCPR = combined calorie and protein restriction; POD 
= postoperative day; POMo = postoperative month; eGFR = estimated glomerular filtration rate. 
*= P<0.05.
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Figure S4. Kidney function of male living kidney donors before and after live kidney donation. 
(A) Absolute levels of serum creatinine of the male kidney donors were significantly higher prior 
to start of the CCPR diet, while no differences between the two intervention groups were seen 
postoperatively. (B) Relative creatinine levels were significantly improved in the CCPR diet on 
postoperative month (POMo)1. (C) Estimated glomerular filtration rate (eGFR) showed a lower 
eGFR in the CCPR prior to start intervention and no differences postoperatively, with similar 
changes (D) in relative eGFR levels. In the kidney transplant recipients of male kidney donors, 
(E) absolute creatinine levels were improved as from POD1 until POD7, while (F) relative 
creatinine levels were better as from POD3 until POD14. (G) Absolute eGFR and the (H) relative 
eGFR showed a trend towards improvement postoperatively. Values are depicted as median ± 
interquartile range. CCPR = combined calorie and protein restriction; POD = postoperative day; 
POMo = postoperative month; eGFR = estimated glomerular filtration rate. *= P<0.05.
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Figure S5. Principal component analysis plot of female and male kidney tissue. An unbiased 
principal component analysis of all kidney tissue samples obtained during kidney transplantation 
revealed a strong separation based on gender on both the principal component axis (PC) 1 and 2. 
Principal component axis 1 is depicted on the x-axis, while component axis 2 is depicted on the 
y-axis. Biopsies from the combined calorie and protein restriction diet kidneys are depicted with 
squares, while biopsies from control kidneys are depicted with circles. F = female; M = male.
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Donors	
	
	
Recipients	
	
Figure S6. Timeline of living kidney donors and recipients participating in the study, from start 
until the end of the trial.
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Table S1.  Baseline characteristics of living kidney donors included in the transciptome analysis 
Parameter CCPR (n=10) Control (n=10) P-value
Donors
Age (years) 59 (53-61) 51 (44-64) 0.19
Gender (Male/Female) 3/7 5/5 0.39
BMI (kg/m2) 25.6 (23.3-28.0) 25.4 (23.4-26.0) 0.59
Systolic blood pressure (mm/Hg) 130 (124-136) 128 (124-136) 0.89
Creatinine (mmol/L) 74 (68-82) 78 (71-90) 0.15
eGFR (mL/min) 83 (66-90) 75 (72-83) 0.68
Urea (mmol/L) 5.2 (4.8-5.6) 5.2 (4.0-5.4) 0.46
Glucose (mmol/L) 5.3 (5.1-5.7) 5.1 (4.8-5.8) 0.56
Albumin (g/L) 47 (45-48) 45 (45-47) 0.85
Triglycerides (mmol/L) 1.2 (0.9-1.8) 1.3 (1.2-1.5) 0.62
Hemoglobin (mmol/L) 8.7 (8.4-9.1) 8.9 (8.6-9.2) 0.63
Trombocytes (109/L) 241 (222-302) 223 (206-289) 0.48
CRP (mg/L) 1.4 (1.0-2.0) 1.3 (0.8-2.4) 0.30
Leukocytes (109/L) 6.5 (5.6-7.6) 5.9 (5.5-6.9) 1.00
Bilirubin (µmol/L) 8.0 (5.3-10.0) 6.0 (5.0-7.3) 0.31
Potassium (mmol/L) 4.5 (4.3-4.6)1 4.4 (4.1-4.8) 0.86
Type of donation (R/U/A) 3/1/6 1/6/3 0.79
Side of nephrectomy (Left/Right) 6/4 6.4 1.00
Method used (Laparoscopic/HARP) 7/3 7/3 1.00
No significant differences (P<0.05) were seen in the baseline characteristics of both groups. BMI = body mass index; eGFR = 
estimated glomerular filtration rate using the CKD-EPI formula; CRP = C-reactive protein. Type of donation: R = related; U = 
unrelated; A = anonymous. HARP = hand-assisted retroperitoneal nephrectomy.
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Table S2.  Perioperative outcome of donors and recipients 
Parameter CCPR (n=15) Control (n=20) P-value
Donors
Duration of surgery (HH:MM) 03:29 ± 00:10 03:53 ± 00:10 0.11
Start surgery (HH:MM) 08:11 ± 00:05 08:18 ± 00:07 0.43
Blood loss (milliliters) 47 ± 17 82 ± 24 0.24
Duration warm ischemia time 1 (MM:SS)) 03:20 ± 00:18 03:23 ± 00:17 0.90
Duration cold ischemia time (HH:MM) 02:37 ± 00:10 02:45 ± 00:12 0.65
Duration of warm ischemia time 2 (MM:SS) 18:47 ± 01:12 20:00 ± 00:48 0.45
Complications during surgery (yes/no) 1/15 0/20 0.33
Recipients
Duration of surgery (HH:MM) 03:08 ± 00:11 03:06 ± 00:13 0.92
Start of surgery (HH:MM) 11:54 ± 00:13 12:18 ± 00:10 0.17
Time of kidney perfusion (HH:MM) 13:41 ± 00:16 14:06 ± 00:15 0.31
Time of biopsy (HH:MM) 13:20 ± 00:17 13:28 ± 00:11 0.77
Blood loss (milliliters) 180 ± 30 231 ± 41 0.33
Urine production during surgery
(yes/no) 1/15 5/20 0.14
Complications during surgery
 (yes/no) 1/15 0/20 0.33
Parameters are depicted as mean ± standard error of the mean. CCPR=combined calorie and protein restriction diet. 
HH:MM=hours:minutes; MM:SS=minutes:seconds. P-value<0.05 is considered significant. 
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Table S3. Pathway and upstream transcription factor analysis in renal tissue of male donors
Ingenuity Canonical Pathways Ratio Up/Down P-value Z-score
Xenobiotic Metabolism Signaling 10/287 (3.5%) 4/6 4.80E-06 N/A
Antigen Presentation Pathway 4/38 (10.5%) 1/3 5.83E-05 N/A
Serotonin Degradation 5/75 (6.7%) 0/5 6.23E-05 N/A
LPS/IL-1-Mediated Inhibition of RXR Function 7/221 (3.2%) 2/5 2.42E-04 N/A
Nicotine Degradation II 4/63 (6.3%) 1/3 4.23E-04 N/A
Superpathway of Melatonin Degradation 4/68 (5.9%) 0/4 5.66E-04 N/A
Allograft Rejection Signaling 4/84 (4.8%) 1/3 1.25E-03 N/A
Thyroid Hormone Metabolism II 3/41 (7.3%) 0/3 1.54E-03 N/A
OX40 Signaling Pathway 4/91 (4.4%) 1/3 1.68E-03 N/A
Autoimmune Thyroid Disease Signaling 3/47 (6.4%) 1/2 2.28E-03 N/A
Graft-versus-Host Disease Signaling 3/48 (6.2%) 1/2 2.43E-03 N/A
Phenylalanine Degradation IV 2/14 (14.3%) 0/2 2.68E-03 N/A
Nicotine Degradation III 3/54 (5.6%) 0/3 3.40E-03 N/A
Type I Diabetes Mellitus Signaling 4/111 (3.6%) 2/2 3.46E-03 N/A
Melatonin Degradation I 3/63 (4.8%) 0/3 5.25E-03 N/A
The top 15 overrepresented pathways derived from the differentially expressed transcripts (DET) in the CCPR diet compared 
to the control group in kidney biopsies of male donors. The pathways show their corresponding ratio of regulated genes as 
percentage of total genes in the pathway, the P-value and the Z-score for predicted activation of inhibition of the pathways. 
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Table 3. (continued)
Upstream 
regulator
Description Z-score P-value Gene 
log ratio
KLF4 Kruppel like factor 4 +2.198 7.17E-04 -0.304
NUPR1 Nuclear protein 1, transcription regulator +2.000 3.39 E-01 +0.081
RELA RELA proto-oncogene, NF-κB subunit +1.970 2.53 E-03 -0.513
KLF5 Kruppel like factor 5 +1.957 2.78 E-04 +0.803
CCND1 Cyclin D1 +1.387 1.37 E-02 +0.294
JUN Jun proto-oncogene, AP-1 transcription factor subunit +1.296 4.75 E-02 -0.129
HIF1A Hypoxia inducible factor 1 alpha subunit +1.250 5.40 E-04 +0.763
MYC MYCN proto-oncogene, bHLH transcription factor +1.224 1.97 E-04 +0.537
NOTCH1 Notch 1 +1.188 1.49 E-02 +0.357
TWIST1 Twist family bHLH transcription factor 1 +1.000 2.04 E-03 -0.152
TP73 Tumor protein 73 +0.639 7.73 E-04 +0.170
NKX2-3 NK2 homeobox 3 +0.447 9.09 E-03 +0.039
SMARCA4
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 4 +0.378 2.59 E-02 -0.350
NFKBIA NFκB inhibitor alpha +0.295 4.07 E-03 +0.163
GATA3 GATA binding protein 3 +0.152 3.62 E-02 -0.181
TP53 Tumor protein 53 +0.128 1.99 E-06 -0.259
TP63 Tumor protein 63 +0.101 7.14 E-03 +0.116
SP1 Sp1 transcription factor -0.063 1.50 E-03 -0.240
ATF3 Activating transcription factor 3 -0.106 1.8e E-03 -0.182
NFE2L2 Nuclear factor, erythyroid 2 like 2 -0.562 3.28 E-02 +0.331
CEBPA CCAAT/enhancer binding protein alpha -0.727 3.54 E-03 +0.441
MYCN MYCN proto-oncogene, bHLH transcription factor -0.923 2.36 E-02 -0.030
HMGA1 High mobility group AT-hook 1 -1.000 1.13 E-02 +0.945
CREBBP CREB binding protein -1.004 8.07 E-03 +0.409
KLF3 Kruppel like factor 3 -1.134 3.35 E-03 -0.302
CEBPB CCAAT/enhancer binding protein beta -1.353 2.65 E-03 -0.186
HNF4A Hepatocyte nuclear factor 4 alpha -3.331 7.37 E-04 -0.470
Differentially regulated upstream transcription factors (TFs) derived from the DET in the CCPR diet compared to the control 
group in kidney biopsies of male donors, with their corresponding Z-score and gene log ratio. Significantly activated or 
inhibited TFs are depicted in bold.
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Table S4. Composition and energy content of the combined calorie and restricted (CCPR) diet
Diet
Average content per 100 gram/mL CCPR diet
Energy     (kcal) 507
             (kJ) 2120
Protein (g) 4.98
Protein (% of energy intake) 4.0
Casein (g) 4.3
Whey protein (g) 0.4
Carbohydrates (g) 67.0
Carbohydrates (% of energy intake) 53.0
Glucose (g) 0.8
Fructose (g) 0.0
Lactose (g) 3.2
Maltose (g) 2.5
Sucrose (g) 14.0
  Polysaccharides (g) 46.3
Other (g) 0.2
Fat (g) 24.5
Fat (% of energy intake) 43
Saturated fat (g) 7.7
Monounsaturated fat (g) 7.3
Polyunsaturated fat (g) 9.4
Linoleic acid (g) 8.1
Α-linoleic acid (g) 0.9
Fibres 0.0
Sodium (mg) 128
Potassium (mg) 272
Chloride (mg) 163
Calcium (mg) 85
Phosphor (mg) 147
Magnesium (mg) 30
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Table S4. (continued)
Diet
Average content per 100 gram/mL CCPR diet
Ferritin (mg) 0.0
Zinc (mg) 0.0
Copper (mg) 0.0
Manganic (mg) 0.0
Fluoride (mg) 0.0
Molybdenum (µg) 0.0
Selenium (µg) 0.0
Chrome (µg) 0.0
Iodine (µg) 0.0
Vitamin A (µg-RE) 0.0
Carotenoids (mg) 0.0
Vitamin D (µg) 0.0
Vitamin E (mg α-TE) 0.0
Vitamin K (µg) 0.0
Thiamin (mg) 0.0
Riboflavin (mg) 0.0
Niacin (mg NE) 0.0
Panthotheenzuur (mg) 0.0
Vitamin B6 (mg) 0.0
Foliumzuur  (µg) 0.0
B12 (µg) 0.0
Biotin (µg) 0.0
Vitamin C (mg) 0.0
Choline (mg) 0.0
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Table S5. Serum parameters measured in living kidney donors at various time points during the 
study
Parameter Assay performed at Time points of measurements
Creatinine (mmol/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
eGFR (mL/min) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
Urea (mmol/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 3 & 6
Glucose (mmol/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
Albumin (g/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
Triglycerides (mmol/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
Hemoglobin (mmol/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
Trombocytes (109/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
CRP (mg/L) Hospital laboratory Outpatient clinic, daily during hospital admission
Leukocytes (109/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
Bilirubin (µmol/L) Hospital laboratory Outpatient clinic, daily during hospital admission 
Potassium (mmol/L) Hospital laboratory Outpatient clinic, daily during hospital admission, POMo 1, 3 & 6
Prealbumin (mg/L) Beckman Outpatient clinic, peroperatively 
Retinol binding protein (mmol/L) Diazyme Outpatient clinic, peroperatively
Leucine (mmol/L) Nightingale Outpatient clinic, peroperatively, POD 1 & 2
Valine (mmol/L) Nightingale Outpatient clinic, peroperatively, POD 1 & 2
eGFR = estimated glomerular filtration rate using the CKD-EPI formula; PoMo = postoperative month; POD = postoperative 
day; CRP = C-reactive protein.
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SUMMARY AND DISCUSSION
An increase in oxidative stress and inflammation has a negative influence on overall quality 
and quantity of life leading to accelerated development of age-associated diseases and a 
decrease in lifespan. An acute induced stress response leads to worse outcome of organ 
transplantation procedures due to the development of ischemia-reperfusion injury (IRI), 
creating a boundary for the possibilities of organ transplantation for patients with end-
stage organ failure. A surgery-related stress response might also influence the outcome of 
patients undergoing elective surgery, especially when comorbidities as in morbid obesity 
are present. Dietary restriction (DR) has been shown to improve lifespan and reduce age-
associated diseases as well as to improve outcome of IRI in various healthy laboratory 
animal models. Many aspects of DR are still unknown, including which components of the 
calories are responsible for the effects of DR, the mechanisms underlying DR, as well as the 
overall applicability of DR in different animal models involving acute stress-related injury. 
Foremost, the translation of DR into a clinical setting has been proven difficult and evidence 
of effects in patients is therefore limited. There is a pressing necessity for improving the 
knowledge about the etiology and clinical applicability of DR to optimize the effects of DR 
on surgical and disease-related stress resistance and postoperative outcome. 
The aims of this thesis were three-fold: One, to assess the effects of current and novel short-
term DR regimens in different mouse models of acute stress; two, to gain more insight 
into the mechanisms underlying DR; and three, to search for a clinically applicable dietary 
intervention in the surgical setting. 
Current and novel short-term dietary restriction regimens
Previously, colleagues showed that two weeks of 30% DR and three days of fasting are able to 
significantly improve survival and kidney function in male C57BL/6 mice that underwent 
renal IRI as compared to ad libitum (AL) fed mice1. These results were among the first 
that showed a beneficial effect of a short-term DR on a model of acute stress and several 
questions arose calling for follow-up research. In this section I will subsequently address 
questions related to the effective components and regimens of short-term DR drawing in 
part on the results in this thesis.
The aforementioned results were obtained in an optimal model for laboratory research with 
young-lean male mice1. However, this model is less suitable to examine whether DR has 
a broader applicability when it comes to differences in age, gender, obesity and genetic 
background. The results in chapter 2 taught us that three days of fasting can indeed be 
reproduced in an optimal model to study aging and obesity. In this study, fasted hybrid 
mice showed improvement of both survival and kidney after induction of IRI, which was 
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accompanied by a reduction of acute tubular necrosis and more tubular regeneration. These 
effects were not as robust as in young-lean mice, yet sufficient enough to induce protection. 
In addition, we showed that female mice were able to withstand longer periods of IRI than 
male mice as an indication that the female gender has a higher endogenous threshold 
against IRI. Therefore, these data concluded that the presence of comorbidities as in age 
and obesity are not able to annul the robust beneficial effects of fasting on the outcome after 
renal IRI. 
Although three days of fasting is able to induce its beneficial effects in different mouse 
models, it does not give insight into which dietary components are precisely responsible 
for the effects of acute stress. After the first results of calorie restriction and its effects on 
health span and lifespan, many researchers examined whether the calorie reduction per se, 
or a specific component, was responsible for these effects. The first studies focused on the 
macronutrients, being protein, carbohydrates and fat2-5. Later the ratio of macronutrients 
became a subject of interest as well6,7. The first evidence of a major role of protein restriction 
was obtained in fruit flies where long-term protein-restriction resulted in increased 
lifespan8-11. In mice, the translation of long-term protein restriction to short-term regimens 
found that six days of deprivation was sufficient to induce beneficial effects against multiple 
forms of IRI12. A major issue with protein restriction proved to be the voluntary calorie 
restriction that mice imposed during the dietary intervention, which made the effects of 
protein restriction still indistinguishable from calorie restriction12. In chapter 4, we are 
the first to show the beneficial effects of protein deprivation for only three days, resulting 
in significant improved mortality and kidney function after renal IRI. In addition, three 
days of 30% DR did not induce protection and therefore we could distinguish the effects 
of protein restriction from calorie restriction. Recent literature also implicated the roles of 
other macronutrients, in particular in the light of aging and health span13,14. Solon-Biet et 
al. showed that the ratio of protein to carbohydrates is responsible for the benefits, in which 
a low amount of protein and high amount of carbohydrates revealed the largest effect on 
both health span and lifespan whereas reduction of carbohydrates gave an opposite image15. 
Several studies followed and pointed towards the same direction6,7. We could also confirm 
the detrimental effects of carbohydrate reduction, since our carbohydrate-free diet resulted 
in an aggravation of mortality and kidney function decline compared to control mice fed 
AL. In comparison, a fat-free diet showed results similar to the control mice fed AL, and 
was implicated to have no major role in the effects of calorie restriction on renal IRI. Indeed, 
Solon-Biet et al. came to the same conclusion in the long-term dietary interventions, 
revealing that fat intake did not contribute to health span and lifespan changes in mice6. 
The authors also pointed towards the role of amino acids, in particular branched chain 
amino acids, in the effects of protein restriction on aging6,15. In chapter 5, we also narrowed 
down the role of protein restriction by providing mice with a 3-day diet lacking one of 
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the following essential amino acids (EAA): methionine, leucine or tryptophan. These diets 
were followed by induction of acute stress in the form of liver IRI. Most literature about 
amino acids and DR studied a methionine restricted diet, and it showed that the results are 
slightly in favor of methionine being responsible for the beneficial effects on aging13,16,17. 
The extent to which tryptophan and leucine deprived diets have been examined is small, 
however do point towards a favorable role of essential amino acids deprivation on increased 
lifespan5. We showed that hepatic IRI, as a model for acute stress, was significantly reduced 
by all three EAA-free diets. These effects were already visible six hours after hepatic IRI in 
the leucine-free and tryptophan-free diets, while all EAA-free diets showed these effects 
at 24 hours post-IRI. We concluded that it is possible to provide robust protection against 
IRI with a diet as short as three days lacking only one essential amino acid and that these 
essential amino acids are able to produce this protection in a similar manner. 
In conclusion, by extending current DR regimens we showed that three days of fasting 
is able to induce protection against renal IRI in different animal models, including aged 
and overweight mice that more resemble the human population. In addition, by exploring 
novel DR regimens we could induce the protection against IRI with protein restriction and 
EAA-restriction as short as three days. Of interest, carbohydrate and fat deprivation were 
not able to induce protection and even aggravated the detrimental effects of IRI. Therefore, 
macronutrients are not equally responsible for the beneficial effects of DR and separation 
of total calorie restriction from protein restriction enabled us to develop a short-term DR 
regimen that is more specific and could be more suited to use in a clinical setting. 
Insight into the mechanisms underlying dietary restriction
Parallel with the vastly increasing number of studies about DR is the amount of studies 
focusing on the mechanisms underlying DR18-20. Many genes and pathways have been 
proposed to play an important role in the beneficial effects of DR, however none of those 
has been validated extensively in different studies19,21-23. Despite the fact that the exact 
mechanisms underlying DR remain to be elucidated, several pathways and genes have 
been put forward by many authors and are therefore of particular interest. These pathways 
include the NRF2-mediated stress response and mTOR nutrient signaling24,25. With an 
unbiased approach, we collected and analyzed transcriptome profiles of kidney and liver 
after various short-term dietary interventions that were either protective or non-protective 
against renal and hepatic IRI in order to examine the responsible mechanisms for ourselves. 
Interestingly, aforementioned pathways were on our top list of pathways and transcription 
factors as well. Transcription factor nuclear factor-erythroid like 2 (NRF2) is known to be 
the initiator of the phase II response, which is a detoxifying response to for instance oxidative 
and xenobiotic metabolism24. The NRF2-pathway was activated by all our protective diets, 
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including three days of fasting in the aged-overweight mice in chapter 2, the protein-free 
diet used against renal IRI in chapter 4, and all EAA-free diets given prior to hepatic IRI 
in chapter 5. Previous gene expression datasets of three days of fasting in young-lean male 
mice and two weeks of 30% DR demonstrated the activation of NRF2 as well1. Despite 
that the importance of NRF2 in the protection against DR has been described in multiple 
studies as well as our studies, a Nrf2 knock-out mice model submitted to DR showed similar 
increase in lifespan as control mice. Therefore, the exclusive role for NRF2 could not be 
determined and other factors are of essence in the protection as well26. Another one of 
those factors could be the nutrient-sensing pathway of mammalian target of Rapamycine 
(mTOR). MTOR has extensively been linked to an increase of lifespan and stress resistance 
and several studies that investigated the effects of a mTOR-inhibitor, rapamycin, show 
promising results25,27-29. In our renal IRI model, the protective diets all activated the 
transcription factor hepatocyte nuclear receptor factor alpha (HNF4A). HNF4A results in 
downregulation of metabolic sensors, in particular the mTOR pathway30,31. Using Western 
blot analysis, we examined S6 phosphorylation as a down-stream target of mTOR through 
immunoblotting. We showed a significant decrease in S6 phosphorylation after three 
days of fasting, indicating downregulation of mTOR25. The EAA-free diets downregulated 
mTOR as well, although not significantly in all diets. Since the mTOR pathway came up 
downregulated in both kidney and liver, this demonstrates its importance in the overall 
induction of stress resistance by DR. Moreover, renal and hepatic gene expression profiles 
showed multiple common features even though different DR regimens were used. The 
nuclear receptor signaling was proposed to be upregulated via the activation of retinoid 
acids (RAs), for instance the PPAR-pathway as seen in the aged-overweight fasting mice 
studied in chapter 2, and FOXO3, which is the transcription factor that was activated the 
most after DR in the kidney in chapter 4. Both RAs and FOXO3 are linked to increased 
stress resistance and protection against various forms of ischemia32-34. The stress resistance 
pathway mediated by all diets was NRF2, as mentioned before, but also the eukaryotic 
translation initiation factor 2a (EIF2a). Via activation of general control nonderepressible 2 
(Gcn2), the EIF2a signaling response activates and mediates genes involved in antioxidant 
defense, reduction of inflammation and cell survival35. Previously, Gcn2 was thought to be 
required for inducing stress resistance in mice, although a more recent study showed that 
Gcn2-deprivation was not sufficient to indeed provide protection against hepatic IRI and 
other factors might be required12,36. One of these additional factors might be the inhibition 
of cellular proliferation via inhibition of transcription factors FOXM1 and SMARCB124,37 
as seen after the EAA-free diets in chapter 5, thereby inducing the adaptive response that 
shifts resources from growth to maintenance as seen by DR38. We concluded that it is 
possible to provide robust protection against IRI with a diet as short as three days lacking 
protein or only one essential amino acid. We propose a mechanism-of-action model, based 
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on both renal and liver array results, in which this protection is induced by activation of 
nuclear receptor signaling, stress resistance pathways as well as inhibition of cell growth 
to a more maintenance state, mediated via key transcription factors mandatory for the 
beneficial effects.
The transcriptome profile analyses of all diets as done in chapter 2, chapter 4 and chapter 
5, were performed in biopsies taken after the dietary intervention but before induction of 
the acute stress of IRI. In chapter 3, we focused on the effects shortly after the induction 
of the stressor, which was in this case the chemotherapeutic agent irinotecan. We applied 
three days of fasting in C26 colorectal carcinoma (CRC)-bearing BALB/c male mice. 
Twelve days after tumor inoculation, mice were either fasted for three days or continued 
to be AL fed after which each group was given one high dose of irinotecan or vehicle. 
The effects of fasting were investigated on a transcriptional level in liver and tumor tissue 
collected 12 hours after the administration of irinotecan, when mice were sacrificed. In 
liver tissue, unbiased transcriptome analysis showed that fasting markedly reduced the 
number of gene expression changes caused by administration of irinotecan. Together with 
more homogenous gene expression profiles in liver tissue of mice subjected to fasting, 
these data point towards a dampening of the changes caused by irinotecan, thereby 
partially protecting healthy tissue from the response to irinotecan. Further evidence of this 
hypothesis is provided by the dysregulation of the genotoxic response due to fasting as 
compared to liver tissue of AL fed mice given irinotecan; the AL fed mice showed activation 
of DNA damage pathways, including RhoA signaling, as well as cellular stress and cytokine 
signaling pathways, whereas fasting mice subjected to irinotecan showed indirect inhibition 
of RhoA via activation of RhoGDI signaling, and vast reduction of chemokine and cytokine 
pathways39. In addition, pathways involved in growth and proliferation, such as the mTOR 
signaling via suppression of the p7056 pathway, were downregulated which points once 
more towards the shift from growth to maintenance as described before38,40. Interesting, the 
NRF2-pathway remained activated in the fasting mice after the stressor (i.e. irinotecan) was 
given, which may indicate a key role for NRF2 in the protection against acute stress. The 
fact that these stress-related pathways are already induced before the induction of stress 
and eventually results in dampening of genotoxicity, implicates that DR is able to induce 
the right amount of stress to eventually protect against high levels of stress as induced by 
either IRI or chemotherapy. This hypothesis has been proposed before, and was named 
hormesis in which low doses of a certain stressor are able to protect against the toxic effects 
of a stressor in high doses21. In this case hormesis is activated via nutrient deprivation, in 
particular via reduction in proteins or essential amino acids. Even more so, in chapter 3 we 
showed that fasting has no effect on the antitumor effect of irinotecan as implied by previous 
findings. For instance, colleagues showed that fasted APC15lox mutant mice given irinotecan 
had similar reduction in tumor size, and inhibited tumor cell proliferation as measured 
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by markers such as Cyclin D141. Although detrimental effects of fasting on the effects of 
chemotherapy or on the main tumors have not been reported, implications have been made 
about the additional beneficial effects of DR on tumorigenesis and cancer treatment20. In 
our data, on a transcriptional level the changes induced by fasting in healthy liver tissue 
were not present in tumor tissue. The transcriptomic profiles of the tumor tissue were very 
heterogeneous, and therefore our analyses could not detect specific changes induced by 
fasting in tumor tissue treated with irinotecan. These data support the differential stress 
sensitization theory, which states that beneficial alterations in normal cells due to nutrient 
deprivation protects them against chemotherapy induced toxicity whilst these changes do 
not occur in cancer cells42. 
The search for a clinically applicable dietary intervention 
The misbalance of increasing body of evidence showing the benefits of both long-term and 
short-term DR in various animal models, including non-human primates, and only few 
clinical studies concerning DR is indicative for the problems associated with translation 
of DR to a clinical setting43,44. Multiple reasons for the absence of clinical implementation 
have been given over time45. Foremost, the metabolic rate of mice is a multitude of that of 
humans which suggests prolonged periods of DR in humans. The difficulty for humans 
to comply to such periods of DR is intense, even though a small group of long-term DR-
believers has been able to restrict themselves of 30% calories for many years now and do 
show signs of improved metabolic profile. Moreover, the generally held belief that the 
advantages of normal to high food intake prior to surgery is in conflict with the principle 
of preoperative nutrient restriction45. Therefore, obtaining more evidence of the safety, 
feasibility and effects of a dietary intervention in a clinical setting was warranted to change 
the current preoperative nutritional care in patients. 
To start with, a model that is opposite to nutrient deprivation might be of additional value 
in order to fully understand the effects of DR and the way it affects surgical outcome. 
Therefore, in chapter 6, the link between inflammation, aging and surgery was investigated 
by examining markers of aging and the immune system in patients with morbid obesity 
undergoing bariatric surgery. Morbid obesity is known to negatively affect mortality and 
increases the risk of age-associated diseases, including diabetes mellitus, cardiovascular 
disease and cancer46. This link is thought to be caused by the chronic subclinical 
inflammatory state as seen in morbidly obese patients, which is caused by an over activation 
of the immune system as induced by white adipose tissue47. This inflammation has a direct 
effect on the immune system and is thought to cause premature aging of the immune 
system, a phenomenon called ‘inflammaging’48. This is possibly even worse in patients who 
are metabolically compromised by the presence of the metabolic syndrome, which might be 
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partially reversed by bariatric surgery. We showed that obesity itself did not affect relative 
telomere length (RTL), however the presence of metabolic syndrome significantly decreased 
the RTL of CD4+ T-cells. This shortening of RTL was accompanied by an increase of fully 
maturated T cells, indicating that the complete T-cell compartment is affected by obesity. 
Bariatric surgery, which is de definitive solution for morbid obesity once all other options 
have failed, could partially forestall this effect49. At three and six months after surgery, the 
significant decrease of RTL seen prior to surgery was no longer present, indicating that 
the shortening was halted. However, RTL at 12 months postoperatively was similar to the 
length prior to surgery, suggesting bariatric surgery affects RTL only in the first phase after 
surgery. These data show that metabolically compromised morbidly obese patients show 
signs of accelerated immune aging, which gives important insight into the increased risk of 
morbidity and mortality of these patients. Therefore, the metabolic syndrome predisposes 
to accelerated T-cell aging and is temporarily reversed by obesity-reducing surgery. 
As it comes to DR, previously colleagues showed the feasibility and safety of a preoperative 
DR regimen in a clinical setting. A preoperative diet including three days of 30% DR 
followed by 24 hours of fasting was well adhered to by living kidney donors, and no 
preoperative, perioperative or postoperative complications due to the diet were seen50. 
However, the diet only induced marginal effects on postoperative outcome51.  In chapter 2 
we used an optimal model to study human aging and obesity and demonstrated that DR is 
applicable independent of age and body weight, although aging did result in a dampening of 
the transcriptomic response. In addition, we showed that both male and female genders are 
protected against IRI by DR. Chapter 4 pointed us towards the additional effects of protein 
restriction on IRI. With our extended knowledge of protein restriction and handling of such 
a diet by patients, in chapter 7 we developed a combined calorie and protein restricted diet 
to further investigate in a clinical setting. We showed the safety, feasibility and adherence 
to the diet in two surgical patient populations, namely living kidney donors and morbidly 
obese patients. A total of 71% of the donors and bariatric surgery patients complied to the 
restricted diet, which induced minor discomfort in about two-third of the patients. All 
discomforts, mainly gastro-intestinal changes, scored low on the visual analogue scale and 
quickly resolved after normal eating pattern was resumed. The patients that did withdraw 
early from the diet, reported discomfort as the main reason. Especially the morbidly obese 
patients awaiting bariatric surgery suffered from discomfort, possibly due to the increased 
prevalence of functional gastrointestinal disorders in obese patients52. Adherence to the 
diet could be objectively measured via metabolic parameters prealbumin (PAB) and retinol 
binding protein (RBP). Serum levels of both markers significantly decreased due to the 
restricted diet compared to the placebo diet and control group.  Branched chain amino acids 
leucine and valine were both significantly decreased in the diet group, while no changes 
occurred in the placebo or control group. One patient in the control group showed no 
15045-jongbloed-layout.indd   249 06/11/2017   17:20
250
CHAPTER 9
reduction in any of these markers, and the compliance of this participant could therefore be 
questioned. Also, the restricted diet induced a significant body weight loss compared to the 
control groups, what could be seen as another marker for adherence to the diet. No increase 
in complications or length of hospital stay occurred in the restricted diet group, indicating 
the safety of the diet. To conclude, in chapter 8 we were able to show the beneficial effects 
of a mild adaptation of this diet in living kidney donors. The diet included more protein-
free snacks that patients could choose from, which might be the reason for the increased 
in compliance rate. The combined calorie and protein restricted (CCPR) diet induced 
vast improvement of kidney function in the living kidney donors, as shown by improved 
clearance of serum creatinine, estimated glomerular filtration rate (eGFR) and serum 
levels of urea in the first postoperative period. In addition, kidney transplant recipients 
of donors whom had received the diet showed an even more remarkable improvement of 
their graft function and outcome, with an average decrease in serum creatinine levels of 
70% in the CCPR group compared to 40% in the control group. This improvement was 
accompanied by a significant lower incidence of acute rejection and slow graft function in 
the first postoperative period. Transcriptome profiles of kidneys subjected to the calorie 
and protein-restricted diet showed more heterogeneity compared to the profiles obtained in 
mice. Even so, the analysis of the human biopsies marked activation of the NRF2-mediated 
stress response and inhibition of various cytokine signaling pathways, indicative of a 
reduction of cellular stress and DNA damage, and therefore revealed a high overlap with 
our data obtained in mice24. Especially the activation of the NRF2-mediated stress response 
indicated the important role of this transcription factor. Furthermore, EIF2 signaling was 
significantly upregulated as well, which is a pathway strongly regulated by fasting in the 
irinotecan-subjected mice as well35. These data provide the effectiveness of a diet to activate 
the stress response in order to increase stress resistance against surgery-related injury. 
Overlaying our data with previously performed transcriptome analyses in human kidney 
biopsies found various genes of interest to the beneficial effect against kidney-related 
injury, including ASB15, EGR2 and AXNA53,54. However, no other studies investigated gene 
expression changes in kidney biopsies subjected to DR up-to-date and an exact comparison 
of studies could therefore not be made. A recent pilot study did show signs of reduced 
hematological toxicity and improved DNA damage recovery in breast cancer patients 
whom were fasted 24 hours before undergoing chemotherapy55. Our study also successfully 
translated DR in a clinical setting, and provided the evidence that short-term DR is able to 
increase stress resistance in humans. Therefore, it paves the way for future implementation 
of DR in elective surgery patients and perhaps in cancer patients undergoing chemotherapy 
as well.
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FUTURE PERSPECTIVES 
The cornerstone of the studies described in this thesis is the effects of dietary restriction 
(DR) on acute stress-related injury. We demonstrated the beneficial effects of three days 
of fasting, a 3-day protein-free diet as well as a 3-day essential amino acid-free diet on 
renal and hepatic ischemia-reperfusion injury (IRI) as well as on chemotherapy induced 
toxicity, and linked the phenotypical protective response to a differentiated network of 
pathways and transcription factors on a transcriptional level. We successfully translated the 
preclinical data to a safe, feasible and effective diet in living kidney donors and their kidney 
transplant recipients, and showed that it improves graft outcome and function. These data 
show a unique comprehensive picture of the effects of nutritional preconditioning from a 
phenotypical, transcriptional and clinical point of view, and has brought us a step further to 
develop the optimal preoperative DR strategy in an elective clinical setting. 
We showed that the beneficial effects of three days of fasting on IRI can be reproduced in 
an animal model that represents human aging and obesity. The effects of DR were more 
pronounced in young-lean mice and female mice were able to resist longer periods of renal 
IRI, indicating that the intensity of stress resistance is dependent on factors as age, body 
weight and gender. Future studies including a large cohort of female and male mice of 
different ages and body weights, could point us further towards understand the extent of 
which these factors play a role in the protection. As a result, factors including age, body 
weight and gender should be held into account when applying DR in the clinic, and future 
studies should include a sufficient number of patients to correct for and investigate the 
exact role of these factors.
As described, the protective effects of a short-term fasting regimen could also be applied 
to reduce the adverse effects of chemotherapy56. Since fasting did not affect the antitumor 
efficacy of chemotherapy treatment, the concept of differential stress sensitization (DSS) 
was confirmed in our studies42. Huisman et al. proposed the role of phase II proteins in the 
increased stress resistance in normal cells, including NRF2 and upregulation of xenobiotic 
metabolism41. We could partially verify this hypothesis with the activation of the NRF2 
stress response in healthy liver cells, whereas the transcriptional changes as seen in the liver 
did not occur in tumor tissue. The role of NRF2 as sole contributor to the beneficial effects 
of fasting on stress resistance has not yet been demonstrated26. Extending the experimental 
setup to different chemotherapeutics, larger groups and various time points of analysis 
could further elucidate the mechanisms responsible for this DSS. As a consequence, higher 
dosages of chemotherapeutics might be applied in the near future, thereby increasing the 
chance of an effective treatment for cancer and survival benefits in cancer patients. 
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We are the first to show the beneficial effect of protein deprivation for only three days and 
this diet could be further narrowed down by showing the beneficial effects of individual 
essential amino acid deprivation on hepatic IRI, suggesting an essential role of amino acid 
sensing in the increased stress resistance. As a final step, transcriptome analyses of all these 
diets enabled us to study their induced changes on mRNA level. However, these data did not 
reveal one mechanism in particular but instead a network of multiple pathways activated by 
a number of transcription factors, evoking the protective response of short-term nutrient 
deprivation. In all studies, we could disentangle a similar pattern of pathway regulation. 
Future studies focusing on overexpression and knock-down of transcription factors such 
as FOXO3, should further elucidate the role of these transcription factors and the pathways 
they activated in the protection of DR. 
We examined the effects of morbid obesity on aging of the immune system, in particular 
the T-cell immune system. Our data suggest that that morbid obesity in combination 
with the presence of metabolic syndrome indeed leads to premature aging of the immune 
system as determined by attrition of telomere length and an increase in T-cell maturation 
in peripheral white blood cells. These changes could be forestalled by applying obesity-
reducing bariatric surgery, and were already present in the first three to six months following 
surgery. This pilot study indicates that morbid obesity is a risk factor for premature aging 
of the immune system, and that bariatric surgery is a valuable treatment to counteract 
this effect. Studying the effects of morbid obesity, the metabolic syndrome and bariatric 
surgery in a larger cohort and on a molecular level in tissue collected during surgery, could 
increase our understanding of the effects of obesity and inflammation on aging as well as 
on stress resistance during a situation of food deprivation, either via DR or via surgery. In 
addition, extending the follow-up period after bariatric surgery could give insight whether 
the decrease in telomere length at 12 months postoperatively is an indication of the short-
term effect of bariatric surgery on immunological aging or the effect of the small sample 
size and therefore not representative. 
We showed the safety, feasibility and objective adherence to the diet in two surgical patient 
populations, namely living kidney donors and bariatric surgery patients. We were able to 
show the beneficial effects of a mild adaptation of this diet in living kidney donors, and 
showed vast improvement of kidney function in both donors and recipients. Transcriptome 
profiles of human kidney biopsies revealed high overlap with our preclinical data, and 
highlighted the importance of gender on the effects on stress resistance. Future studies are 
needed in order to validate these results, and these studies should focus on larger cohorts, 
different patient populations as well as other DR regimens. 
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In overall conclusion, in this thesis we provide new evidence that various short-term dietary 
restriction interventions are able to induce beneficial effects on acute-stress related injury 
in various mouse models, human living kidney donors and their transplant recipients, and 
substantiated these results with promising new insights into the molecular mechanisms 
using gene expression analyses. We are only a few steps away from the successful application 
of nutritional precondition in elective surgery. Future studies should finalize these steps 
by validating the clinical results in larger and different patient cohorts as well as provide 
posttranscriptional mechanisms underlying dietary restriction. These data should bring us 
to the optimal preoperative nutritional regimen, either via dietary restriction or a dietary 
restriction mimetic, to implement in standard care for elective surgery patients.
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Een toename in oxidatieve stress en inflammatie heeft een nadelig effect op de kwaliteit 
en kwantiteit van leven en leidt zowel tot versnelde ontwikkeling van ouderdomsziekten 
als tot een afname van de levensduur. Een acute toename in oxidatieve stress, de acute 
stressrespons, resulteert in een slechtere uitkomst van orgaantransplantaties vanwege het 
optreden van ischemie-reperfusie schade (IRS). Dit leidt tot een beperkte hoeveelheid 
mogelijkheden voor orgaantransplantatie bij patiënten met eindstadium nierfalen. Een 
stressrespons gerelateerd aan een operatie kan eveneens de uitkomst van de operatie 
beïnvloeden bij patiënten die electieve chirurgie ondergaan, in het bijzonder wanneer 
bijkomende aandoeningen zoals morbide obesitas aanwezig zijn. Dieetrestrictie (DR) heeft 
een bewezen positief effect op de levensduur en op het verminderen van ouderdomsziekten 
alsmede een verbeterde uitkomst van IRS in verscheidene gezonde diermodellen. Vele 
aspecten van DR zijn nog steeds onbekend, zoals welke componenten van de calorie 
verantwoordelijk zijn voor de effecten van DR, welke mechanismen ten grondslag liggen 
aan DR en de toepasbaarheid van DR in meerdere diermodellen van acute stress. Daarbij 
is de translatie van DR naar de klinische setting moeilijk gebleken en blijft het bewijs over 
de effecten van DR in patiënten vooralsnog beperkt. Om deze redenen is er een dringende 
behoefte voor het verbreden van de kennis over de etiologie en klinische toepasbaarheid 
van DR om de effecten van DR op chirurgische- en ziekte-gerelateerde stress alsmede de 
postoperatieve uitkomst te optimaliseren. 
De doelen van dit proefschrift waren: het vaststellen van de effecten van de huidige regimes 
kortdurende diëten in verschillende muismodellen, het onderzoeken van de effecten van 
macronutriënten en aminozuren op de effecten van DR, om de kennis te verbreden over 
de moleculaire mechanismen die ten grondslag liggen aan DR en om een veilig en effectief 
dieet te ontwikkelen om toe te passen in een klinische, chirurgische setting. 
Modellen en mechanismen van nutritionele preconditionering
In hoofdstuk 2 hebben we de eerdere resultaten van DR op IRS toegepast op een ander 
muismodel om zo de effecten van DR in een wijder perspectief te plaatsen. Eerder hebben 
we aangetoond dat 2 weken 30% DR en 3 dagen vasten zorgen voor een significante 
verbetering van zowel overleving als nierfunctie in C57BL/6 mannetjes muizen die totaal 
37 minuten IRS hebben ondergaan in tegenstelling tot muizen die onbeperkt, ad libitum, 
toegang hadden tot voedsel. In dit hoofdstuk laten we zien dat deze positieve effecten ook 
geïnduceerd konden worden in een muismodel met een andere genetische herkomst, 
van oudere leeftijd, met overgewicht en in zowel het mannelijke als vrouwelijke geslacht. 
Mannetjes en vrouwtjes F1-FVB/C57BL6-hybride muizen die 3 dagen hadden gevast, 
lieten een verbetering van overleving zien na het toepassen van IRS waarbij de vrouwtjes 
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muizen tevens in staat waren langere IRS-tijden te weerstaan dan mannetjes. Analyse van 
de nierfunctie na inductie van IRS liet zien dat vasten zorgde voor significant lagere serum 
ureum waarden, vermindering van acute tubulaire necrose en meer tubulair herstel. We 
concludeerden dat een hogere leeftijd en de aanwezigheid van obesitas niet zorgden voor 
afname van de robuuste effecten van vasten op de uitkomst na IRS in de nier en dat het 
vrouwelijke geslacht in staat is langere IRS-tijden te kunnen weerstaan. 
Vervolgens hebben we deze fenotypische resultaten geanalyseerd op transcriptieniveau door 
microarray analyse te verrichten op nieren van zowel jonge slanke als oudere mannetjes 
muizen met overgewicht, nadat ze 3 dagen hadden gevast. Een sterk vergelijkbaar patroon 
van clusters en richting van genen was zichtbaar in het nierweefsel van zowel de jonge als 
oudere muizen, alhoewel de genexpressie wel sterker was in de jonge muizen. Dit resultaat 
suggereert dat de transcriptie effecten van DR minder duidelijk aanwezig zijn in oude muizen 
met overgewicht maar uiteindelijk wel voldoende zijn voor het induceren van bescherming. 
Hierdoor werd het mogelijk om de beschermende effecten van DR te onderzoeken door 
naar de overlappende respons tussen beide groepen te kijken. Een pathway-analyse van 
deze overlappende respons liet een anti-inflammatoir patroon zien, waarbij er sprake 
was van activatie van de retinoid X-receptor (RXR), de peroxisome proliferator-activated 
receptor (PPAR) en de nuclear factor erythroid like 2 (Nrf2) pathways. Deze pathways zijn 
allemaal gerelateerd aan de activatie van de acute fase respons via stimulatie van vetzuur 
verbranding, vermindering van de ontstekingsprocessen of via de inductie van bescherming 
door detoxificatie. Met dit hoofdstuk hebben we de inductie van een netwerk van een aantal 
pathways kunnen bevestigen, wat leidt tot een toename van weerstand tegen oxidatieve 
stress in zowel jonge slanke als oudere muizen met overgewicht. 
In hoofdstuk 3 hebben we de zoektocht naar de effecten van vasten voortgezet door 
vasten toe te passen in een ander diermodel en daarbij de mechanismen van vasten op 
transcriptieniveau verder uit te zoeken. We hebben nogmaals 3 dagen vasten uitgevoerd 
maar dit keer in BALB/c muizen die subcutaan werden geïnjecteerd met C26 colorectale 
carcinoomcellen. Twaalf dagen na tumor injectie werden de muizen verdeeld in een groep 
die 3 dagen ging vasten en een groep die ad libitum toegang had tot eten. De muizen in 
beide groepen werden vervolgens weer onderverdeeld in een groep die een hoge dosis van 
het chemotherapeuticum irinotecan kreeg of een placebo injectie. De effecten van vasten op 
irinotecan werden onderzocht in zowel het bloed, lever- als tumorweefsel dat was verzameld 
op het moment van opoffering van de muizen, namelijk op tijdstip 12 uur na de injectie. 
Analyse van de lever- en nierfunctie in de controle muizen liet duidelijke lever- en nierschade 
zien samen met beenmergdepressie als gevolg van de gift irinotecan, terwijl de gevaste 
muizen significante vermindering van deze schade liet zien en geen beenmergdepressie 
optrad. In gezond leverweefsel werd vervolgens een transcriptoom analyse verricht na 
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dieetinterventie en chemotherapie behandeling. Hierbij werd zichtbaar dat 3 dagen vasten 
zorgde voor zowel een verminderd aantal genexpressie veranderingen door irinotecan 
als een gelijkmatiger genexpressie profiel. Deze data suggereren dat vasten leidt tot een 
verminderde respons zoals veroorzaakt door irinotecan, daarbij het gezonde leverweefsel 
deels beschermend tegen de toxische respons geïnduceerd door het chemotherapeuticum. 
Deze hypothese werd verder bevestigd door de dysregulatie van de genotoxische respons 
van irinotecan door vasten in vergelijking met de controlegroep. Met name de expressie 
van meerdere DNA-schade pathways, zoals de RhoA en MAPK signaling, was geremd 
door vasten. Zowel RhoA als MAPK zijn gelinkt aan ziektewinst bij kanker in de literatuur 
en meerdere klinische studies worden momenteel verricht betreffende MAPK-remmers 
als behandeling tegen kanker. Ook pathways die geassocieerd zijn met stress resistentie 
waren aangedaan door vasten, zoals remming van de mTOR pathway via demping van de 
p7056 pathways en de activatie van de NRF2-gemedieerde stress respons. Naar aanleiding 
van deze data stelden we de hypothese dat de bijwerkingen van chemotherapie kunnen 
worden geremd door vasten in gezond leverweefsel via inbreuk doen op de regulatie van 
de celcyclus en de remming van DNA-schade alsmede de activatie van anti-inflammatoire 
en stressrespons pathways in gezonde cellen om zo de weerstand tegen stress te verhogen. 
Eerdere resultaten hebben laten zien dat vasten geen verandering geeft op het anti-tumor 
effect van irinotecan, en deze resultaten konden worden gevalideerd in onze transcriptoom 
analyse. Tumorweefsel liet namelijk grote heterogeniteit tussen weefsels zien en daardoor 
kon geen duidelijk patroon worden gezien zoals geïnduceerd door vasten. Daarom waren 
de veranderingen geïnduceerd door vasten zoals in gezond leverweefsel niet zichtbaar in 
tumorweefsel. Deze data ondersteunen de differentiële stress sensitisatie theorie, welke 
inhoudt dat veranderingen in normale cellen als gevolg van vermindering van voeding 
zorgen voor bescherming tegen chemotherapie-gerelateerde toxiciteit terwijl deze 
veranderingen niet zichtbaar zijn in kankercellen. 
In hoofdstuk 4 hebben we vervolgens de rol van macronutriënten onderzocht in de effecten 
van DR, waarbij we gebruikt hebben gemaakt van nier IRS als model voor schade als gevolg 
van acute stress. Het eerste bewijs van de rol van eiwitrestrictie werd gezien in fruitvliegen, 
waarbij eiwitrestrictie op lange termijn zorgde voor een verlenging van de levensduur. Wij 
gaven mannetjes C57BL/6 muizen een van de volgende diëten: 3 of 10 dagen eiwitvrij, 
3 of 14 dagen koolhydraatvrij en 3 of 14 dagen vetvrij. De diëten werden gevolgd door 
inductie van IRS van de nier. Zowel mortaliteit als nierfunctie verslechterden door een 
koolhydraatvrij en een vetvrij dieet, terwijl een 10-daags eiwitvrij dieet een verbetering van 
overleving en nierfunctie liet zien na IRS. Wel gaf eiwitrestrictie tevens een restrictie van 
calorieën van ongeveer 30%, waardoor de effecten van calorische en eiwitrestrictie niet van 
elkaar konden worden onderscheiden. Een eiwitvrij dieet gedurende 3 dagen zorgde tevens 
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voor bescherming tegen IRS, vergelijkbaar met 2 weken 30% DR, terwijl 3 dagen 30% DR 
geen bescherming bood. Hierdoor konden we alsnog bescherming tegen IRS toeschrijven 
aan de eiwitrestrictie. Vervolgens hebben we de eerdere mRNA genexpressie datasets 
uitgebreid met array data na een 3 dagen eiwitvrij, koolhydraatvrij en vetvrij dieet. Door het 
excluderen van alle genen die tevens gereguleerd werden door de niet-beschermende diëten 
(koolhydraatvrij, vetvrij en 3 dagen 30% DR), kwamen slechts marginale veranderingen in 
genregulatie naar voren die niet verder konden leiden naar inzicht in het beschermende 
mechanisme van DR. We stelden de hypothese op dat de genexpressie profielen van de 
niet-beschermende diëten deels zouden overlappen met die van de beschermende diëten 
en dat de bescherming werd geïnduceerd door additionele veranderingen dan wel sterkere 
regulatie van pathways. Met deze hypothese hebben we een meta-analyse uitgevoerd met 
alle diëten, waarna een pathway en upstream transcriptiefactor analyse volgden. Hieruit 
kwam naar voren dat bij het beschermende effect pathways betrokken zijn die invloed 
hebben op nucleaire receptoren, stressrespons, stress-gerelateerde schade en biosynthese. 
Ook kwam de NRF2-gemedieerde stressrespons pathway naar voren, een pathway die 
tevens naar voren kwam in onze vorige studies.  Deze pathways werden gereguleerd door 
activatie van verscheidene transcriptiefactoren, de belangrijkste daarbij FOXO3, HMGA1 
en HNF4A, waarbij een gedetailleerde meta-analyse liet zien dat deze transcriptie factoren 
niet of minimaal werden gereguleerd in het niet-beschermende koolhydraatvrije dieet. 
FOXO3 speelt een belangrijke rol in meerdere processen waaronder die van weerstand 
tegen cellulaire stress en die van celcyclus regulatie. Deze beider processen zijn eerder 
beschreven als belangrijke pionnen in het induceren van de beschermende effecten van 
DR op IRS. HMGA1 is een van de factoren betrokken bij de insuline receptor pathway die 
is aangedaan door DR. Daarbij kan HMGA1 ook de binding van FOXO’s aan nucleaire 
receptoren bevorderen, waarbij de nucleaire signalering wordt geactiveerd. Activatie van 
HNF4A leidt tot remming van metabole sensoren, met name die van de mTOR pathway. 
Zoals eerder beschreven is remming van mTOR gerelateerd aan verlenging van levensduur 
en toename van weerstand tegen stress. Via Western blot analyse hebben we deze remming 
van mTOR gevalideerd. Samenvattend hebben we met deze analyse de betrokkenheid van 
verscheidene bekende en eerdergenoemde pathways betrokken bij de bescherming van DR 
tegen IRS kunnen valideren en zijn nieuwe transcriptiefactoren aan het licht gekomen die 
waarschijnlijk aan de basis staan van de regulatie van deze pathways. Desalniettemin zijn 
meer studies in verschillende diermodellen van DR en stress tezamen met het uitbreiden 
van de genexpressie analyses nodig zijn om het optimale dieet te vinden wat uiteindelijk 
ook toepasbaar is in mensen. 
Om die reden hebben we in hoofdstuk 5 de rol van eiwitrestrictie en de effecten op 
transcriptieniveau verder onder de loep genomen in een ander IRS-model. We hebben 
muizen een dieet van 3 dagen gegeven waarbij een van de volgende essentiële aminozuren 
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ontbrak: methionine, leucine of tryptofaan. Vervolgens hebben deze muizen IRS van de 
lever ondergaan via afklemmen van een groot deel van de bloedtoevoer van en naar de 
lever gedurende 75 minuten. Het meten van de voedselinname, gewichtsveranderingen, 
markers voor leverschade en genexpressie analyses werden verricht en vergeleken met een 
controlegroep zonder dieet. Alhoewel alle diëten zorgden voor 30% reductie in calorie 
inname, waren markers voor leverschade significant verlaagd in alle dieetgroepen. Deze 
effecten waren al na 6 uur na IRS zichtbaar in de leucine- en tryptofaangroepen, en na 24 
uur in alle dieetgroepen. Op transcriptieniveau lieten de leucine- en tryptofaangroepen een 
hoge mate van overlap zien wat betreft genvariatie, pathway en transcriptiefactor analyse. 
Deze respons was minder sterk in de methionine groep. Desalniettemin was een duidelijk 
vergelijkbaar patroon van genexpressie en –richting zichtbaar tussen alle dieetgroepen. 
Pathway en upstream transcriptiefactor analyses van de overlappende genen wezen weer 
richting de rol van nucleaire receptoren en pathways betrokken bij weerstand tegen 
cellulaire stress, waarbij er grote gelijkenis te zien was tussen de nier en lever modellen 
van IRS. NRF2 en mTOR waren bekende factoren die tevens gereguleerd waren in de lever 
en versterkten zo hun belangrijke rol die zij spelen in de beschermende effecten van DR 
op IRS in beide diermodellen. Ook FOXO was geactiveerd, echter was dit niet significant 
in alle dieetgroepen. Een model voor bescherming op transcriptieniveau werd ontworpen 
dat was gebaseerd op de gezamenlijke resultaten in de nier en lever. Dit model beschrijft 
de effecten van DR die geïnduceerd zijn via regulatie van nucleaire receptoren, pathways 
betrokken bij weerstand tegen acute stress en de remming van cellulaire proliferatie. Aan de 
basis van het beschermende effect staat daarbij de nucleaire receptor signalering die zorgt 
voor activatie van retinoïde zuren, FOXO en remming van steroïden wat leidt tot toename 
van de stressresistentie en bescherming tegen verscheidene vormen van ischemie. Andere 
stressresistentie pathway waren tevens sterk geactiveerd door de aminozuurvrije diëten, 
waaronder de eerdergenoemde NRF2 pathway alsook de EIF2α signalering via Gcn2. De 
activatie van de EIF2α pathway via Gcn2 zorgt voor regulatie van genen die betrokken zijn 
bij de activatie van antioxidanten, de afname van inflammatie en bij cellulaire overleving. 
Eerder werd gedacht dat Gcn2 essentieel was voor de inductie van stressresistentie in 
muizen, echter werd dit in een recentere studie weer ontkracht. Als laatste speelt remming 
van cellulaire proliferatie door DR een belangrijke rol, waarbij deze remming werd 
bewerkstelligd door remming van transcriptiefactoren FOXM1 en SMARCB1. Hierdoor 
werd een adaptieve respons geïnduceerd die zorgt voor de verschuiving van celgroei naar 
onderhoud. 
We concluderen dat het weglaten van een essentieel aminozuur voor 3 dagen dezelfde 
bescherming biedt tegen lever IRS als een eiwitvrij dieet. Deze data worden ondersteund 
door een model waarin de bescherming wordt geïnduceerd door activatie van nucleaire 
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receptoren, stressresistentie pathways alsmede de verschuiving van celgroei naar onderhoud 
en wordt gemedieerd door transcriptiefactoren die essentieel blijken voor het ontstaan van 
bescherming. 
De connectie tussen inflammatie, veroudering en chirurgie
Om de effecten van DR op chirurgie en het postoperatieve herstel in zijn volledigheid te 
kunnen begrijpen, is een model dat lijnrecht tegenover DR staat daarbij van toegevoegde 
waarde. Daarom hebben we in hoofdstuk 6 de connectie tussen inflammatie, veroudering en 
chirurgie onderzocht door te kijken naar markers van veroudering en het immuunsysteem 
in patiënten met morbide obesitas die bariatrische chirurgie ondergaan. De aanwezigheid 
van morbide obesitas heeft een negatief effect op zowel mortaliteit als morbiditeit, waarbij 
het met name gaat om het risico op het ontstaan van ouderdomsziekten zoals diabetes 
mellitus, hart- en vaatziekten en kanker. De veronderstelling bestaat dat deze connectie 
wordt veroorzaakt door het ontstaan van chronische en subklinische inflammatie in 
patiënten met morbide obesitas. Deze inflammatie wordt veroorzaakt door een overactiviteit 
van het immuunsysteem geïnduceerd door wit vetweefsel en heeft een direct effect op het 
immuunsysteem. Deze overactiviteit zou de oorzaak zijn van de versnelde veroudering van 
het immuunsysteem en is in ergere mate aanwezig bij mensen die het metabool syndroom 
hebben. Bariatrische chirurgie zou een rol kunnen spelen in het tegenhouden van deze 
versnelde veroudering. Twee maten voor veroudering zijn telomeerlengte enerzijds en de 
T-cel differentiatiestatus anderzijds, wat de rijping van het T-cel immuunsysteem vaststelt. 
Om uiteindelijk de effecten van morbide obesitas, het metabool syndroom en bariatrische 
chirurgie op de versnelde veroudering van het immuunsysteem te onderzoeken, hebben 
we telomeerlengte en de T-cel differentiatiestatus gemeten in patiënten met morbide 
obesitas die wel of niet het metabool syndroom hadden. Deze metingen zijn gedaan in 
bloedmonsters die zowel voor als op meerdere tijdstippen na bariatrische chirurgie zijn 
afgenomen. Zowel relatieve telomeerlengte (RTL) als meerdere markers voor de T-cel 
differentiatiestatus zijn bepaald. Deze bepalingen lieten zien dat alleen morbide obesitas 
de RTL niet aantast, maar dat de aanwezigheid van het metabool syndroom wel de RTL 
in CD4+ T-cellen significant verkort. Deze verkorting ging gepaard met een toename van 
volledig gerijpte T-cellen, waarbij duidelijk werd dat het gehele T-cel compartiment was 
aangedaan door obesitas en het metabool syndroom. Bariatrische chirurgie, de definitieve 
oplossing voor morbide obesitas op het moment dat alle andere opties hebben gefaald, 
zorgde voor het deels terugdringen van dit effect. Op 3 en 6 maanden na chirurgie was de 
significante verkorting van RTL, zoals zichtbaar was voor chirurgie, niet meer aanwezig 
als teken van het tot staan brengen van de verkorting. Echter was de RTL na 12 maanden 
wel weer gelijk aan de lengte zoals gemeten vóór chirurgie, wat suggereert dat bariatrische 
chirurgie de RTL alleen in de eerste fase beïnvloedt.  De veroudering van het T-cel systeem 
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zoals zichtbaar vóór chirurgie, was in een minder sterke mate aanwezig na chirurgie. Deze 
data laten zien dat patiënten met morbide obesitas en het metabool syndroom tekenen van 
versnelde veroudering laten zien. Dit geeft een belangrijk inzicht in de mogelijke redenen 
voor het toegenomen risico op mortaliteit en morbiditeit in deze patiënten. Het feit dat 
deze negatieve effecten deels kunnen worden tegengegaan door chirurgie is een indicatie 
dat bariatrische chirurgie bevorderlijk kan zijn voor zowel gezondheid als levensduur. Om 
deze reden zou de versnelde veroudering bij mensen met morbide obesitas en het metabool 
syndroom een criterium kunnen zijn om bariatrische chirurgie toe te passen, naast het al 
bekende criterium van gewichtsreductie. De criteria voor het ondergaan van bariatrische 
chirurgie zouden daarom onder de loep moeten worden genomen om de behandeling voor 
morbide obesitas in de toekomst te kunnen optimaliseren. 
Klinische toepasbaarheid van nutritionele preconditionering
De eerste klinische vertaling van alle diëten zoals verricht in de diermodellen is verricht in 
hoofdstuk 7. In dit hoofdstuk hebben we de haalbaarheid en veiligheid van een calorie- en 
eiwitbeperkt dieet onderzocht in mensen. Daarvoor hebben we zowel levende nierdonoren 
als bariatrische chirurgie patiënten gerandomiseerd in één van de volgende 3 groepen: 
de eerste groep kreeg een experimenteel, synthetisch vloeibaar dieet met 30% calorische 
restrictie en 80% eiwitrestrictie voor 5 dagen; de tweede groep kreeg een placebo synthetisch 
vloeibaar dieet voor 5 dagen wat isocalorisch was aan hun dagelijkse energiebehoefte; 
de derde groep was de controlegroep en deze mensen kregen geen restricties wat betreft 
voedsel inname. De haalbaarheid en veiligheid van de diëten werden bepaald aan de hand 
van gerapporteerde ongemakken, gewichtsveranderingen en metabole parameters zoals 
gemeten in bloedmonsters voor en na alle dieetinterventies. Totaal had 71% van de donoren 
en bariatrische chirurgie patiënten zich aan het restrictie-dieet gehouden, waarbij het dieet 
in 2/3 van de gevallen voor lichte ongemakken zorgde. Deze ongemakken, voornamelijk 
gastro-intestinaal van aard, werden laag gescoord en verdwenen snel op het moment van 
hervatten van het normale eetpatroon. Het merendeel van de patiënten dat het dieet echter 
niet had volgehouden, gaf wel aan dat de ongemakken hiervan de reden waren. Met name 
de bariatrische chirurgie patiënten gaven deze ongemakken vaker aan, mogelijk vanwege de 
connectie tussen obesitas en functionele gastro-intestinale klachten. 
De haalbaarheid van het dieet kon objectief worden gemeten via de metabole parameters 
prealbumine (PAB) en retinol binding protein (RBP): serumwaarden van beide parameters 
waren significant verlaagd na het volgen van het restrictieve dieet in tegenstelling tot de 
groepen met het placebodieet en geen dieet. De vertakte keten aminozuren leucine en 
valine waren ook beide significant verlaagd in de dieetgroep in tegenstelling tot de placebo- 
en controlegroep. De dieetgroep liet geen hoger percentage complicaties of een langere 
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opnameduur zien, als indicatie van de veiligheid van het dieet. Deze eerste klinische studie 
laat zien dat een gecombineerd calorie- en eiwitbeperkt (GCEB) dieet haalbaar en veilig 
is in een klinische setting en dat de haalbaarheid objectief gemeten kan worden aan de 
hand van een combinatie van parameters. Kleine aanpassingen aan het dieet zouden de 
gastro-intestinale ongemakken kunnen verminderen waardoor de haalbaarheid van een 
dergelijk dieet verbeterd kan worden. Deze aanpassingen zou gedaan kunnen worden door 
bijvoorbeeld meer eiwitvrije snacks aan het dieet toe te voegen naar wens van de patiënt. 
Tevens kan het toevoegen van vast voedsel ook de haalbaarheid verhogen, de ongemakken 
verminderen en kan het dieet zo verder worden geoptimaliseerd om nutritionele 
preconditionering in een klinische setting te onderzoeken. 
Tenslotte hebben we in hoofdstuk 8 de perioperatieve en postoperatieve effecten van 
een GCEB-dieet onderzocht in levende nierdonoren en hun transplantaat ontvangers. 
Dit GCEB-dieet was een kleine aanpassing ten opzichte van het eerdergenoemde dieet 
en gaf de mogelijkheid voor meer variatie in eiwitvrije snacks. In totaal werden 35 
donoren gerandomiseerd in ofwel de GCEB-groep (n=15) ofwel de controlegroep zonder 
voedingsrestricties (n=20). Het dieet werd gedurende de 5 dagen voor de operatie aan de 
donoren gegeven. Alle donoren hadden zich aan het dieet gehouden en lieten geen ernstige 
bijwerkingen zien. De primaire eindkomstmaat van deze studie was de postoperatieve 
nierfunctie van de donoren. Deze nierfunctie was significant beter in de GCEB-dieet groep 
vanaf dag 2 tot aan maand 1 postoperatief en werd gezien als verbeterende klaring van het 
serum creatinine, de filtratiesnelheid en serumwaarden van ureum. De levende nierdonoren 
in beide groepen lieten geen verschil zien tussen de opnameduur of de postoperatieve 
complicaties. De nierontvangers van de donoren die het GCEB-dieet hadden gevolgd lieten 
tevens een significante verbetering van de nierfunctie zien, waarbij de gemiddelde daling 
van het serum creatinine 70% bedroeg in de GCEB-groep in vergelijking met 40% in de 
controlegroep. Deze verbetering van nierfunctie ging gepaard met een significant lagere 
incidentie van acute afstoting, zichtbaar in nierbiopten die op indicatie waren afgenomen, 
en een significant lagere incidentie van een vertraagde functie van het transplantaat in 
de eerste postoperatieve periode. Vervolgens werden de transcriptoom profielen tussen 
beide dieetgroepen vergeleken in nierbiopten die direct na preservatie en voor implantatie 
van de nier in de ontvanger waren afgenomen. Deze vergelijking liet de grootste variatie 
van de genexpressie zien als gevolg van het geslacht van de donor. Door de verdeling van 
geslacht te maken, bleek de groep van mannelijke donoren in de GCEB-groep te klein om 
verdere analyse te verrichten. De analyse werd alleen verricht in de vrouwelijke donoren 
en hieruit werd zichtbaar dat het dieet zorgde voor een remming van genexpressie in het 
algemeen. Pathway analyse liet een remming van meerdere immunoregulatoire pathways 
zien, waaronder de Primary Immundeficiency Signaling, en een activatie van verscheidene 
stressrespons pathways zoals de NRF-gemedieerde stressrespons en de EIF2α signaling 
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respons. De resultaten van deze klinische gegevens laten een grote gelijkenis zien met onze 
preklinische data en tonen aan dat de effectiviteit van het GCEB-dieet wordt bewerkstelligd 
via de activatie van de stressrespons om zo meer weerstand tegen chirurgisch geïnduceerde 
stress te geven. Deze klinische data werden vervolgens vergeleken met data van eerdere 
genexpressies verricht in nierbiopten zoals beschreven in de literatuur, en bij deze 
vergelijking kwamen enkele interessante genen naar boven waaronder ASB15. Echter zijn 
er nog geen andere studies verricht waarin is gekeken naar veranderingen in genexpressie 
in nierbiopten na het volgen van een dieet. Samenvattend is deze studie de eerste in zijn 
soort die de positieve effecten van kortdurende DR op de stressresistentie heeft kunnen 
vertalen naar de kliniek en zorgt voor het bewijs dat kortdurende DR inderdaad in staat is 
om stressresistentie te verhogen in mensen. 
Concluderend heeft dit proefschrift het bewijs geleverd dat verscheidene kortdurende 
dieetinterventies kunnen zorgen voor positieve effecten op de acute stressrespons in 
meerdere muismodellen, levende nierdonoren en hun transplantaat ontvangers en 
hebben deze resultaten bijgedragen aan de voortschrijdende inzichten in de moleculaire 
mechanismen achter dieetrestrictie via genexpressie analyses. We zijn nu slechts een aantal 
stappen verwijderd van de succesvolle implementatie van nutritionele preconditionering 
bij electieve chirurgie. Toekomstige studies moeten de genoemde resultaten gaan valideren 
in grotere en andere patiënten cohorten en moeten op post-transcriptioneel niveau de 
mechanismen achter dieetrestrictie verder gaan ontrafelen. Uiteindelijk zullen al deze 
studies leiden tot het optimale preoperatieve dieet, ofwel via dieetrestrictie of wel via een 
dieetvervanger, om te kunnen implementeren in de standaardzorg voor electieve patiënten.
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DANKWOORD
Dit proefschrift in deze hoedanigheid is tot stand gekomen door de bijdrage van vele 
mensen. Voor deze bijdrage wil ik iedereen bedanken; enkelen wil ik graag in het bijzonder 
bedanken. 
Mijn copromotor, dr. R.W.F. de Bruin. Beste Ron, ruim 6 jaar geleden belde je me in de 
avond op om te zeggen dat ik was aangenomen. Zelf had ik nooit bedacht dat ik er nu zo voor 
zou staan, maar uiteraard riep jij het al vanaf jaar 1. Waarschijnlijk had ik wat vaker en wat 
eerder naar je moeten luisteren, maar daarover discussiëren we later nog weleens. Bedankt 
voor het veelvuldig nakijken van mijn ‘poëzie’, en het feit dat het altijd beter kan. Bedankt 
voor je meest waardevolle input en je support op de juiste momenten, je onuitputtelijke 
bron van verhalen en de borrels die het een onvergetelijke tijd op het lab hebben gemaakt. 
Mijn promotor, Prof. dr. J.N.M. IJzermans. Beste prof., vooral het laatste jaar waren onze 
gesprekken veelvuldiger en intensiever. Op de juiste momenten kwam u altijd wel een met 
een kritische noot, waardoor ik zelf weer anders naar de analyses ging kijken. Bedankt voor 
de ruimte om het onderzoek grotendeels mijn eigen draai te geven. Tevens bedankt voor 
het vertrouwen en de aanbevelingen, ook op het moment dat ik de keuze had gemaakt om 
mijn carrière over een hele andere boeg te gaan gooien. 
Mijn andere copromotor, dr. M.E.T. Dollé. Beste Martijn, jij hebt je vanaf dag 1 ingezet om 
mij welkom te laten voelen op het RIVM. Hierdoor werd het RIVM mijn tweede thuis wat 
betreft onderzoek. Bij elke vraag die we niet direct konden beantwoorden, wist jij binnen no-
time de expertise in huis te vinden wat ervoor heeft gezorgd dat we alles uit het onderzoek 
hebben gehaald wat mogelijk is. Jouw oog voor detail is niet te evenaren. Bedankt voor alle 
tijd, (financiële) support en gezelligheid tijdens mijn onderzoektijd. 
Mijn andere promotor, Prof. dr. H. van Steeg. Beste Harry, onze besprekingen waren niet 
veelvuldig, maar zijn mij wel stuk voor stuk bijgebleven. Je kijk op het onderzoek (en op het 
leven) heeft ook mijn kijk hierop zo nu en dan doen veranderen. Binnenkort mag je gaan 
genieten van je welverdiende pensioen. Het is een eer voor mij dat je nog in mijn commissie 
plaats zal nemen voor die tijd. Hartelijk dank hiervoor!
Beste Prof. dr. J.H.J. Hoeijmakers. Beste Jan, dank voor de correcties van mijn artikelen, de 
hernieuwde kijk op het onderzoek en het enthousiasme voor alles wat betreft veroudering 
en dieetrestrictie. Tevens dank voor het zitting nemen in mijn leescommissie. 
Beste Prof. dr. A.H.J. Mathijssen, beste Prof. dr. H. Pijl, zeer veel dank voor het zitting 
nemen in mijn leescommissie. 
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Beste Prof. dr. R. Zietse, ons eerste contact stamt nog van het keuzeonderzoek tijdens mijn 
studiejaren waarbij u mij heeft begeleid vanuit Nederland terwijl ik van mijn tijd in Milaan 
aan het genieten was. Het feit dat u nu zitting wilt nemen in mijn commissie voelt daarom 
als vertrouwd; hartelijk dank hiervoor. 
Beste Prof. dr. K. Willems van Dijk, hartelijk dank voor het zitting nemen in mijn commissie. 
Mijn grootste dank gaat uit naar alle nierdonoren, niertransplantatie patiënten en 
bariatrische chirurgie patiënten die hebben deelgenomen aan mijn klinische studies en dit 
onderzoek mogelijk hebben gemaakt.
Beste dr. E. van der Harst. Beste Erwin, dankzij de betrokkenheid van het Maasstad en de 
bariatrische chirurgie heeft het onderzoek een unieke vorm aangenomen. Met je initiële idee 
over de telomeren hebben we samen de succesvolle Telomeerstudie opgezet en uitgevoerd. 
Graag blijf ik betrokken bij het vervolg! Veel dank voor de begeleiding bij het uitvoeren van 
mijn onderzoek in het Maasstad.
Beste dr. R.A. Klaassen. Beste René, vooral in het begin ben je betrokken geweest bij de 
opzet en uitvoering van alle klinische studies in het Maasstad waarbij de logistiek ook op 
langere termijn perfect bleef verlopen. Dank voor de begeleiding en het mogelijk maken 
van het onderzoek in het Maasstad.
Veel dank aan alle poli-assistenten, physician assistents, assistenten en chirurgen die 
betrokken zijn geweest bij de uitvoering van mijn studies in het Maasstad! In het bijzonder 
bedank ik graag Daisy Verhoeven, Corry van Rooijen en Wouter Roosink.
Beste Conny, iedereen weet eigenlijk wel dat jij de spil bent van de laboratoria van A3/A4 op 
het RIVM. Jouw hulp bij de uitvoering van alle RNA-isolaties en PCRs is van grote waarde 
geweest. Bedankt voor al je tijd, geduld, uitleg en gezelligheid op het lab! 
Beste Jeroen, jij hebt mij alle beginselen van microarray analyses met het geduld van de 
wereld uitgelegd. Bedankt dat je te pas en te onpas klaar stond voor het beantwoorden van 
mijn vragen en het oneindig aanpassen van alle PCA-plots en heatmaps. 
Beste Sandra, dank voor de uitvoering van de Western blots en de gezelligheid op het RIVM! 
Beste Paul, dank voor je hulp bij de transcriptoom analyses van de humane nierbiopten. 
Beste Nicolle, dankzij jouw kennis op het gebied van de telomeren is de Telomeerstudie een 
groot succes geworden. Het is ontzettend fijn om te weten dat jij altijd beschikbaar bent 
voor vragen en brainstormen. Heel veel dank voor je input en je begeleiding!
15045-jongbloed-layout.indd   274 06/11/2017   17:20
275
A
APPENDICES
Beste Ruud, onze kortstondige samenwerking met de Telomeerstudie was ontzettend 
gezellig. Zowaar gaan we de studie tot een succes brengen! Heel veel succes met je verdere 
carrière. 
Veel dank aan alle poli-assistenten, verpleegkundigen van 9-Zuid en alle transplantatie-
chirurgen die betrokken zijn geweest bij de opzet en uitvoering van de PROTECT-
studie. Sabrina van Unnik en Linda van Duijvenbooden, bedankt voor de hulp bij de 
voedingsdagboeken.
Carola, jij bent de beste en meest gezellige secretaresse die een onderzoeker zich mag 
wensen. Altijd en overal wist jij een antwoord op mijn vragen en had je tijd om tijdens mijn 
‘wachttijd’ voor een volgende afspraak koffie te drinken. Veel succes nu in de Z-flat!
Alle onderzoekers van labje #1: bedankt voor alle gezelligheid, dankzij jullie was ik altijd 
op de hoogte van alles wat er op Facebook gebeurde. Stef, Eline, Ruth, Chloë, Daniël, 
Hester: bedankt en veel succes met jullie onderzoek! Büttner, bedankt en tot snel in het 
SFG. Sander, jouw kijk op alles heeft er bij mij ook voor gezorgd dat ik alles wat meer 
cum grano salis ging bekijken. Bedankt voor je gezelligheid en onze samenwerking. Van je 
bruine vest op het lab kunnen we inmiddels wel soep koken. Jeroen, jij kwam op het laatst 
even binnenstormen en walste iedereen plat met je wervelwind aan publicaties. Bedankt 
voor je gezelligheid en al onze (vaak onzinnige) gesprekken. Veel succes met je opleiding!
Tanja, onze samenwerking op het lab was nog wel het meest intensief. Al was het alleen al 
maar omdat we 3 jaar lang een tafel hebben moeten delen op het lab zonder daglicht. Er 
zijn maar weinig mensen die zo hard werken als jij, waardoor onze artikelen samen zeker 
succesvol zijn geweest. Ik weet zeker dat je er gaat komen, daar hoef je niet over te twijfelen. 
Bedankt voor je hulp en gezelligheid!
Lieve Sandra en Gisela, jullie zijn allebei absoluut onmisbaar op het lab. Bedankt voor alle 
gezelligheid op het lab tijdens het plakken, knippen en vullen van alle materialen voor de 
studies maar ook tijdens de koffie- en lunchpauzes en de labuitjes; het was nooit saai! 
Alle collega-onderzoekers uit de Z-flat en de Daniel: bedankt voor de gezelligheid!
Dear dr. Maurizio Gallieni, dear Prof. dr. Diego Brancaccio: thank you so much for the 
perfect research master I had in Milan, it will be remembered!
Alle collega’s uit het Ikazia: heel erg bedankt voor de gezellige, intensieve maar vooral 
leerzame tijd! Dr. P.T. den Hoed, beste Ted, de leerschool van de chirurgie in het Ikazia heeft 
de perfecte basis gelegd voor mij als arts, dank voor de begeleiding hierbij. Dr. A.M.E. van 
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Well, beste Annemarie, dank voor je input als mentor. Nina, dank ook, voor de gezelligheid 
en de raadzame koffiemomenten. Heel veel succes nog, ook! Inge en Mostafa, de tijd met 
jullie in de PKV-tussenruimte was fantastisch. Ilse en Marja, met jullie op de SEH was het 
altijd feest, dank voor alle gezellige diensten!
Alle collega’s in het Alrijne Leiderdorp: bedankt voor de gezellige tijd! Beste dr. A.M. 
Zeillemaker, dank voor het vertrouwen en de kortstondige begeleiding. Laura, het was altijd 
leuk om met jou samen de acute poli/SEH te runnen!
Lieve collega’s uit het SFG: bedankt dat jullie me vanaf dag 1 al welkom hebben laten voelen 
bij de interne. Ik kijk ernaar uit om nog lang met jullie samen te werken! Beste dr. Y.C. 
Schrama, bedankt voor het vertrouwen.
Jeff, jij en je poloshirt of –overhemd waren onmisbaar voor de gezelligheid tijdens alle 
congressen maar ook tijdens onze tijd samen in het Ikazia. Altijd even tijd om te zeuren op 
alles, vooral op mijn (beperkte) Apple skills en jouw (eenkennige) smaak als het gaat om 
mooie kleding en goed eten. Bedankt voor al je steun!
Kirsten, het is altijd gezellig met jou, vooral als we (net niet) gaan sporten. Gelukkig hebben 
we niet als doel om zwemkampioenen te worden. Bel me gerust over alle elektrolytstoornissen 
op de afdeling; voor jou doe ik het graag.  
Natasja, mijn oud-huisgenootje, onze dinersessies aan de gammele bar in de keuken van 
de Hofdijk zullen me altijd bijblijven. Gelukkig zijn we contact blijven houden. Worden we 
ook nog eens collega’s! Bedankt voor al je steun en gezelligheid!
Hanna, al het lief en leed wat ik met je deel, kan jij weer zo’n draai geven dat we altijd 
lachend eindigen. Jouw ironie, never-ending doorzettingsvermogen en positiviteit zijn en 
zullen altijd een voorbeeld voor me blijven. Ik kijk met smart uit naar ons volgende lunch/
borrel avontuur! 
Jochem, of Wosti, hooikist, cobblestone. Ik had nooit gedacht dat we een week lang vakantie 
konden vullen met onzinverhalen en er zo hard om konden lachen ook. En dat inmiddels 
alweer meerdere keren; ik kijk uit naar de volgende keer! Bedankt dat je zo’n ongelofelijk 
goede vriend bent en altijd voor me klaarstaat!
Romy, jij komt voor in al mijn herinneringen aan het Maerlant. Van de eeuwigdurende 
fietstochten ernaartoe, de meezinguren tijdens Aardrijkskunde, de skireizen en de vele uren 
buiten schooltijd om. Een avond met jou staat altijd gevuld met gezelligheid, overheerlijk 
(zelf gebrouwen) eten, en wijn. Met jou kan ik echt alles delen. Bedankt dat je al zolang mijn 
vriendinnetje bent!
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Myrthe, mijn basisschool-vriendinnetje. Bij jou gaat er niets boven Groningen, maar 
gelukkig is daar de digitale wereld. Beloofd, ik kom snel een keer langs!
Mijn lieve beste vriendinnetjes, jullie zijn geweldig! Hanke, jou ken ik nog het ‘minst lang’ 
maar ik kan echt alles met je delen. Elke keer weer raak ik gefascineerd door je fantastische 
kapsel, je collectie schoenen en je aanstekelijke lach. Zjwan, met jouw kleine Adam is je 
droom uitgekomen. Wat heb jij een transformatie doorgemaakt vanaf het moment dat ik je 
ken! Ik ben trots op je dat jij je hart bent blijven volgen en gelukkig dat je er altijd voor me 
bent. Michelle, onze reis naar Italië was onvergetelijk en onze tijd samen in het Ikazia was 
fantastisch, maar onze wekelijkse tot bijna dagelijkse koffiemomenten tijdens onderzoek 
hebben ervoor gezorgd dat ik gekomen ben waar ik nu sta. Ik kan niet wachten om je 
nieuwe huisje in Oostvoorne te bewonderen. Bedankt dat je mijn paranimf wilt zijn!
Lieve familie, bedankt voor jullie steun. Oma, Anne Marie en Aart, bedankt voor het 
vertrouwen in mijn kunnen en alle bemoedigende woorden. 
Arnold, het was altijd weer een verrassing vanaf welke coördinaten ergens op zee je weer 
contact zocht. Van de avonden gevuld met pogingen om Jamie Oliver te evenaren en 
analyses hoe alles altijd beter kan, gevolgd door een ‘biosje’, heb ik genoten. Patrick, als 
het eens tegenzat wist jij wel met je non-stop verhalen overal weer een positieve draai aan 
te geven op het moment dat het nodig was. Vele uren van geluk heb ik doorgebracht met 
jou, Sandra en mijn lieve nichtjes Emily en Lily. Gerda, je staat altijd achter me en je bent 
de allerliefste zus die ik me kan wensen. Met de kleine Lize kan het geluk niet meer op; wat 
ben ik verliefd op je fantastische dochter! Bedankt dat je mijn paranimf wilt zijn, zonder 
jou was dit niks geworden. 
Tot slot: lieve papa en mama, lieve Piet en Francien. Echt alles wat ik bereikt heb, wijt ik 
aan jullie onvoorwaardelijke steun, liefde en eeuwige geduld. Hoe jullie het altijd maar weer 
voor elkaar krijgen voor ons allemaal is bewonderenswaardig. Lieve Piet, alle telefoontjes 
in de avond- en nachturen, alle technische problemen, even zinloos kletsen bij een biertje: 
altijd en overal sta je voor me klaar. Lieve Francien, wat heb je toch altijd alles voor ons over. 
Jij weet overal het goede antwoord op en bent er altijd voor me. Dankzij jou weet ik dat ik 
uitzicht heb en ga hebben op het beste leven wat ik me kan wensen. Zei ik het niet? Het 
komt altijd goed. Ik hou van jullie.
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